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Abstract 
 
Haematological malignancies (HM) are a diverse group of relatively rare, but 
often life-threatening cancers. Over 900 000 people worldwide are expected 
to receive a HM diagnosis in 2018. Most types of HM have an increasing 
incidence with age, which is often associated with poor survival due to the 
inadequate treatment options available. Two types of HM with a particularly 
poor outlook are acute myeloid leukaemia (AML), which is an acute cancer 
of immature myeloid blood cells, and multiple myeloma (MM) which is an 
incurable malignancy with primary focus in the bone marrow (BM). 
Oncolytic viruses (OV) preferentially infect and kill malignantly transformed 
cells. OV therapy (OVT) is a promising treatment strategy which has recently 
been approved for clinical use in the treatment of melanoma. In addition to 
direct lytic killing, the induction of an anti-tumour immune response is 
thought to be essential for efficient OVT with establishment of long-term 
protection against tumour recurrence. While research efforts into OVT for 
solid malignancies have seen a surge in recent years, HM remains under-
investigated in this context, in particular with regards to the anti-tumour 
immune response. Thus, the overall aim of this study was to examine the 
role of OV-induced anti-tumour immunity in HM. 
Two OV were evaluated in the context of MM; both reovirus and 
coxsackievirus A21 (CVA21) were found to induce anti-tumour immune 
responses in vitro comprising cytokine-mediated killing, natural killer cell-
mediated cytotoxicity, and the generation of tumour-specific cytotoxic T cells. 
Moreover, reovirus treatment showed efficacy in an immunocompetent in 
vivo model, along with evidence of the onset of an immune response 
primarily in the spleen. 
Pivotally, this study is the first to evaluate CVA21 as a treatment for AML. 
CVA21 was able to induce anti-tumour immunity in AML in vitro using both 
AML cell lines and a cohort of primary AML samples, despite resistance to 
lytic killing. Furthermore, examination of peripheral blood samples from 
patients with solid malignancies following intravenous administration of 
CVA21 provided “proof of principle” evidence that CVA21 was able to 
activate immune cells in the peripheral circulation in a state of malignancy, 
which is crucial for the future development of CVA21 OVT. 
The obtained results also established the cellular mechanisms responsible 
for CVA21-induced anti-tumour immunity. Plasmacytoid dendritic cells were 
 v 
identified as the main detectors of CVA21 infection and were responsible for 
orchestrating both innate and adaptive anti-tumour immune responses. 
These findings provide novel insights into the immunobiology of CVA21 with 
importance for the continued clinical development of this OV. 
In conclusion, this study has demonstrated that OVT, as a well-tolerated, 
specific, and long-lasting therapy, has the potential to improve the treatment 
of both MM and AML through the induction of a multi-component anti-tumour 
immune response. 
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Chapter 1  
Introduction 
1.1 Cancer and the immune system 
1.1.1 Background 
It has been known for over a hundred years that the immune system is 
intricately linked to the development of cancer. Early observations of tumour 
regression following infections with various pathogens, including bacteria 
and viruses, led William Coley to develop the world’s first immunotherapy in 
the late 1800s. After observing one of his sarcoma patients experience a 
spontaneous tumour regression following a severe bacterial infection, he 
developed a preparation of two heat-inactivated bacterial strains as a 
treatment strategy for cancer patients (1). Coley’s toxin demonstrated some 
therapeutic efficacy and was the start of an intense period of research into 
the immune system and its involvement in the development and progression 
of cancer, pioneered by Paul Ehrlich (2). This fundamental research has 
enabled the development of a range of different cancer immunotherapies 
which are transforming cancer treatment today and might finally give us a 
new weapon in this long-standing battle. Cancer immunotherapy aims to 
activate the immune system to recognise and destroy malignant cells and 
has the potential to generate long term anti-tumour immunity through the 
induction of immunological memory. 
 
1.1.2 Immunosurveillance and anti-tumour immunity 
Although Ehrlich had made similar hypotheses, the concept that 
lymphocytes can recognise and destroy nascent malignantly transformed 
cells was first formally introduced as the immunosurveillance hypothesis by 
Burnet and Thomas 50 years later. While this hypothesis was met with much 
scepticism in the beginning, it has been the focus of intense research efforts 
in the past 20 years and the role of the immune system in cancer 
development has become ever more apparent. Key experiments using 
knock-out mice initially highlighted the importance of different components of 
the immune system in cancer immunosurveillance, including interferon 
(IFN)-g, perforin, interleukin (IL)-12, T cells, natural killer T (NKT) cells, and 
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natural killer (NK) cells (3). Accordingly, both the innate and adaptive 
immune systems play an integral role in cancer immunosurveillance.  
 
1.1.2.1 Innate immune surveillance 
The innate immune system is rapid and efficient and relies on the 
recognition of a broad range of pathogens via conserved non-self molecules 
(pathogen-associated molecular patterns), rather than specific antigens. 
Cells of the innate immune system utilise pattern recognition receptors 
(PRR), such as Toll-like receptors (TLR), for the detection of foreign 
pathogens. The cellular innate immune system is mainly comprised of 
neutrophils, macrophages, NK cells, NKT cells, gd T cells, and dendritic cells 
(DC). IFN-g is a key mediator of both innate and adaptive immune 
responses. The importance of IFN-g for anti-tumour immunity was confirmed 
using murine models genetically deficient in the IFN-g receptor or the IFN 
transcription factor STAT-1 (signal transducer and activator of transcription 
1), which led to an increased rate of both spontaneous and chemically-
induced tumours (4, 5). The source of IFN-g was identified by a series of 
experiments utilising mice deficient in effector molecules of NK cells and 
their respective receptors, or lacking NKT cells, or gd T cells. The increased 
tumour frequency observed in these mice confirmed the importance of NK 
cells, NKT cells, gd T cells, in cancer immunosurveillance (6, 7). 
1.1.2.1.1 NK cells 
One of the most important parts of the innate immune system for recognising 
and destroying malignantly transformed and virally infected cells are the NK 
cells. NK cells monitor cells around the body for the expression of major 
histocompatibility complex (MHC) Class I molecules and cell stress markers, 
relying on the detection of self-molecules rather than foreign antigens for 
initiation of a response. The main regulator of NK cell cytotoxicity is the 
critical balance between engagement of activating and inhibitory receptors 
(Table 1-1). Healthy cells express high levels of MHC Class I and low levels 
of activating ligands on their surface. According to the “missing self” 
hypothesis, when tumour cells or virally infected cells down-regulate the 
expression of MHC Class I molecules on the cell surface, NK cells lose their 
inhibitory stimulation and their killing instinct is released (8). NKG2D has 
been identified as a dominant activating receptor on NK cells and ligation to 
one of its ligands (e.g. MIC A/B, ULBP-1, or ULBP-2) results in target cell 
lysis, independent of MHC Class I expression. Thus, NKG2D plays an 
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important role in recognition and killing of nascent tumour cells which 
manage to maintain the cell surface expression of  MHC Class I (9, 10). 
Type I IFNs (IFN-a and IFN-b) also have a critical role in the recruitment and 
activation of NK cells in response to viral infection. The role of IFN in NK cell 
function is discussed in detail below (Section 1.4.1.2.1). The main 
mechanism of NK cell-mediated killing is a tightly regulated degranulation 
process resulting in the release of cytotoxic granules directed towards the 
target cell. Cytotoxic granules contain perforin, a pore-forming glycoprotein, 
and various proteases, such as granzyme B, which enter cells and induce a 
proteolytic cascade resulting in cell death (11, 12).  
NK cells and the innate immune system should not be considered entirely in 
isolation. NK cells are able to act as a link between the innate and adaptive 
immune responses and have been shown to have ‘helper’ functions by 
assisting the development of an adaptive anti-tumour T cell response. One 
example is local secretion of IFN-g by NK cells at the tumour site which can 
stimulate DCs, which in turn promote the generation of CD8+ T cell anti-
tumour responses (13, 14).  
 
 
 
Table 1-1: Human NK cell receptors and their ligands (15). 
Receptors Ligands 
Activating Receptors 
NKp30, NKp44, NKp46 Viral haemagglutinins and others 
undefined 
NKG2D MICA/B and ULBP 1-5 
DNAM-1 PVR and Nectin-2 
CD16 Immunoglobulin (Ig) G 
NKG2C HLA-E, HLA-C (low affinity) 
Inhibitory Receptors 
Killer-cell immunoglobulin-like receptors (KIRs) MHC Class I (HLA-A,B,C) 
NKG2A/CD94 HLA-E 
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1.1.2.1.2 Dendritic cells (DC) 
DC form a heterogenous population of both lymphoid- and myeloid-derived 
cells with importance for innate, as well as adaptive immune responses. DC 
are professional antigen-presenting cells (APC) which can prime both naïve 
T cells and B cells. Immature DC (iDC) reside in peripheral tissues, such as 
the skin, and continuously sample the local environment to capture antigens  
(16). While iDC have a high capability for phagocytosis and receptor-
mediated endocytosis, their ability to activate T cells is limited, with low 
expression of MHC Class II, and co-stimulatory molecules CD80 and CD86 
on the cell surface (17). Following antigen uptake, the DC matures, which is 
associated with several phenotypic changes including a redistribution of 
MHC molecules to the DC surface, down-regulation of antigen 
internalisation, and an increase in the surface expression of CD80 and 
CD86. Mature DC migrate to secondary lymphoid organs where the antigen 
is presented to T cells on MHC molecules  (16). 
As a result of their extracellular origin, the majority of antigens taken up by 
DC are presented on MHC Class II molecules to naïve CD4+ T cells. Two 
main signals are thought to be required for DC activation of naïve CD4+ T 
cells. The first signal is the engagement of peptide:MHC complexes on DC 
to a complementary T cell receptor (TCR) on the T cell. The second signal is 
mediated by the ligation of co-stimulatory molecules, such as CD80 and 
CD86, to their ligands on T cells (e.g. CD28 and CD40L). Both signals are 
essential for the differentiation of naïve T cells into mature T helper cells. In 
addition, a third cytokine signal determines whether the T cell response will 
be polarized towards a Th1 or a Th2 response. In addition to DC cytokine 
secretion, this often requires a contribution from other innate cells such as 
NK cells for generation of the appropriate cytokine milieu (18). The functions 
of T helper cells are further described below (Section 1.1.2.2.1). 
Although phagocytosed antigen is normally presented on MHC Class II, 
adaptation of the endocytic and phagocytic pathways enable DC to also 
cross-present extracellular antigen on MHC Class I and thereby directly 
activate CD8+ T cells (19). The cross-presentation of tumour-associated 
antigen (TAA) on MHC Class I is important for the generation of anti-tumour 
CD8+ T cell responses (20). 
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1.1.2.2 Adaptive immune surveillance 
The adaptive immune response employs two arms; the cell-mediated T cell 
response and the humoral B cell response. Unlike the innate immune 
system, which recognises non-self in an unspecific manner through PRRs, 
the adaptive immune response relies on specific antigen detection. Foreign 
antigens are detected by individual T or B cells specific for a single antigen, 
which results in the development of specific effector responses, and 
immunological memory with long-lived memory cells reactive to a specific 
antigen. CD8+ T cells in particular have been identified as key components 
of cancer immunosurveillance, as mice lacking CD8+ T cells fail to reject a 
tumour challenge which is rejected by immunocompetent mice, and similarly 
fail to control dormant tumour cells resulting in nascent malignancy (21-23). 
1.1.2.2.1 CD4+ T helper cells 
As described above, DC induce activation of naïve CD4+ T cells and 
stimulate their differentiation into mature helper T cells. Helper T cells 
provide stimulatory help to CD8+ T cells or B cells to allow for an appropriate 
immune response depending on the type of infection encountered. Figure 
1-1 demonstrates that following antigen presentation, a helper T cell can 
differentiate into either a Th1 or a Th2 cell based on the local cytokine milieu. 
In the presence of IFN-g and IL-12, a Th1 response is mounted. Secretion of 
IL-2 and IFN-g from Th1 cells is crucial for the activation and priming of 
antigen-specific CD8+ cytotoxic T lymphocytes (CTL). CTLs are able to 
efficiently kill target cells suffering from an intracellular infection, e.g. a viral 
infection. In the presence of IL-4 and IL-2, a Th2 response is generated, 
where the T cell provides help for the activation of B cells. IL-4 secretion 
from Th2 cells is required for isotype switching in B cells, resulting in 
abundant secretion of antigen-specific antibodies, which are important for 
clearing extracellular infections, e.g. by bacteria or parasites. Under certain 
conditions, naïve CD4+ T cells can also differentiate into other T cell subsets, 
such as regulatory T cells (Treg) and Th17 cells (24). 
1.1.2.2.2 CD8+ cytotoxic T cells 
Upon recognition of intracellular antigen presented on an MHC Class I 
molecule, naïve CD8+ T cells differentiate into CTL. As described above, due 
to their high cytotoxic potential, CTLs are tightly regulated and usually 
require activation help from CD4+ T cells (25). However, DC can also directly 
cross-present exogenous antigen on MHC Class I to CD8+ T cells (Section 
1.1.2.1.2). When CTLs encounter antigen they have been primed against, 
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they can kill that target cell using a mechanism similar to that of NK cells. 
Following antigen-specific degranulation, cytotoxic granules containing 
perforin and granzyme are released, which resulting in the death of the 
target cell.  
The genetic instability of tumour cells often leads to the presentation of 
mutated, overexpressed, or germline-related proteins which are uniquely 
related to tumour cells, so called TAA, on MHC molecules. Examples of 
different types of TAA related to haematological malignancies are presented 
in Table 1-2. In the case of leukaemia, these can be either leukaemia-
specific antigens (LSA), leukaemia-associated antigens (LAA), or cancer-
testis/germline antigens (26). LSAs are exclusively expressed on leukaemic 
cells and are often fusion proteins arising from chromosomal translocations, 
e.g. AML1-ETO, or tumour-specific mutated proteins such as the internal 
tandem duplication (ITD) of the FMS-like tyrosine kinase 3 gene (FLT3). 
LSAs are the most ideal targets for development of leukaemia-specific 
immunotherapies. LAA can be expressed on both normal and leukaemic 
cells, e.g. Wilms’ tumour protein 1 (WT1). In B cell malignancies, including 
multiple myeloma, the variable regions or idiotypes of immunoglobulin heavy 
and light chains can serve as tumour-specific antigens following malignant 
proliferation of a selected B cell clone, with all daughter cells expressing the 
same idiotype (27). The recognition of TAA by CD8+ T cells can lead to the 
priming of tumour-specific CTLs, an important function of 
immunosurveillance. 
As discussed below, the identification of TAA and their importance for 
adaptive anti-tumour immunity has allowed the development of 
immunotherapeutic strategies such as DC vaccines. 
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Figure 1-1: T cell responses following antigen presentation. 
Following uptake of exogenous antigen in the peripheral tissues, APCs such as DC 
migrate to secondary lymphoid organs where they present antigen to T cells. DC 
can either present antigen on MHC Class II to CD4+ T cells, or cross-present 
antigen directly to CD8+ T cells on MHC Class I. Antigen presentation to naïve 
CD4+ T cells, in combination with co-stimulatory signals from the APC, results in 
maturation of naïve cells into T helper cells. Different types of antigens induce 
different types of cytokine responses from innate immune cells, which determines 
the differentiation of helper T cells into either Th1 or Th2 cells. Through the secretion 
of IL-2 and IFN-g, Th1 cells provide help in the activation and antigen priming of 
CD8+ cytotoxic T cells which are responsible for T cell-mediated immunity and 
eradication of cells with an intracellular infection. Through the secretion of IL-4, Th2 
cells provide help to B cells in the production of antigen-specific antibodies as part 
of humoral immunity and eradication of extracellular infections. APC: antigen-
presenting cell. 
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Table 1-2: Common tumour-associated antigens in haematological 
malignancies (26, 28). 
 
 
 
 
 
 
 
 
 
 
  
Disease Category Examples 
 
Multiple 
Myeloma 
 
Overexpressed 
genes 
Mucin-1 
PRAME 
hTERT 
 
Cancer-testis/ 
germline 
MAGE-A1-4 
NY-ESO-1 
GAGE-1,2 
BAGE 
Multiple 
Myeloma & 
Lymphoma 
 
Idiotype 
 
Patient-specific 
 
AML 
 
Leukaemia-
specific (LSA) 
AML1-ETO  
PML-RARa  
FLT3-ITD  
NPM1 
 
Leukaemia-
associated 
(LAA) 
WT1 
Mucin-1 
Survivin 
hTERT 
Bcl-2 
RHAMM 
 
Cancer-testis/ 
germline 
PRAME 
MAGE 
RAGE-1 
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1.1.3 Revised model of immunosurveillance: immunoediting 
Although the immune system might protect us against cancer to some 
extent, we still see tumours forming even in the presence of an intact 
immune system. Thus, the immunosurveillance hypothesis of interaction 
between the immune system and malignant cells was expanded on with the 
immunoediting model. This model, first described by Dunn et al., describes 
in more detail the effect that the immune system has on cancer progression. 
Three dynamic processes known as the three Es: elimination, equilibrium, 
and escape, describe how tumour cells are initially eradicated, but gradually 
become less immunogenic due to selective pressure, finally resulting in 
immune escape (3, 29). 
 
1.1.3.1 The three Es of immunoediting 
1.1.3.1.1 Elimination 
The first step in immunoediting is the elimination phase, which represents 
the original idea of cancer immunosurveillance. The immune system detects 
and eliminates nascent malignant cells, and if all transformed cells are 
eradicated, this completes the immunoediting process without progression to 
the next phase (3). As described above, immunological rejection of 
developing tumour cells likely involves both innate and adaptive immune 
responses (30). 
1.1.3.1.2 Equilibrium 
As it was observed that tumours, nonetheless, develop in immunocompetent 
individuals, it was proposed that some tumour cells which avoid immune cell 
elimination eventually enter the equilibrium phase. In this phase, tumour 
cells exist in a dynamic equilibrium with the immune system. Immune cells 
confer a selection pressure on tumour cells which is enough to contain, but 
not fully eliminate a genetically unstable tumour. This is a delicate balance 
as although many of the original tumour cells are successfully eliminated, 
new mutations arise concurrently in progeny cells, resulting in selection of 
tumour cells with increased resistance to anti-tumour immunity. Eventually, 
this generates a population of tumour cell clones with reduced 
immunogenicity and/or the capability of evading the anti-tumour immune 
response (3). 
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1.1.3.1.3 Escape 
The escape phase details how tumour cells evade anti-tumour immunity and 
explains how, eventually, tumours arise even in individuals with a fully 
functional immune system. Tumour variants which have evolved under an 
immunological selection pressure finally escape immune system control and 
are able to proliferate uncontrollably in an immunologically intact 
environment resulting in progression to clinically overt malignant disease (3). 
Mechanisms of tumour escape are detailed in the following sections. 
 
1.1.4 Tumour immune evasion 
As discussed by Hanahan and Weinberg in their Next Generation Hallmarks 
of Cancer hypothesis, tumour cells acquire an ability to avoid the immune 
system, escape immunosurveillance and successfully establish an 
independently growing tumour (31). Tumours evade the immune system by 
a variety of mechanisms, including 1) reduced immunogenicity, which limits 
immune recognition, 2) increased resistance to immune-mediated cell death, 
and 3) induction of immune tolerance.  
 
1.1.4.1 Loss of immunogenicity 
One way of evading immune detection is to lose characteristics that are 
recognised as “non-self” or foreign by the immune system. As discussed 
above, TAA unique to tumour cells can be presented on MHC Class I 
molecules and mediate an adaptive anti-tumour immune response. Thus, 
one way of avoiding this response is to down-regulate the surface 
expression of classical MHC Class I molecules (HLA-A/B/C), or various 
components of the antigen presentation machinery (32, 33). However, while 
escaping adaptive immunity, loss of MHC Class I expression attracts the 
attention of NK cells and render abnormal cells targets for NK cell 
cytotoxicity (8). To also escape this response, many tumour cells maintain 
the expression of non-classical MHC Class I molecules, (e.g. HLA-E and 
HLA-G) which can protect them from NK cell recognition and 
immunocytotoxicity (34).  
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1.1.4.2 Increased resistance to immune cell death 
Another way of escaping anti-tumour immunity is to increase resistance to 
immune-mediated death. Examples of this include manipulating the Fas/Fas 
ligand (FasL) and TRAIL (tumour necrosis factor-related apoptosis-inducing 
ligand) apoptotic pathways, modulating immune checkpoint molecules, as 
well as increased expression of the anti-phagocytosis protein, CD47. 
1.1.4.2.1 Apoptosis pathways 
Fas (first apoptosis signal) receptor is a death receptor which can be present 
on different types of cells, including immune cells. Activation of this receptor 
is mediated by binding to FasL, which results in induction of apoptosis in 
receptor-expressing cells. FasL can be overexpressed on several types of 
tumour cells, which enables them to induce apoptosis of immune cells (35). 
While tumour cells can also express Fas receptor and therefore become 
susceptible to apoptosis by immune cells, many tumour cells down-regulate 
the expression of Fas receptor, which in combination with the increased 
expression of FasL is an efficient strategy for immune evasion (36). In a 
similar strategy, TRAIL receptors, which also activate the extrinsic apoptosis 
pathway following binding of their ligand, TRAIL, is down-regulated in many 
cancers, resulting in a more aggressive phenotype (37, 38). Additionally, the 
intrinsic apoptosis pathway can be exploited by tumour cells to evade 
apoptosis. Through overexpression of anti-apoptotic proteins, such as Bcl-2, 
engagement of the pathways leading to caspase activation is prevented, 
resulting in increased resistance to apoptosis (39). 
1.1.4.2.2 Immune checkpoint molecules 
Due to their potency, T cell responses are tightly regulated. Immune 
checkpoints play an important role in the balance between stimulatory and 
inhibitory signals in the T cell response. One of the most well-studied 
inhibitory immune checkpoint molecules is programmed cell-death protein 1 
(PD-1) and its ligand (PD-L1). When engaged, PD-1 conducts inhibitory 
signals in T cells which result in inhibition of both T cell proliferation and 
secretion of important T cell cytokines like IL-2 and IFN-g (40, 41). Thus, as 
an immune evasion strategy, tumour cells upregulate the expression of PD-
L1 to limit immune effector cell functions. The importance of immune 
checkpoint molecules in immunotherapy is discussed further below (Section 
1.3.3.4) (42). 
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1.1.4.2.3 Phagocytosis 
Phagocytosis of dead and dying cells, so called programmed cell removal, is 
another important way for the immune system to remove abnormal cells and 
thus, evasion of phagocytosis is another strategy for increasing resistance to 
immune cell-mediated death (43). CD47 is normally expressed on healthy 
cells to prevent them from being phagocytosed. CD47 binds to its receptor, 
SIRPa, on macrophages and DCs and inhibits their phagocytic activity. 
Similarly, by increasing the expression of CD47 on the surface, tumour cells 
can evade immune cell phagocytosis (44).  
 
1.1.4.3 Induction of immune tolerance 
In addition to central tolerance (thymus depletion), which is critical for the 
development of T and B cells that only react to “non-self” antigen, peripheral 
tolerance acts as a backup to eliminate or inhibit cells which escaped central 
tolerance. Peripheral immune tolerance can also be exploited by tumour 
cells to evade immune attack. The induction of immune tolerance requires a 
specific, suppressive environment in which antigen-presenting cells are 
incapable of generating and supporting an effective immune response and 
instead induce tolerance against specific TAA. Both soluble factors and 
suppressive cells contribute to generate this local suppressive tumour 
microenvironment (TME). 
1.1.4.3.1 Soluble suppressive factors 
Tumour cells can secrete a range of immunosuppressive cytokines in the 
local microenvironment, including e.g. transforming growth factor b (TGF-b), 
vascular endothelial growth factor (VEGF), prostaglandin E2 (PGE2), and IL-
10. While TGF-b is a potent inhibitor of proliferation in most cells, many 
tumour cells have developed mutations to resist this effect. However, as 
immune cells remain responsive to TGF-b, its secretion can have detrimental 
effects on the anti-tumour immune response (45). TGF-b also induces the 
differentiation of Tregs (discussed below) (46). VEGF has important 
implications both as an angiogenic agent to promote tumour growth, but also 
for recruiting immature myeloid cells to the local environment (47). However, 
the local immunosuppressive environment induced by e.g. TGF-b, VEGF, 
and IL-10 suppresses the differentiation and maturation of immature myeloid 
precursors into professional APCs, such as DCs and macrophages. 
Ultimately, this results in an impaired adaptive immune response where TAA 
are not presented efficiently to T cells within the TME (48). The role of IL-10 
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and its effect on the immune response remains controversial, but similar to 
PGE2, a range of effects on cancer progression have been reported. 
Importantly, secretion of both IL-10 and PGE2 contributes to tumour-induced 
suppression of both NK cell function and IFN-g secretion (49). 
1.1.4.3.2 Induction of suppressive cells 
A range of different cells have suppressive roles in the immune system with 
the ultimate goal of protecting the body against auto-immune disease. When 
hijacked by a tumour, these cells can limit the onset of efficient anti-tumour 
immune responses. One cell type which is critical for the maintenance of 
peripheral tolerance against self-antigens is Tregs, and many studies have 
indicated that the presence of Tregs in the TME correlates with a worse 
prognosis in several types of cancers (50-52). Tregs inhibit the immune 
response by multiple mechanisms, including perforin-mediated direct 
cytotoxicity against CD4+ and CD8+ T cells, monocytes, and DC; secretion of 
immunosuppressive cytokines which, as discussed above, can have direct 
suppressive effects on immune cells; as well as the induction of T cell 
inhibitory receptors on APC, such has B7-H4 (53, 54). 
Tumour-associated macrophages (TAM) are macrophages present at high 
numbers in the TME which often have a tumour-promoting phenotype. 
Classically, TAMs have been categorised as either M1 or M2 macrophages. 
M1 macrophages have a pro-inflammatory phenotype and can be both 
directly cytotoxic through the production of nitric oxide and reactive oxygen 
species (ROS), or as mediators of a Th1 response with recruitment of CTL 
(55). On the contrary, M2 macrophages have an anti-inflammatory and 
tissue-healing phenotype and are thereby often tumour-promoting. However, 
according to recent research, these cells are likely forming a much more 
heterogeneous spectrum depending on the individual tumour and its local 
environment. TAMs with an M2 phenotype are most prevalent in the TME 
and can utilise many of the immune evasion strategies previously discussed. 
For example, they produce IL-10, TGF-b, and PGE2, and express PD-L1 as 
well as FasL and TRAIL (56, 57). 
Finally, myeloid-derived suppressor cells (MDSC) are a heterogeneous 
population of cells consisting of both myeloid progenitor cells and immature 
myeloid cells. Two subsets have been identified; the monocytic MDSCs 
which are phenotypically and morphologically similar to monocytes, and the 
granulocytic MDSCs which are more similar to neutrophils. In addition to 
immunosuppressive effects which promote immune evasion, MDSCs also 
promote tumour angiogenesis and growth through the secretion of various 
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cytokines and growth factors (58). MDSCs have several elaborate ways of 
inhibiting T cell responses including arginine depletion, and production of 
nitric oxide and ROS. Arginine is crucial for the production of the CD3 ζ-
chain, which is an essential part of the TCR (59). Nitric oxide can induce 
apoptosis in T cells and interfere with IL-2 signalling, critical for T cell 
activation and proliferation. Through both secreted and membrane-bound 
TGF-b, MDSCs also suppress the function of NK cells and recruit Tregs to the 
TME (58). Similar to TAMs, a higher level of MDSCs in the peripheral blood 
is correlated with a worse prognosis in many types of solid and 
haematological malignancies (58). 
With such an extensive range of immune evasion strategies available to 
tumour cells, identifying methods for reversing tumour-induced immune 
tolerance and local immunosuppression is critical for the generation of 
efficient anti-tumour immunity. 
 
Figure 1-2: Examples of tumour immune evasion strategies. 
Tumour cells have many different methods for escaping the immune system, 
including loss of immunogenicity, increased resistance to immune cell-mediated 
death, and induction of immune tolerance. Loss of immunogenicity can be mediated 
by defects in the antigen-processing machinery (APM) and a reduced expression of 
classical MHC Class I molecules, resulting in T cell escape. Maintained expression 
of non-classical MHC Class I molecules circumvents NK cell detection. An 
increased expression of FasL enables tumour cells to induce apoptosis of immune 
cells. In combination with reduced expression of Fas, the tumour cell can evade 
eradication attempts from immune cells utilising this pathway, e.g. NK cells. In 
addition, tumour cells secrete a range of immunosuppressive cytokines in the local 
TME, such as TGF-b, VEGF, PGE2, and IL-10. These cytokines can on their own 
dampen immune cell responses, but can also lead to the recruitment and 
differentiation of immunosuppressive cells such as T regulatory cells and MDSCs.  
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1.2 Haematological malignancies 
Haematological malignancies (HM) are cancers of the blood and immune 
cells. An overview of normal human haematopoiesis is provided in Figure 
1-3. Typically, HM arise as a result of malignant transformation of immature 
blast cells during haematopoiesis, but can also arise in terminally 
differentiated cells such as plasma cells. The HM are a diverse group of 
diseases as they include both acute and chronic diseases, cells of both 
myeloid and lymphocytic origin, and various tumour sites, including the 
peripheral blood, bone marrow (BM), and lymph nodes. As described in 
Figure 1-4, the three main groups of HM are: leukaemias, which arise from 
abnormal white blood cells in the blood and BM; lymphomas, which arise 
from lymphocytes and target the lymphatic system and lymph nodes; and 
finally, multiple myeloma which is a plasma cell malignancy predominantly 
residing in the BM. 
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Figure 1-3: Human haematopoiesis. 
All haematopoietic cells arise from multipotent haematopoietic stem cells in the BM. 
Following complex interactions of growth factors, transcription factors, and gene 
expression patterns, common progenitor cells committed to either the myeloid or 
lymphoid lineage develop. Within each lineage, the common progenitor cells give 
rise to a range of different cell types with specialised functions following extensive 
differentiation. Mutations in common progenitor cells or other immature cells during 
differentiation can give rise to leukaemia, e.g. acute myeloid leukaemia. Mutations 
can also occur in terminally differentiated cells, e.g. plasma cells, which give rise to 
multiple myeloma.  
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Figure 1-4: Main subtypes of haematological malignancies. 
Haematological malignancies have been subdivided based on their haematopoietic 
origin and tumour location. Leukaemias predominantly reside in the BM and 
peripheral blood and can be either acute or chronic in their development. 
Depending on the cell types involved, the leukaemias can be further subdivided into 
myeloid or lymphocytic, giving four main types (orange). Lymphomas are located to 
lymph nodes and exclusively involve lymphoid cells. Based on the presence or 
absence of multinucleated B cell-derived Reed-Sternberg cells, lymphomas are 
further subdivided into Hodgkin’s or non-Hodgkin lymphomas (NHL), respectively. 
NHL is further subdivided into more than 60 unique subtypes (not shown). Multiple 
myeloma is a malignancy of terminally differentiated B cells (plasma cells) primarily 
residing in the BM. 
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1.2.1 Multiple Myeloma 
As discussed, multiple myeloma (MM) is a tumour of terminally differentiated 
plasma cells (Figure 1-3) which reside and expand in the BM. One of the 
hallmarks of MM is the onset of osteolytic bone disease due to increased 
bone resorption by osteoclasts and a complete loss of osteoblast function, 
resulting in a net loss of bone tissue. This rapid and extensive bone 
destruction is one of the most debilitating features of MM and often results in 
bone pain, fractures, hypercalcaemia, and spinal cord compression 
syndromes, which has extensive impact on the overall quality of life and 
expected survival (60). Furthermore, like their normal counterparts, MM cells 
produce large amounts of immunoglobulin, but in MM these proteins (known 
as paraprotein or M-band) are abnormal and dysfunctional, and largely 
contribute to the progression of the disease due to their role in the 
development of kidney and heart disease (61). Two premalignant stages of 
MM exist; monoclonal gammopathy of undetermined significance (MGUS) 
and smouldering MM (SMM). While both diseases are asymptomatic with no 
end-organ damage (hypercalcaemia, renal failure, anaemia, or bone 
lesions), MGUS has a 1% per year progression rate to MM, compared to 
10% for SMM (62).  
Another characteristic of MM is the heterogeneous chromosomal aberrations 
and often numerous mutations in a multitude of genes, which makes 
therapeutic targeting difficult. The transformation of normal, terminally 
differentiated plasma cells into proliferating cells requires genetic changes 
that disrupt the cell cycle arrest, commonly in the cyclin D protein family 
which regulates the G1/S transition of the cell cycle (62). Chromosomal 
translocations resulting in activation of cyclin D proteins are one of the most 
common initiating events of MGUS (62). Several genetic alterations are 
related to the transition from MGUS to MM, such as mutations in oncogenes 
Myc, and Ras, as well as further chromosomal deletions and translocations. 
Overt MM is often characterized by additional mutations in genes such as 
KRAS, NRAS, BRAF, TP53, and DIS3. Further progression involves 
increased genomic instability with an enhanced proliferation rate and 
decreased dependence on the BM microenvironment, resulting in plasma 
cell leukaemia and extramedullary metastasis with formation of 
plasmacytomas. One of the main contributors to BM independence is a 
constitutive activation of  the NF-kB pathway (62, 63). 
There is a worldwide incidence of myeloma of about 114 000 cases per 
year, with an average 5700 cases diagnosed in the UK. It is the second most 
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common HM, and incidence is expected to increase over the coming 
decades (64). MM is a chronic disease which is developing slowly and the 
average five-year survival rate across all age groups in the UK is 47.0%. 
However, in patients >85 years of age, where incidence is the highest, five-
year survival is only 24.0% (64). 
While autologous stem cell transplantations have proven successful for 
prolonging survival in systemic MM and have become an important part of 
MM management, many patients are ineligible for such radical treatment due 
to frailty and comorbidities. For chemotherapeutic regimens, first-line 
treatments include traditional drugs such as melphalan, 
prednisone/dexamethasone, and thalidomide in combination with more novel 
therapeutics such as the proteasome inhibitor, bortezomib, 
immunomodulatory drugs, such as lenalidomide or pomalidomide (Section 
1.3.3.2), and monoclonal antibodies (Section 1.3.3.5). After 12-18 months, 
treatment is usually switched to a consolidation/maintenance strategy. 
Treatment of relapsed MM is complicated and the therapeutics used depend 
on initial treatment chosen and resistance patterns. New agents specifically 
approved for the treatment of relapsed/refractory MM include the 
proteasome inhibitor, carfilzomib, pomalidomide, and the histone 
deacetylase (HDAC) inhibitor, parabinostat (65). 
However, despite recent advances in treatment which have prolonged 
overall survival rates, MM remains an incurable disease. With an expected 
rise in the incidence in an ageing population, it is evident that new 
treatments which are efficient, durable, and less harsh on elderly patients 
are urgently required. As described below, several immunotherapeutic 
strategies, including oncolytic viruses, are being tested in MM and have the 
potential to prolong survival or even be curative. 
 
1.2.1.1 The bone marrow microenvironment in multiple myeloma 
The BM microenvironment is intricately linked to successful establishment of 
MM lesions and has extensive impact on disease progression and 
resistance. As a protective niche, the BM microenvironment provides 
support for MM cell infiltration, growth, proliferation, adhesion, and migration. 
It also affords a structural and nutritional sustenance for drug-resistant, 
dormant MM cells (66). As illustrated in Figure 1-5, the BM has a diverse 
cellular composition. In addition to haematopoietic stem cells (HSC) which 
are responsible for the continuous production of haematopoietic cells, 
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mesenchymal stem cells (MSC) are important for regulating bone 
remodelling and can differentiate into various types of BM cells including 
osteoblasts, adipocytes, and chondrocytes. Stromal cells such as endothelial 
cells and fibroblasts provide structural support for the growth of HSCs, 
together with the extracellular matrix. Normally, the BM is a relatively 
hypoxic niche, which is imperative for normal haematopoiesis. However, MM 
cells have been shown to modulate the oxygen supply both by inducing 
neovascularisation to make the local microenvironment more supportive of 
tumour expansion and through increased expression of the transcription 
factor hypoxia-inducible factor (HIF-1a), promoting several cellular changes 
improving resistance to the effect of hypoxia (67). Moreover, a host of 
immunomodulatory cells reside in the BM including NK cells, T cells, B cells, 
Tregs, MDSC, and macrophages (68). These cells can provide inflammatory 
agents such as cytokines, chemokines, adipokine, and growth factors which 
can contribute to MM cell growth and drug resistance, as well as toxicity 
against healthy cells. Tregs and MDSCs can induce local immunosuppression 
to further protect MM cells (9). A wide range of soluble factors in the BM 
microenvironment influence the growth of MM cells in the BM, but IL-6 is of 
particular importance for MM cell proliferation and survival (69).  
Recently, a lot of research has been invested in examining the interaction of 
MM cells with the BM microenvironment. As a complement to standard 
treatment, therapies that target the BM microenvironment specifically, such 
as bisphosphonates, find increasingly more use in MM treatment and 
demonstrates that targeting the BM niche can be yet another strategy in 
eradicating MM (70, 71).  
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Figure 1-5: Cellular components of the bone marrow microenvironment. 
The BM is a microenvironment with a unique cellular composition which provides a 
protective niche for tumour cells. Stem cells give rise to haematopoietic cells (HSC) 
and the mesenchymal cells (MSC) such as osteoblasts, adipocytes, and 
chondrocytes. Immune cells, such as T and B cells return to the BM following 
maturation in lymphoid organs and contribute to modifying the local environment. 
Subniches are created within the BM based on the proximity to sinusoids and 
microvessels, which determines the local level of hypoxia. The BM is encased in 
solid bone, which similarly is an intricate organ with complicated local homeostasis 
primarily maintained  by osteoblasts and osteoclasts. 
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1.2.2 Acute Myeloid Leukaemia 
Acute myeloid leukaemia (AML) is the collective term for malignant disease 
of blood precursor cells (blast cells) of the myeloid lineage, which includes 
granulocytes, erythrocytes, monocytes, and thrombocytes (Figure 1-3). 
Compared to chronic leukaemia, it has a rapid progression and many 
patients would only survive a couple of months without treatment 
intervention. The disease develops in the BM and is characterised by 
uncontrolled proliferation and accumulation of one or more types of 
immature blast cells, along with inhibited maturation of normal blasts (72). 
As opposed to MM, dependence on the BM microenvironment is limited and 
blast cells are widely present in the peripheral circulation. Myelodysplastic 
syndromes (MDS) are similar to AML and characterised by BM failure, but 
with a blast count <20% in the blood and BM. Acute expansion of immature 
cells along with a decrease in the mature cell populations lead to symptoms 
of either isolated haematopoietic deficiencies (anaemia, leukopenia, or 
thrombocytopenia) or pancytopenia, along with common symptoms such as 
bleeding, bone pain, fatigue, and pallor. The lack of mature immune cells 
also leads to an impaired immune response, leaving AML patients 
immunocompromised and susceptible to infections which can be fatal even 
when caused by commensal pathogens. During later stages of the disease, 
extramedullary organ infiltration may present as hepatosplenomegaly or 
lymphadenopathy and may be fatal if involving the brain or lungs (72). 
Similar to the common dogma of oncogenesis, proliferation, immortality, and 
impaired differentiation in AML is the combined result of mutations in two 
different classes of genes (two-hit hypothesis). Class I mutations lead to a 
proliferative and/or survival advantage in the transforming cells through 
activating mutations in cell surface receptors (e.g. FLT3 and c-kit). Class II 
mutations, or fusion of genes, results in impaired differentiation and 
apoptosis. The genetic makeup of transformed cells in each individual case 
has great implications for chemotherapy sensitivity and disease outcome 
(72, 73). A thorough genetic workup is today part of AML diagnostics and 
routinely examined genes include FLT3 (FMS-like tyrosine kinase 3), NPM1 
(nucelophosmin-1), CEBPA (CCAAT enhancer binding protein), KIT (v-kit 
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), TET2 (Tet 
methylcytosine dioxygenase 2), DNMT3A (DNA methyltransferase 3A), IDH1 
(isocitrate dehydrogenase 1), and IDH2 (74). As an example, an isolated 
mutation in NPM1, or in both alleles of CEBPA, improves disease prognosis 
while an ITD in FLT3 is associated with poor prognosis (75). The extensive 
range of cell types, genetic changes, causes, and clinical features involved 
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in the pathogenesis of AML result in a highly heterogeneous disease with a 
wide spectrum of unique disease presentations. An overview of the World 
Health Organisation (WHO) classification of AML is provided in Table 1-3 to 
illustrate the diversity of the disease.  
AML is most common in adults and the elderly with a median age of onset of 
70 years. There are around 3100 new cases of AML in the UK every year, 
making it marginally rarer than MM. However, the average five-year survival 
in the UK is only 15%, decreasing to just 5% in patients >65 years of age 
(76). With improved BM transplantation techniques, the survival of young 
patients has improved significantly, but as for MM, the main patient group is 
not eligible for such drastic treatment regimens. Chemotherapeutic treatment 
strategies for AML have only prolonged survival marginally over the past 30 
years, with no new drugs being approved for AML treatment until 2017. 
Following approval of several new therapeutics, the treatment landscape is 
changing, and some improvement in the survival of elderly patients has been 
observed (77, 78). Standard treatment consists of two parts; induction and 
consolidation therapy. Standard induction therapy is given as a 3+7 regimen 
with three days of intravenous (i.v.) daunorubicin followed by seven days of 
cytarabine (79). Due to its heterogeneity, treatment strategies are diverse 
and often need to be tailored specifically to the individual patient. New 
therapeutics which have recently been approved for combination with 
standard treatments include the hypomethylating agents, azacytidine and 
decitabine (Section 1.3.3.3), the multikinase inhibitor midostaurin, IDH 
inhibitors, enasidenib and ivosidenib, and anti-CD33 monoclonal antibody 
gemtuzumab ozogamicin (Section 1.3.3.5) (78). Several immunotherapeutic 
strategies for targeting AML are also currently being explored as detailed 
below (Section 1.3). When the patient enters remission, consolidation 
therapy is started with several cycles of high-dose cytarabine or 
anthracyclines to prevent the return of malignant cells. However, although 
approximately 50% of all patients enter complete remission, one of the 
biggest challenges of AML treatment is a high relapse rate (79). Similar to 
MM, chemotherapy-resistant leukaemic stem cells often find protection in the 
BM microenvironment. The leukemic cells remaining in the BM following 
treatment are known as minimal residual disease (MRD) and frequently 
cause disease relapse at a later stage following reactivation (80). 
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Although the treatment for AML seems to be improving, much work remains 
to stratify treatment strategies to disease subtype and individual 
characteristics and likely, more specialized therapeutics, including 
immunotherapies, will improve overall survival for AML patients, independent 
of age, in the coming years.  
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Table 1-3: World Health Organisation (WHO) classification of AML and related 
neoplasms. 
The table provides an excerpt of the 2016 revised version of the WHO classification 
of myeloid neoplasms and acute leukaemia (81). 
 t: translocation, inv: inversion, APL: Acute promyelocytic leukaemia, PML-RARA: 
promyelocytic leukaemia/retinoic acid receptor-a fusion, GATA2: GATA-binding factor-2, 
MECOM: MDS1 and EVI1 complex locus protein EVI1. 
  
Acute myeloid leukaemia and related neoplasms 
AML with 
recurrent 
genetic 
abnormalities 
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
APL with PML-RARA 
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
AML with t(6;9)(p23;q34.1);DEK-NUP214 
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, 
MECOM 
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 
Provisional entity: AML with BCR-ABL1 
AML with mutated NPM1 
AML with biallelic mutations of CEBPA 
Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
AML, not 
otherwise 
specified (NOS) 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Pure erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
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1.3 Immunotherapy of haematological malignancies 
1.3.1 Background 
Cancer immunotherapies are novel treatment strategies which aim to 
harness the anti-tumour abilities of the immune system by manipulating the 
patient’s own immune system to recognise and kill tumour cells. Successful 
immunotherapy has the potential to generate immunological memory and 
thereby induce long-term remission. Initially, ideas for immunotherapies 
were developed following the observation of the cellular reactions to 
allogeneic haematopoietic stem cell transplantations (HSCT) in HM. 
Allogeneic HSCTs take advantage of the generation of graft-versus-tumour 
effects where donor immune cells recognise and kill recipient tumour cells 
(82). Immunotherapy strategies exploiting both the functions of immune cells 
directly, as well as various other ways of stimulating the immune system, 
have been explored. 
 
1.3.2 Cellular immunotherapy 
Cellular immunotherapy takes advantage of the possibility to culture patient 
immune cells ex vivo to potentiate their functions and reverse a suppressed 
state induced by the TME, followed by re-infusion into the patient to initiate 
anti-tumour immunity (adoptive transfer). Several different strategies have 
been explored which are described below. 
 
1.3.2.1 Alloreactive NK cells 
NK cells have many characteristics that make them attractive for 
immunotherapy. In addition. As a part of the innate immune system, they do 
not depend on specific antigen recognition to initiate an anti-tumour 
response. The basics of NK cell cytotoxicity regulation was introduced in 
Section 1.1.2.1. Normally, inhibitory receptors, such as the killer-cell 
immunoglobulin-like receptors (KIR) interact with HLA molecules on normal 
cells, which prevents activation of NK cells (Table 1-1). The “missing self” 
strategy is particularly interesting in relation to allogeneic HSCT, where NK 
cell immunotherapy has been explored for the induction of a graft-versus-
leukaemia response. Intentional KIR ligand mismatch between donors and 
recipients in AML has generated some remarkable improvements in 
outcomes following HSCT, generating significantly reduced relapse rates, 
more frequent progression-free survival at relapse and remission, as well as 
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a survival advantage (83, 84). One particular benefit of NK cells is that they 
do not induce the graft-versus-host disease (GVHD) that is often seen as a 
complication of HSCT due to the presence of donor T cells. Alloreactive NK 
cells have even been shown to protect against GVHD, which led to the 
exploration of T cell-depleted allogeneic grafts as a method for preventing 
GVHD (84, 85). However, as T cell depletion caused an increased mortality 
rate and risk of relapse, GVHD is now commonly prevented by the use of 
immunosuppressive drugs which also inhibit the function of NK cells and 
therefore limit the efficiency of KIR ligand mismatch (8). As many elderly 
patients are still not eligible for HSCT, adoptive transfer of allogeneic NK 
cells independent of HSCT has also been explored in AML, but the best 
strategy for culturing NK cells ex vivo has yet to be clarified. A recently 
completed clinical trial (Phase I) used allogeneic NK cells from related HLA-
identical donors, which were activated with a leukaemia cell line lysate 
before adoptive transfer, which resulted in significantly improved relapse-
free survival times (86). A novel strategy to overcome the issues of ex vivo 
culture of NK cells is the development of bispecific and trispecific killer cell 
engager antibody technology (BiKEs and TriKEs). One of the first BiKEs 
generated was aimed at AML therapy. With specificity for CD16 and CD33 it 
could physically link NK cells and tumour cells together in vivo and thereby 
potentiate the cytotoxic effect of NK cells (87). This has been further 
developed into TriKEs, which additionally can express e.g. IL-15 to stimulate 
the in vivo expansion of NK cells (88). 
Various strategies for ex vivo activation and expansion of NK cells for MM 
treatment have been explored. In particular co-culture of autologous NK cells 
with K562 feeder cells expressing 4-1BB ligand and IL-15 has proven 
successful with the generation of large numbers of highly cytotoxic NK cells. 
Encouraging results have been demonstrated following adoptive transfer of 
ex vivo expanded NK cells in early clinical trials of MM (89, 90). One 
particularly interesting strategy recently presented by Chang et al. utilises a 
combination of ex vivo expanded NK cells and carfilzomib treatment, which 
reduces the expression of HLA Class I on MM cells, thereby making them 
more attractive targets for NK cell attack (89).  
 
1.3.2.2 Dendritic cell vaccines 
DC vaccines are DC-based tumour immunotherapies which exploit the 
versatile functions of DCs to generate tumour-specific CTLs with the ability 
to eradicate tumour cells. DCs are either isolated from the patient or 
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generated ex vivo from patient-derived precursor cells. The DCs can then be 
activated and matured in culture and loaded with TAA before re-introduction 
into the patient. Overall, clinical trials have demonstrated that DC vaccines 
are safe and have moderate immunological activity, but only limited clinical 
efficacy to date (82). DC vaccines have been explored in both MM and AML. 
One strategy which has been particularly successful in MM is the use of 
patient-specific idiotype protein as the DC antigen load. As previously 
discussed, following malignant transformation of plasma cells, all of the 
malignant clones have the same unique variable region sequences in the 
heavy and light chains of the secreted immunoglobulins (the idiotype) hence, 
this can serve as a tumour-specific antigen. In a clinical trial, matured, 
idiotype-loaded DCs were infused into patients with MM which resulted in 
the generation of idiotype-specific CTLs in 5/9 patients and five years stable 
disease in 4/9 patients (91). Similar results have been obtained by pulsing 
DCs with whole tumour cell lysates (92). In AML, DC vaccines have been 
explored as a more tolerable form of treatment in the elderly with particular 
efficacy in MRD and early remission (82). In particular, a DC vaccine 
generated using DCs electroporated with the LAA, WT1, was tested in a 
Phase II clinical trial and prevented, or delayed, relapse in 9/13 patients. 
Moreover, long-term clinical response was correlated with an increased 
frequency of circulating WT1-specific CTLs (93). Autologous apoptotic 
leukaemic cells have also been used successfully as antigens, specifically in 
elderly patients, which is an encouraging development (94). Another antigen, 
which is currently being tested in a Phase I/II trial as a post-remission 
therapy in AML, is the germline TAA PRAME (preferentially expressed 
antigen in melanoma) (95). 
 
1.3.2.3 Lymphokine-activated killer (LAK) cells 
Similar to NK cells, LAK cells kill by unspecific mechanisms independent of 
MHC Class I and therefore provide a good alternative to T cell based-
therapies which can generate problems with GVHD. LAK cells are generated 
ex vivo by treating PBMCs with IL-2 and thus, they consist of a 
heterogenous population of NK, NKT, and T cells, which can then be re-
introduced into the patient by adoptive transfer (96). Initial strategies 
employed adoptive transfer of LAK cells in combination with IL-2 treatment, 
but this generated systemic IL-2 toxicity in clinical trials and the efficacy was 
poor (97). 
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1.3.2.4 Cytokine-induced killer cells 
Cytokine-induced killer (CIK) cells are CD3+CD56+ cells closely related to 
LAK and NKT cells with a mixed NK- and T cell phenotype. CIK cells were 
investigated as a development of LAK cell therapy, as the need for systemic 
IL-2 treatment could be bypassed (98). CIK cells can exert their anti-tumour 
response using both antigen-dependent and -independent mechanisms. 
They are terminally differentiated cells which, similar to LAK cells, are 
generated ex vivo by treating PBMCs with IL-2, IFN-g, IL-1, and anti-CD3 
antibodies. CIK cells have been used in both autologous and allogeneic 
strategies for the treatment of HM with varying results (99). Unfortunately, 
GVHD remained a problem when allogeneic CIK cells were used in clinical 
trials and more recently, the focus has been switched to other 
immunotherapeutic strategies. 
 
1.3.2.5 Chimeric Antigen Receptor (CAR) T cells 
One of the major advances in immunotherapy, and in the treatment of HM, is 
the development of the chimeric antigen receptor (CAR) and CAR-T cells. 
Briefly, T cells are obtained from patients or healthy donors and then 
genetically engineered to express a recombinant TCR with specificity for a 
given TAA. The CAR-T cells are then expanded ex vivo and re-introduced 
into the patient through adoptive transfer where they are destined to find, 
and destroy, tumour cells expressing the chosen TAA. This is a novel 
strategy, but so far, it has shown promise in several HM, not least following 
the development of CAR-T cells with specificity for CD19, which is 
ubiquitously expressed on immature B cells (100). Encouragingly, CD19-
targeted CAR-T cells for the treatment of diffuse large B cell lymphoma and 
acute lymphoblastic leukaemia (ALL) were approved by the FDA (US Food 
and Drug Administration) in 2017 as the first CAR-T cell therapies to enter 
the market (101). As opposed to other B cell malignancies, CD19 is not 
expressed on malignant plasma cells and other targets have been explored 
in the MM setting. Early trials of CD138-targeted CAR-T cells showed 
promising results with stable disease in 4/5 treated patients at the seven 
month follow-up and no immediate toxicity issues (102). Another dose-
escalation trial tested targeting of CAR-T cells to the B cell maturation 
antigen (BCMA). Following treatment of two patients with MM refractory to 
chemotherapy and 80-90% malignant plasma cells in the BM prior to 
treatment, plasma cells remained undetectable in the BM for up to 28 weeks 
(103). Another target which has recently gained a lot of attention is SLAMF7 
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which, as described below, is also a promising target for monoclonal 
antibody therapy in MM (104).  
Identifying suitable surface proteins for CAR-T cell targeting in AML has 
proven more difficult as many of the proteins are not exclusively expressed 
on haematopoietic cells leading to an elevated risk of off-target effects. 
Although a large number of targets, including CD33, CD7, CD25, CD123, 
CD38, and the FLT3 receptor, have been investigated in preclinical studies, 
translation into clinical studies has been slow (105). Currently, Phase I 
clinical trials of CD33-, CD38-, and CD56-specific CAR-T cells are on-going 
with no results published to date (105). Interestingly, oncolytic viruses (OV) 
have been suggested as a potential novel combination treatment with CAR-
T cells to enhance T cell recruitment to the TME, reverse local 
immunosuppression, and enhance the effector function of CAR-T cells (106). 
 
1.3.2.6 Marrow-infiltrating lymphocytes 
Another T cell-based immunotherapy strategy which is specifically aimed at 
HM, and MM in particular, is the use of marrow-infiltrating lymphocytes 
(MIL). While the BM is the primary site of the disease, it can also be 
considered a reservoir of memory T cells. Similar to tumour-infiltrating 
lymphocytes, MILs are tumour-specific effector T cells which are present in 
the BM of HM patients and have a greater polyclonal antigen specificity than 
peripheral blood lymphocytes (107). However, due to the local suppressive 
environment, MILs are not able to fully eradicate BM disease as a 
monotherapy. In conjunction with HSCT, MILs are isolated, and then 
expanded and activated ex vivo to promote their potency. Upon transfer 
back to the patient via adoptive transfer, MILs provide a strategy which is 
autologous, tumour-specific, and does not require any genetic manipulation. 
In the first clinical trial in MM it was confirmed that the likelihood of achieving 
a complete response was associated with greater anti-tumour specificity of 
activated MILs. Persistence of tumour-specific immunity in the BM for up to 
one year was also demonstrated (107). Based on these encouraging results, 
MILs are being further tested in clinical trials for MM (Phase II) and are also 
gradually expanded to other HM (108, 109). 
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1.3.3 Drug-based immunotherapy strategies 
In addition to cellular therapies, various types of drugs have been explored 
for their potential to trigger the immune system and generate an anti-tumour 
immune response. This includes both synthetic compounds and biological 
therapies, some of which are discussed in more detail below. 
 
1.3.3.1 IFN-a treatment 
Early in the era of immunotherapy, the cytotoxic effect of IFN-a on malignant 
cells was recognised. In addition to direct cytotoxicity and inhibition of 
proliferation, IFN-a was also shown to have a potentiating effect on the anti-
tumour immune response, in particular for the generation of a durable 
adaptive response (110). IFN-a progressed to Phase III clinical trials as a 
monotherapy for MM but due to limited improvement in overall survival, as 
well as high frequency toxicities, interest in continued development subsided 
(111). Similarly, IFN-a was extensively studied in AML with many clinical 
trials completed. Although several studies indicated impressive anti-
leukaemia activity of IFN-a, there was large variability in the outcomes and 
an ideal treatment strategy was not identified before interest swayed to other 
immunotherapies (112). More recently, with a better understanding of anti-
tumour immune responses, IFN-a has regained interest in different contexts 
of AML treatment, for example in the elimination of MRD (113). 
 
1.3.3.2 Immunomodulatory imide drugs (IMiDs) 
Immunomodulatory drugs such as lenalidomide and pomalidomide are 
widely used as part of the standard treatment of MM today. These drugs are 
analogues of thalidomide, and cereblon has recently been identified as their 
main target (114). Although the exact mechanisms of action for these drugs 
are unclear, they have a range of immunostimulatory effects such as 
reduced secretion of TNF-a, IL-1β, IL-6, and IL-12, along with an increased 
IL-2 and IFN-g synthesis, improved T cell priming, enhanced antigen 
presentation by DCs, and boosted activity of both NK and NKT cells (115-
118). More recent research has also implied IMiDs as a potential treatment 
in AML (119). Early clinical trials using lenalidomide in AML achieved 
complete response rates of 16-30% (120, 121). 
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1.3.3.3 Hypomethylating agents 
As described above, hypomethylating agents such as azacytidine and 
decitabine are now part of the standard treatment in AML, in particular for 
elderly and unfit patients, and chemotherapy refractory AML (122). The main 
mechanism of action of hypomethylating agents is to induce 
hypomethylation of tumour suppressor gene promoters by inhibiting DNA 
methyltransferase, leading to a reactivation of their transcription in tumour 
cells. However, these agents also have several other effects, including 
modulation of the immune response. In particular, effects on the adaptive 
immune response have been demonstrated, including improved antigen 
expression, processing, and presentation, as well as improved T cell priming 
and effector functions (123). Hypomethylating agents also upregulate both 
the PD-1/PD-L1 and CTLA-4/CD80/86 axes and have therefore been 
suggested in combination treatments with immune checkpoint inhibitors in 
AML as described below (124). 
 
1.3.3.4 Immune checkpoint inhibitors 
The development of immune checkpoint inhibitors is another significant 
breakthrough in the treatment of cancer. As discussed above, immune 
checkpoints tightly control the immune response by regulating the balance 
between stimulatory and inhibitory signals in the T cell response. The two 
most widely studied immune checkpoints for cancer therapy are the co-
inhibitory T cell receptors PD-1 and cytotoxic T-lymphocyte-associated-
protein 4 (CTLA-4). The ligands of PD-1 (PD-L1, PD-L2) and CTLA-4 (CD80, 
CD86) are often overexpressed on tumour cells as an immune evasion 
strategy. Through the development of monoclonal antibodies, which target 
the inhibitory receptors and disrupt the suppressive effect of the tumour 
cells, the immune system can be re-stimulated to generate an anti-tumour 
immune response. With great success in solid malignancies, in particular 
melanoma, the use of checkpoint inhibitors is now also being trialled in HM 
(125). Successful results have been obtained for a range of lymphomas 
using anti-PD-1 treatment, in particular for Hodgkin’s lymphoma. In clinical 
trials, a response rate of up 87%, with 70% of patients showing a partial 
response, has been achieved (126). Despite this, the use of checkpoint 
inhibitors in MM has been disappointing with some clinical trials reporting a 
complete lack of response to anti-PD-1 monotherapy (127). These results  
led to other strategies being tested and more positive results were achieved 
when checkpoint inhibitors were used in combination with standard 
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therapies, in particular IMiDs (127). Encouragingly, anti-PD-1 treatment in 
combination with standard therapy is now being tested in several Phase III 
clinical trials of MM (128, 129). 
Various anti-PD-1 and anti-CTLA-4 antibodies have also been tested as 
monotherapies in AML and MDS with modest results. However, in different 
combination strategies, e.g. with hypomethylating agents and chemotherapy, 
more encouraging results have been achieved (125). As discussed, 
azacytidine treatment can increase the expression of both PD-1, PD-L1, and 
PD-L2 on tumour cells, including AML blasts. Several clinical trials 
evaluating anti-PD-1 antibodies in combination with hypomethylating agents 
are on-going and preliminary results are encouraging (130). As CTLA-4 
expression on CD8+ T cells in the TME is thought to induce resistance to 
anti-PD-1 treatment, and to utilise the distinct molecular mechanisms of 
action of PD-1 and CTLA-4 blockade, co-treatment with both checkpoint 
inhibitors is also currently being evaluated in AML (131). 
 
1.3.3.5 Monoclonal antibodies 
Monoclonal antibody (mAb) treatment is another immunotherapeutic 
treatment strategy that was first developed in HM, with anti-CD20 rituximab 
pioneering the field with its FDA approval for the treatment of chronic 
lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL). As 
opposed to monoclonal checkpoint inhibitor antibodies, these antibodies aim 
to target proteins specifically expressed on the surface of tumour cells and, 
via the Fc portion of the antibody, stimulate immune-mediated killing 
mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC), 
antibody-dependent phagocytosis, and complement-dependent cytotoxicity. 
mAbs can also block signalling pathways important for cancer progression 
by binding to selected receptor targets, and deliver conjugated 
chemotherapeutics directly to the cancer cell. The two main mAbs which 
have been developed in MM are daratumumab (anti-CD38) and elotuzumab 
(anti-SLAMF7) which were both approved for clinical use in 2015 and have 
contributed significantly to advance the treatment of MM (132). While 
daratumumab has shown good efficacy as a monotherapy, the effect of 
elotuzumab has been optimised in combination with lenalidomide and 
dexamethasone. Other possible MM targets for mAbs which are being tested 
in clinical trials include CD138, CD56, IL-6, and RANK ligand (133).  
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The mAb strategy has also been explored in AML with the main targets 
being CD33 and CD123. One anti-CD33 mAb, gemtuzumab ozogamicin, 
which is conjugated to the cytotoxic agent calicheamicin, was originally 
approved for the treatment of AML but was withdrawn due to toxicity issues 
and lack of efficacy. However, following continued research, gemtuzumab 
ozogamicin was recently re-approved for the treatment of newly diagnosed 
AML in combination with induction chemotherapy (134). Other strategies 
include conjugating CD33 to radioactive isotopes. Both treatment with 
radioactive actinium and bismuth conjugated to a CD33 mAb have shown 
encouraging results in clinical trials, with good specificity and safety (135). 
Furthermore, a second generation mAb binding to CD123 has recently been 
shown to induce potent NK cell-mediated ADCC of AML blasts in a 
preclinical study and was also proven well-tolerated in a Phase I clinical trial 
(136, 137). Interestingly, mAb therapy with rituximab has been shown to be 
potentiated in combination with oncolytic virotherapy (OVT) in preclinical 
studies of CLL, which indicates the potential for new combination therapy 
strategies in HM (138).  
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1.4 Oncolytic virotherapy (OVT) 
1.4.1 Background 
OVT is a type of biological immunotherapy which has gained increasing 
attention in recent years. Already in the late 1800s it was noted that viral 
infection sometimes coincided with tumour regression, in particular in 
leukaemia patients. At this time, knowledge about both oncology and 
virology was limited and the therapeutic potential of viruses was not realised. 
Apart from a brief resurgence in the 1950s and 60s, where several viruses 
were investigated clinically but abandoned due to efficacy and safety 
concerns, OVT had not gained significant attention again until the last 10-15 
years. With a greater understanding of both virology and molecular 
techniques, research into the possibility of exploiting the anti-tumour 
potential of oncolytic viruses (OV) has sky-rocketed (139). Today, OVs are 
defined as viruses which preferentially infect and kill malignant cells and/or 
engage the immune system to mount an anti-tumour immune response, 
while sparing healthy cells due to their inherent antiviral defences. OVs can 
be naturally occurring, attenuated, or genetically modified; the pioneering 
OVs first approved for clinical use were genetically engineered. The very first 
OV to gain approval was the genetically modified adenovirus H101, which 
was approved in China in 2005 (140). However, it was not until ten years 
later that another OV was approved for clinical use by the FDA. Talimogene 
laherparepvec (T-Vec) is a herpes simplex virus-1 (HSV-1) which has been 
modified to 1) delete the ICP34.5 gene, which limits neurovirulence and 
replication in normal cells, and 2) express granulocyte-macrophage colony-
stimulating factor (GM-CSF), which has an immunostimulatory effect (141, 
142). In addition to genetically modified viruses, several wild-type (WT) OV 
have a natural tropism for tumour cells and generally produce asymptomatic, 
or mild symptom infection in humans. These include e.g. reovirus, 
coxsackievirus A21 (CVA21), Newcastle disease virus (NDV), vesicular 
stomatitis virus (VSV), and parvovirus H1 (143-147). Moreover, naturally 
attenuated vaccine strains of viruses, such as the Edmonston strain of 
measles virus (MV), have also been shown to have OV efficacy (148).  
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1.4.2 Mechanisms of action 
It is now well established that OVs have several mechanisms of action, the 
two most well-defined; direct oncolysis and potentiation of anti-tumour 
immunity are described in detail below with an overview provided in Figure 
1-6. Other mechanisms which contribute to tumour eradication include 
disruption of tumour-associated vasculature, as well as modulation of the 
TME (149-151). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-6: Overview of the main mechanisms of action of OV. 
In normal cells (dark green), antiviral immune responses limit the replication of 
viruses following infection and thereby prevent lytic killing. However, tumour cells 
(orange) often have defective antiviral responses, rendering them susceptible to the 
effects of OV. OV can eradicate tumour cells through direct cytotoxicity (1) and 
induction of innate (2) and adaptive (3) anti-tumour immunity. Direct cytotoxicity is 
the lytic killing resulting from replication of the virus in a host cell, with subsequent 
spread of new viral progeny to surrounding tumour cells and amplification of the 
lytic effect. Infection of tumour cells can also lead to the release of both cytokines 
and TAA which initiate an anti-tumour immune response. Innate anti-tumour 
immunity can consist of both cytokine-mediated bystander killing and NK cell-
mediated cytotoxicity against tumour cells. Adaptive anti-tumour immunity is 
generated following the phagocytosis of TAA by antigen-presenting cells (APC) and 
presentation of TAA to either CD4+ or CD8+ T cells, ultimately resulting in the 
priming of tumour-specific cytotoxic CD8+ T cells. 
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1.4.2.1 Direct oncolysis 
The primary mechanism of action of OVs was initially thought to be direct 
lysis of tumour cells following replication, resulting in the release of progeny 
viruses spreading to surrounding cells and perpetuating the oncolytic effect. 
The preferential replication of OV in tumour cells is due to several cellular 
defects that arise during malignant transformation which can be exploited by 
the virus, either naturally or through genetic modification. 
1.4.2.1.1 Receptor-targeted viruses 
Many OVs take advantage of proteins which are overexpressed on the 
surface of tumour cells to mediate cell entry, making tumour cells more 
susceptible than the non-transformed parental cells. In some cases, these 
proteins are involved in adhesion and migration of tumour cells, such as 
intercellular adhesion molecule-1 (ICAM-1), decay-accelerating factor (DAF), 
and junctional adhesion molecule-A (JAM-A). Some OVs have a natural 
tropism for these proteins, e.g. CVA21 which utilises ICAM-1 and DAF for 
host cell entry (152). It is also possible to genetically engineer OVs to 
change their tropism and thereby improve their specificity. For example, 
adenovirus (serotype 5) has a natural tropism for the coxsackie- and 
adenovirus receptor (CAR), which has limited expression on tumour cells. 
Instead, it was engineered to preferentially use cell surface integrins or other 
adenoviral receptors with higher expression on tumour cells to improve its 
specificity (153, 154). 
1.4.2.1.2 Defects in antiviral responses 
1.4.2.1.2.1 Interferon response 
The interferon (IFN) response is the main cellular defence against viral 
infection. As described in Figure 1-7, several types of PRRs such as TLRs 
and retinoic acid-inducible gene-I (RIG-I) can detect pathogen-associated 
molecular patterns (PAMP) such as viral genomes in healthy cells. The 
respective signalling pathways of the different receptors converge on the 
production of type I IFN via activation of interferon inducible factor (IRF)-3 
and -7. The secretion of IFN renders the surrounding cells hostile to viral 
replication through activation of the JAK-STAT signalling pathway. This 
pathway ultimately leads to the increased expression of cell cycle regulators 
such as protein kinase R (PKR), which can stop cell division and thereby 
limit viral replication (Section 1.4.2.1.2.2) (155). Alongside this, many viruses 
have developed resistance mechanisms to overcome the effects of the IFN 
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response, such as the ICP0 protein in HSV-1, which can bind and block the 
effect of IRF3 (156). One of the original hypotheses to explain OV tumour 
specificity was based on the fact that tumour cells often have defective IFN 
responses and therefore an increased susceptibility to viral infection (Figure 
1-7). Tumour cells can down-regulate the expression of RIG-I, IRF3, and 
IRF7 which limits their ability to detect viral infection and initiate an IFN 
response. They can also have defects in the IFN signalling pathway, 
including down-regulation of both JAK, STAT, and PKR proteins, which 
reduces the protective effects of the IFN response (155). 
Some OVs, such as VSV and NDV, are naturally dependent on defective 
IFN responses for their replication (157, 158), but viruses can also be 
engineered to further exploit the inefficient IFN responses to enhance 
tumour specificity. One example of this would be deletion of the ICP0 gene 
from HSV-1, rendering the virus susceptible to IFN and unable to infect 
normal cells while tumour cells with defective IFN signalling pathways 
become ideal targets (159). Viruses have also been engineered to express 
IFN genes, such as the VSV-IFN-b, and thereby induce a virus hostile state 
in normal cells but not tumour cells with defective IFN pathways (160). 
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Figure 1-7: Overview of interferon responses in healthy and cancerous cells. 
Following detection of viral genomes in healthy cells (left panel), the transcription of 
type I IFNs is initiated via various signalling pathways converging on IRF3 and -7. 
Following binding of secreted IFN to the IFN receptor (IFNR), JAK-STAT signalling 
is initiated in healthy cells, resulting in PKR expression which renders the cell 
hostile to viral replication. In cancer cells (right panel), many antiviral defence 
proteins, including PRRs, IRF3 and -7, JAK, STAT, and PKR are down-regulated, 
leaving the cancer cell susceptible to viral infection. This provides an opportunity for 
specific targeting of cancer cells using OV, while sparing healthy cells. 
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1.4.2.1.2.2 Double-stranded RNA-dependent protein kinase 
PKR, which is induced by IFN signalling as described above, is a dsRNA-
dependent protein kinase which functions as a dsRNA detector and 
regulator of the cell cycle in the cytosol of healthy cells. When it detects 
dsRNA, it becomes activated and phosphorylates, thus inhibiting, the 
translation initiation factor, eIF2, a critical mediator of protein translation. 
Effectively, this also prevents the translation of viral transcripts and thereby 
the replication of viruses (161). Mutations activating the Ras pathway, 
common in many tumour types, prevents phosphorylation of PKR and 
results in a defective antiviral response, rendering tumour cells particularly 
susceptible to infection (162, 163). This is exploited naturally by viruses such 
as reovirus, or through genetic modification, such as ICP34.5 deletion in 
HSV-1, to prevent the ICP34.5 protein inhibition of PKR activity (163, 164). 
1.4.2.1.3 Pro-apoptotic targeting 
Another method for enhancing tumour specificity using genetic engineering 
is to exploit the apoptotic effect of viruses. Many tumour cells acquire 
mutations in tumour suppressor proteins, such as p53 and pRb, which 
regulate apoptosis and cell cycle arrest in normal cells, resulting in 
uncontrolled cell proliferation. Viruses can have a similar effect following 
infection of normal cells, suppressing the activity of p53 or pRb to delay 
apoptosis and allow viral replication using the host cell replication 
machinery. One example of this is adenovirus. The adenovirus E1A proteins 
can push the infected cell into the S phase of the cell cycle, which is 
beneficial for viral replication. However, this can lead to an accumulation of 
p53, which forces the cell into apoptosis before the viral life cycle has been 
completed. To prevent this, the adenovirus E1B proteins can mediate the 
degradation of p53, which allows cell replication to continue. This can be 
exploited to engineer OV with tumour cell specificity. Thus, the E1B-deleted 
ONYX-15 adenovirus is incapable of disrupting p53-dependent apoptosis, 
which prevents viral replication as the host cell dies. However, tumour cells 
with a dysfunctional p53 response would specifically support the continued 
replication of the E1B-deficient virus as cellular replication ensues with no 
induction of apoptosis, allowing the viral life cycle to be completed (165-
167). 
1.4.2.1.4 Transcriptional targeting 
It is also possible to use genetic engineering to generate viruses where 
essential viral genes are under the control of tumour-specific promoters, 
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thereby creating a virus that exclusively replicates in tumour cells. This 
method can only be used for DNA viruses, such as adenovirus and HSV. 
Tumour-specific promoters can be active in several cancer types (e.g. 
hTERT and survivin), generating a virus with wider specificity, while other 
promoters such as prostate-specific antigen (PSA) are specific for a single 
cancer type (168). Adenoviruses have been successfully engineered to be 
controlled by both hTERT and PSA promoters (169, 170), and more 
recently, this has also been combined with other genetic modifications to 
enhance their cytotoxic effects, such as virus-induced TRAIL secretion 
(171). 
 
1.4.2.2 OV-induced anti-tumour immune responses 
More recently, the importance of anti-tumour immunity for successful OV 
therapy has gained more recognition. The induction of anti-tumour immunity 
is thought to both have an immediate effect through innate anti-tumour 
immunity mechanisms and a more long-term protective effect through the 
generation of immunological memory and adaptive responses. Some of the 
initial studies pointing out the importance of the immune system for 
successful OVT were performed by Toda et al., demonstrating that HSV 
treatment was effective in an immunocompetent mouse while the effect was 
lost in athymic mice, pointing out the importance of T cells for an efficient 
response (172). Later, both NK cells and CD8+ T cells were also identified as 
critical mediators for successful VSV therapy (173).  
1.4.2.2.1 Innate anti-tumour immunity mechanisms 
As described in Figure 1-6, both cytokine secretion as part of an 
inflammatory response and NK cell activation are important mechanisms for 
the innate anti-tumour immune response induced by OV. Both immune cells, 
infected cells, and neighbouring cells can secrete pro-inflammatory 
cytokines in response to a viral infection. In addition, both PAMPs (viral 
particles) and danger-associated molecular pattern signals (DAMPs, host 
cell protein) are released by virally infected and dying tumour cells, which 
can stimulate activating receptors like TLRs and further propagate the 
inflammatory response (155). The generation of an inflammatory 
environment has several effects on tumour cells and the local 
microenvironment. For example, the immunosuppressive state of the 
microenvironment induced by the tumour can be reversed to activate 
immune recognition of transformed cells. Secreted cytokines have also 
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induced bystander killing of tumour cells through the toxic effect of the 
cytokines themselves on tumour cells (174, 175). Secretion of cytokines 
such as TNF-a, IFN-g, and IL-12 are also important for initiation of the 
adaptive immune response, as described below. 
The recruitment and activation of NK cells as a part of OV therapy is well-
described and NK cell-mediated killing is crucial for some viruses to have full 
effect (173). NK cells can be triggered to kill by OV in various ways. As 
discussed previously, one of the main NK cell signals for cellular 
abnormalities is the down-regulation of MHC Class I expression, resulting in 
reduced presentation of self-antigen (176). In an attempt to avoid adaptive 
immunity, OVs can decrease the expression of MHC Class I on the surface 
of infected tumour cells, thereby increasing their visibility to NK cells (177). 
Additionally, both malignant transformation and viral infection can increase 
the expression of activating NK cell ligands on the surface of tumour cells 
(178). Tumours also induce a local immunosuppressive environment which 
can inhibit NK cells, however, OVs have the potential to stimulate and 
activate NK cells directly or via cytokine secretion from alternative immune 
cells (138). In particular type I IFNs, which are widely secreted in response 
to viral infection, have immense effects on the NK cell response, including 
NK cell activation, potentiation of cytotoxicity, and induction of TRAIL 
expression. Both conventional DC, plasmacytoid DC (pDC), and monocytes 
are common sources of type I IFN for NK cells (179). The main mechanism 
of NK cell-mediated killing is a tightly regulated degranulation process 
resulting in the release of cytotoxic granules directed towards the target cell 
(Section 1.1.2.1). However, another way for NK cells to kill is to engage 
death receptors on target cells, via FasL or TRAIL expression on the NK cell 
surface. Death receptor signalling leads to the activation of the caspase 
cascade resulting in target cell apoptosis (180). 
1.4.2.2.2 Adaptive anti-tumour immunity mechanisms 
Figure 1-6 also illustrates how, in addition to PAMPs and DAMPs, both TAA 
and viral antigens are released during OV infection of tumour cells. The 
secretion of cytokines, as well as PAMPs and DAMPs, as part of the innate 
response can induce maturation of APCs. As described in Section 1.1.2.2.1, 
when TAA are phagocytosed by APCs, such as DCs, they can either be 
presented on MHC Class II to naïve CD4+ T cells, or cross-presented on 
MHC Class I to naïve CD8+ T cells to activate antigen-specific T cell 
responses. CD4+ T cells can provide help to CD8+ T cells in their 
differentiation into tumour-specific CTLs, or CD8+ T cells can be primed 
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directly following cross-presentation of antigen on DCs (155). Along with 
tumour-specific CTLs, immunological memory and a durable anti-tumour 
response are also generated as part of the adaptive response. Long-term 
protection against tumour recurrence has been demonstrated in several in 
vivo models using e.g. adenovirus, Maraba virus (MG-1), and VSV (181-
183). Importantly, the adaptive response is also able to mediate tumour 
regression at distant sites not directly exposed to virus (155).  
 
1.4.3 Clinical experience with oncolytic viruses 
A multitude of WT and genetically modified OVs are in clinical trials today, 
however, only T-Vec and adenovirus H101, for the treatment of melanoma 
and head and neck cancers, respectively, have been approved for clinical 
use. Initially, in line with the hypothesis that direct oncolysis was the most 
important mechanism of action, virus was administered intratumourally and 
was thus only considered for solid malignancies. However, following a 
number of disappointing trials with limited viral spread, i.v. delivery was 
employed despite the fear of rapidly inducing an antiviral immune response. 
Several OVs have now been administered i.v. in clinical trials and have been 
safe and well-tolerated (184, 185). Moreover, results have also indicated that 
it is possible to achieve therapeutic efficacy despite the onset of an antiviral 
response. As an example, reovirus was successfully recovered from tumour 
sites following i.v. administration, despite the presence of neutralizing 
antibodies (nAb) (186). 
Based on results from early clinical trials, as well as the surge in preclinical 
studies, many recent clinical studies have investigated combination 
regimens including OV. In particular combinations with checkpoint inhibitors, 
such as anti-PD-1 and anti-CTLA-4 antibodies, have been the focus of many 
studies and have generated promising results for example using T-Vec in 
combination with an anti-CTLA-4 and CVA21 in combination with anti-PD-1 
(187). 
It remains controversial whether a single, high dose of OV or repeated 
injections are required to generate an optimal OVT response. Both 
strategies have been tested, along with prime/boost regimens utilising a 
combination of two different viruses. In a Phase I trial of MV expressing the 
thyroidal sodium iodide symporter (NIS), one patient with relapsing drug-
refractory MM achieved a complete, durable response with regression of 
distant plasmacytomas following a single i.v. dose of MV (188). Although a 
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single-dose regimen would be preferable for patients, most trials are 
currently employing a repeat-dosing treatment schedule with an initial low 
dose to induce seroconversion, followed by repeated larger doses until 
tumour regression (187). Only with continued analysis of clinical trial results, 
with comparison of different dosing strategies, can the ideal treatment 
strategy for each OV be devised. Taken together, clinical trials have 
demonstrated that OVT is safe with limited off-target effects and adverse 
reactions and has displayed encouraging results in a variety of 
malignancies. 
 
1.4.4 Oncolytic viruses in the haematological malignancy setting 
Since the early observations that influenza and other viruses could induce 
regression of leukaemia, the progress in OV therapy for HM has been 
remarkably slow compared to solid malignancies. As discussed above, 
intratumoural injection, which by nature of the disease are impossible in 
many HM, were the gold standard administration route. Gradually, as i.v. 
administration has been proven feasible, more attention has been directed 
towards HM (184). Sporadic reports of successful OVT in chronic myeloid 
leukaemia (CML) and in lymphocytic malignancies such as CLL, NHL, and 
ALL exist, but none of these have progressed to clinical trials (138, 148, 189-
192). The studies examining OV for the treatment of MM and AML are 
detailed below (Table 1-4 and Table 1-5). In addition, most studies have 
focused on the direct oncolytic effect of OV in HM, with very few 
investigations of the potential for induction of anti-tumour immunity in this 
setting. HM are easily accessible through i.v. administration and in 
immediate proximity to immunological sites such as the blood stream, 
spleen, and lymph nodes. HM are under-investigated in the field of OVT, 
despite a requirement for novel treatments, in particular for elderly patients 
which are the most common patient groups in MM and AML. Therefore, the 
efficacy of OVT warrants further investigation in this context. 
  
 46 
1.4.4.1 Oncolytic virotherapy in multiple myeloma 
MM is the HM where most progress with OVT has been made and several 
Phase I clinical trials have been initiated, but only MV in combination with 
cyclophosphamide has progressed to Phase II trials so far. An overview of 
OV tested in MM is provided in Table 1-4. Reovirus, MV, and VSV have 
been evaluated in MM in clinical trials, while vaccinia virus (VV), myxoma 
virus, adenovirus, and CVA21 have shown promising results in preclinical 
studies (193). Only myxoma virus has been evaluated in the context of the 
immune system and was shown to initiate priming of tumour-specific CTLs in 
vivo (194). 
Table 1-4: Overview of oncolytic viruses investigated for the treatment of MM.  
Disease OV Results References 
Multiple 
Myeloma 
 
Reovirus One Phase I clinical trial completed. Phase I 
trials testing combination with standard 
chemotherapy initiated. Virus well tolerated 
following i.v. administration. 
 
(195) 
(193) 
VSV VSV-hIFN-β-NIS progressed to Phase I clinical 
trials (awaiting results). Efficient responses in 
immunocompetent mouse models. 
(196) 
(197) 
Measles virus One Phase I clinical trial completed. Virus well 
tolerated following i.v. administration. One 
complete response. Phase II trial of MV + 
cyclophosphamide initiated. 
 
(198) 
(199) 
Myxoma virus Rapid oncolysis in vivo independent of 
replication, priming of a CTL-mediated 
response. Immune cell activation and virus 
carriage in treated BM transplants. 
 
(194) 
(200) 
Vaccinia virus Vaccinia virus induced replicative cell death in 
myeloma cell lines. 
(201) 
CVA21 CVA21 induced replicative cell death in MM 
cell lines and purged patient BM biopsies of up 
to 98.7% of CD138+ plasma cells. 
 
(202) 
Adenovirus 
(AdV) 
Efficient oncolysis by Ad5, Ad6, Ad26, and 
Ad48. Enhanced efficacy with CD40L-
expressing AdV. 
(203) 
(204) 
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1.4.4.2 Oncolytic virotherapy in AML 
Only a handful of studies have evaluated OV for the treatment of AML to 
date. Various viruses have been tested in preclinical studies, including VSV, 
reovirus, HSV-1, myxoma virus, and adenovirus and an overview of these 
studies is presented in Table 1-5. Interestingly, NK cell-mediated killing has 
been shown to contribute to the treatment efficacy of VSV, reovirus, and 
HSV-1 in AML. Moreover, VSV can also induce priming of tumour-specific 
CTLs in AML (205). Disappointingly, only one virus so far, VSV-NIS 
expressing human IFN-b, has been taken forward to clinical trials in AML 
(Phase I). The outcomes from this trial have not yet been published. 
 
 
Table 1-5: Overview of oncolytic viruses investigated for the treatment of 
AML. 
  
Disease OV Results References 
Acute 
Myeloid 
Leukaemia 
 
VSV VSV-hIFN-β-NIS progressed to Phase I clinical 
trials (awaiting results). Dependence on NK 
cells and priming of CTLs in vivo, which was 
potentiated in combination with anti-PD-L1 ab. 
 
(196) 
(205) 
Reovirus Killing of both AML cell lines and tumour cells, 
enhancement of NK cell-mediated anti-tumour 
immunity. 
 
(206) 
HSV-1 Stimulation of NK cell-mediated cytotoxicity 
against AML cells using UV-inactivated HSV-1. 
(207) 
Myxoma 
virus 
Efficient killing of AML cell lines in vivo in the 
absence of replication in vitro. 
(208) 
 
Adenovirus 
(AdV) 
Direct cytotoxicity against AML cells using an 
Ad5/11 chimeric virus expressing IL-24. 
(209) 
Measles and 
mumps virus 
combination 
Enhanced efficacy compared to either virus 
alone. Significant toxicity in vivo and against 
primary AML blast cells, which was further 
enhanced in combination with cytarabine.  
 
(210) 
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1.4.5 Reovirus 
1.4.5.1 Background 
Respiratory enteric orphan virus (reovirus) is a member of the Reoviridae 
family which is divided into 12 genera based on genome segmentation. All 
reoviruses are non-enveloped, dsRNA viruses with two concentric 
icosahedral protein capsids approximately 85 nm in diameter (211).  The 
capsid protects the dsRNA genome which in the orthoreovirus genus 
comprises a total of 23.5 kbp in ten segments, termed either large (L), 
medium (M), or small (S) depending on their size, as described in Figure 1-8 
(211-213). The genome encodes 12 proteins with some of the most 
important being µ1 and s3 which are part of the outer capsid, s1 and l2 
which are important for attachment and engagement with the host cell entry 
receptor, and l3 and µ1 which form subunits of the RNA polymerase (Figure 
1-8) (211). Three serotypes of mammalian orthoreovirus have been 
identified; Type 1 Lang, Type 2 Jones, and Type 3 Abney and Dearing (214). 
Reovirus Type 2 Jones was first observed to replicate specifically in 
malignantly transformed, but not normal, cell lines by Hashiro et al. in 1977 
(147), but it is the WT reovirus Type 3 Dearing strain (T3D), manufactured 
as Reolysin®, which has now made significant progress as an OV 
therapeutic agent. Reoviruses are widespread in the environment and as 
suggested by its full name, it can cause a mild enteric or respiratory illness in 
young children, but is relatively non-pathogenic in adults (214). Reovirus can 
kill host cells both through lytic (necrotic, immune-stimulating) killing, 
induction of apoptosis in infected cells, and via non-apoptotic mechanisms, 
such as necroptosis (215-217). Apoptosis can be a result of both viral 
infection or a consequence of the IFN response. Reovirus can manipulate 
both extrinsic and intrinsic apoptosis pathways, with the mitochondrial 
pathway augmenting the effect of extrinsic death receptor signalling (218, 
219). Infection can lead to secretion of TRAIL with subsequent death 
receptor activation, as well as translocation of Smac/DIABLO to the cytosol 
for cleavage of the pro-apoptotic protein, Bid, to its active form as part of the 
intrinsic pathway (219, 220). Expression of the pro-apoptotic proteins Noxa 
and Puma are also induced during later stages of reovirus infection as a 
result of NF-kB pathway stimulation (221, 222). 
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Figure 1-8: Structure of the reovirus virion. 
Reoviruses are non-enveloped, dsRNA viruses with two icosahedral protein 
capsids. The capsid protects a core which harbours the 23.5 kbp genome. The ten 
genome segments (S1-4, M1-3, L1-3) encode 12 proteins which are required for the 
virus to propagate. The outer capsid is made up of µ1 and s3 proteins and s1 and 
l2 proteins facilitate attachment to the entry receptor. 
 
1.4.5.2 Tumour specificity 
Reovirus utilises JAM-A as its receptor for entering host cells (223). JAM-A 
is ubiquitously expressed throughout the body on endothelial and 
haematological cells, in particular progenitor cells and HSCs (224). JAM-A 
has several important roles in normal cellular processes such as tight 
junction formation, leukocyte migration, and angiogenesis. However, JAM-A 
can also be overexpressed in several types of cancers, including 
haematological malignancies such as NHL, CLL, AML, and MM (138, 206, 
225, 226). When hijacked during cancer transformation, processes like 
migration and angiogenesis are favourable for tumour progression and JAM-
A has been linked to a worse prognosis and reduced survival in several 
malignancies (227, 228). Following JAM-A engagement, the virus is 
internalised via receptor-mediated endocytosis, which is dependent on b1 
integrin (229). The outer capsid is degraded in the endosome by acid-
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dependent cathepsin proteases B and L and thus, both b1 integrin and 
cathepsin B and L expression are factors which can affect tumour cell 
susceptibility to reovirus (230, 231). Although JAM-A is important for host 
cell entry, gain-of-function mutations activating Ras signalling, ubiquitous in 
malignant cells (232), have also been implicated as a determining factor of 
the preferential replication of reovirus in cancer cells. Following successful 
cell entry via JAM-A, Ras transformation can promote three key steps in 
reovirus replication: uncoating of the virus capsid, generation of progeny with 
higher infectivity, and sensitising cells to the apoptosis-dependent release of 
virus progeny (233). These specific characteristics of reovirus contribute to 
its selective replication in malignant cells and its oncolytic activity has been 
demonstrated in a variety of malignancies in both pre-clinical and clinical 
trials (Table 1-6).  
 
1.4.5.3 Reovirus and the immune system 
Both innate and adaptive immunity play important roles for the immune 
response to reovirus. As with most viral infections, the secretion of type I IFN 
is a key component of the innate response to reovirus. IFNs can be secreted 
from both infected cells and from immune cells; both DCs and monocytes 
are important in the detection of reovirus and subsequent secretion of IFN-a 
(138, 234). As described above, viral dsRNA in the cytoplasm of infected 
cells is detected by PRRs such as RIG-I, melanoma differentiation-
associated protein 5 (MDA5), TLR3, and PKR (235, 236). Binding to PRRs 
triggers various signalling pathways, which all converge on transcription of 
type I IFNs. While IFN-a itself is important for NK cell activation in response 
to reovirus infection (138), a range of other pro-inflammatory cytokines are 
secreted in response to reovirus, which mediate the recruitment of both NK 
cells and DC (237, 238). DCs are thought to be one of the key mediators of 
innate immune cell recruitment during reovirus infection, and reovirus can 
stimulate DC maturation, causing an upregulation in maturation markers 
such as CD80, CD86, and MHC Class II. In addition to recruitment, cytokine 
secretion from DCs in response to reovirus can potentiate the cytotoxic 
function of NK cells (234). While NK cells are important for the anti-tumour 
effects of reovirus, they do not limit reovirus infection on their own (239). 
Neutrophils are also recruited as part of the innate immune response during 
reovirus infection in the respiratory tract (240). 
Reovirus replicates extensively in the respiratory tract of neonatal mice and 
in tissues of adult SCID mice (lacking T and B lymphocytes), but not in 
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immunocompetent adult mice, which indicates a role for the adaptive 
immune system in controlling reovirus infection (241-243). Accordingly, 
reovirus-specific CTLs with significant cytotoxicity against reovirus-infected 
target cells have been generated in vivo (244). The adaptive immune 
response also plays an important role in OV efficacy. Similar to NK cells, 
reovirus-treated DCs can activate T cells and induce antigen-independent 
cytolysis of target cells (234). Moreover, reovirus treatment of DC can 
enhance their ability to present TAA with subsequent priming of tumour-
specific CTLs (245, 246). Interestingly, it has been proposed that direct 
reovirus oncolysis might not be necessary to generate adaptive anti-tumour 
immunity, as tumour-specific CTLs were successfully generated using 
reovirus-resistant melanoma cells (247). 
The humoral arm of adaptive immunity also plays an important role in 
reovirus infection through the generation of nAb. Due to its widespread 
presence in the environment, the majority of the population have 
encountered reovirus and seropositivity between 50 and 100% has been 
reported (248, 249). While nAb have a positive effect in the immune 
protection against reovirus, they were previously thought to be detrimental to 
the reovirus activity with the high seropositivity in the general population 
being a concern for treatment efficacy. However, both DCs, T cells, and 
monocytes can act as protective cell carriers of reovirus with efficient hand-
off to tumour cells, despite pre-existing antiviral immunity (250-253). 
Interestingly, when mice were co-treated with reovirus and GM-CSF, the 
presence of nAb enhanced treatment efficacy (252).  
While the immune system has several elaborate ways of protecting the body 
against reovirus infection, the virus has also developed ways of protecting 
itself from immune-mediated eradication. For example, the outer capsid 
protein s3 can engage with dsRNA and interfere with the binding of PKR to 
dsRNA, thereby preventing the onset of an IFN response (254). Moreover, 
Stanifer et al. recently showed that one of the non-structural proteins 
encoded by reovirus, µNS, can sequester the IFN transcription factor IRF3, 
thereby preventing its translocation to the nucleus and the induction of an 
IFN response (255). 
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1.4.5.4 Reovirus clinical trials 
As discussed, Reolysin® is a promising candidate for OVT and it has made 
significant progress in clinical trials. Preference for malignantly transformed 
cells has been confirmed, and it has demonstrated high tolerability in 
patients with only low grade adverse effects in clinical trials (256-258). The 
majority of clinical trials have examined reovirus efficacy in solid 
malignancies, although early trials for MM have also been initiated (Table 
1-6). Most recently, the Myeloma UK eleven (MUK11/ViRel/NCT03015922) 
Phase Ib trial of i.v. administered reovirus in combination with lenalidomide 
or pomalidomide in refractory MM has been introduced (259). A treatment 
schedule overview is presented in Figure 3-1A. Both intratumoural and i.v. 
administration of reovirus have been examined in clinical trials of solid 
malignancies with successful results. Interestingly, i.v. administration of 
reovirus in a Phase I trial of heavily pre-treated patients with advanced 
cancers induced an increase in the populations of both CD4+ T cells, CD8+ T 
cells, and NK cells, as well as abundant cytokine production, indicating the 
onset of an anti-tumour immune response (260). Furthermore, in brain 
tumours, i.v. administration of reovirus led to a local IFN response with 
recruitment of CTLs and upregulation of PD-1/PD-L1 axis (261). As 
expected, i.v. administration has been shown to significantly increase nAb 
titres in clinical trials, but despite this, reovirus could be successfully 
recovered from tumour sites, such as the liver and from head and neck 
tumours (186, 262). 
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Table 1-6: Selected reovirus clinical trials. 
Disease Combinations Phase Trial ID Results 
Gliomas N/A I NCT00528684 No DLT, 1/12 patients 
remained disease free for 
>6 years (263). 
Pancreatic 
Cancer 
Carboplatin/ 
Paclitaxel 
II NCT01280058 No significant 
enhancement of PFS with 
reovirus vs drugs alone 
(4.9 vs 5.2 months) (264). 
Head and 
Neck 
Cancers 
Carboplatin/ 
Paclitaxel 
II NCT00753038 4/13 patients had PR, 
2/13 had stable disease 
for >12 weeks (265). 
Carboplatin/ 
Paclitaxel/ 
Placebo 
III NCT01166542 Not reported. 
Melanoma N/A II NCT00651157 Virus was well tolerated, 
viral replication was 
detected in 2/15 patients 
despite nAb, average 
PFS 45 days (266). 
Carboplatin/ 
Paclitaxel 
II NCT00984464 Virus well tolerated, ORR 
21%, no complete 
responses (267). 
Multiple 
Myeloma 
N/A I NCT01533194 No DLT reported, 
reovirus localization to 
BM, SD up to 8 months 
(195). 
Lenalidomide/ 
Pomalidomide 
I NCT03015922 
MUK11/ViRel 
Recruiting (259). 
Dexamethasone/ 
Carfilzomib 
I NCT02101944 Recruiting (268). 
Dexamethasone/ 
Bortezomib 
I  Evaluating (269). 
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Lung 
Cancer 
 
Carboplatin/ 
Paclitaxel 
 
 
II NCT00861627 11/37 partial responses, 
20/37 stable diseases, 
PFS 4 months (270). 
II NCT00998192 Treatment well tolerated, 
12/25 partial responses, 
10/25 stable diseases 
(271). 
Pemetrexed/ 
Docetaxel 
II NCT01708993 Virus was well tolerated, 
no enhancement of PFS 
with reovirus vs drugs 
alone (2.96 vs 2.83 
months) (272). 
Prostate 
Cancer 
Docetaxel and 
Prednisone 
II NCT01619813 Poorer overall survival in 
virus and drug 
combination arm, vs drug 
alone (273). 
Breast 
Cancer 
Paclitaxel II NCT01656538 Combination arm showed 
improved overall survival 
vs drug alone arm (17.4 
vs 10.4 months) (274). 
All trials included were completed at the time of publication of this thesis except the 
MM trials. DLT: dose-limiting toxicity, PFS: progression-free survival, PR: partial 
response, ORR: overall response rate, SD: stable disease. 
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1.4.6 Coxsackievirus A21 
1.4.6.1 Background 
Coxsackieviruses belong to the family of Picornaviridae, which are non-
enveloped, single-stranded (ss), positive-sense RNA viruses. The RNA core 
of the particle is surrounded by an icosahedral capsid approximately 28 nm 
in diameter, with a protein coat made up of 60 subunits (275). The prototype 
picornavirus genome consists of 7000-8000 nucleotides which encode a 
single polyprotein. As described in Figure 1-9, the polyprotein is cleaved into 
four structural proteins which make up the capsid subunits, as well as virally 
encoded proteases, and proteins involved in RNA replication and alteration 
of the host cell environment (275, 276). The picornavirus family comprises 
nine heterogenous genera and several well-known human pathogens such 
as hepatitis A virus, poliovirus, and the coxsackieviruses. The 
coxsackieviruses belong to the Enterovirus genus. Within this genus, a total 
of 29 serotypes of coxsackievirus have been identified. For extended 
classification, the coxsackieviruses were divided into two subgroups (CVA 
and CVB) based on their pathogenicity in mice (277). Eleven of the CVA 
serotypes, including coxsackievirus A21 (CVA21), belong to the species of 
human enterovirus C (HEV-C). Two prototype strains of CVA21 have been 
identified, Coe and Kuykendall, with Kuykendall being the strain that has 
been taken forwards as a therapeutic OV. All the CVA in the HEV-C species 
cause symptoms of the common cold following infection of adults (278). 
 
 
 
Figure 1-9: Picornavirus genome and polyprotein organisation. 
The picornavirus genome is made up of 7000-8000 nucleotides and a single open 
reading frame. Translation and proteolytic cleavage results in three main 
polyprotein products, P1-3. The P1 protein is the precursor for the four structural 
capsid proteins (VP1-4). The P2 and P3 polyproteins contain additional proteins 
required for genome replication and modification of the host cell environment. UTR: 
untranslated region. 
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1.4.6.2 Tumour specificity 
CAVATAK™ is a non-manipulated clinical-grade formulation of the CVA21 
Kuykendall strain. As discussed, both ICAM-1 and DAF are important for 
mediating host cell entry of CVA21. While DAF acts as the attachment 
receptor accumulating CVA21 on the cell surface, ICAM-1 is responsible for 
mediating cell entry (152, 278, 279). DAF alone can mediate cell entry of 
some clinical isolates of CVA21, but for the Kuykendall strain both receptors 
are required for successful infection and thus, ICAM-1 expression has been 
defined as the determining factor for tumour cell susceptibility to CVA21 
treatment (152, 279).  ICAM-1 is a glycoprotein, which belongs to the 
immunoglobulin family and has widespread functions around the body. As 
an adhesion molecule, the main function of ICAM-1 is to induce cell-cell 
adhesion and facilitate cell communication, e.g. in the regulation of leukocyte 
trafficking across epithelial barriers (280, 281). ICAM-1 is normally 
expressed on cells involved in immune protection such as leukocytes, 
epithelial cells, and endothelium, as well as on some haematopoietic cells, 
including myeloid blasts, monocytic cells, B lymphocytes, and plasma cells 
(281, 282). More important for the oncolytic effect of CVA21, an increased 
expression of ICAM-1 has been identified on a range of tumour cells 
including renal carcinoma (283), malignant melanoma (284), pancreatic 
cancer (285), and colorectal cancer (286). For the haematological 
malignancies, high ICAM-1 expression has been observed mainly in B cell 
malignancies, including MM, CLL, and NHL (202, 287). Furthermore, ICAM-
1 is involved in cancer metastasis with increased expression on metastatic 
disease being reported, which expands the applicability of CVA21 further 
(284, 288, 289). Other determinants of CVA21 susceptibility, such as factors 
affecting replication following host cell entry, have yet to be elucidated. 
 
1.4.6.3 CVA21 and the immune system 
Very few studies have focused on the specific immunobiology of CVA21 and 
the exact mechanism for detection of CVA21 by the immune system is not 
yet known. The interactions of CVB with the immune system have been 
more widely studied and can provide a generalised picture for all the 
coxsackieviruses. Coxsackieviruses can be detected by a variety of PRRs, 
such as MDA5 and TLR3, -7, and -8 (290-294). Recognition on either 
receptor triggers signalling pathways that induce the production of type I   
IFNs. Antibody-opsonised CVB3 is detected on TLR7 in the endosomes of 
pDC, which subsequently secrete large amounts of IFN-a (291). Several 
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other innate cell types, including NK cells and macrophages, have been 
shown to be essential for limiting replication of CVB (295, 296). Moreover, 
the complement system, with C3 opsonisation, has been implicated for the 
splenic antiviral response against CVB3 (297). As discussed below, 
antibodies against coxsackieviruses are generated soon after infection as 
part of the humoral immune response. In addition, it is widely accepted that 
CD4+ T cells play an important role in CVB protection, while the role of CD8+ 
T cells is more controversial (298, 299). Coxsackieviruses activate both 
CD4+ and CD8+ T cells, and CD8+ T cells can limit viral replication, however, 
efficient priming of CTLs specific for defined epitopes has not been 
documented (300). The ability of CVA21 to induce anti-tumour immunity has 
not previously been thoroughly described. However, in a study by Annels et 
al., CVA21 induced immunogenic apoptosis in bladder cancer cell lines, 
which resulted in successful tumour vaccination in vivo, which was 
confirmed to be dependent on CD4+ T cells (301). 
As discussed for reovirus, the coxsackieviruses are also widely present in 
the environment, resulting in widespread exposure of the general population 
with subsequent generation of nAb. In a study from 1959, the prevalence of 
serum antibodies to a virus identical to the Coe strain of CVA21 was 
examined in the British population, which revealed the presence of nAb in 
approximately 36.1% of males and 18.4% of females (302, 303). In a more 
recent small-scale study, pre-existing nAb against CVA21 was present in 
14.3% (3 of 21) of samples tested (304). Additionally, early clinical trials 
indicated that nAb might not develop in patients until Day 7 after i.v. infusion 
of CVA21 (305). The exact role of nAb for CVA21 treatment remains 
unknown, but similar to reovirus, monocytes can act as carriers of antibody-
neutralised CVA21 with successful delivery to melanoma cells, resulting in 
oncolytic killing (253). While it is likely that the immune response to CVA21 
is similar to those described for CVB, it is evident that documentation on 
CVA in general, and CVA21 in particular, needs to be expanded so that this 
virus can be optimally used in OVT. 
While the immune system has developed efficient strategies for protection 
against coxsackievirus infection, the viruses have also developed immune 
evasion strategies. For example, CVB3 specifically cleaves both MAVS and 
TRIF, which are downstream adaptor molecules in the signalling pathways 
of MDA-5 and TLRs, respectively, thereby interfering with the IFN antiviral 
response pathway (306, 307). Moreover, CVB3 can inhibit antigen 
presentation through interference with protein trafficking and downregulation 
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of MHC class I, resulting in evasion of CD8+ T cell immunity, which might 
also explain the ambiguous evidence regarding CD8+ T cell immune 
responses against CVB (308). No interference with MHC Class II has been 
documented, meaning that CD4+ T cell immunity may be unaffected. 
 
1.4.6.4 CVA21 clinical trials 
CVA21 is a more novel oncolytic agent than reovirus and has only been 
tested in Phase I and II clinical trials to date. As shown in Table 1-7, a range 
of solid malignancies have been included in the clinical trials, but no trials 
have yet been initiated for HM. CVA21 has made its greatest progress in 
melanoma where a Phase II trial for late stage melanoma was completed 
with 63 patients with stage IIIc or IV melanoma receiving 10 intratumoural 
injections of CAVATAK™ during 18 weeks. In addition, CVA21 is being 
tested extensively in combination with checkpoint inhibitors, mainly 
pembrolizumab, for both melanoma, bladder cancer, and lung cancer. Only 
one clinical trial (STORM/KEYNOTE-200/NCT02043665, Phase I) has 
investigated i.v. delivery of CVA21 (309). The first part of the study, using 
CVA21 as a monotherapy, has been completed and was extended with a 
second part using CVA21 and pembrolizumab in combination. A total of 27 
patients with various solid malignancies were recruited to the first part of this 
trial which employed a non-randomised, open-label, dose escalation study 
design. Patients were recruited in three cohorts receiving repeated doses of 
1x108, 3x108, or 1x109 TCID50 CAVATAKä, respectively. A treatment 
schedule overview is presented in Figure 3-1B. Although a recent addition to 
the OV family, CVA21 has proven safe and well-tolerated in clinical trials and 
was recently acquired by Merck & Co. for continued development.  
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Table 1-7: CVA21 clinical trials initiated to date 
 
Disease Combinations Phase Trial ID Results 
Melanoma Pembrolizumab I NCT02565992 
CAPRA 
Recruiting, 18/23 disease 
control rate (310). 
Ipilimumab I NCT02307149 
MITICI 
Recruiting, combination 
well-tolerated, 14/18 
disease control rate 
(311). 
I NCT03408587 
CLEVER 
Recruiting (312). 
N/A II NCT01227551 
CALM 
22/57 immune-related 
progression-free survival 
(313). 
I NCT02043665 
STORM 
KEYNOTE-200 
Virus was well-tolerated 
(305). 
Bladder 
Cancer 
Mitomycin C I NCT02316171 
CANON 
Virus was well-tolerated 
(314). 
Pembrolizumab I NCT02043665 
STORM Part 2 
Recruiting (315). 
Lung Cancer Pembrolizumab I NCT02824965 Recruiting (316). 
Pembrolizumab I NCT02824965 
STORM Part 2 
Recruiting (315). 
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1.5 Conclusions 
The immune system has a critical role in reducing the occurrence of cancer, 
as well as in elimination of already transformed cells. OVT can efficiently 
exploit the immune system to potentiate anti-tumour immune responses and 
thereby successfully eradicate tumours. However, HM are under-
investigated in the field of OVT, in particular with respect to anti-tumour 
immunity and in the search for better treatments, OVT needs further 
investigation in this setting. 
1.6 Project hypothesis and aims 
The efficacy of OV against HM remains largely underexplored compared to 
that of solid malignancies. In particular, the role of anti-tumour immunity 
remains unclear. This is reflected in the limited translation of OV in the 
haematological setting. In terms of reovirus, the cellular mechanisms by 
which reovirus activates immune cells have been defined, and a role for 
direct oncolysis and NK cell-mediated anti-tumour immunity has been 
reported against AML. However, in the context of MM, whilst the direct 
oncolytic effects of reovirus have been extensively studied,  the role for anti-
tumour immunity has not been established. In terms of CVA21, a role for 
direct oncolysis has been confirmed in MM, but not AML. Moreover, the 
importance of anti-tumour immunity for CVA21 treatment efficacy has not 
been defined in either MM or AML and remains to be elucidated also for 
solid malignancies. Additionally, the specific cellular mechanisms behind 
CVA21-induced immune cell activation remain largely unknown. 
Therefore, this study aimed to develop the understanding of how OV, 
specifically reovirus and CVA21, may regulate anti-tumour immunity and to 
do this, the following overlapping but complementary aims were devised: 
1. Characterise reovirus and CVA21 direct cytotoxicity and anti-tumour 
immune responses against human MM and confirm the role for anti-
tumour immunity in the context of BM stromal support. 
2. Explore reovirus treatment of MM in vivo, in particular characterise 
changes in immune cell populations, and their state of activation, in 
the spleen and BM following reovirus treatment. 
3. Evaluate the potential of CVA21 as a treatment for AML using both 
AML cell lines and a cohort of primary AML patient samples. 
4. Elucidate the cellular mechanisms behind CVA21-mediated anti-
tumour immunity.  
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Chapter 2  
Materials & Methods 
2.1 Cell culture 
2.1.1 Cell culture methods 
All cells were maintained in a humidified atmosphere with 5% CO2 at 37°C 
using a CO2 incubator with continuous UV decontamination (Sanyo). Cells 
were cultured in vented plastic tissue culture flasks and were harvested and 
washed using serological pipettes (both Corning Costar). Adherent cell lines 
were passaged near confluence by first washing cells with sterile phosphate-
buffered saline (PBS, prepared using Dulbecco’s A PBS tablets in dH2O 
[Oxoidä]), followed by addition of trypsin at 37°C (10x stock diluted 1:10 in 
Hanks’ Balanced Salt Solution (HBSS), both Sigma-Aldrich). Suspension cell 
lines were passaged following centrifugation and re-suspension in fresh 
culture medium. Cells were centrifuged at 400 xg for 5 min at room 
temperature (RT) using an Eppendorf 5810 centrifuge, unless otherwise 
stated. All cell culture was performed under aseptic conditions using Nuaire 
Class II Microbiological Safety Cabinets. Cells were counted using trypan 
blue (0.2% in PBS, Sigma-Aldrich) and an Improved Neubauer 
haemocytometer. All cell lines were routinely tested for mycoplasma 
contamination and were found free from infection.  
 
2.1.2 Cell lines 
An overview of all cells used and their respective culture medium is available 
in Table 2-1. All culture media were obtained from Sigma-Aldrich and 
supplemented with 10% foetal bovine serum (FBS, Gibcoâ) unless 
otherwise stated. Additional supplements were also obtained from Sigma-
Aldrich. An overview of culture media used for primary cells is available in 
Table 2-2. 
 
2.1.3 Cryopreservation 
In general, cell lines were harvested and resuspended in culture medium + 
10% dimethyl sulphoxide (DMSO, Sigma-Aldrich) for freezing. 5TGM1 cells 
were frozen in culture medium containing  20% FBS and 10% DMSO, PBMC 
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were frozen in 90% FBS and 10% DMSO. Cells were aliquoted in Nuncä 
Cryogenic tubes and frozen to -80°C overnight in a Mr. Frostyä freezing 
container (both ThermoFisher Scientific). Subsequently, cells were 
transferred to the vapour phase of liquid nitrogen for long-term storage. For 
recovery, cells were rapidly thawed in a 37°C water bath, washed in 10x 
excess fresh culture medium, and isolated by centrifugation before 
resuspension in fresh culture medium and transfer to tissue culture flasks. 
 
2.1.4 ICAM-1 transduction 
ICAM-1-expressing KG-1 cells were obtained following lentiviral transduction 
with a vector expressing human ICAM-1, green fluorescent protein (GFP), 
and puromycin resistance genes under a CMV promoter (GenTarget). KG-1 
cells were infected with 0.5 plaque-forming units (pfu)/cell of either an ICAM-
1-expressing or empty control vector for 24 hrs in RPMI-1640 with 20% FBS. 
Stably transduced cells were selected by addition of 2 µg/mL puromycin 
(Sigma-Aldrich) to the culture medium for up to 6 weeks. 
 
2.1.5 CellTrackerä staining 
Cell Trackerä Green CMFDA (CTG) and Cell Trackerä Violet BMQC (both 
Invitrogenä) were used. A 5 mM stock solution of Cell Trackerä fluorescent 
dye was prepared in DMSO. A 2.5 µM working dilution was prepared in pre-
warmed serum-free RPMI-1640 and cells were stained at 106/ml for 30 min 
at 37°C. Subsequently, cells were washed three times in complete RPMI-
1640 (at least three times staining volume/wash) before use in experiments. 
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Table 2-1: Cell lines and culture media 
 
 CELL LINE CELL TYPE SPECIES CULTURE MEDIUM 
 
 
AML 
KG-1 Macrophage (BM) Human Rosewell Park Memorial Institute-1640 medium 
containing 1% L-glutamine + 
10% (v/v) foetal bovine serum 
(Complete RPMI-1640). 
HL-60 Promyeloblast (PB) Human Complete RPMI-1640 
THP-1 Monocyte (PB) Human Complete RPMI-1640 
kasumi-1 Myeloblast (PB) Human Complete RPMI-1640 
ML-1 Myeloblast (PB) Human Complete RPMI-1640 
OCI-M2 Derived from 
erythroleukemia 
Human Iscove’s modified Dulbecco’s 
medium containing 1% L-
glutamine + 10% (v/v) FBS. 
 
 
Multiple 
myeloma 
H929 IgAk MM, (BM) Human Complete RPMI-1640 
U266B IgEl MM, (PB) Human Complete RPMI-1640 
JIM3 (PE) Human Complete RPMI-1640 
OPM2 IgGl MM, (PB) Human Complete RPMI-1640 
5TGM1 IgG2b MM, (BM) Murine Complete RPMI-1640, supplemented with 1mM sodium 
pyruvate and 100 mM non-
essential amino acids. 
BM: bone marrow, PB: peripheral blood, PE: pleural effusion 
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Table 2-1 continued: Cell lines and culture media 
 
 CELL LINE CELL TYPE SPECIES CULTURE MEDIUM 
Bone marrow 
stroma 
HS-5 Fibroblast Human Complete RPMI-1640 
HS-27 Epithelium Human Complete RPMI-1640 
 
 
Additional 
K562 Chronic myeloid 
leukaemia 
Human Complete RPMI-1640 
Daudi Burkitt lymphoma Human Complete RPMI-1640 
Raji Non-Hodgkin 
lymphoma 
Human Complete RPMI-1640 
Mel624 Melanoma Human Dulbecco’s modified Eagle’s medium containing 1% L-
glutamine and 4500 mg/L 
glucose + 10% (v/v) FBS 
(Complete DMEM). 
SK-Mel-28 Melanoma Human Complete DMEM 
L929 Fibroblast Murine Complete DMEM 
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Table 2-2: Primary cell culture media 
 
CELL TYPE CULTURE MEDIUM 
Monocytes (for iDC generation) Complete RPMI-1640 containing 1% L-
glutamine + 10% (v/v) FBS + 500 U/ml 
IL-4 + 800 U/ml GM-CSF 
CTL priming cultures RPMI-1640 containing 1% L-glutamine + 
7.5% human AB serum + 1 mM sodium 
pyruvate + 10 mM HEPES + 100 mM 
non-essential amino acids + 20 µM b-
mercaptoethanol + 30 U/mL IL-2 + 5 
ng/mL IL-7 
Peripheral blood mononuclear 
cells (PBMC) 
Complete RPMI-1640 
Primary AML blast cells Complete RPMI-1640 
Murine splenocytes DMEM + 5% FBS + 1% 
penicillin/streptomycin + 50µM b-
mercaptoethanol 
IL-4: BioLegend, GM-CSF: MBL International, IL-2: R&D Systems, b-mercaptoethanol: 
Sigma-Aldrich, IL-7: BioLegend, human AB serum: GemCellä, Seralabs, 
penicillin/streptomycin: Sigma-Aldrich. 
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2.1.6 Stromal cell co-cultures 
To investigate the effect of the bone marrow microenvironment on MM cells, 
MM cell lines H929, U266B, and JIM3 were co-cultured with BM stromal cell 
lines HS-5 and HS-27, respectively. An overview of the protocol is provided 
in Figure 2-1. HS-5 and HS-27 cells were seeded and allowed to attach 
overnight. The following day, MM cell lines were stained with CTG (Section 
2.1.5), then added to wells with stromal cells at a 1:1 cell ratio and 1:1 
medium ratio, i.e. direct addition of MM cells in an equal volume fresh 
medium to pre-conditioned stromal medium already in the wells. MM cells 
and stromal cells were co-cultured for 24 hrs before addition of viral 
treatments. When used as targets in NK cell and CTL killing assays, MM 
cells were co-cultured with stromal cells for 48 hrs before inclusion in killing 
assays. 
 
2.1.7 Cytokine treatments 
2.1.7.1 TNF-a for induction of ICAM-1 expression 
All cells were treated with human recombinant TNF-a (R&D Systems) for 24 
hrs before evaluation of ICAM-1 expression (Section 2.13.2) or subsequent 
viral treatment. Based on toxicity studies, the TNF-a doses for KG-1 and 
THP-1 cells were 10, 100, and 1000 U/mL (Low/Intermediate/High). For 
kasumi-1 cells, the corresponding doses were 1, 10, and 100 U/mL. 
 
2.1.7.2 Cytotoxicity of IFNs 
KG-1 and HL-60 cells were treated with human recombinant IFN-a 
(Peprotech) alone or in combination with human recombinant IFN-g (R&D 
Systems) for 96 hrs before evaluation of cell viability by flow cytometry 
(Section 2.13.1). Cells were either untreated or treated with Low (500 
pg/mL), Intermediate (2500 pg/mL), or High (5000 pg/mL) doses of IFN-a. 
For combination treatment, IFN-g doses of 500 (Low), 1500 (Interm.), and 
3000 (High) pg/mL were used, combining Low IFN-a with Low IFN-g etc. 
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Figure 2-1: Illustration of BM microenvironment co-culture protocol. 
A: On Day 1, stromal cells (HS-5 or HS-27) were seeded and allowed to adhere to 
the cell culture dish. On Day 2, MM cells were stained with Cell Tracker Green 
(CTG) and added to stromal cells at a 1:1 ratio. Any medium already in the culture 
wells (conditioned by the stromal cells) was diluted 1:1 with fresh medium on the 
addition of MM cells. B: Representative images of U266B cells cultured alone, or 
together with HS-5, or HS-27 stromal cells, respectively. Cells were co-cultured for 
24 hrs and images taken using an EVOS® FL Cell Imaging System (ThermoFisher 
Scientific). 
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2.2 Peripheral blood mononuclear cells (PBMC) 
2.2.1 Isolation of human PBMCs 
For all AML work, except T cell priming, peripheral blood was collected in 
K3EDTA-coated Vacuetteâ blood samples tubes (Greiner Bio-One) from 
healthy volunteers by peripheral vein phlebotomy after informed consent. 
For T cell priming experiments (AML+MM), and MM NK cell experiments, 
healthy donor blood was collected and processed in leukocyte apheresis 
cones by the National Health Service Blood and Transplant (NHSBT). 
PBMCs were isolated from donated blood using Lymphoprep™ (Fresenius-
Kabi) density gradient centrifugation. Blood from apheresis cones was 
diluted 1:5 in HBSS prior to layering on the Lymphoprepä medium at a 2:1 
ratio. Following centrifugation for 20 min at 800 xg without brake, PBMCs 
were harvested using a wide-tipped Pasteur pipette (Alpha Laboratories) 
and washed three times in 50 mL HBSS (1x 400 xg for 10 min, 2x 300xg for 
5 min). PBMCs were seeded at 2x106 cells/mL for all experiments and 
maintained in complete RPMI-1640 (Table 2-2). 
 
2.2.2 PBMC-conditioned cell culture medium (CM) 
To generate CM, PBMCs were seeded at 2x106 cells/mL and treated with 
0.1 or 1 pfu/cell of CVA21 or reovirus, or mock treated with PBS. After 48 hrs 
incubation, cells were removed by centrifugation at 400 xg for 5 min, and the 
culture medium supernatant was sterile filtered using a 0.2 μm syringe filter 
(Millex®, Merck Millipore) and stored at -20°C until use. For MM experiments, 
CM was UV irradiated as described below (Section 2.6.3) to inactivate OV. 
The toxicity of CM was evaluated using MTS assays as described in Section 
2.8. 
 
2.3 Primary AML patient samples 
Primary leukemic blast cells were obtained from the peripheral blood of 
patients diagnosed with AML under the care of St. James’s University 
Hospital, Leeds, UK (Table 5-1). The cohort included samples from both 
newly diagnosed and relapsed patients with a variety of AML subtypes and 
pre-AML diagnoses (MDS and RAEB). Samples collected both prior to, and 
during standard treatment were included. The PBMC fraction, including 
leukemic blasts, was isolated as previously described (Section 2.2.1), 
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seeded in complete RPMI-1640 and used in experiments immediately. 
Patient PBMCs were used at a density of 2x106 cells/mL in all experiments. 
Blast phenotype was determined by flow cytometry (Section 2.13.2) using 
FITC-conjugated anti-CD45, VioBlue-conjugated anti-CD34 and PE-Vio770-
conjugated CD117 antibodies. Details of antibodies used are provided in 
Table 2-3 along with the gating strategy in Figure 2-2. Written, informed 
consent was obtained from all patients in accordance with local institutional 
ethics review and approval, ethics number 06/Q1206/106. Patient-CM was 
obtained as previously described for CM (Section 2.2.2). 
 
 
Table 2-3: Flow cytometry antibodies for AML primary samples 
The following antibodies were used to identify blast cells in the PBMC fraction of 
peripheral blood. Additional markers detailed in Table 2-4 were included for 
immunophenotyping. 
 
Target 
molecule 
Fluorochrome Volume 
added 
Species 
of origin 
Clone Supplier 
CD45 FITC 2 µL Mouse 5B1 Miltenyi Biotec 
CD34 VioBlue 2 µL Mouse AC136 Miltenyi Biotec 
CD117 PE-Vio770 2 µL Mouse A3C6E2 Miltenyi Biotec 
PE: phycoerythrin, FITC: fluorescein isothiocyanate. 
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Figure 2-2: AML primary samples gating strategy for blast cell identification. 
The phenotype of blast cells in primary AML patent samples was determined by 
flow cytometry using FITC-conjugated anti-CD45, VioBlue-conjugated anti-CD34 
and PE-Vio770-conjugated CD117 antibodies. The bottom panels show samples 
from two individual AML patients. Blast cells were identified as CD45- and either 
CD34+CD117+ (left panel) or CD34-CD117+ (right panel) depending on the individual 
diagnosis. Flow cytometry analysis was performed using Attuneä software (Section 
2.13). 
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2.4 STORM clinical trial patient samples 
Peripheral blood samples were obtained from patients taking part in the 
STORM Phase 1 clinical trial (NCT02043665/Keynote-200/VLA009A). 
Written, informed consent was obtained from all patients in accordance with 
local institutional ethics review and approval, ethics number 06/Q1206/106.  
Five patients were included in this study and received an i.v. infusion of 
1x108 or 1x109 TCID50 clinical grade CVA21 (Table 3-1) on Day 1, 3 and 5. 
Peripheral blood samples were taken prior to infusion, then 1 hr, 3 days and 
21 days post first infusion (Figure 3-1B). Whole blood samples were treated 
with BD Pharm Lyseä buffer (BD Biosciences) according to the 
manufacturer’s instructions to lyse red blood cells before phenotypic analysis 
of NK cells, CD4+ T cells, and CD8+ T cells using flow cytometry. Relevant 
antibodies are detailed in Table 2-4. 
 
2.5 Myeloma UK Eleven (MUK11) clinical trial patient samples 
Peripheral blood samples were obtained from patients taking part in the 
MUK11 Phase 1b clinical trial (NCT03015922/ViRel). Written, informed 
consent was obtained from all patients in accordance with local institutional 
ethics review and approval, ethics number 16/YH/0388. Only one patient 
was included in this study and peripheral blood samples were taken 
immediately prior to reovirus infusion (1010 TCID50), then at 24 hrs, 72 hrs, 
and seven days post infusion. Blood samples were processed as described 
in Section 2.2.1 to obtain PBMCs and then the activation of NK cells, CD4+ T 
cells, and CD8+ T cells was measured by flow cytometry (Section 2.13.2 and 
Table 2-4). 
 
2.6 Oncolytic viruses 
WT coxsackievirus A21, Kuykendall strain (CVA21, CAVATAK™), was 
provided by Viralytics Ltd. or propagated in-house (Section 2.6.2) from WT 
CVA21 Kuykendall strain V-024-001-012 obtained from ATCCâ (ATCCâVR-
850ä). Respiratory enteric orphan virus (reovirus) Type 3 Dearing strain 
(ReolysinÒ) was provided by Oncolytics Biotech Inc. Both virus stocks were 
stored long term at -80°C. CVA21 was used immediately after removal from 
-80°C, whilst reovirus was stored at 4°C for up to two weeks. 
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2.6.1 In vitro virus treatment of cells 
MM and AML cell lines were treated at a density of 5x105 cells/mL, healthy 
donor PBMCs and AML patient samples were treated at a density of 2x106 
cells/mL. For stromal cell co-cultures, the viral dose was adjusted for the 
total number of cells (stroma and MM cells). Both reovirus and CVA21 were 
diluted in PBS and added to cells at various concentrations. For reovirus, the 
following doses were used: 0, 0.01, 0.1, 1, and 10 pfu/cell. For CVA21, the 
following doses were used: 0, 0.01, 0.1, and 1 pfu/cell. Cells and 
supernatants were harvested at various time points post treatment for 
determination of cell viability (Section 2.13.1), cytokine/chemokine 
production (Section 2.12), and generation of CM (Section 2.2.2).  
 
2.6.2 CVA21 propagation 
CVA21 was propagated using Mel624 cells. Following CVA21 infection for 
24 hrs (0.001 pfu/cell), all supernatants were harvested, filtered (65 µm), and 
transferred to Thinwall polypropylene tubes (Beckman Coulter). CVA21 in 
the supernatant was pelleted by centrifugation at 36 000 rpm for 2 hrs at 4°C 
(SW45 rotor, Optimaä L-80 ultra centrifuge, Beckman Coulter). Virus was 
harvested and then purified using OptiPrepä (Sigma-Aldrich) density 
gradient centrifugation. The OptiPrepä gradients were prepared in advance 
using two different solutions; Solution 1: 0.3 M Tris and 0.3 mM EDTA in 
dH2O, pH 7.4, Solution 2: 0.1 M NaCl, 50 mM Tris, and 0.5 mM EDTA in 
dH2O, pH 7.4. 5 mL of Solution 1 was added to 20 mL 60% OptiPrepä 
medium, which was then diluted in Solution 2 to obtain the following 
concentrations: 
 
• 15%: 3 mL diluted Optiprepä + 7 mL Solution 2 
• 23%: 4 mL diluted Optiprepä + 6 mL Solution 2 
• 28%: 6 mL diluted Optiprepä + 4 mL Solution 2 
• 35%: 7 mL diluted Optiprepä + 3 mL Solution 2 
 
Starting with the 35% Optiprepä, 2.5 mL of each concentration was gently 
layered in two Thinwall Ultra-Clearä open-top tubes (Beckman Coulter). 
Gradient tubes were stored at 4°C overnight prior to use. The harvested 
virus pellet was equally distributed across both gradient tubes and 
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centrifuged at 36 000 rpm for 1.5 hrs at 4°C using an SW41 Ti rotor. Approx. 
1 mL of virus-containing solution was harvested, aliquoted, and stored at -
80°C until use. Viral titre was determined by plaque assay in Mel624 cells 
(Section 2.7.2). 
 
2.6.3 Ultraviolet (UV) irradiation of virus and CM 
To render viral particles replication incompetent, virus stocks were treated 
with UV irradiation using a C-1000 UV Crosslinker (UVP). Reovirus stock 
was UV treated for 2 min (1200 µJ/cm2) in 100 µL aliquots in an open 48-
well plate. CVA21 in PBS was UV treated for 3 min in 100 µL aliquots in an 
open 48-well plate. CM generated using reovirus was UV treated for 2 min in 
2 mL aliquots in an open 6-well plate before addition to susceptible cells. UV 
inactivation times of up to 10 min were used for CM generated using CVA21. 
 
2.7 Quantification of virus titre 
2.7.1 CVA21 TCID50 assay 
CVA21 replication was determined using a TCID50 assay with SK-Mel-28 
cells. Samples were prepared by harvesting both cells and supernatants, 
followed by lysis of the cells using three rounds of freezing in methanol 
chilled by solid CO2 (dry ice) and thawing in a 37°C water bath. 6x103 SK-
Mel-28 cells in 100 µL complete DMEM were seeded per well in a flat-
bottom 96-well plate and allowed to adhere overnight. An additional 100 µL 
complete DMEM was then added to each well and all samples were diluted 
1:10 in complete DMEM before addition in eight replicates to the first column 
of a plate. Subsequent 10-fold serial dilutions were made across the plate to 
10-10 using a multi-channel pipette, and cells were incubated for five days. 
Viral cytopathic effect (CPE) was assessed following methylene blue 
staining; the culture medium was removed and all wells were washed once 
in PBS before fixation of remaining cells in 1% paraformaldehyde (PFA) in 
PBS for 10 min at RT. After removal of the PFA, 30 µL/well of methylene 
blue (1% methylene blue hydrate [Sigma-Aldrich] in 35% EtOH) was added 
for 5 min, then plates were rinsed in tap water and air dried. The number of 
methylene blue negative wells per dilution was counted and the TCID50/mL 
was calculated using the Spearman-Kärber method and the following 
formula (317): 
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Where L = log10 of the lowest dilution with CPE, d = log difference of dilution 
(i.e. 1 for 10-fold dilutions), s = sum of the ratios of CPE/no CPE per dilution. 
 
2.7.2 Plaque assay 
Plaque assays were used to determine stock titres of both CVA21 and 
reovirus, and to determine reovirus replication. Mel624 cells (9x105/well in a 
6-well plate) were used for the CVA21 plaque assay and L929 cells 
(5x105/well in a 6-well plate) were used for reovirus. Cells were seeded on 
Day 1 and allowed to adhere overnight. On Day 2, 10-fold serial dilutions of 
virus samples were prepared in serum-free DMEM. Culture medium in all 
wells was removed and replaced by 500 µL/well serum-free DMEM and 100 
µL/well of each virus dilution to be tested (usually 10-2 to 10-10 dilution 
range). CVA21 plates were incubated for 2 hrs, then serum-free DMEM was 
removed and replaced by 2 mL 1:1 2x DMEM (20% FBS) and 3% 
carboxymethyl cellulose in dH2O (CMC, Sigma-Aldrich). For reovirus, plates 
with virus dilutions were incubated for 2.5 hrs and serum-free DMEM was 
replaced by 2 mL 2:1 1x DMEM (10% FBS) and 1.6% CMC. All plates were 
incubated for a further 72 hrs. Then, methylene blue staining was performed 
as described above (Section 2.7.1). 2 mL PBS/well was used to rinse off 
excess CMC, then 0.5 mL PFA/well was used for fixation and 0.5 mL 
methylene blue/well was used for staining. Finally, the number of plaques 
were counted to determine the pfu/mL titre using the following formula: 
 9:; ,!⁄ = 	<".		":	9=>?;@AB	C	D  
Where d = the dilution where plaques were counted, and V = the volume of 
diluted virus added (i.e. 0.1 mL here). 
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2.8 MTS assay 
MTS assays were performed to evaluate cell viability in CM monocultures 
and the toxicity of UV treated reovirus. 5x104 cells were seeded in 50 µL 
fresh RPMI-1640 (complete)/well in a flat-bottom 96-well plate. For CM 
experiments, 50 µL CM was added per well in triplicate (1:1 dilution in fresh 
medium). For UV-reovirus experiments, UV treated reovirus was added in 50 
µL/well RPMI-1640 (complete) to final doses of 0.1 or 1 pfu/cell doses, 50 µL 
complete RPMI-1640 was used as a negative control. Plates were incubated 
for 96 hrs, then 20 µL MTS reagent (tetrazolium dye, Abcam) was added to 
each well followed by 2.5 hrs incubation at 37°C. The optical density of the 
converted formazan product was measured at 450 nm using a Multiscan EX 
microplate reader (ThermoFisher Scientific).  
2.9 Type I IFN neutralization assay  
PBMCs were obtained from healthy donors as previously described (Section 
2.2.1). Prior to CVA21 treatment, PBMCs were either treated with a type I 
IFN blocking antibody mix (1.5% sheep polyclonal anti-human IFN-a, 1.5% 
sheep polyclonal anti-human IFN-b, and 3% mouse monoclonal anti-human 
IFN-α/β receptor chain 2, all antibodies from PBL Assay Science), isotype 
control antibody mix (3% sheep-serum and 3% anti-mouse IgG2a isotype 
antibody, Sigma-Aldrich and R&D systems, respectively), or left untreated 
for 30 min at 37°C. Subsequently, the PBMCs were exposed to 0 or 1 
pfu/cell CVA21 for 24 hrs before evaluation of NK cell activation and 
degranulation (Sections 2.13.2 and 2.13.3) with and without IFN 
neutralization.  
2.10 ICAM-1 neutralization assay 
PBMCs were obtained from healthy donors as previously described (Section 
2.2.1). Prior to CVA21 treatment, PBMCs were either treated with 10 µg/mL 
LEAFä purified anti-human ICAM-1-blocking antibody, a mouse IgG1k 
isotype control antibody (both BioLegend), or left untreated for 30 min at 
37°C. Subsequently, the PBMCs were exposed to 0, 0.1, or 1 pfu/cell 
CVA21 for 24 hrs, before evaluation of NK cell activation (Section 2.13.2) 
with and without ICAM-1 neutralization and collection of culture supernatants 
for ELISA (Section 2.12.1). 
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2.11 Magnetic cell sorting 
2.11.1 CD14+ cells 
CD14+ monocytes were isolated or depleted from whole PBMCs using 
magnetic cell sorting with MACSâ columns and MidiMACSä separator 
magnets (Miltenyi Biotec), according to the manufacturer’s instructions. 
Whole PBMCs were labelled with 2 µL/106 cells MACSâ CD14 MicroBeads 
(Miltenyi Biotec) in 3 mL MACS buffer (PBS + 1% FBS, 2mM EDTA)  for 15 
min at 4°C. Then, cells were washed in MACS buffer at 4°C, resuspended in 
3 mL MACS buffer, and added to MACSâ columns for selection. PBMCs 
depleted of CD14+ cells were collected following 3x washes of the column 
with MACS buffer. CD14+ cells were collected by releasing the column from 
the magnet and flushing with 5 mL MACS buffer. Purity of depleted PBMC 
was evaluated by flow cytometry and was consistently >95% (data not 
shown). 
 
2.11.2 pDC 
pDC were isolated or depleted from whole PBMC using the pDC Isolation Kit 
II, MACSâ columns, and MidiMACSä separator magnets (Miltenyi Biotec) 
according to the manufacturer’s instructions. Whole PBMCs were 
resuspended in 0.5 mL MACS buffer (Section 2.11.1) and labelled with 100 
µL/108 cells Non-pDC Biotin-Antibody Cocktail for 10 min at 4°C. After a 
wash in MACS buffer, cells were resuspended in 1 mL MACS buffer and 
labelled with 100 µL/108 cells Non-pDC Microbead Cocktail for 15 min at 
4°C. Cells were then washed in MACS buffer at 4°C, resuspended in MACS 
buffer, and added to MACSâ columns for selection. Lin-, BDCA-2+, BDCA-4+, 
CD123+, CD4+, CD45RA+, BDCA-3dim, BDCA-1-, CD2- pDC were collected 
following 3x washes of the column with MACS buffer. PBMCs depleted of 
pDC were collected by releasing the column from the magnet and flushing 
with 5 mL MACS buffer. Purity of depleted PBMC was evaluated by flow 
cytometry and was consistently >95% (data not shown). 
 
2.11.3 Double depletion 
To obtain double-depleted PBMCs (without CD14+ cells and pDC), PBMCs 
were first depleted of CD14+ cells according to the protocol above (Section 
2.11.1), followed by a pDC depletion (Section 2.11.2). 
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2.12 Cytokine detection 
2.12.1 Enzyme-linked immunosorbent assay (ELISA)  
Flat-bottomed 96-well plates (Nunc MaxisorpÒ) were coated with capture 
antibodies diluted in coating buffer (100 nM NaHCO3 in dH2O) or PBS as 
indicated in the Appendix (p. 308). Plates were then wrapped in cling film 
and incubated at 4˚C overnight. Antibody-coated plates were washed three 
times with PBS-T (0.05% TWEENÒ 20 [Sigma-Aldrich] in PBS) using a 
SkanWasher 300 (Molecular Devices). 200 µL/well blocking solution (PBS-T 
+ 10% FBS) was added for 2 hrs at RT. The plates were washed a further 
three times with PBS-T before 100 µL of recombinant protein standards 
(Appendix p. 309) and sample supernatants were added in triplicate. Protein 
standards were serially diluted (2-fold) seven times and a blank control with 
culture medium only was included. Plates loaded with samples were 
wrapped in cling film and incubated at 4˚C overnight. Next, plates were 
washed six times with PBS-T and diluted biotinylated detection antibodies 
were added (dilution in blocking buffer according to the table in the Appendix 
p. 308) and plates were incubated for 2 hrs at RT. Following incubation, 
plates were washed six times with PBS-T and 100 µL of ExtrAvidinâ-alkaline 
phosphatase conjugate (Sigma-Aldrich), diluted 1:5000 in PBS-T, was 
added to each well for 1 hr at RT. Plates were then washed three times with 
PBS-T, followed by three times with dH2O. 100 μL of substrate solution (1 
mg/mL p-nitrophenyl phosphate) in 0.2 M TRIS buffer (both Sigma-Aldrich) 
was added per well and plates were placed in the dark to develop for 10-20 
mins. The optical density was determined using a Multiskan EX plate reader 
(ThermoFisher Scientific) at a wavelength of 405 nm. 
 
2.12.2 Magnetic bead-based multiplex immunoassay (Luminex) 
Supernatants from CVA21-treated healthy donor PBMCs were collected 48 
hrs post infection. The levels of 48 cytokines and chemokines were 
assessed using two Luminex plates (Bio-Plex Proä Human Cytokine 27-plex 
and 23-plex Assay, Bio-Rad Laboratories) over consecutive days, as per the 
manufacturer’s instructions. Briefly, the assay plate was first coated with the 
antibody-conjugated magnetic beads and washed twice with the supplied 
wash buffer (100 µL/well) using the hand-held magnetic washer 
accompanying the kit. A standard dilution series for an eight-point curve with 
a three-fold dilution between each point was prepared using the supplied 
standard control. Then, 50 µL/well of each standard and sample was added 
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to the assay plate in duplicate. The plate was incubated on a plate shaker 
(850 rpm) for 1 hr at RT in the dark. Following incubation, the plate was 
washed three times with 100 µL/well washing buffer before addition of 25 µL 
detection antibody. Plates were incubated with the detection antibody on a 
shaker (850 rpm) for 30 min at RT in the dark. After antibody incubation, the 
plate was washed three times in wash buffer (100 µL/well) and 50 µL/well 
Streptavidin-phycoerythrin (SA-PE) was added, followed by incubation on a 
plate shaker for 10 min at RT in the dark. Following three washes with wash 
buffer, the beads were resuspended in 125 µL assay buffer per well before 
analysis on a Bio-Plex 100 plate reader with Bio-Plex Managerä software 
(Bio-Rad Laboratories). 
 
2.13  Flow cytometry analysis 
All flow cytometry was performed on a 2-laser Attuneä Acoustic Focusing 
Cytometer (Applied Biosystems®) or on a 4-laser CytoFLEX S (Beckman 
Coulter). For analysis, Attuneä software and CytExpert software were used, 
respectively. Details of all antibodies used are provided in Table 2-3, Table 
2-4, and Table 2-5. 
 
2.13.1 Cell viability assay using a Live/Deadâ discrimination staining 
kit 
Cell viability was evaluated using a LIVE/DEAD® Fixable Yellow Dead Cell 
Stain Kit (Invitrogenä). Samples were harvested into 5 mL round-bottom 
FACS tubes (BD Falconä) and washed in 1 mL PBS by centrifugation at 400 
xg. Each sample was stained in 500 µL staining mix (LIVE/DEAD dye diluted 
1:1000 in PBS) for 30 min at 4°C in the dark. Next, samples were washed 
with 2 mL PBS and then fixed with 300 µL 1% PFA in PBS, or the 
LIVE/DEAD® stain was combined with further antibody labelling for 
phenotyping before fixation.  
 
2.13.2 Cell phenotyping by flow cytometry 
For flow cytometry analysis, 5x105-106 cells were harvested into FACS tubes 
and washed in 1 mL FACS buffer (PBS, 1% FBS, 0.1% sodium azide). The 
cell pellet was resuspended in the residual volume and fluorescently 
conjugated antibodies relevant to each assay were added according to 
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Table 2-4. Samples were incubated for 30 mins at 4˚C in the dark and then 
washed with 2 mL FACS buffer. Following fixation in 300 µL 1% PFA in PBS, 
cells were stored at 4˚C until data acquisition. 
For immunophenotyping of murine cells in Chapter 4, Experiments 1-3 
(Table 4-2) were analysed using the Attuneä flow cytometer as described 
above.  For Experiments 4 and 5, samples were stained and acquired in a 
96-well plate using the CytoFLEX S flow cytometer (Beckman Coulter). 106 
cells were added per well, and each well was washed in 200 µL FACS 
buffer. Antibody master mixes were prepared and added to appropriate wells 
according to Table 2-5. Following incubation for 30 mins at 4˚C in the dark, 
wells were topped up with 100 µL FACS buffer, centrifuged for 5 min at 400 
xg, then washed in an additional 200 µL FACS buffer. Cells were fixed in 
100 µL/well 1% PFA in PBS and acquired in a total volume of 250 µL/well. 
 
2.13.3 NK cell and CTL degranulation assay 
Lymphocyte degranulation was determined by cell surface expression of 
CD107a/b. Effector lymphocytes were incubated alone or with target tumour 
cells at a 2:1 ratio as indicated for each experiment. Cells were added to 
FACS tubes in a total volume of 400 µL complete RPMI-1640 and were then 
incubated at 37˚C. After 1 h, antibodies against CD107a, CD107b, and 
either CD3/CD8 (CTL population) or CD3/CD56 (NK cells) were added to 
each tube (Table 2-4), along with 10 µg/mL Brefeldin A (BioLegend). 
Samples were then incubated for a further 4 hrs at 37˚C, washed with 2 mL 
FACS buffer, fixed in 300 µL 1% PFA and stored at 4ºC until acquisition. For 
NK cell degranulation assays with AML primary samples and autologous 
blasts, AML blasts were stained with CTV as described in Section 2.1.5 
before inclusion in the degranulation assay. 
 
2.13.4 Intracellular IFN-g staining 
Primed PBMCs were co-cultured with tumour target cells or peptide-loaded 
CD14+ cells (Section 2.14.2.2) and treated as described for the CD107 
degranulation assay (Section 2.13.3), without the addition of CD107 
antibodies. Following fixation in 1% PFA in PBS overnight, the cells were 
washed in 2 mL FACS buffer, then permeabilised in 1 mL 0.3% saponin 
(Sigma-Aldrich) in FACS buffer for 15 min at RT. Samples were washed in 2 
mL FACS buffer and a FITC-conjugated IFN-γ antibody (Table 2-4) was 
added at a 1:20 dilution in 0.1% saponin (in FACS buffer) for 30 min at 4°C. 
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Finally, cells were washed in 1 mL 0.1% saponin and resuspended in 300 µL 
FACS buffer for immediate acquisition and analysis using the Attuneä flow 
cytometer. 
 
2.13.5 Flow cytometry-based killing assay 
Flow cytometry-based killing assays were performed in 96-well round-bottom 
cell culture plates using the CytoFLEX flow cytometer to examine the ability 
of primed CTLs to kill target cells, in particular those pre-cultured on BM 
stromal cells. Target cells were either stained with CTG (Section 2.1.5) 
immediately prior to the assay, or for target cells pre-cultured with BM 
stromal cells, CTG staining took place prior to seeding on BM stroma 
(Section 2.1.6). Cells were cultured on BM stroma for 48 hrs prior to the 
assay and following harvest, cells were washed once in PBS + 2.5 mM 
EDTA to disrupt any remaining tumour cell binding to BM stromal cells. 
Primed CTL effector cells were harvested and added to each well together 
with CTG-labelled target cells at a 25:1 ratio in a total volume of 250 µL 
complete RPMI-1640 (2.5x104 target cells in total). Cells were co-cultured for 
5 hrs at 37°C, then cells were pelleted by centrifugation at 400 xg for 5 min 
and the supernatants were discarded. Following a wash in 250 µL/well PBS, 
cells were stained with the yellow Live/Deadâ discrimination staining kit 
(Section 2.13.1). The Live/Deadâ fluorescent dye was diluted 1:500 in PBS 
and 100 µL of staining mix was added to each well. Plates were incubated 
for 30 min at 4°C in the dark. Following incubation, cells were washed in 
PBS and then fixed in 150 µL/well 1% PFA in PBS and stored at 4ºC until 
acquisition. 
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Table 2-4: Human flow cytometry antibodies used for immunophenotyping 
and functional assays. 
 
Target 
molecule 
Fluorochrome Volume 
added 
Species 
of origin 
Clone Supplier 
NK cell activation 
CD3 PerCP 5 µL Mouse SP34-2 BD Biosciences 
CD56 PE 2 µL Mouse AF13-7H3 Miltenyi Biotec 
CD69 FITC 5 µL Mouse L78 BD Biosciences 
IgG1 FITC 5 µL Mouse MOPC-21 BD Biosciences 
 NK cell degranulation  
CD3 PerCP 5 µL Mouse SP34-2 BD Biosciences 
CD56 PE 2 µL Mouse AF13-7H3 Miltenyi Biotec 
CD107a FITC 5 µL Mouse H4A3 BD Biosciences 
CD107b FITC 5 µL Mouse H4B4 BD Biosciences 
T cell activation 
CD3 VioBlue 2 µL Mouse BW264/56 Miltenyi Biotec 
CD4 PE 5 µL Mouse SK3 BD Biosciences 
CD8 PerCP 2 µL Mouse BW135/80 Miltenyi Biotec 
CD69 FITC 5 µL Mouse L78 BD Biosciences 
IgG1 FITC 5 µL Mouse MOPC-21 BD Biosciences 
CTL degranulation 
CD3 VioBlue 2 µL Mouse BW264/56 Miltenyi Biotec 
CD56 PE 2 µL Mouse AF13-7H3 Miltenyi Biotec 
CD8 PerCP 2 µL Mouse BW135/80 Miltenyi Biotec 
CD107a FITC 5 µL Mouse H4A3 BD Biosciences 
CD107b FITC 5 µL Mouse H4B4 BD Biosciences 
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Table 2-4 continued: Human flow cytometry antibodies  
 
Target 
molecule 
Fluorochrome Volume 
added 
Species 
of origin 
Clone Supplier 
NK ligand phenotyping 
MIC A/B PE 5 µL Mouse 6D4 BD Biosciences 
ULBP-1 PE 5 µL Mouse #170818 R&D Systems 
ULBP-2/5/6 PE 5 µL Mouse #165903 R&D Systems 
PVR PE 5 µL Mouse PV404.19 Miltenyi Biotec 
Nectin-2 PE 5 µL Mouse R2.525 BD Biosciences 
HLA A/B/C PE 5 µL Mouse EMR8-5 BD Biosciences 
IgG2a PE 5 µL Mouse G155-178 BD Biosciences 
IgG2b PE 5 µL Mouse 27-35 BD Biosciences 
 Virus entry receptor phenotyping  
ICAM-1 PE 5 µL Mouse LB-2/6D4 BD Biosciences 
IgG2b PE 5 µL Mouse 27-35 Miltenyi Biotec 
JAM-A PE 5 µL Mouse M.Ab.F11 BD Biosciences 
IgG1 PE 5 µL Mouse H4B4 BD Biosciences 
DC phenotyping 
CD80 PE 5 µL Mouse L307.4 BD Biosciences 
CD86 FITC 5 µL Mouse 2331 BD Biosciences 
HLA-DR PerCP 5 µL Mouse L243 BD Biosciences 
IgG1 PE 5 µL Mouse MOPC-21 BD Biosciences 
IgG1 FITC 5 µL Mouse MOPC-21 BD Biosciences 
IgG2b PerCP 5 µL Mouse G155-178 BD Biosciences 
Intracellular IFN-g staining (CTL) 
CD3 VioBlue 2 µL Mouse BW264/56 Miltenyi Biotec 
CD56 PE 2 µL Mouse AF13-7H3 Miltenyi Biotec 
CD8 PerCP 2 µL Mouse BW135/80 Miltenyi Biotec 
IFN-g FITC 7 µL Mouse 45-15 Miltenyi Biotec 
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Table 2-4 continued: Human flow cytometry antibodies  
 
Target 
molecule 
Fluorochrome Volume 
added 
Species 
of origin 
Clone Supplier 
Additional markers 
BDCA-2 
(pDC) 
VioBlue 2 µL Mouse AC144 Miltenyi Biotec 
CD123 
(pDC) 
FITC 5 µL Mouse 7G3 BD Biosciences 
CD14 
(monocytes) 
PE 5 µL Mouse M5E2 BD Biosciences 
PE: phycoerythrin, PerCP: peridinin chlorophyll protein complex, FITC: fluorescein 
isothiocyanate. 
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Table 2-5: Murine flow cytometry antibodies used for immunophenotyping. 
 REA: recombinant antibody  
Target 
molecule 
Fluorochrome Volume 
added 
Species 
of origin 
Clone Supplier 
Lymphocyte phenotyping 
CD3 PE-Vio770 2 µL Hamster 145-2C11 Miltenyi Biotec 
DX5 
(CD49d) 
PE 2 µL Rat R1-2 Miltenyi Biotec 
CD4 VioBlue 2 µL Rat GK1.5 Miltenyi Biotec 
CD8a PerCP 2 µL Rat 53-6.7 Miltenyi Biotec 
CD44 FITC 2 µL Rat IM7.8.1 Miltenyi Biotec 
CD62L APC 2 µL Rat MEL14-
H2.100 
Miltenyi Biotec 
CD69 FITC 2 µL Hamster H1.2F3 Miltenyi Biotec 
PD-1 APC 2 µL Rat HA2-7B1 Miltenyi Biotec 
4-1BB FITC 2 µL Hamster 17B5-1H1 Miltenyi Biotec 
CTLA-4 APC 2 µL Hamster UC10-4B9 Miltenyi Biotec 
 Myeloid cell phenotyping  
CD45 APC-Cy7 2 µL Mouse 104 BioLegend 
F4/80 PE-Vio770 5 µL REA REA126 Miltenyi Biotec 
CD11b FITC 5 µL REA REA592 Miltenyi Biotec 
Ly6C BV421 1 µL Rat HK1.4 BioLegend 
Ly6G PerCP 1  µL Rat 1A8 BioLegend 
CD80 PE 2 µL Hamster 16-10A1 Miltenyi Biotec 
CD86 APC 2 µL Rat PO3.3 Miltenyi Biotec 
I-Ab  (MHC-II) Alexa 647 1  µL Mouse AF6-120.1 BioLegend 
Tumour burden 
CD138 PE 2 µL REA REA104 Miltenyi Biotec 
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2.14 Priming of tumour-specific cytotoxic T cells 
2.14.1 Generation of human myeloid-derived DC 
CD14+ monocytes were isolated from whole PBMCs as previously described 
(Section 2.11.1). CD14+ cells were cultured at 8x105/mL in complete RPMI-
1640 containing GM-CSF and IL-4 (Table 2-2) for 5 days to obtain iDC. A 
proportion of CD14+ cells were frozen for later use in peptide stimulations of 
primed CTLs (Section 2.14.2.2). 
 
2.14.2 Generation of tumour-specific CTL  
PBMCs were obtained from healthy donor leucocyte apheresis cones as 
previously described (Section 2.2.1). Approx. 2.5x108 PBMC were used for 
the generation of iDCs as described above (2.14.1) and the remaining 
PBMCs were frozen in 90% FBS and 10% DMSO (Sigma-Aldrich). Target 
cells were either left untreated, or treated with 1 pfu/cell reovirus or 0.1 
pfu/cell CVA21 for 24 hrs. iDC were loaded with untreated or treated target 
cells, respectively, at a 3:1 tumour cell:DC ratio and cultured in 50:50 DC 
medium:RPMI-1640 for 48 hrs. Tumour-loaded DC were then cultured with 
autologous PBMC (thawed from frozen) at a 1:20-1:30 DC:PBMC ratio in 
CTL medium (Table 2-2). Cells were incubated in 25 cm2 flasks (positioned 
upright) for 7 days at 37˚C; CTL cultures were monitored daily and 
supplemented with extra CTL medium when required. The remaining frozen 
PBMC were thawed and used to generate new iDC, which were then 
cultured with target cells (±OV treatment) to allow re-stimulation of T cells. 
On Day 7, CTLs were harvested, pelleted by centrifugation, and re-
stimulated with fresh target cell-loaded DCs. All CTL culture medium was 
replenished. Cells were then cultured for another six days before harvesting 
for use in 51Cr release assays (Section 2.15), CTL degranulation assays 
(Section 2.13.3), and for intracellular IFN-g flow cytometry (Section 2.13.4).  
 
2.14.2.1 MHC Class I (HLA-ABC) blockade during CTL 
degranulation assays 
To block HLA-ABC:TCR interaction, target cells were harvested and 
incubated with 50 µg/mL LEAFä purified anti-human HLA-ABC (BioLegend), 
or mouse IgG2a isotype control (R&D Systems) antibodies, for 30-60 min at 
37°C before inclusion in CTL degranulation assays as described in Section 
2.13.3. 
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2.14.2.2 Peptide pool stimulation of primed CTLs 
PepTivatorâ Peptide Pools (Miltenyi Biotec) consisting mainly of 15-mer 
sequences of amino acids with 11 amino acids overlap covering the 
PRAME, Mucin-1, and MAGE-A1, respectively, proteins were used. All 
PepTivatorâ Peptide Pools were reconstituted in dH2O according to the 
manufacturer’s instructions, resulting in a stock concentration of 30 nmol/mL 
of each peptide. Aliquots were stored at -80°C. For TAA stimulation of CTLs, 
autologous CD14+ cells were thawed from frozen, washed in complete 
RPMI-1640, and allowed to rest for approx. 60 min. 2x106 CD14+ cells were 
incubated with either peptide pool for 60 min at 37°C at a final concentration 
of 6 nmol/mL. CD14+ cells incubated in the absence of peptide were used as 
controls. CD14+ cells were then co-cultured with primed, autologous CTLs at 
a 2:1 ratio and included in the intracellular IFN-g assay as described in 
Section 2.13.4. 
 
2.15 51Chromium release assay  
51Chromium (Cr) release assays were used to examine the cytotoxicity of NK 
cells and in vitro generated CTLs (Section 2.14.2). Target cells were 
harvested and labelled with 100 μCi 51Cr/106 cells (PerkinElmer) for 1 hr at 
37°C. Effector cells were harvested, counted, and added in triplicate to 96-
well round-bottom cell culture plates. Serial halving dilutions of effector cells 
were made in complete RPMI-1640 to create known effector:target (E:T) 
ratios, starting at 50:1. Following incubation with 51Cr, target cells were 
washed three times in HBSS by centrifugation, and resuspended in 
complete RPMI-1640. 5x103 target cells were added to each well of effector 
cells followed by co-culture for 4 hrs at 37°C. Spontaneous release controls 
were established using target cells alone in complete RPMI-1640 and target 
cells alone cultured in 1% Triton-X (Sigma-Aldrich) in complete RPMI-1640 
were used as maximum release controls. In CTL assays, unlabelled K562 
and Daudi target cells (5x103 each/well) were added to all wells to mitigate 
NK cell and LAK cell activity. Following incubation, cells were pelleted and 
50 μL of each supernatant was transferred to a LumaPlate™ (PerkinElmer) 
and left to dry overnight. The level of 51Cr in the supernatant was then 
measured using a Microbeta2 scintillation counter (PerkinElmer) and the 
percentage of target cell lysis was calculated using the following formula 
(cpm: counts per minute):  
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2.15.1 EGTA-mediated inhibition of exocytosis in 51Cr assays 
As Ca2+ is needed for the efficient exocytosis of cytotoxic granules from NK 
cell and CTLs, the chelating agent EGTA (egtazic acid) was used in 51Cr 
assays to establish the requirement of exocytosis for target cell lysis. 51Cr 
assays were set up as described above (Section 2.15), but effector cells 
were resuspended in complete RPMI-1640 supplemented with 4 mM EGTA 
prior to addition to 96-well plates. Following the addition of target cells, the 
final concentration of EGTA during co-cultures was 2 mM. The release of 
51Cr into the culture medium was measured as described above (Section 
2.15). 
 
2.16 Gene Expression Analysis 
2.16.1 Isolation of RNA from cells 
RNA was isolated from STORM PBMC samples (pre-CVA21 infusion and 
three days post-CVA21 infusion) stored in liquid nitrogen, and from murine 
BM samples stored in RNAprotect Cell Reagent (Qiagen) at -80°C. First, 
mRNA was isolated using the RNeasy Plus Mini kit (Qiagen) according to 
the manufacturer’s instructions. Briefly, cells were lysed in the provided RLT 
buffer, then homogenised using QIAshredder columns (Qiagen). 
Contaminating genomic DNA was removed using gDNA eliminator spin 
columns from the RNeasy Plus Mini kit. After addition of one volume 70% 
ethanol (EtOH), the samples were applied to an RNeasy Mini spin column. 
Following several wash steps to remove contaminants, RNA was eluted in 
RNase-free water. The final RNA concentration in each sample was 
measured using a NanoDrop™1000 spectrophotometer (ThermoFisher 
Scientific).  
 
2.16.2 Isolation of reovirus RNA using TRIzolâ 
250 µL of reovirus stock was mixed with 1 mL TRIzolâ reagent and 
incubated for 5 min at RT. Next, 200 µL of chloroform (Sigma-Aldrich) was 
added and the sample was incubated for a further 2-3 min, followed by 15 
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min centrifugation at 12 000 xg at 4°C using an Eppendorf 5415D 
microcentrifuge. The aqueous phase was aspirated, mixed with 500 µL 
isopropanol, and incubated for 10 min at RT. RNA was pelleted by 
centrifugation for 10 min at 12 000 xg at 4°C and then washed in 1 mL 70% 
EtOH by centrifugation for 5 min at 7 500 xg at 4°C. The supernatant was 
aspirated and the pellet air-dried before resuspension in RNase-free water 
and measurement of RNA concentration using a NanoDrop™1000 
spectrophotometer (ThermoFisher Scientific). 
 
2.16.3 Generation of cDNA (STORM samples) 
For STORM samples, 0.1 µg purified RNA was converted to cDNA using the 
SuperScriptä III Reverse Transcriptase kit (ThermoFisher Scientific). All 
reactions were prepared in individual 0.2 mL PCR tubes. The primer 
annealing reaction consisted of RNA, 5 µM oligo(DT)20, 1 mM dNTP mix, 
and DEPC-treated water in a total volume of 10 µL which was heated to 
65°C for 5 min. The whole primer reaction was used in the cDNA Synthesis 
Mix, in addition to reagents with the following final concentrations: 1x RT 
buffer, 5 mM MgCl2, 10 mM DTT, 40 U RNaseOUT™, and 200 U 
SuperScriptä III reverse transcriptase in a total volume of 20 µL. Reactions 
were heated to 50°C for 50 min, followed by termination of the reaction at 
85°C for 5 min and cooling on ice. Finally, contaminating RNA template was 
removed by RNase H treatment for 20 min at 37ºC. All heating for DNase 
treatment and cDNA conversion was performed on a Veriti Thermo Cycler 
(Applied Biosystemsä). 
 
2.16.4 Quantitative real-time polymerase chain reaction (qPCR) 
2.16.4.1 TaqManä qPCR (STORM samples) 
The STORM cDNA was used in a two-step qPCR reaction with TaqManä 
reagents to examine the expression of 18S RNA, IFIT1, IFI44L, and OAS1. 
Reactions were prepared in triplicate in 96-well MicroAmpä Optical Reaction 
plates (Applied Biosystemsä) and consisted of 2 µL cDNA, 1x TaqManä 
Fast Advanced Master Mix (10 µL), 1x TaqManä Gene Expression Assay (1 
µl), and nuclease-free water in a total volume of 20 µL (all reagents Applied 
Biosystemsä). The following Gene Expression Assays with a FAMä reporter 
were used: Hs000356631_g1 (IFIT1), Hs00199115_m1 (IFI44L), 
Hs009733637_m1 (OAS1), and Hs03003631_g1 (18S). Plates were sealed 
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with optical adhesive film and then centrifuged briefly to collect the reaction 
and eliminate air bubbles. Thermal cycling was performed on the 
QuantStudioä 5 Real-Time PCR System (Applied Biosystemsä) with the 
following protocol: 2 min at 50°C, 20 sec at 95°C, then 40 cycles of 10 sec at 
95°C and 20 sec at 60°C. Results were normalized to 18S RNA and the fold 
change in expression was calculated using the DDCt method. 
 
2.16.4.2 SYBRä green reovirus RT-qPCR (murine samples) 
The presence of reovirus in murine BM was analysed in a one-step qPCR 
reaction with SYBRä green reagents. Reactions were prepared in triplicate 
in 96-well MicroAmpä Optical Reaction plates (Applied Biosystemsä) using 
the Power SYBRä Green RNA-to-CTä 1-Step Kit (ThermoFisher Scientific). 
0.3 µg RNA was used in each reaction, in addition to 1x Power SYBR Green 
RT-PCR Mix, 1x RT Enzyme Mix, 0.5 µM forward primer, 0.5 µM reverse 
primer, and RNase-free water to a total volume of 20 µL. Primers used are 
detailed in Table 2-6. An eight-point 10-fold serial dilution series of reovirus 
RNA isolated from reovirus stock as described in Section 2.16.2 was 
included for the quantification of reovirus s3 RNA. GAPDH expression in 
each sample was measured to ensure good quality of input RNA. Thermal 
cycling was performed on the QuantStudioä 5 Real-Time PCR System 
(Applied Biosystemsä) with the following protocol: 30 min at 48°C, 10 min at 
95°C, followed by 40 cycles of 15 sec at 95°C and 60 sec at 60°C.  
 
 
Table 2-6: Primers used for one-step RT-qPCR 
 
TARGET F/R SEQUENCE (5’ – 3’) Tm (°C) 
Reovirus s3 F GGGCTGCACATTACCACTGA 59.3 
R CTCCTCGCAATACAACTCGT 56.0 
GAPDH (mouse) F ACTGAGCAAGAGAGGCCCTA 57.7 
R TATGGGGGTCTGGGATGGAA 57.7 
All primers were obtained from Integrated DNA Technologies. 
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2.17 5TGM1 in vivo model 
All animal work was approved by the University of Leeds Local Ethical 
Review Committee and conducted under a project license (PF0BA8592) 
approved by the UK Home Office. I.v. injections were performed by Dr. 
Gemma Migneco. C57BL/KaLwRij mice were purchased at age 4-10 weeks 
from a colony already established at the University of Leeds, which was 
originally purchased from Harlan Laboratories. From the start of each 
experiment, mice were housed in individually ventilated, positive pressure 
ISOcages with a maximum of five mice per cage. All mice had free access to 
water, standard mouse feed, nesting material, and were subjected to a 
regulated daylight cycle. All animals were monitored daily and any mice 
exhibiting hind limb paralysis (HLP), hunched posture, reduced activity 
levels, skin ulceration, weight loss, difficulty breathing, or other distress were 
removed from the colony and euthanized by cervical dislocation; at the end 
of experiments animals were similarly euthanized by cervical dislocation.  
 
2.17.1 In vivo passage and bone marrow harvest 
To obtain bone-homing 5TGM1 cells, parental 5TGM1 cells were passaged 
in vivo using 8-10 weeks old female mice. 2x106 5TGM1 cells in 100 µL PBS 
were injected in the lateral tail vein and upon development of HLP (21-35 
days later) mice were sacrificed. Following post-mortem dissection, both 
femora and tibia were isolated, epiphyses removed and bones flushed with 
RPMI-1640 supplemented with 10% FBS and 1% penicillin/streptomycin 
(Sigma-Aldrich) to harvest BM cells. The BM was strained through a 70µm 
cell strainer (Greiner BioOne) and lymphocytes, including 5TGM1 cells, were 
isolated from whole BM by density gradient centrifugation on Lympholyteâ-
M medium (Cedarlane). The recovered cells were washed twice in complete 
RPMI-1640 and then cultured in complete 5TGM1 medium (Table 2-1) with 
1% penicillin/streptomycin. Bone-homing 5TGM1 cells were expanded in 
vitro for up to 7 days and then either re-injected or cryopreserved for future 
experiments. 
 
2.17.2 Harvest and processing of spleens 
Spleens were harvested from all mice in reovirus therapy experiments. 
Following post-mortem dissection, spleens were immediately processed to 
obtain splenocytes in suspension. Spleens were crushed through a 70 µm 
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cell strainer (Greiner BioOne) into splenocyte medium (Table 2-2). Cells 
were pelleted and red blood cells were lysed in 5 mL ACK buffer (0.15M 
ammonium chloride, 10mM KHCO3, 0.1mM EDTA, pH 7.2-7.4) for 2 min. 
Excess cold splenocyte medium was added and cells were centrifuged at 
400 xg for 5 min. The cell pellet was washed two more times in pre-warmed 
splenocyte medium and then the splenocytes were counted and included in 
experiments. 
 
2.17.3 Reovirus therapy experiment – intraperitoneal (i.p) 
administration 
As the reovirus treatment protocol required several repeated injections, i.p. 
delivery was first tested due to concerns that tail vein scarring would make 
repeated i.v. injections problematic. 16 female mice aged 6-8 weeks were 
used and 14 mice were injected with 2x106 bone-homing 5TGM1 cells in 100 
µL PBS  i.v. on Day 0, while two mice were left tumour- and treatment naïve. 
Therapy started on Day 13 with i.p. injection of either 2x107 pfu reovirus in 
100 µL PBS, or 100 µL PBS alone. Four injections were administered on a 
Mon/Wed/Fri schedule before development of HLP in PBS mice. Following 
development of HLP in the first mouse, all mice were sacrificed and bone 
marrow and spleens were harvested as described above for in vitro analysis 
(Section 2.13.2 and Table 2-5). 
 
2.17.4 Reovirus therapy experiment – intravenous (i.v) administration 
Both female and male mice aged 4-8 weeks were used in experiments. An 
overview of all i.v. experiments performed can be found in Table 4-2, 
detailing the number of mice used in each experiment, gender, the number 
of naïve mice included, the number of reovirus doses before HLP, and 
experimental read-outs used. On Day 0, mice were injected with 2x106 bone-
homing 5TGM1 cells in 100 µL PBS in the lateral tail vein (naïve mice left 
untreated). On Day 7-9, reovirus or control (PBS) treatment was initiated 
with three weekly injections (Mon/Wed/Fri) of 2x107 pfu/mL reovirus in 100 
µL PBS or 100 µL PBS alone, respectively. Treatment continued until 
development of HLP in PBS-treated mice (20-27 days), then all mice were 
sacrificed and the BM and spleen were isolated from each mouse. Tumour 
burden and immunophenotyping was performed as described in (Section 
2.13.2 and Table 2-5). 
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2.17.4.1 Experimental read-outs 
Tumour burden in the BM and spleen was examined by flow cytometry using 
CD138 antibodies as described in Section 2.13.2. NK cells, CD4+ T cells, 
CD8+ T cells, monocytes, macrophages, and MDSCs were identified and 
phenotyped as described in Section 2.13.2 using antibodies detailed in 
Table 2-5. RT-qPCR for reovirus s3 RNA presence in the BM was performed 
as described in Section 2.16.4.2. Supernatants for IFN-g ELISA were 
generated by co-culture of splenocytes with 5TGM1 cells at a 1:1 ratio for 48 
or 72 hrs. Cell-free supernatants were harvested and the secretion of IFN-g 
was measured by ELISA according to the protocol in Section 2.12.1. 
2.18 Statistical analysis 
All statistical analysis was performed using Graphpad Prism 7.0 (GraphPad 
Software, La Jolla, CA). p-values were calculated using either Student’s t-
test with two-tailed distribution for comparing two groups, or one-way 
analysis of variance (ANOVA) or two-way ANOVA with post-hoc tests and 
correction for multiple testing when comparing three or more groups. The 
following post-hoc tests were used: 
• Tukey’s: multiple pairwise comparisons between all test groups 
• Dunnett’s: multiple pairwise comparisons of all test groups to a given 
control group 
• Šídák’s: multiple pairwise comparisons of selected test groups 
 
Results were considered significantly different from the null hypothesis if 
p<0.05. Pearson’s r was calculated to evaluate correlation. Details of 
replicates and numbers of donors are given in each figure legend. 
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Chapter 3  
A comparison of anti-tumour immunity induced by reovirus 
and coxsackievirus A21 in multiple myeloma 
 
3.1 Introduction 
As discussed, MM is a haematological disease which is still considered 
incurable, and novel, more efficient treatments are urgently needed. The 
work described in this chapter aimed to compare the anti-tumour immune 
responses induced by two different OVs, and their role in the treatment of 
MM. While both Reolysinâ (reovirus) and CAVATAKä (CVA21) have shown 
preclinical efficacy in MM with regards to direct oncolysis (202, 225, 318-
321), no previously published studies have examined the anti-tumour 
immune response induced by either virus in detail in a MM setting. 
Reolysinâ has progressed to early phase clinical trials (195, 259, 269, 322), 
while CAVATAKä remains a novel, and unexplored agent for the treatment 
of MM.  
Early work by Thirukkumaran et al., and Au et al. demonstrated that a range 
of MM cell lines are highly susceptible to the direct lytic effects of both 
reovirus (320, 323) and CVA21 (202). However, preliminary data generated 
in earlier projects demonstrated that some cell lines remain resistant to 
direct oncolysis due to low entry receptor expression, which has also been 
confirmed in earlier studies (225). Furthermore, the BM microenvironment is 
well known to induce resistance to chemotherapeutics in MM by providing a 
protective niche for malignant cells (324). To date, it has not been clarified 
whether the BM microenvironment can also induce resistance to OVT. The 
evidence is conflicting regarding the interactions of OV with the local TME, 
and OV effects on tumour-supportive cells can both aid (150) and oppose 
therapy (325, 326). However, no studies have investigated the role of the 
BM microenvironment in OVT of MM, specifically. Therefore, the work 
presented here examined the effect of the BM microenvironment on OV 
susceptibility and determines the role for OV-induced anti-tumour immunity 
for eradication of MM cells. To do this, in vitro cell culture models 
incorporating MM cell co-culture with BM stromal cells, and immunological 
models of NK cell degranulation and killing, and priming of tumour-specific 
CTLs were used. 
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To support the in vitro results obtained from healthy donors, primary 
samples from two different clinical trials were analysed to assess the onset 
of anti-tumour immunity in a malignant in vivo environment. The Myeloma 
UK Eleven (MUK11) Phase Ib trial aimed to evaluate i.v. Reolysinâ in 
combination with lenalidomide or pomalidomide in refractory/relapsed MM; 
Figure 3-1A shows a treatment schedule overview. The STORM Phase I 
dose-escalation trial evaluated i.v. infusion of CVA21 in patients with late-
stage solid malignancies; Figure 3-1B and Table 3-1 show the treatment 
schedule overview and patient demographics. Although not from MM 
patients, the onset of an immune response in the peripheral circulation of 
immunocompromised cancer patients (327-330) would support the use of 
OVT in MM.  
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Figure 3-1: Clinical trials treatment schedule overview.  
A: MUK11 trial, cycle 1. Patients received Reolysinâ i.v. (Patient 2; 1010 TCID50) on 
Days 1, 8, 15, and 22, and either lenalidomide (10 mg) or pomalidomide (1 mg) 
daily. Peripheral blood samples were taken prior to reovirus infusion and then at 24 
hrs, 72 hrs , and 7 days post infusion. B: STORM trial, cycle 1. Patients received 
CAVATAKä i.v. (108 or 109 TCID50) on Days 1, 3, and 5. Peripheral blood samples 
were taken prior to CVA21 infusion and then at 1 h, 72 hrs, and 21 days post 
infusion. All samples except sample B were taken prior to the next CVA21 infusion.
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Table 3-1: STORM trial patient demographics. 
Five patients with late-stage, refractory solid malignancies were recruited to the STORM Phase I dose-escalation trial. All patients had previous 
treatments as indicated before taking part in the STORM trial. Orange symbols indicate a 1x108 TCID50 dose of CAVATAKä per injection 
throughout the results section, black symbols indicate a 1x109 TCID50 dose. 
 
SAMPLE ID SYMBOL MALIGNANCY STAGE ON 
RECRUITMENT 
PREVIOUS 
TREATMENTS 
CVA21 DOSE LYMPHOCYTE 
COUNT (A/B/C/D) 
 
STORM-1 
 
▼ 
Adenocarcinoma of 
the lung 
Metastatic disease 
to the lung 
CT-322 trial, Erlotinib, 
Pemetrexed, 
Gemcitabine, Fiesta trial 
 
1x108 TCID50 
A: 1.05, B: 0.78,  
C: 0.75, D: 0.70 
 
STORM-2 
 
▲ 
Lentigo maligna 
melanoma 
Metastatic disease 
to the lung, liver, 
LNs 
Excision of primary 
tumour, Dacarbazine, 
Ipilimumab 
 
1x108 TCID50 
A: 1.16, B: 0.94,  
C: 1.03, D: 1.07 
 
STORM-4 
 
◼ 
Metastatic 
carcinoma of the 
prostate 
Metastatic disease 
to LNs and bone 
Docetaxel, Abiraterone, 
Cabazitaxel 
 
1x109 TCID50 
A: 1.01, B: 1.38,  
C: 1.19, D: 0.80 
 
STORM-5 

 
Malignant 
melanoma 
Cutaneous, 
subcutaneous and 
LN metastases 
Multiple surgical 
excisions, isolated limb 
perfusion 
 
1x109 TCID50 
A: 1.39, B: 1.17,  
C: 1.10, D: 1.07 
 
STORM-6 • 
Poorly differentiated 
squamous cell 
carcinoma of the 
lung 
Pleural, lung and 
subcutaneous 
metastases 
Excision of chest wall, 
MK3475 trial 
 
1x109 TCID50 
A: 1.02, B: 1.89,  
C: 0.79, D: 0.94 
LN: lymph nodes, Fiesta trial: AZD4547 with gemcitabine and cisplatin, MK3475 trial: pembrolizumab. 
Sample A: prior to first infusion, Sample B: one hour post infusion, Sample C: Day 3 post infusion, Sample D: 22 days post infusion. 
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3.2 Results 
3.2.1 Direct oncolysis of multiple myeloma cells 
In accordance with previous literature (202, 225), it was confirmed by flow 
cytometry that a number of MM cell lines (H929, U266B, and JIM3) express 
both the reovirus entry receptor JAM-A, and the CVA21 entry receptor, 
ICAM-1 (Figure 3-2 A and B). Overall, ICAM-1 expression was markedly 
higher than JAM-A expression on both H929, U266B, and JIM3 cells. 
Interestingly, one cell line, OPM2, was found to be both JAM-A and ICAM-1 
negative, with no expression of either receptor above the isotype control 
(Figure 3-2 A and B). To confirm whether entry receptor expression 
corresponded with susceptibility to oncolysis, all cell lines were treated with 
either reovirus or CVA21, and cell viability was assessed by flow cytometry, 
using a Live/Deadâ discrimination kit as described in Section 2.13.1. 
Following reovirus treatment with up to 10 pfu/cell for 72 and 96 hrs (Figure 
3-2C and D), or CVA21 treatment with up to 1 pfu/cell for 48 and 72 hrs 
(Figure 3-2 E and F), it was confirmed that H929, U266B, and JIM3 cell lines 
were susceptible to the direct lytic effects of both viruses. CVA21 showed a 
more pronounced oncolytic effect than reovirus, with >90% of all cells (H929, 
U266B, and JIM3) dead after 72 hrs treatment with just 0.1 pfu/cell (Figure 
3-2F). To achieve a similar level of cell death with reovirus, treatment had to 
be extended to 96 hrs with a 10 pfu/cell dose, which still only killed 64% of 
JIM3 cells on average (Figure 3-2D). Thus, the more pronounced oncolytic 
effect of CVA21 seemed to correlate with the higher expression of ICAM-1. 
The H929 cell line was the most susceptible to reovirus (Figure 3-2 C and 
D), while the U266B cell line was the most susceptible to CVA21 (Figure 3-2 
E and F). This did not directly correlate with the level of entry receptor 
expression on individual cell lines, as U266B cells had the highest 
expression of JAM-A (Figure 3-2A), and JIM3 cells had the highest 
expression of ICAM-1 (Figure 3-2B). As expected, OPM2 cells, which did not 
express JAM-A or ICAM-1, remained resistant to direct oncolysis. 
To evaluate susceptibility to reovirus and CVA21 in the context of the BM 
microenvironment, a MM:BM co-culture system was developed using two 
different types of BM stromal cell lines, HS-5 and HS-27 as described in 
Section 2.1.6. Co-culture with stromal cells improved the viability of MM cells 
overall (data not shown) therefore, all results presented in Figure 1-4 were 
normalised to the untreated control for each co-culture condition. HS-27 
stromal cells provided significant protection of both H929, U266B, and JIM3 
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cells against reovirus direct oncolysis with an average reduction in cell death 
of 38.2%, 30.7%, and 33.2%, respectively (Figure 3-3 A-C). Moreover, HS-5 
stromal cells provided protection against reovirus for H929 and JIM3 cells 
(Figure 3-3 A and C, an average 35.1% and 20.8% reduction in cell death, 
respectively). Interestingly, neither stromal cell type was able to significantly 
protect against CVA21 oncolysis in H929 or U266B cells (Figure 3-3 D and 
E), while some protection was observed in the JIM3 cells when cultured 
together with HS-27 cells (Figure 3-3F, average 35.0% reduction in cell 
death). Based on these results, the HS-27 cells were selected for mimicking 
the BM microenvironment in subsequent immunological experiments (except 
for conditioned medium experiments where both stromal cell types were 
used). Having established the direct oncolytic effects of both viruses, next 
the induction of anti-tumour immune responses by each virus was examined, 
along with the ability to exploit these anti-tumour immunity mechanisms for 
the eradication of MM cells. 
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Figure 3-2: MM cell line expression of virus entry receptors and susceptibility 
to reovirus and CVA21.  
MM cell lines H929, U266B, JIM3, and OPM2 were phenotyped for baseline 
expression of JAM-A (A) and ICAM-1 (B) using flow cytometry. Expression is 
shown as the fold change in MFI compared to an isotype control (n=3). C and D: All 
cell lines were left untreated (0 pfu/cell) or treated with either 0.01, 0.1, 1, or 10 
pfu/cell reovirus for 72 (C) or 96 hrs (D). E and F: All cell lines were left untreated (0 
pfu/cell) or treated with either 0.01, 0.1, or 1 pfu/cell CVA21 for 48 (E) or 72 (F) hrs. 
Cell death was estimated by flow cytometry at each time point, using a Live/Deadâ 
discrimination stain (n=3). Statistical significance was calculated using a two-way 
ANOVA with Tukey’s post-hoc test, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001. Error bars indicate s.e.m. 
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Figure 3-3: Co-culture of MM cells with BM stromal cells can reduce 
susceptibility to direct oncolysis. 
H929, U266B, and JIM3 cells were either treated alone, or co-cultured with HS-5 or 
HS-27 BM stromal cells at a 1:1 ratio for 24 hrs before treatment with 10 pfu/cell 
reovirus (A-C) or 1 pfu/cell CVA21 (D-F). Cell death was evaluated by flow 
cytometry using a Live/Deadâ discrimination stain, gating on CTG+ MM cells. 
Percentages were normalised to the untreated control for each co-culture condition. 
Statistical significance was calculated using one-way ANOVA with Dunnett’s post-
hoc test. * = p<0.05, ** = p<0.01, error bars indicate s.e.m, n=3. 
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3.2.2 OV-mediated innate and adaptive anti-tumour immunity in 
multiple myeloma 
In order to thoroughly evaluate the induction of anti-tumour immunity in MM, 
both innate (cytokine-mediated bystander killing, and NK cell-mediated 
cytotoxicity), and adaptive (priming of tumour-specific cytotoxic CTLs) 
immune mechanisms were examined. 
 
3.2.2.1 Pro-inflammatory cytokines secreted in response to reovirus or 
CVA21 treatment induce bystander killing of MM cells 
Several cytokines have previously been proposed for the treatment of 
malignant diseases, the most common being IL-2 and type I IFNs. Both type 
I and type II IFNs have been implicated as treatments of MM (331-334), and 
are also an important part of the innate immune response to viral infection. 
Thus, the secretion of IFN-a and IFN-g from healthy donor PBMC in 
response to 48 hrs reovirus or CVA21 treatment (0.1 or 1 pfu/PBMC) was 
first examined using an ELISA (Section 2.12.1). Significant amounts of IFN-a 
were secreted in response to both viruses, with absolute levels being higher 
following reovirus treatment (Figure 3-4 A and B). On average, 11 400 
pg/mL IFN-a was secreted in response to treatment with 1 pfu/PBMC 
reovirus, compared to 2700 pg/mL for CVA21 treatment. Interestingly, the 
secretion of IFN-g was more pronounced in response to CVA21 treatment 
than to reovirus treatment (on average 1000 pg/mL with CVA21, compared 
to 160 pg/mL with reovirus at the 1 pfu/PBMC dose, Figure 3-4 C and D). 
IFN secretion in response to CVA21 was further confirmed utilising a 
Luminex multiplex assay, which measures cytokine secretion in a high 
throughput manner (Section 2.12.2). Two separate Luminex plates, 
measuring the secretion of 48 cytokines and chemokines in conditioned 
medium (CM) were used. This data demonstrated that, in addition to IFNs, 
CVA21-CM contained several other cytokines and chemokines, such as 
TRAIL, IL-15, IL-2, TNF-a, GM-CSF, and IP-10 (CXCL10) among others 
(Figure 3-4E). A significant increase in secretion, compared to untreated 
PBMC, was seen for IFN-a2, TRAIL, IL-15, CTACK (CCL27), TNF-b, IL-1A, 
LIF (leukaemia inhibitory factor), Eotaxin, IL-4, and Basic FGF (fibroblast 
growth factor). Interestingly, secretion of Rantes (CCL5), normally induced 
by IFN-g, was reduced in response to CVA21. Along with the IFNs, both 
TRAIL, IL-2, and GM-CSF have previously been shown to have cytotoxic 
effects in MM, alone or in combination with other drugs (333, 335-337). 
 104 
Next, the cytotoxic bystander killing effect of these cytokines, secreted in 
response to OV treatment, was assessed. CM from PBMC was harvested 
after 48 hrs of OV treatment, and MM cells were cultured in the CM (diluted 
1:1 in fresh medium) for 96 hrs before evaluation of cell viability using an 
MTS assay (Figure 3-5A and Section 2.8). In an attempt to neutralise the 
direct cytotoxic effect of the virus on oncolysis-susceptible cell lines, CM was 
treated with UV-irradiation as described in Section 2.6.3. 2 min of UV 
irradiation neutralised the majority of reovirus particles when treated in either 
PBS or CM (Figure 3-5B). However, while 3 min of UV treatment neutralised 
the majority of CVA21 when treated in PBS, up to 10 min of irradiation had 
no effect on the replicative potential of CVA21 in CM (Figure 3-5C). Thus, 
UV-irradiated reovirus-CM was tested on all cell lines, while CVA21-CM 
could only be tested on OPM2 cells which were resistant to direct CVA21 
oncolysis (Figure 3-6). Both reovirus-CM, and CVA21-CM had a significant 
toxic effect on OPM2 cells after 96 hrs, with reovirus-CM (1 pfu/PBMC) 
reducing cell viability from 100% (normalised) to 76.9% on average, and 
CVA21-CM reducing cell viability to 82.5% on average (Figure 3-6A). The 
UV-treated reovirus-CM was also significantly toxic to H929, U266B, and 
JIM3 cells (Figure 3-6B). Cell viability was reduced to 44.7%, 62.5%, and 
66.1%, respectively, with 1 pfu/PBMC CM, making H929 cells the most 
susceptible to reovirus-mediated bystander killing. To confirm whether the 
cell death observed was specifically due to the effect of secreted cytokines, 
rather than residual toxicity of UV-inactivated virus due to s1-protein binding 
to JAM-A or multiplicity reactivation (338, 339), cell death induced by UV-
inactivated reovirus particles, in the absence of cytokine-containing medium, 
was investigated. Figure 3-6C shows that some, but not all, of the toxic 
effect on H929 and U266B cells at the higher viral dose of 1 pfu/cell may be 
accounted for by residual toxicity of UV-inactivated viral particles. In 
contrast, the lower dose of  0.1 pfu/cell  of UV-Reo did not induce toxicity, 
which confirms the bystander killing effect of the cytokines present in the CM 
at this dose.  
After confirming a cytotoxic effect of UV-inactivated reovirus-CM on MM cells 
grown in isolation, the ability of UV-inactivated CM to kill MM cells in the 
context of the protective BM microenvironment was evaluated. The co-
culture model described in Section 2.1.6 was used, diluting the residual 
stromal culture medium 1:1 in reovirus-CM instead of fresh medium. Due to 
the long-term nature of the co-culture model, cells could only be cultured in 
CM for an additional 72 hrs (compared to 96 hrs in previous experiments) 
before excessive death of stromal cells due to over-confluency, with 
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subsequent loss of their protective effect on MM cells. Furthermore, cell 
viability was evaluated by flow cytometry using a Live/Deadâ discrimination 
stain, rather than an MTS assay, to allow quantification of cell death in the 
CTG-labelled MM cells only. The results demonstrated that there was no 
significant difference in H929 viability following culture alone in 1 pfu/PBMC 
CM, compared to culture in reovirus-CM in the context of HS-27 cells. This 
indicated that in the case of H929 cells, reovirus-CM could overcome the 
protective effect induced by HS-27 stromal cells (Figure 3-7A). However, co-
culture with HS-5 cells protected H929 cells against the toxic effect of 
reovirus-CM, similar to the protection observed for direct reovirus oncolysis 
(Figure 3-3); the percentage of live H929 cells increased from 26.7% to 
68.3% following co-culture with HS-5 stromal cells. Similarly, the cytotoxic 
effect of reovirus-CM was not able to overcome the stromal protection 
induced in U266B cells as both HS-5 and HS-27 stromal cells protected 
U266B cells against reovirus-CM to some extent (Figure 3-7B). After 72 hrs 
culture in 1 pfu/PBMC CM, the percentage of live U266B cells increased 
from an average 77.4% without stromal protection to 90.0% after co-culture 
on either stromal cell line. Encouragingly, no protection of JIM3 cells was 
observed, but the overall cytotoxicity towards these cells was low in the 72 
hrs assay (Figure 3-7C). On the contrary, JIM3 cell death was increased by 
an average 11% (not statistically significant) following co-culture with HS-5 
stromal cells, indicating some potentiation of CM-induced death in the 
context of bone marrow stromal support. As discussed later, HS-5 cells are 
highly secretory compared to HS-27 cells, raising the question of potential 
synergistic toxicity between stromal CM and reovirus-CM on JIM3 cells.  
Taken together, the results presented in this section demonstrate that 
cytokines secreted by immune cells in response to both reovirus and CVA21 
treatment can generate an inflammatory milieu with a toxic effect on MM 
cells. Encouragingly, CM showed toxicity against OPM2 cells which were 
completely resistant to direct oncolysis, and in the case of H929 cells, was 
able to overcome the protective effect induced by HS-27 stromal cells. 
However, the experiments performed in this section also indicated that the 
BM microenvironment can protect MM cells not only against oncolysis, but 
also against the cytotoxic effects of virus-CM, thus additional anti-tumour 
immune mechanisms would be required to target these cells. 
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Figure 3-4: Cytokine secretion from healthy donor PBMC in response to 
reovirus and CVA21. 
Healthy donor PBMC were treated for 48 hrs with 0.1 or 1 pfu/cell of reovirus (n=10) 
or CVA21 (n=6 for IFN-a, n=3 for IFN-g), respectively. Cell-free supernatants were 
harvested and secretion of IFN-a (A and B) and IFN-g (C and D) was measured by 
ELISA. Statistical significance was calculated using one-way ANOVA with Dunnett’s 
post-hoc test. E: The secretion of 48 different cytokines was measured in 
supernatants from PBMC treated with 1 pfu/cell CVA21. The graph shows the mean 
fold change (n=3) compared to untreated PBMCs. Where a sample reading was out 
of the detection range, cytokine amounts were estimated using the assay range 
limits (indicated by x). Statistical significance was calculated using unpaired, two-
tailed t-tests, comparing the treated to untreated PBMC non-transformed readings. 
* = p<0.05, ** = p<0.01, **** = p<0.0001. Error bars indicate s.e.m. 
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Figure 3-5 Illustration of conditioned medium (CM) culture protocol and UV-
inactivation or reovirus and CVA21. 
A: CM was harvested from PBMC treated with either 0, 0.1, or 1 pfu/cell of reovirus 
or CVA21 for 48 hrs (1). Before use on cell lines susceptible to direct oncolysis, 
reovirus-CM was UV-irradiated for 2 min (2). Cells were resuspended in CM diluted 
1:1 in fresh culture medium, each condition was set up in triplicate with a 100% 
fresh culture medium control (3). After 96 hrs incubation, cell viability was measured 
using an MTS assay (4). B and C: Representative plaque assays showing loss of 
viral replication following UV-irradiation in PBS for 2 (B, reovirus) or 3 (C, CVA21) 
min, respectively. 2 min UV-irradiation of reovirus in culture medium resulted in a 
loss of replication, while up to 10 min UV-irradiation of CVA21 in medium had no 
effect on replication. 
 108 
0 0.1 1
0
20
40
60
80
100
120
pfu/PBMC
%
 v
ia
bi
lit
y
OPM2 - Reo
*
***
0 0.1 1
0
50
60
80
100
120
pfu/PBMC
%
 v
ia
bi
lit
y
OPM2 - CVA21
****
***
0 0.1 1
0
20
40
60
80
100
120
pfu/PBMC
%
 v
ia
bi
lit
y
H929 - CM
****
****
0 0.1 1
0
20
40
60
80
100
120
pfu/PBMC
%
 v
ia
bi
lit
y
U266B - CM
****
****
0 0.1 1
0
20
40
60
80
100
120
pfu/PBMC
%
 v
ia
bi
lit
y
JIM3 - CM
****
****
0 0.1 1
0
20
40
60
80
100
120
pfu/cell
%
 v
ia
bi
lit
y
H929 - UV-Reo
n.s
****
0 0.1 1
0
20
40
60
80
100
120
pfu/cell
%
 v
ia
bi
lit
y
U266B - UV-Reo
*n.s
0 0.1 1
0
20
40
60
80
100
120
pfu/cell
%
 v
ia
bi
lit
y
JIM3 - UV-Reo
n.s
n.s
A
B C
  
 109 
Figure 3-6: Cytokine-induced bystander killing of MM cells. 
Cells were cultured in reovirus- or CVA21-CM for 96 hrs as indicated. All CM was 
diluted 1:1 in fresh culture medium. After 96 hrs, cell metabolism was measured 
using an MTS assay and the percentage of viable cells was normalised to 0 
pfu/PBMC CM. A: Toxicity of reovirus- and CVA21-CM, respectively, to OPM2 cells 
(n=7). B: Toxicity of reovirus-CM to H929, U266B, and JIM3 cells (n=10). C: As a 
control, neat reovirus was UV-inactivated in fresh culture medium for 2 min with 
reovirus doses equivalent to reovirus-CM. Toxicity of UV-inactivated reovirus 
against H929, U266B, and JIM3 cells, respectively, was determined using MTS 
assays after 96 hrs incubation (n=5). Statistical significance was calculated using 
one-way ANOVA with Dunnett’s post-hoc test. * = p<0.05, *** = p<0.001, **** = 
p<0.0001, n.s = not significant. Error bars indicate s.e.m. 
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Figure 3-7: Cytokine-mediated killing of MM target cells in the context of BM 
stroma. 
H929 (A), U266B (B), and JIM3 (C) cells were co-cultured at a 1:1 ratio with either 
HS-5 or HS-27 BM stromal cells for 24 hrs before addition of UV-inactivated 
reovirus-CM. Reovirus-CM was diluted 1:1 in existing culture medium. After 72 hrs, 
cell viability was measured by flow cytometry using a Live/Deadâ discrimination 
stain, gating on CTG+ MM cells. The percentage of live cells was normalised to 
treatment with 100% fresh medium for each co-culture condition. Statistical 
significance was calculated using two-way ANOVA with Tukey’s post-hoc test. * = 
p<0.05, **** = p<0.0001, error bars indicate s.e.m, n=4.  
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3.2.2.2 OV-activated NK cells show cytotoxicity against MM cells  
Pro-inflammatory cytokines, and type I IFNs in particular, secreted as part of 
the innate immune response have also been shown to be important for the 
maturation, activation, and function of NK cells (186). Hence, the ability of 
reovirus and CVA21 to activate NK cells, and potentiate their anti-myeloma 
cytotoxicity, was next examined. All experiments in this section were 
performed using PBMC isolated from healthy donors and NK cells were 
treated with virus as part of the whole PBMC population to mimic important 
aspects of normal physiology, including cell-cell crosstalk. Using flow 
cytometry, NK cells were identified as CD3-CD56+ cells (Figure 3-8A) and 
NK cell function following OV treatment was examined through assessment 
of phenotypic activation, degranulation, and target cell killing.  
As shown in Figure 3-8, NK cells significantly up-regulated the expression of 
the early activation marker CD69 following treatment with either reovirus or 
CVA21 for 48 hrs, indicating a heightened state of activation in these cells 
following OV treatment (Figure 3-8 B and C). With reovirus treatment at 0.1 
pfu/cell, over 80% of NK cells expressed CD69, and only a 5% enhancement 
was observed by increasing the dose to 1 pfu/cell (Figure 3-8B). For CVA21 
however, a larger difference (15.1%) was detected in the percentage of 
CD69-positive cells between 0.1 and 1 pfu/cell, resulting in an average 
93.3% of NK cells expressing CD69 after treatment with 1 pfu/cell CVA21 
(Figure 3-8C). Evaluation of the fold increase in CD69 MFI following 
treatment with either reovirus or CVA21, compared to untreated NK cells, 
generated comparable results, with both viruses behaving in a similar way 
(data not shown). Importantly, in a representative patient from the MUK11 
reovirus clinical trial, a peak in CD69 expression was observed on NK cells 
72 hrs after reovirus i.v. infusion (Figure 3-8D). In addition, a small increase 
in CD69 positive NK cells was detected 24 hrs post reovirus infusion and by 
Day 7, the percentage of CD69 positive NK cells had decreased to a similar 
level, still above that prior to infusion. Similarly, 72 hrs after CVA21 i.v. 
infusion, the expression of CD69 was also increased on NK cells in the 
peripheral blood of patients taking part in the STORM clinical trial, in 
particular, those who received the highefr dose (1x109 TCID50) of CVA21 
(Figure 3-8E). No change in CD69 expression was detected on NK cells 
from patients receiving the lower dose of CVA21, and there was no 
difference in the level of CD69 positive NK cells at the 1 hr or 21-day time 
points, compared to pre-infusion. Degranulation and release of cytotoxic 
granules is required for NK cells to kill target cells upon recognition. Thus, 
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NK cell degranulation against MM target cells was examined using a flow 
cytometry-based degranulation assay as described in Section 2.13.3. PBMC 
from healthy donors were pre-activated with either reovirus or CVA21 for 48 
hrs, and their propensity for degranulating against MM target cells compared 
to untreated NK cells was examined when cultured at a 2:1 effector:target 
ratio. Figure 3-9A shows representative flow cytometry plots from a 
degranulation assay using reovirus-activated NK cells challenged with 
U266B target cells. Spontaneous degranulation (no targets) was low, with 
only 1.3% CD107+ NK cells (left panel). Similarly, without any reovirus 
treatment, degranulation in response to U266B targets was only 5.2% 
(middle panel), increasing to 18.9% CD107+ NK cells following pre-activation 
with reovirus (right panel). This trend was similar  for H929, JIM3, and OPM2 
target cells, with a significant enhancement in NK cell degranulation 
following reovirus pre-treatment of PBMC (Figure 3-9B). For all target cells, 
except JIM3, a higher level of NK cell degranulation was observed following 
treatment with 1 pfu/PBMC, compared to 0.1 pfu/PBMC reovirus. For H929, 
U266B, and JIM3 cell targets the levels of NK cell degranulation were similar 
(average 9.3% increase with 0.1 pfu/PBMC reovirus treatment), with very 
low degranulation in the absence of virus treatment. Encouragingly, a 
significant increase in NK cells degranulation was also observed against the 
oncolysis-resistant target cells OPM2. While baseline degranulation against 
these targets without any reovirus pre-activation was higher (average 17.5% 
CD107+ NK cells), the relative potentiation with reovirus treatment was 
similar to that for other targets tested (average 7.1% increase with 0.1 
pfu/PBMC reovirus).  
Pre-treatment of PBMC with CVA21 had a similar effect on NK cell 
degranulation, with a significant enhancement observed against all MM 
target cells tested (Figure 3-9C). For CVA21 treatment, a maximum level of 
degranulation was reached with 0.1 pfu/PBMC treatment, with CD107 
expression decreasing at the higher dose of 1 pfu/cell. The levels of 
degranulation achieved against H929, U266B, and JIM3 targets cells were 
slightly lower with CVA21 treatment compared to reovirus treatment 
(average 6.7% increase with 0.1 pfu/PBMC CVA21 treatment). As observed 
in the reovirus experiment, baseline NK cell degranulation against OPM2 
targets without CVA21 pre-treatment was high, but still increased to a similar 
extent as for the other target cells (average 5.4%). 
Next, the cytotoxic functionality of virus-activated NK cells was tested using 
a flow-cytometry based killing assay (Section 2.13.5). NK cells were pre-
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activated with either virus and subsequently challenged with MM target cells 
(H929, U266B, JIM3, or OPM2) at a 25:1 effector:target ratio. Overall, killing 
of all target cells was significantly enhanced after pre-treatment of PBMC 
with either reovirus (Figure 3-9D) or CVA21 (Figure 3-9E). The cytotoxic 
effect was most pronounced against H929 cells and, notably, OPM2 cells. 
With reovirus treatment (1 pfu/PBMC) the average killing of these target cells 
increased to 26.1% compared to untreated NK cells. With CVA21 treatment 
(1 pfu/PBMC), an average 43.7% and 35.5% increase in the killing of H929 
and OPM2 targets, respectively, was observed, suggesting that CVA21 was 
the more potent agent for enhancing NK cell-mediated cytotoxicity, despite 
the lower induction of NK cell degranulation (Figure 3-9). Importantly, this 
demonstrated that the enhanced degranulation following OV treatment was 
correlated with an enhanced cytotoxic function of the NK cells. 
To examine the ability of NK cells to overcome the protection of MM cells 
induced by the BM microenvironment, the stromal cell co-culture model was 
used as described previously (Section 2.1.6). As co-culture with HS-27 
stromal cells induced the greatest protection against direct oncolysis overall 
(Section 3.2.1), this stromal cell line was chosen for the NK cell killing 
assays. H929, U266B, and JIM3 cells stained with CTG were co-cultured 
with HS-27 stromal cells for 48 hrs to generate MM cells with reduced 
susceptibility to direct oncolysis, then cells were harvested and used as 
targets in NK cell killing assays. Despite some reduction in the NK cell 
cytotoxicity observed (for U266B target cells particularly), importantly, there 
was no significant decrease in the ability of reovirus-activated NK cells to kill 
MM cells cultured on HS-27 cells, compared to MM target cells alone (Figure 
3-10 A-C). This was also true for CVA21-treated NK cells, with no significant 
difference in the levels of NK cell-mediated killing observed for either H929, 
U266B, or JIM3 cells cultured on HS-27 stromal cells, compared to each cell 
type alone (Figure 3-10 D-F). Although not significant, H929 cells appeared 
to be less affected by co-culture with BM stroma, compared to U266B and 
JIM3 cells, with identical levels of cell death with and without stromal cell 
support (Figure 3-10A and D). 
The results presented in this section show that NK cells activated with either 
reovirus or CVA21 can degranulate against, and kill, MM cells, including 
those completely resistant to direct oncolysis (OPM2) and those with 
reduced susceptibility to oncolysis in the BM niche. Together with the 
experiments presented in Section 3.2.2.1 on the cytotoxicity of CM, these 
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results indicate a role for innate anti-tumour immune mechanisms in the 
eradication of MM cells.  
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Figure 3-8: Reovirus and CVA21 activate NK cells in vitro and in vivo 
following i.v. administration. 
A: NK cell flow cytometry gating strategy. For all NK cell experiments, NK cells 
were treated with virus in the context of whole PBMC and identified by flow 
cytometry as the CD3-CD56+ population. B and C: PBMCs from healthy donors 
were treated with 0.1 or 1 pfu/cell of reovirus (B) or CVA21 (C) for 48 hrs. CD69 
expression was measured by flow cytometry on CD3-CD56+ NK cells and is 
presented as the percentage of CD69+ cells (n=4). Statistical significance was 
calculated using one-way ANOVA with Tukey’s post-hoc test, **** = p<0.0001. Error 
bars indicate s.e.m. D: CD69 expression on NK cells from one patient treated with 
i.v. reovirus as part of the MUK11clinical trial. Peripheral blood samples were taken 
prior to infusion, then 24 hrs, 72 hrs, and 7 days post infusion. E: CD69 expression 
on NK cells from five patients treated with i.v. CVA21 as part of the STORM trial. 
Peripheral blood samples were taken prior to viral infusion, then at 1 h, 72 hrs, and 
21 days post infusion. Bars indicate the mean CD69 expression, orange = 108 
TCID50 CVA21, black = 109 TCID50 CVA21 (Table 3-1). 
  
 116 
Figure 3-9: NK cell degranulation against, and killing of, MM target cells 
following activation with reovirus or CVA21. 
For NK cell degranulation assays, whole PBMC were pre-activated with either 0.1 
or 1pfu/cell reovirus or CVA21, respectively, for 48 hrs. PBMC were co-cultured 
with MM target cells at a 2:1 effector:target ratio for 1 h, followed by another 4 hrs 
incubation in the presence of Brefeldin A. Surface expression of CD107a/b was 
measured by flow cytometry on CD3-CD56+ NK cells. A: Representative flow 
cytometry plots showing CD107a/b expression on NK cells in the absence of target 
cells (left panel), and in the presence of U266B targets cells, after co-culture with 
untreated- (middle panel) and reovirus-treated PBMC (right panel), respectively. B: 
CD107a/b expression on NK cells pre-activated with reovirus following co-culture 
with H929, U266B, JIM3, or OPM2 cells. C: CD107a/b expression on NK cells pre-
activated with CVA21 following co-culture with H929, U266B, JIM3, or OPM2 cells. 
D and E: For NK cell killing assays, MM target cells were labelled with CTG and co-
cultured with reovirus (D) or CVA21 (E) pre-activated PBMC at a 25:1 
effector:target ratio for 5 hrs, before staining with a Live/Deadâ discrimination stain. 
Percentage cell death is shown as the increase in death with OV-activated NK cells, 
compared to untreated NK cells. Statistical significance was calculated using one-
way ANOVA with Tukey’s post-hoc test, * = p<0.05, ** = p<0.01, *** = p<0.001,  **** 
= p<0.0001. Error bars indicate s.e.m, n=4.  
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Figure 3-10: NK cell-mediated killing of MM target cells with reduced 
susceptibility to direct oncolysis after culture on BM stromal cells. 
MM target cells (H929, U266B, and JIM3) were co-cultured with HS-27 BM stromal 
cells for 48 hrs before inclusion in a flow cytometry-based NK cell killing assay. 
PBMC treated with either 0.1 or 1 pfu/cell of reovirus (A-C) or CVA21 (D-F) were 
co-cultured with either target cells alone (black) or target cells pre-cultured on HS-
27 (purple) for 5 hrs before staining with a Live/Deadâ discrimination stain. Cell 
death was measured on CTG+ MM cells and was normalised to an untreated PBMC 
control. Statistical significance was calculated using two-way ANOVA with Šídák’s 
post-hoc test, error bars indicate s.e.m, n=4, n.s. = not significant.  
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3.2.2.3 Both reovirus and CVA21 can induce priming of MM-specific 
cytotoxic T cells 
Further analysis of PBMC from the MUK11 and STORM trials showed 
significant upregulation of CD69 on both CD4+ (Figure 3-11 A and B) and 
CD8+ (Figure 3-11 C and D) T cells following i.v. infusion of reovirus or 
CVA21, respectively. By 72 hrs, the percentage of CD69-positive CD4+ T 
cells increased from 0.7% to 16.0% in the patient receiving Reolysinâ 
(Figure 3-11A). The response was similar in patients receiving CVA21, with 
a significant increase in CD69 expression on CD4+ T cells 72 hrs after 
CVA21 infusion (Figure 3-11B). Interestingly, up-regulation of CD69 was 
seen in response to both the higher and the lower dose of CVA21, and for 
patients STORM-2, -4, and -6, the elevated CD69 expression was sustained 
until the 21-day time point. Activation of CD8+ T cells was detected  24 hrs 
after reovirus infusion, with a 22.0% increase in the number of CD69 positive 
CD8+ T cells (Figure 3-11C). Activation was sustained until the 72 hrs time 
point and reduced by Day 7. Similarly, CD8+ T cells from patients in the 
STORM trial showed an increase in CD69 expression 72 hrs after CVA21 
treatment (Figure 3-11D). However, CD8+ T cell activation was 
predominantly seen in patients receiving the higher dose (109 TCID50) of 
CVA21. Activation of T cells in the peripheral circulation of patients in 
response to virus administration was encouraging for subsequent studies 
investigating the ability of reovirus and CVA21 to induce an adaptive CTL 
immune response in vitro.  
Mature DCs display a high expression of T cell co-stimulatory molecules 
CD80 and CD86, as well as MHC Class II, and are pivotal for the generation 
of functional CTL responses (340-342), while iDCs (low expression of CD80, 
CD86, and MHC Class II) are generally tolerogenic (Section 1.1.2.1.2). 
Thus, the next step in the evaluation of the potential for successful CTL 
priming was to examine the response of iDC to reovirus and CVA21, 
respectively. iDC differentiated from CD14+ cells were treated with reovirus 
or CVA21 for 24 hrs, and the expression of CD80, CD86, and HLA-DR, was 
analysed by flow cytometry. Interestingly, reovirus treatment induced a more 
pronounced upregulation of CD80, CD86, and HLA-DR on DCs (Figure 
3-12A), compared to 24 hrs CVA21 treatment (Figure 3-12B). Increasing 
treatment time to 48 hrs with CVA21 did not enhance the DC maturation 
(data not shown). Although significant, upregulation of CD80 and CD86 was 
less than two-fold following CVA21 treatment (1 pfu/DC), compared to three-
fold and 27-fold, respectively, following reovirus treatment. As reovirus was 
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more capable of maturing DCs, it was also hypothesized that this OV may 
be more effective in the priming of MM-specific CTLs than CVA21.  
A protocol for priming of tumour-specific CTL in a haematological context 
was adapted from a protocol developed for melanoma (246). The protocol 
involved loading of iDCs with virus-treated MM target cells and subsequent 
co-culture of DCs with autologous PBMC, including the T cells. Following a 
re-stimulation of the T cells with target-loaded DCs, the primed CTLs were 
evaluated for their ability to kill the (relevant) MM targets cells used for 
priming, and for their antigen specificity, using irrelevant target cells and TAA 
peptide stimulation (protocol overview in Appendix, Figure A-1). Based on 
susceptibility to oncolysis (Figure 3-2), 1 pfu/cell reovirus and 0.1 pfu/cell 
CVA21 were chosen for the pre-treatment of target cells. Target cells were 
treated for 24 hrs to allow tumour cell infection without excessive cell death. 
First, CTLs were generated in the presence of OV-loaded U266B cells, and 
their ability to kill relevant and irrelevant target cells was evaluated using 
chromium release assays (Section 2.15). Figure 3-13 demonstrates the 
ability of CTLs generated in the presence of either reovirus (Figure 3-13A) or 
CVA21 (Figure 3-13B) to specifically kill relevant U266B targets (purple), 
with no enhanced killing of irrelevant myeloid target cells (KG-1, orange). 
CTLs primed using reovirus were more efficient at killing U266B targets cells 
than those primed using CVA21 with an average 65.0% of U266B cells lysed 
using reovirus, compared to 50.8% using CVA21 at a 50:1 E:T ratio. No 
CTLs with cytotoxicity against U266B targets could be generated without 
virus present during the priming.  
CTLs rely on the Ca2+-dependent exocytosis of cytotoxic granules for the 
killing of target cells (Section 1.1.2.2.2). Thus, the first step in confirming that 
target cell killing was mediated by MM-specific CTLs was to include a 
chelating agent (egtazic acid, EGTA) during the killing assay to prevent 
Ca2+-dependent exocytosis. In the presence of 2mM EGTA, killing of U266B 
cells in the chromium release assay was completely abrogated (Figure 3-13 
C and D), indicating that death was mediated through the exocytosis of 
cytotoxic granules from CTLs. It is worth noting that in these experiments, 
the level of target cell killing was similar independent of which OV was used 
for priming, demonstrating that these experiments are susceptible to large 
donor variation. 
To also examine the ability of CTLs to target MM cells protected against 
oncolysis by the BM niche, CTL killing was evaluated using U266B target 
cells pre-cultured on HS-27 stromal cells. As demonstrated in previous 
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sections, co-culture with HS-27 induced protection against reovirus-
mediated oncolysis and CM cytotoxicity in U266B but was not able to protect 
against NK cell-mediated killing. CTLs were generated in the presence of 
reovirus- (Figure 3-14A) or CVA21-loaded (Figure 3-14B) U266B cells, then 
target cell killing was measured using a flow cytometry-based killing assay, 
comparing U266B cells alone as targets with U266B cells co-cultured with 
HS-27 stromal cells for 48 hrs. Encouragingly, there was no significant 
reduction in the killing of U266B target cells with prior co-culture on HS-27 
stromal cells, regardless of the virus used for CTL priming. Interestingly, 
CTLs primed against U266B using CVA21 were also able to kill OPM2 target 
cells inherently resistant to oncolysis (Figure 3-14C) with an average 
increase in cell death of 11.8% at a 25:1 E:T ratio, compared to CTLs primed 
without CVA21.  
To further characterise the cells generated using the priming protocol, and to 
confirm the importance of CTLs in the eradication of relevant target cells, the 
specific response of CD8+ T cells to relevant and irrelevant target cells was 
evaluated using flow cytometry. First, CTL degranulation against relevant 
and irrelevant targets was measured after 5 hrs co-culture as described in 
Section 2.13.3. Figure 3-15A shows that when using CTLs primed in the 
presence of reovirus, degranulation against relevant U266B target cells, but 
not irrelevant cells, was significantly enhanced compared to CTLs generated 
without virus. This further confirmed the results in Figure 3-13C, which 
indicated that target cell killing was mediated by a Ca2+-dependent 
mechanism. Interestingly, CTLs generated using CVA21 showed very low 
levels of degranulation against relevant targets, only 1.4% CD107-positive 
CTLs generated against relevant targets, compared to 5.0% using reovirus 
(Figure 3-15B), again indicating reovirus as the more efficient agent in the 
CTL priming context. The generation of antigen specific CTLs was further 
evaluated by blocking the interaction of CD8 with MHC Class I, which is 
essential for antigen recognition and activation of CTL cytotoxicity (343). 
U266B target cells were pre-labelled with an MHC Class I-blocking antibody 
or an isotype control, and then included in the degranulation assay as 
previously described. Using CTLs primed in the presence of reovirus, co-
culture with U266B target cells without any antibody labelling stimulated 
approximately 6.2% of CTLs to transport CD107 to the cell surface. 
However, this degranulation was completely abrogated when MHC Class I 
on the target cells was blocked. Following labelling of target cells with an 
isotype control antibody, the degranulation response was restored to 6.1% 
(Figure 3-15C). This confirmed the importance of MHC-I:CD8 interaction for 
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the degranulation of primed CTLs and implicated that successful antigen 
recognition was required to generate an efficient CTL response. As the 
degranulation of CTLs generated in the presence of CVA21 was negligible, 
no response to MHC Class I blockade was expected. However, while not 
significant, the overall response indicated a similar trend for CTLs primed 
using CVA21-loaded U266B, with a reduction in the percentage of CD107-
positive cells following MHC Class I blockade, which was restored following 
labelling with an isotype control (Figure 3-15D).  
IFN-g is important for CTL activation and proliferation, and is secreted in 
large amounts upon antigen recognition by CTL, and also by NK cells, and 
Th1 CD4+ T cells (344, 345). Thus, the next step in characterising the primed 
CTL response was to examine the secretion of this cytokine. First, an ELISA 
was used to confirm abundant secretion of IFN-g in both reovirus and CVA21 
priming cultures with an average 25 600 pg/mL secreted in reovirus cultures 
(Figure 3-16A) and 13 100 pg/mL secreted in CVA21 cultures (Figure 
3-16B), suggestive of the generation of a Th1-skewed immune response, as 
expected during priming of CTLs (346, 347). To confirm that IFN-g was truly 
secreted by CTLs in response to antigen recognition, rather than as an 
innate response to virus, IFN-g production was next examined using 
intracellular flow cytometry. CTLs primed using OV-loaded U266B cells were 
co-cultured with relevant (U266B) or irrelevant (KG-1) target cells for 5 hrs. 
Then, cells were fixed, permeabilised, and stained with an anti-IFN-g 
antibody as described in Section 2.13.4. These data demonstrated that 
CTLs primed using either reovirus (Figure 3-16C) or CVA21 (Figure 3-16D) 
produced IFN-g specifically against relevant, but not irrelevant, target cells. 
Interestingly, the percentage of IFN-g-positive CTLs was similar in CTLs 
primed using both reovirus (4.0%) and CVA21 (3.0%), suggesting that CTLs 
primed using CVA21 can also mount an efficient response in an antigen-
dependent manner, despite the lack of DC maturation seen in response to 
CVA21 treatment (Figure 3-12B). In keeping with the results presented in 
Figure 3-14C, showing that CTLs primed against U266B target cells using 
CVA21 could also kill OPM2, it was confirmed that CTLs, while not 
producing IFN-g in response to an irrelevant myeloid target, did produce IFN-
g upon recognition of OPM2 cells (Figure 3-16F). IFN-g production in 
response to OPM2 in CTLs primed against U266B using reovirus was not 
statistically significant due to donor variability but did indicate an increase 
compared to CTLs primed without reovirus (Figure 3-16E). These results 
suggest the possibility of shared antigens between U266B and OPM2 cells, 
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and the potential of CTLs primed against a CVA21-susceptible target to also 
eliminate CVA21-resistant targets, depending on the antigen repertoire. 
To confirm the antigen specificity of primed CTL discussed above, the IFN-g 
response was further explored by challenging CTLs with TAA peptide pools 
generated from TAA expressed in MM; PRAME, Mucin-1, and MAGE-A1. As 
discussed (Section 1.1.2.2.2), these TAA are some of the most commonly 
expressed in MM, both on primary cells and MM cell lines (28). Autologous 
CD14+ APCs were loaded with either peptide pool and then co-cultured with 
primed CTLs for 5 hrs as previously described. CTLs generated against 
U266B in the presence of reovirus showed significantly enhanced production 
of IFN-g in response to both PRAME and MAGE-A1 peptides (Figure 3-17A), 
with the increase in the number of IFN-g-producing CTLs being 
approximately 3.0% and 4.0%, respectively. The responses were variable 
depending on the donor, and some donors also showed a response, 
although not significant, against Mucin-1 peptides. CTLs primed against 
U266B in the presence of CVA21 showed significantly enhanced production 
of IFN-g  in response to Mucin-1 and MAGE-A1 peptides (3.1% and 5.4% 
increase, respectively), with some donors also responding favourably to 
PRAME peptides (Figure 3-17B). These findings are particularly 
encouraging as they demonstrate that both reovirus and CVA21 can be used 
to prime CTLs specific not only for non-self/allo-antigen, but for well-
recognised and reported TAA in MM.  
To demonstrate the broad applicability of this approach, and further examine 
whether there was a role of anti-tumour immunity in the absence of direct 
oncolysis, the priming assay was next performed using H929 cells, 
susceptible to reovirus and CVA21, and OPM2 cells, which were resistant to 
both viruses. Using chromium release assays, the ability of primed cells to 
kill relevant (H929 or OPM2) and irrelevant (KG-1) cells was assessed. As 
shown in Figure 3-18, CTLs that specifically killed relevant, but not irrelevant 
target cells, could be primed using H929 cells in the presence of either virus 
(Figure 3-18 A and B). Using reovirus, the level of H929 target cell lysis was 
comparable to that seen with CTLs primed against U266B (average 68.2% 
at a 50:1 effector:target cell ratio). The efficacy was again lower when CTLs 
were primed using CVA21 (average 40.7% lysis). When priming CTLs 
against resistant OPM2 cells using reovirus, a small improvement in killing of 
target cells was seen (maximum 10.2% lysis of target cells at 50:1 
effector:target cell ratio), compared to using reovirus-susceptible cells 
(Figure 3-18C). Furthermore, no successful priming was possible using 
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CVA21, resulting in no difference in the lysis of relevant and irrelevant target 
cells (Figure 3-18D). The fact that CTLs primed using U266B cells were in 
fact able to kill OPM2 cells in an antigen-dependent manner (Figure 3-14C 
and Figure 3-16F), suggests that the inefficient priming against OPM2 cells 
might be due to absence of viral replication rather than resistance to CTL-
mediated killing (225).  
Taken together, the findings presented in this section demonstrated that 
treatment of MM cells with either reovirus or CVA21 could induce efficient 
priming of MM-specific CTLs. While both viruses generated CTLs with high 
cytotoxicity against relevant, but not irrelevant, targets and specificity to well-
recognised TAA in MM, reovirus constantly generated a more potent 
response. However, it was possible to prime efficient CTLs using CVA21, 
despite limited maturation of DC following CVA21 treatment. Importantly, 
there was no difference in the levels of target cell killing when target cells 
were subjected to the protective effects of the BM niche. This section 
demonstrates the generation of adaptive anti-tumour immunity and together 
with the data presented previously, demonstrates that both innate and 
adaptive anti-tumour immune responses could play a role in the eradication 
of MM following OV treatment.  
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Figure 3-11: T cell activation after i.v. infusion of reovirus or CVA21. 
CD69 expression was evaluated by flow cytometry on CD4+ (A and B) and CD8+ (C 
and D) T cells from one patient treated with i.v. reovirus as part of the MUK11 trial 
(A and C), and five patients treated with i.v. CVA21 as part of the STORM trial (B 
and D). Peripheral blood samples were taken prior to infusion, then 24 hrs, 72 hrs, 
and 7 days post infusion for MUK11 patients and prior to infusion, then at 1 h, 72 
hrs, and 21 days post infusion for STORM patients. Bars indicate the mean CD69 
expression, orange = 108 TCID50 CVA21, black = 109 TCID50 CVA21 (Table 3-1). 
Statistical significance was calculated using one-way ANOVA with Tukey’s post-hoc 
test, * = p<0.05, ** = p<0.01. 
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Figure 3-12: Reovirus and CVA21 treatment increase the expression of T cell 
co-stimulatory molecules on DCs. 
iDCs were differentiated from CD14+ cells obtained from healthy donor PBMC by 
MACS cell separation (n=4). Following differentiation, DCs were treated with 0.1 or 
1 pfu/cell of reovirus (A) or CVA21 (B) for 24 hrs and the expression of CD80, 
CD86, and MHC Class II (HLA-DR) was evaluated by flow cytometry. Expression is 
shown as the fold increase in MFI compared to untreated DCs. Statistical 
significance was calculated using one-way ANOVA with Tukey’s post-hoc test, * = 
p<0.05, ** = p<0.01, *** = p<0.001,  **** = p<0.0001. Error bars indicate s.e.m.  
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Figure 3-13: Killing of relevant, but not irrelevant, MM target cells following 
CTL priming. 
Primed CTLs were generated after co-culturing PBMC with autologous DC, pre-
loaded with U266B cells treated with either 1 pfu/cell reovirus (A), or 0.1 pfu/cell 
CVA21 for 24 hrs (B). Following one re-stimulation with OV-U266B-loaded DC, CTL 
generated with or without reovirus or CVA21, were co-cultured with 51Cr-labelled 
relevant (U266B) and irrelevant (KG-1) target cells for 4 hours at different 
effector:target ratios.  The percentage of cell lysis was determined after 4 hours 
(n=6). C and D: CTLs were co-cultured with relevant target cells in the presence or 
absence of 2 mM EGTA (untreated), n=3. C: CTLs generated using reovirus-loaded 
U266B cells. D: CTLs generated using CVA21-loaded U266B cells. Statistical 
significance was calculated using two-way ANOVA with Tukey’s post-hoc test and 
refers to comparison between Relevant + virus and Irrelevant + virus, * = p<0.05, ** 
= p<0.01, *** = p<0.001,  **** = p<0.0001. Error bars indicate s.e.m. 
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Figure 3-14: CTL-mediated killing of MM target cells with reduced 
susceptibility to direct oncolysis. 
A and B: U266B CTLs, primed using either reovirus (A) or CVA21 (B), were co-
cultured with CTG-stained U266B target cells alone, or CTG-stained U266B cells 
pre-cultured on HS-27 stromal cells for 48 hrs, at a 25:1 effector:target ratio for 5 
hrs before staining with a Live/Deadâ discrimination stain. A: Representative flow 
cytometry plots using cells primed in the presence (right panels) or absence (left 
panels) of reovirus. The percentage of dead cells (orange gate) is indicated in each 
plot. Top plots: U266B targets alone. Bottom plots: U266B cells pre-cultured with 
HS-27 stromal cells (n=1). B: CTLs primed in the presence of CVA21 (n=3). Cell 
death was measured on CTG+ U266B cells and was normalised to the viability of 
the respective target cell alone. Statistical significance in A and B was calculated 
using one-way ANOVA with Šídák’s post-hoc test. C: CTLs primed in the presence 
of CVA21 (n=3) were co-cultured with CTG-stained OPM2 target cells. Target cell 
death was measured as described for A and B, and normalised to the viability of 
OPM2 cells alone. Statistical significance in C was calculated using paired, two-
tailed t-tests, * = p<0.05, n.s = not significant. Error bars indicate s.e.m.  
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Figure 3-15: For CTLs primed using reovirus, degranulation against relevant 
targets is dependent on CD8:MHC-I interaction 
PBMCs primed in the presence of reovirus (A) or CVA21 (B) were co-cultured with 
relevant (U266B) or irrelevant (KG-) target cells at a 2:1 effector:target ratio for 1 h, 
followed by another 4 hrs incubation in the presence of Brefeldin A. Surface 
expression of CD107a/b was measured by flow cytometry on CD3+CD8+ CTL (n=8). 
C and D: U266B targets were pre-labelled with either an MHC Class I-blocking 
antibody or an isotype control for 30 min at 37°C before inclusion in the CTL 
degranulation assay (n=3). C: CTLs generated using reovirus. D: CTLs generated 
using CVA21. Statistical significance was calculated using one-way ANOVA with 
Tukey’s post-hoc test, * = p<0.05, n.s = not significant. Error bars indicate s.e.m. 
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Figure 3-16: Primed CTL secrete IFN-g in response to relevant, but not 
irrelevant, target cells. 
A and B: IFN-g secretion into culture medium was measured at the end of the 
priming protocol using an ELISA with matched paired antibodies (n=6). C-E: 
Intracellular IFN-g in CTLs generated using reovirus- or CVA21-treated U266B cells 
was measured by flow cytometry after permeabilization of cells with saponin and 
staining with an anti-IFN-g antibody. C and D: PBMCs primed in the presence of 
reovirus (C, n=7) or CVA21 (D, n=10) were co-cultured with relevant (U266B) or 
irrelevant (KG-1) target cells at a 2:1 effector:target ratio for 1 h, followed by 
another 4 hrs incubation in the presence of Brefeldin A. E: PBMCs primed in the 
presence (+) or absence (-) of reovirus (n=3) were co-cultured with OPM2 target 
cells as described for C and D. F: PBMCs primed in the presence (+) or absence (-) 
of CVA21 (n=6) were co-cultured with OPM2 target cells as described for C and D. 
Statistical significance was calculated using paired, two-tailed t-tests, * = p<0.05, *** 
= p<0.001, **** = p<0.0001, n.s = not significant. Error bars indicate s.e.m  
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Figure 3-17: Primed CTL secrete IFN-g in response to MM-associated antigen 
peptide pools. 
Autologous CD14+ cells were loaded with PRAME, Mucin-1, and MAGE-A1 peptide 
pools, respectively (1 hr at 37°C), and co-cultured with PBMC primed in the 
presence of either reovirus (A) or CVA21 (B). Cells were co-cultured at a 2:1 
effector:target ratio for 1 h, followed by another 4 hrs incubation in the presence of 
Brefeldin A. Intracellular IFN-g was measured by flow cytometry after fixation of 
cells in 1% PFA, permeabilization with saponin, and staining with an anti-IFN-g 
antibody (n=5). Statistical significance was calculated using paired, two-tailed t-
tests, * = p<0.05, *** = p<0.001, **** = p<0.0001, n.s = not significant. Error bars 
indicate s.e.m. 
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Figure 3-18: Priming of CTLs using virus-susceptible H929 cells and virus-
resistant OPM2 cells. 
CTL priming was performed as previously described using H929 cells pre-treated 
with either reovirus (A) or CVA21 (B) as target cells. The ability of primed cells to 
lyse relevant (H929) and irrelevant (KG-1) target cells was evaluated using a 
chromium release assay at various effector:target (E:T) ratios (n=3). C and D: CTL 
priming using virus resistant OPM2 target cells treated with reovirus (C) or CVA21 
(D), respectively (n=3). Statistical significance in was calculated using two-way 
ANOVA with Tukey’s post-hoc test and refers to comparison between Relevant + 
virus and Irrelevant + virus, **** = p<0.0001. Error bars indicate s.e.m. 
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3.3 Summary & Discussion 
This chapter has compared and evaluated reovirus and CVA21 as oncolytic 
agents in MM. While the main focus was on the induction of anti-tumour 
immunity, a screen for the susceptibility of MM cell lines to the direct 
oncolytic effect of each virus was introduced in Figure 3-2. This confirmed, in 
agreement with previous studies (202, 318, 320, 323), that MM cell lines 
H929 and U266B are susceptible to the direct oncolytic effect of both 
reovirus and CVA21. While these cell lines have been commonly used in 
previous studies, it is the first time that susceptibility to reovirus and CVA21 
has been shown in JIM3 cells. A range of other MM cell lines have also been 
shown to be susceptible to reovirus (RPMI-8226, MM1S, LP-1, KMS-18-BM, 
SKMM-2, and L363) (225, 318, 319, 323, 348) and CVA21 (RPMI-8226, 
Kas6/1) (202, 349). However, in accordance with the findings published by 
Kelly et al., the results presented in this chapter also demonstrated that MM 
cell line OPM2 was completely resistant to reovirus-mediated oncolysis 
(225), and additionally, to CVA21-mediated oncolysis. Kelly et al. suggested 
that reovirus resistance was likely due to low expression of the viral entry 
receptor, JAM-A, on the surface of OPM2 cells, which was also confirmed in 
this chapter (Figure 3-2A). Interestingly, Kelly et al. also reported that 
overexpression of JAM-A could sensitise OPM2 cells to reovirus oncolysis 
(225).  
While many MM cell lines are susceptible to reovirus and CVA21 in isolation, 
the data presented in Figure 3-3 demonstrated that the susceptibility of cells 
that are normally permissive to infection can be reduced in the context of the 
BM microenvironment. Co-culture of MM cell lines with BM stromal cells HS-
27 for 24 hrs before viral treatment significantly reduced the susceptibility of 
both H929, U266B, and JIM3 cells to reovirus, and also protected JIM3 cells 
against CVA21-mediated oncolysis. While it is the first time that the BM 
microenvironment has been shown to induce protection against OVs in MM, 
it is commonly known that the protective BM niche induces resistance to 
several common chemotherapeutic agents in MM, including bortezomib, 
melphalan, and dexamethasone (350-352). BM-induced resistance can be 
mediated both by the secretion of soluble mediators and by cell-cell contacts 
(353). As shown in Table 2-1, HS-5 cells are fibroblastoid, while HS-27 are 
epithelial-like cells, both derived from normal BM stroma (354). In this study, 
HS-27 cells induced the largest overall protection against OV in MM cells. 
HS-5 cells have been shown to be more secretory, with abundant secretion 
of several haematopoietic growth factors and IL-6 (354). This could lead to 
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enhanced proliferation of MM cells, resulting in less protection against virus-
mediated death. Furthermore, interaction of MM cells with stroma has been 
shown to modify the expression of pro- and anti-apoptotic proteins, 
ultimately making MM cells more resistant to apoptosis induced by 
chemotherapeutics (355-357). The co-culture model used in this study is a 
simple 2D model and not entirely representative of the complexity of the BM 
microenvironment (Figure 2-1), and it can only be assumed to underestimate 
the actual protective effect against direct oncolysis (358). While BM-induced 
drug resistance remains a concern for successful treatment, the data 
presented in this chapter show that induction of anti-tumour immunity by 
OVs may have an important role in eradicating MM cells resistant to 
oncolysis due to low expression of entry receptors, or resistance 
mechanisms induced in MM cells residing in close proximity to BM stromal 
cell compartments. Many more advanced in vitro 3D models of the BM 
microenvironment exist, taking into account the various subniches, hypoxic 
gradients, and local milieu established by a multitude of cell types, but 
developing such models was beyond the scope of this study. Another 
concern for efficient therapy in MM is therapeutic access to the BM. In a 
Phase I clinical trial, it was confirmed that reovirus can access the BM 
following i.v. administration also in the presence of nAb (195). In addition, 
several studies have documented the ability of reovirus to interact with 
PBMC, facilitating the trafficking of replication-competent reovirus to tumours 
and metastatic sites (186, 250, 251). Such cellular hijacking could be a way 
for OVs to target MM cells within the BM niche, a prospect which warrants 
further investigation. Early in vitro studies have also confirmed successful 
cell carriage of CVA21, resulting in protection from antiviral nAb and OV 
delivery to target cells (253).  
 
This study is the first to examine the onset of anti-tumour immunity in 
response to both reovirus and CVA21 in MM, and has confirmed that an 
anti-myeloma response can be induced by both viruses. The anti-myeloma 
response consisted of both innate and adaptive immune mechanisms 
including 1) cytokine-mediated bystander killing, 2) NK cell-mediated cellular 
cytotoxicity, and 3) priming of MM-specific CTLs. 
Both reovirus and CVA21 were able to induce the secretion of cytokines 
from PBMC, which in turn induced a bystander killing effect on MM cells 
(Figure 3-4 and Figure 3-6). It was particularly encouraging that culture of 
OPM2 cells in either reovirus-CM or CVA21-CM could kill a significant 
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proportion of these oncolysis-resistant cells (Figure 3-6A). Similarly, 
reovirus-CM was able to overcome the protective effect induced following 
co-culture of H929 cells with HS-27 stromal cells (Figure 3-7A). A number of 
cytokines have been suggested as part of immunotherapy alone, or to 
enhance the efficacy of chemotherapeutics in MM, including IFN-a, IL-2, IL-
12, GM-CSF, and TRAIL (111, 333, 335-337, 359). The results presented in 
Figure 3-6 suggest that in a mixed cocktail, these cytokines can have 
significant anti-tumour effects on their own. As expected, IFN-a was one of 
the abundantly secreted cytokines in response to both reovirus and CVA21 
(Figure 3-4 A and B). Secretion of IFN-a from PBMC in response to reovirus, 
but not CVA21, has been previously documented in chronic lymphocytic 
leukaemia (CLL) (138). The role of IFN-a in OVT is controversial, as it has 
both been shown to have anti-tumour effects in several haematological 
malignancies, including MM (111, 113, 360, 361), however, it is also one of 
the main antiviral cytokines as discussed in Section 1.4.2.1.2.1. Interestingly, 
OVs have been engineered to function as delivery vectors for local delivery 
of cytokines, including IFN-b, to  facilitate the generation of an anti-tumour 
immune response within the TME (197, 362-364). Under the assumption that 
malignantly transformed cells frequently possess a dysfunctional IFN 
signalling response (155, 365), secretion of IFN within the TME improves the 
specificity of OVT, as viral replication occurs in malignant, but not normal, 
cells regardless of the presence of IFN (362). Thus, overall the anti-tumour 
effects of IFN-a are believed to outweigh its antiviral effects, in particular as 
anti-tumour immunity is now considered pivotal for the long-term success of  
OVT.   
The interplay between cytokines, viruses, tumour cells, and immune cells is 
complex. Several cytokines identified in the Luminex screen of CVA21 
(Figure 3-4E) have been shown to have pro-tumour effects, with IL-6 being 
particularly important in the MM setting with its proliferative and anti-
apoptotic effect. However, IL-6 in the TME has also been shown to sensitise 
tumour cells to certain OVs (366). Similarly, a synergistic anti-tumour effect 
was suggested following co-culture of JIM3 cells with HS-5 stromal cells in 
reovirus-CM (Figure 3-7C), indicating that cytokine release from the BM 
niche might, under certain circumstances, synergise with cytokines secreted 
from immune cells as a response to OV. Additionally, while the majority of 
cytokines secreted in response to viral infection have downstream activating 
effects on the immune system, others, such as IL-10, can also have an 
immunosuppressive effect (367, 368). Thus, while the toxic effect of the 
cytokine milieu induced in response to OVT is positive, off-target and 
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downstream effects will require careful future analysis to ensure the anti-
tumour effects of OV-induced cytokines outweigh any pro-tumour effects. 
Another important aspect of innate anti-tumour immunity is the enhanced 
cytotoxic function of NK cells. Figure 3-8 demonstrated that both reovirus 
and CVA21 treatment leads to the activation of NK cells, both in vitro, and 
following i.v. infusion as part of the MUK11 and STORM trials, respectively. 
In Figure 3-9, it was confirmed that activation of NK cells resulted in 
enhanced degranulation and killing of MM target cells, including the 
oncolysis-resistant OPM2 cells. Susceptibility of OPM2 cells to NK cell-
mediated killing has previously been reported by Garg et al. and van Rhee et 
al. (369, 370). Importantly, there was no significant reduction in the ability of 
virus-activated NK cells to kill MM cells that had been pre-cultured on BM 
stromal cells HS-27 (Figure 3-10), compared to MM target cells alone. 
Reovirus-induced potentiation of NK cell-mediated cytotoxicity has 
previously been demonstrated in several disease settings, including AML 
and chronic lymphocytic leukaemia (CLL) (138, 206, 234, 371), while this is 
the first study to report the effect of CVA21 on NK cells. As discussed in 
Section 1.4.4.1, other OVs, including MV and myxoma virus, have been 
evaluated as therapies for MM, however; no studies have documented 
induction of NK cell cytotoxicity in MM in response to other OVs. 
Interestingly, when comparing reovirus and CVA21, reovirus seemed to 
have a more stimulating effect on NK cells overall with the highest 
stimulation of NK cell activation and degranulation (Figure 3-8 and Figure 
3-9), but CVA21 induced the largest enhancement in NK cell-mediated killing 
(Figure 3-9). This dichotomy is interesting and warrants further exploration. 
Possible mechanisms could be induction of a more cytotoxic subpopulation 
of NK cells in response to the CVA21-induced cytokine secretion or an 
enhanced killing via degranulation-independent mechanisms such as Fas- or 
TRAIL-mediated killing induced by CVA21. 
The prospect of enhancing anti-tumour immunity induced by OVs using 
various combination treatments is an interesting avenue to develop to 1) 
enhance their anti-myeloma activity, and 2) better tailor therapies to the 
individual patient. One option for such combination therapies is monoclonal 
antibodies. Reovirus has previously been shown to enhance rituximab-
induced NK cell-mediated ADCC of malignant B cells in CLL (138). Two 
monoclonal antibodies targeting plasma cells have recently been approved 
for the treatment of MM, anti-CD38 daratumumab and anti-SLAMF7/CD319 
elotuzumab (372). Encouragingly, elotuzumab can enhance ADCC of 
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oncolysis-resistant OPM2 cells (369), but neither antibody has been tested 
in combination with OVs to date. Another interesting option for combination 
with OVs is the histone deacetylase inhibitor, valproate (VPA), which has 
previously been implicated as a treatment for MM (373-375). VPA can 
increase the expression of activating NK ligands on MM cells, making them 
more attractive targets for NK cells (376) and thus, could be an interesting 
combination with OVT which, as demonstrated here, boosts the cytotoxic 
effect of NK cells. 
 
Adaptive anti-tumour immunity was introduced in Section 3.2.2.3 with the 
successful priming of MM-specific CTLs using both reovirus- and CVA21-
loaded MM target cells. Figure 3-13 demonstrated that cells primed in the 
presence of either reovirus or CVA21 were highly cytotoxic towards relevant, 
but not irrelevant, target cells. Importantly, primed CTLs were equally 
effective at killing MM targets cells when they had been pre-cultured on BM 
stromal cells HS-27, and CTLs primed against oncolysis-susceptible target 
cells U266B were able to recognise and kill oncolysis-resistant OPM2 cells 
(Figure 3-14). The data presented in subsequent figures characterised the 
primed cells and confirmed their specificity towards MM target cells and well-
known TAA peptides. CTLs primed in the presence of reovirus degranulated 
specifically towards relevant, but not irrelevant targets, and CTL 
degranulation was shown to be dependent on CD8:MHC-I interaction (Figure 
3-15). Furthermore, CTLs primed using either virus secreted IFN-g 
specifically upon recognition of relevant, but not irrelevant target cells 
(Figure 3-16). Importantly, CTLs were able to recognise peptides from 
common TAAs in MM (PRAME, Mucin-1, and MAGE-A1) when presented on 
autologous APCs (Figure 3-17). As opposed to CTLs primed using reovirus, 
antigen-specificity of CTLs primed using CVA21 did not seem correlate with 
an enhanced degranulation against relevant target cells (Figure 3-15). 
However, while the percentage of degranulation was low, the overall trend 
was similar to CTLs primed using reovirus, with specific degranulation 
against relevant, but not irrelevant, target cells. It is possible that, with an 
increased number of donors tested, variability will be reduced to generate a 
statistically significant result, and that even low levels of degranulation are 
sufficient for successful target cell killing. Interestingly, sporadic studies have 
indicated the possibility for antigen-specific CTL-mediated killing through the 
Fas/FasL pathway, independent of CTL degranulation, which again could 
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indicate a role for Fas/FasL in CVA21-mediated anti-tumour immunity (377, 
378).  
In the experiments presented here, reovirus generated the more potent 
response overall compared to CVA21. However, in the EGTA experiment 
(Figure 3-13), levels of target cell death were similar, independent of which 
virus was used for priming, indicating that these experiments are susceptible 
to donor variation. It is possible that with continued experimental repetition, 
differences in performance between the viruses would be less pronounced. 
It is also interesting to consider if a given virus performs better in a subset of 
donors depending on the individual immunological landscape. It is also 
important to note that CVA21 was able to prime efficient CTLs despite 
limited DC maturation (Figure 3-12B). Additionally, while it was possible to 
successfully prime CTLs using two reovirus- and CVA21-susceptible cell 
lines (U266B and H929), this proved more challenging using oncolysis-
resistant OPM2 cells. A minor increase in killing of relevant, but not 
irrelevant, target cells was observed at high E:T ratios following priming in 
the presence of reovirus, but no priming was evident using CVA21 (Figure 
3-18), posing the question whether successful oncolysis is required to kick 
start an anti-tumour immune response. These observations will be 
investigated in more detail in the next chapters. Similar to NK cell-mediated 
anti-tumour immunity, the priming of myeloma-specific CTLs has not been 
investigated using other OVs. Reovirus has previously been shown to 
enhance the priming of tumour-specific CTLs in other malignancies, 
including ovarian cancer and several studies of melanoma (246, 250, 379, 
380), but no such data exists for CVA21 to date. Several studies have 
documented the successful priming of CTLs specific for Mucin-1 and MAGE-
A1 in vitro, as well as demonstrated the presence of CTLs specific for these 
antigens at high frequencies in MM patients (28, 381-384). 
Interestingly, CTLs primed against U266B cells using CVA21 were able to 
kill not only U266B cells, while ignoring irrelevant myeloid target cells, but 
also OPM2 cells (Figure 3-14C). The onset of IFN-g production in CTLs 
challenged with OPM2 cells (Figure 3-16F) suggested that killing occurred in 
an antigen-specific manner and was not due to non-specific innate killing by 
residual PBMCs in priming cultures. These results suggest that, while CTLs 
could not be primed directly against virus-resistant cells, shared antigens 
between susceptible and resistant cells could result in the eradication of 
virus-resistant cells by primed CTLs. Priming of such pan-myeloma CTLs 
have previously also been documented by Lu et al (385), and both U266B 
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cells and OPM2 have been shown to express MGUS-related antigen OFD1 
(386). 
 
Albeit anecdotal, important signs of immune cell activation was shown in 
vivo following i.v. infusion of either virus as part of the MUK11 (reovirus) and 
STORM (CVA21) clinical trials throughout this chapter. Only samples from 
one patient were analysed on the MUK11 MM trial as part of this study, but 
these showed a convincing peak in activation of both NK cells, CD4+, and 
CD8+ T cells 72 hrs after reovirus infusion (Figure 3-8 and Figure 3-11). 
Importantly, this was in a patient with myeloma refractory to standard 
immunomodulatory treatment (lenalidomide/pomalidomide). While patients 
included in this trial are refractory to the anti-tumour effect of IMiDs, 
preliminary studies have indicated that combination of reovirus with 
lenalidomide might potentiate the anti-tumour immune response, providing 
another interesting avenue for combination treatments in MM (387). The 
lymphocyte activation observed in the present study is also in accordance 
with previously published literature demonstrating that reovirus can activate 
immune effector cells following i.v. administration (186, 261, 388). The 
previously completed Phase I clinical trial evaluating reovirus in MM did not 
examine immune cell responses in treated patients (195). None of the 
patients analysed as part of the STORM clinical trial had MM, but they all 
had late stage solid malignancies known to induce an immunocompromised 
physiological state, like MM (327-330). Thus, it is an encouraging first step 
towards clinical applicability that both NK cells, CD4+, and CD8+ T cells in the 
peripheral circulation were activated in response to i.v. administration of 
CVA21 (Figure 3-8 and Figure 3-11). I.v. administration is the preferred route 
of delivery in MM where direct access to tumours residing in the BM is 
challenging. The ability of reovirus to induce a local immune response in the 
BM following i.v. administration in vivo is examined in Chapter 4. 
Interestingly, two patients on the STORM CVA21 trial received checkpoint 
inhibitor treatment prior to taking part in the STORM trial. Patient STORM-6 
received pembrolizumab and patient STORM-2 received ipilimumab. Both 
patients showed good responses to CVA21 treatment, with patient STORM-
6, who also received the higher dose of CVA21, displaying the most potent 
response. Checkpoint blockade (anti-PD1) initially seemed to have little 
effect in MM, but has more recently shown promise when combined with 
IMiDs (389, 390). In a Phase II clinical trial, an objective response rate of 
60% was documented, with 8% of participants achieving a complete 
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response (390). Unfortunately, several clinical trials have been suspended 
due to safety concerns with the checkpoint inhibitor. As demonstrated in this 
chapter, OVs can, like both IMiDs and checkpoint inhibitors, have an 
immunomodulatory effect in MM. CVA21 is already being successfully 
trialled in combination with pembrolizumab for melanoma (391), while 
reovirus has been shown to upregulate the expression of PD-L1 on tumour 
cells in both MM and other malignancies, with subsequent potentiation of 
both anti-PD1 and anti-PD-L1 treatments (261, 392, 393). Hence, both 
reovirus and CVA21 in combination with anti-PD1, or anti-PD-L1 antibodies 
might be interesting options for synergistic combination therapies with 
favourable safety profiles in MM. 
 
Based on the results demonstrated throughout this chapter, comparing 
reovirus and CVA21 in the MM setting, CVA21 appears to have a more 
pronounced oncolytic effect than reovirus, while both viruses show some 
immunogenic character. CVA21 was able to induce a higher level of NK cell-
mediated killing despite low NK cell degranulation while reovirus induced the 
more potent adaptive response overall. While tumour cell killing by primed 
CTL was comparable using both viruses, it is interesting to note that CTLs 
primed in the presence of CVA21, similar to NK cells, also showed very low 
levels of CTL degranulation. Previous immunological studies in other 
malignancies have shown onset of anti-tumour immunity using reovirus 
alone (237, 394), while most studies on CVA21 have chosen to enhance 
anti-tumour immunity using combination treatments (301, 395). Reovirus has 
also made significant progress in several clinical trials, including early trials 
for MM. However, as discussed, its ability to induce anti-tumour immunity in 
this setting has not been thoroughly documented. CVA21 has mainly made 
progress in clinical trials for melanoma in combination with immune 
checkpoint inhibitors, and has not been taken forward in the MM setting. 
Taken together, the results presented in this chapter indicate that CVA21 
could also be a useful agent in MM and future pre-clinical studies, as well as 
clinical trials, will be required to determine its fate in this context. As 
discussed previously (Section 1.4.5.3), reovirus is recognised by immune 
cells through both RIG-I and MDA5 pathways, and subsequent NK cell 
activation is thought to be dependent on IFN-a secretion from CD14+ 
monocytes (138, 394, 396), while very little is known about the 
immunobiology of CVA21. The experiments performed in Chapter 5 will 
examine the immune recognition and response to CVA21 in more detail. In 
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addition, the work presented in Chapter 4 has examined the use of reovirus 
in an in vivo model of MM to  further characterise the anti-tumour immune 
response induced by this virus. 
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Chapter 4  
Effects of reovirus in an in vivo model of multiple 
myeloma 
 
4.1 Introduction 
The experiments outlined in Chapter 3 provided evidence that both reovirus 
and CVA21 can induce an anti-tumour immune response against MM in 
vitro. It was previously hypothesised that CVA21 is dependent on human 
ICAM-1 for entering host cells and accordingly, does not naturally infect 
murine cells (397). This has necessitated the use of xenograft models to 
study CVA21 and so far, no suitable immunocompetent model has been 
described. In line with this, the work performed in this chapter aimed to 
establish whether an anti-tumour immune response could be induced 
following reovirus treatment of an immunocompetent in vivo model of MM. 
The majority of in vivo studies previously published utilising reovirus and MM 
have been performed using immunocompromised models with humanised 
xenografts (318-320, 323). A range of different immunocompetent models 
exist as well, including both transgenic and syngeneic models, which all 
represent different features and stages of MM, and resemble human MM to 
varying extents (398). The most common syngeneic in vivo model of MM is 
the 5T series, comprising a series of cell line subclones established from 5T 
cells first isolated from the BM of aging C57Bl/KaLwRij mice (398). Around 
0.5% of C57Bl/KaLwRij mice spontaneously develop a myeloma-like disease 
with age (399). The 5T series includes 5T2, 5T7, 5T8, 5T13, 5T14, 5T21, 
5T33, and 5T41 cell lines which all have different growth characteristics. In 
addition, stroma-independent subclones, such as 5TGM1 (derived from 
5T33), have been established, which enable in vitro passage of cells after 
isolation from the bone marrow following in vivo passages (398, 400). 
Along with a fully competent immune system, similar to that of WT C57Bl/6 
mice, the 5TGM1 model produces a disease which mimics many features of 
human MM, such as secretion of paraprotein, hypercalcaemia, and 
generation of lytic bone disease with decreased bone mineral density (401, 
402). Moreover, the disease is largely confined to the BM and the spleen, 
which has haematopoietic capacity in mice. Taking all these features 
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together, the 5TGM1 model allows considerable flexibility and is well suited 
to answer the questions posed in this chapter. 
While the model has been used for many studies of MM before, including for 
the development of IFN-b-expressing oncolytic VSV, it has only been 
reported on twice before in the context of reovirus treatment (197, 403). 
Kelly et al. first demonstrated efficacy of reovirus in combination with 
bortezomib in the 5TGM1 model (318). More recently, this was expanded to 
an immunological study demonstrating that reovirus treatment increased  the 
expression of PD-L1 on MM cells, with subsequent potentiation of 
therapeutic efficacy when used in combination with an anti-PD-L1 antibody 
(392). However, to date, the cellular mechanisms responsible for  tumour 
eradication in response to reovirus treatment alone, or in combination  
therapy strategies, have not been reported. Thus, the work described in this 
chapter aimed to characterise  the immune response to reovirus treatment in 
the 5TGM1 model, and establish the contribution of anti-tumour immunity to 
reovirus treatment efficacy.  
 145 
4.2 Results 
4.2.1 Ex vivo reovirus and CVA21 susceptibility of 5TGM1 cells 
Before inclusion in in vivo experimentation, the susceptibility of 5TGM1 to 
reovirus and CVA21 in vitro was established (Figure 4-1). 5TGM1 cells were 
treated with either reovirus or CVA21 for 48 (Figure 4-1A) or 72 hrs (Figure 
4-1B) and cell death was analysed by flow cytometry. After 48 hrs of reovirus 
treatment, a dose-dependent response was seen with a maximum of 86.6% 
cell death at the 10 pfu/cell dose. Following 72 hrs of treatment, over 95% of 
5TGM1 cells were eradicated, even at the lowest dose of 0.01 pfu/cell 
(Figure 4-1B). As expected, this experiment further confirmed the CVA21 
dependency on human ICAM-1 for host cell infection as no changes in 
5TGM1 cell viability were observed following treatment for 48 or 72 hrs. As 
direct oncolysis might not be strictly necessary to study anti-tumour 
immunity, the potential for using CVA21 in the 5TGM1 model was further 
explored. It was hypothesised that CVA21 might still be able to elicit an 
immune response in a murine model through engagement with PRRs. To 
test this, splenocytes from WT C57Bl/6 mice were isolated and treated with 
CVA21 ex vivo. Splenocyte activation in response to CVA21 was measured 
by flow cytometry and confirmed that, in addition to the lack of direct 
oncolysis, CVA21 also had no activating effect on murine splenic immune 
cells (data not shown). As a result, reovirus was chosen as the preferred 
agent to use in the subsequent in vivo experiments. 
 
4.2.2 Optimisation of an in vivo reovirus treatment protocol 
After in vitro propagation, 5TGM1 cells were passaged in vivo to obtain 
bone-homing 5TGM1 cells. Following re-injection i.v., bone-homing 5TGM1 
cells generated bone disease within a more reliable timeframe (described in 
Section 2.17.1). As expected (404), 5TGM1 cells disseminated to the 
skeleton following i.v. injection and untreated mice developed HLP within 21-
25 days. Next, an optimised protocol for reovirus treatment was developed. 
  
 146 
 
 
Figure 4-1: Ex vivo susceptibility of 5TGM1 to reovirus and CVA21. 
Murine MM cells 5TGM1 were either left untreated (Untr.) or treated with reovirus 
(0.01, 0.1, 1, or 10 pfu/cell) or CVA21 (0.01, 0.1. or 1 pfu/cell) for 48 (A) or 72 (B) 
hrs (n=3). Cell viability was measured by flow cytometry at each time point using a 
Live/Deadâ discrimination stain. Statistical significance was calculated using one-
way ANOVA with Dunnett’s post-hoc test, * = p<0.05, **** = p<0.0001. Error bars 
indicate s.e.m. 
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4.2.2.1 Reovirus treatment with intraperitoneal administration  
As described in Section 2.17.3, all in vivo experiments started with the 
injection of 2x106 5TGM1 cells in the tail vein of C57Bl/KaLwRij mice. As 
intraperitoneal (i.p.) delivery is the preferred systemic route of delivery for 
repeated injections in mice, a treatment schedule with four i.p. injections of 
2x107 pfu reovirus/injection before development of HLP was first tested 
(Figure 1-2A). A total of 16 female mice, aged 6-8 weeks old, were 
randomised, age-matched, between Naïve (2), PBS (7), and Reo (7) 
treatment groups and treatment efficacy was evaluated by examining the 
presence of tumour cells in the BM and spleen. Upon sacrifice, the BM and 
spleen were harvested and the percentage of CD138+ 5TGM1 cells at each 
site was evaluated by flow cytometry. Disappointingly, there was no 
significant reduction in tumour burden in either the BM or the spleen 
following reovirus treatment. In the BM, the percentage of CD138+ cells was 
reduced from an average 81.5% to 64.4% (Figure 1-2B), indicating that 
reovirus treatment did have some effect, however, these data suggested that 
the treatment schedule required further optimisation. Some variability in the 
tumour burden in both the BM and spleen of PBS-treated mice was 
observed, ranging from 3.4% to 82.8% in the BM and from 4.4% to 23.9% in 
the spleen, suggesting that large group sizes were required to perform well 
powered experiments. 
Next, the potential for the induction of an anti-tumour immune response 
induced by reovirus in the BM of treated mice was examined. An overview of 
all phenotypic markers used in the in vivo experiments throughout this 
chapter is provided in Table 4-1. First, the presence of NK cells and CD4+ T 
cells in the BM, with and without reovirus treatment, was assessed. While 
not significant, some enlargement of the NK cell and CD4+ T cell populations 
in the BM was observed in reovirus-treated mice compared to PBS 
treatment. The percentage of NK cells increased by an average 0.5%, and 
the percentage of CD4+ T cells increased by 0.4% (Figure 4-2D). Significant 
variation within the groups made comparison to the naïve control mice 
difficult. However, a significant negative correlation between the tumour 
burden in the BM and both the size of the NK cell (p<0.0001, Pearson’s r=-
0.99) and CD4+ T cell (p=0.010, Pearson’s r=-0.87) populations was 
identified, indicating that the BM might be repopulated with immune cells as 
the tumour burden is reduced. 
Next, immune cell activation in response to reovirus treatment  was 
evaluated by measuring the expression of the activation marker CD69 on NK 
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cells and CD4+ T cells (Figure 4-2E). As described in Chapter 3 and in 
several previous studies, CD69 is a common marker of both NK and T cell 
activation (405). However, no significant increase in CD69 expression was 
detected on either NK or CD4+ T cells in this experiment. To better mimic the 
human clinical scenario, and provide a more relevant treatment schedule to 
examine reovirus efficacy, and its in vivo mechanism of action, the protocol 
was next adapted to i.v. delivery.   
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Table 4-1: Overview of phenotypic markers used in in vivo experiments. 
ANTIBODY TARGET NAME FUNCTION/PURPOSE 
CD138 Syndecan-1 MM cell identification 
 
CD3 T cell co-receptor T cell identification 
DX5 (CD49b) Integrin-a2 NK cell identification 
CD4 T cell co-receptor CD4+ T cell/helper T cell identification 
CD8 T cell co-receptor CD8+ T cell/cytotoxic T cell identification 
 
CD44 CD44 Effector-memory T cell identification, up-
regulated in response to T cell activation 
CD62L L-selectin Naïve T cell identification, required for T 
cell homing to secondary lymphoid tissues 
 
CD69 CD69 Early activation of lymphocytes, C-type 
lectin 
4-1BB (CD137) 4-1BB T and NK cells activation, marker of 
antigen-recognition in CTLs 
PD-1 (CD279) Programmed cell 
death protein-1 
Immune checkpoint, prevents 
autoimmunity, marker of T cell activation 
and exhaustion 
CTLA-4 (CD152) Cytotoxic T 
Lymphocyte Antigen-4 
Immune checkpoint, induced on activated T 
cells, negative regulator of activation 
 
CD80 B7-1 CD28 and CTLA-4 ligand on APCs, 
provides co-stimulation for T cells; 
monocyte and macrophage activation 
CD86 B7-2 See CD80 (above) 
I-Ab MHC Class II Extracellular antigen-presentation molecule 
on professional APCs 
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Figure 4-2: Effects of reovirus treatment administered i.p. 
A: Schematic demonstrating the in vivo treatment schedule. 16 mice were injected 
with 2x106 5TGM1 cells i.v. on Day 0 (orange). Reovirus (or PBS vehicle) therapy 
(2x107 pfu) was started on Day 13 (purple). Four injections were administered 
before development of HLP in control mice. Following sacrifice, the BM and spleen 
were harvested from all mice. B and C: The tumour burden in the BM (B) and 
spleen (C) after PBS or reovirus treatment was measured by flow cytometry and 
was estimated as the percentage of CD138+ cells. D: The percentage of NK cells 
and CD4+ T cells in the BM following PBS or reovirus treatment, respectively, was 
measured by flow cytometry. NK cells were identified as CD3-DX5+, CD4+ T cells 
were identified as CD3+CD4+. Naïve mice were non-tumour bearing and untreated. 
E: The activation state of NK cells and CD4+ T cells following PBS or reovirus 
treatment was estimated by CD69 expression, measured by flow cytometry. The 
percentage of CD69+ cells is shown. In B, C, and E statistical significance was 
calculated using two-tailed, unpaired t-tests. In D, a one-way ANOVA with Tukey’s 
post-hoc test was used. n.s = not significant, error bars indicate s.e.m.  
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4.2.2.2 In vivo eradication of MM tumours following i.v. treatment with 
reovirus 
As i.v. delivery is the preferred route of administration in MM patients, the 
efficacy of i.v. reovirus was next tested in vivo. Early pilot experiments in our 
lab using this model, and results in the studies by Kelly et al. indicated that 
i.v. administration can provide good efficacy for reovirus treatment (318, 392, 
406). In an attempt to enhance efficacy compared to the i.p. experiment 
(Section 4.2.2.1), reovirus treatment was started earlier in subsequent 
experiments (Day 7-9 after tumour administration). After establishment of 
tumours, mice received reovirus or PBS i.v. according to a Mon/Wed/Fri 
schedule until development of HLP in PBS control groups (Figure 4-3A). The 
data presented within this section show the combined result of several 
repeated experiments, as indicated in figure legends and Table 4-2, to 
enable reproducible changes to be identified. Both female and male mice 
were included in the experiments. While all mice received the same tumour 
challenge at the start of each experiment (2x106 5TGM1 cells i.v.) and the 
same reovirus dose (2x107 pfu/injection), treatment continued until 
development of HLP in each individual control group, resulting in a different 
number of injections given in different experiments (Table 4-2). In particular 
one experimental repeat stood out as mice received up to eight injections 
(eight injections for males, seven for females) compared to the average five. 
As the mice in this experiment responded particularly well to reovirus 
treatment, these mice have been highlighted in purple (both males and 
females) on the relevant figures. Including these mice in the overall 
evaluation did not change the decision to accept or reject the null hypothesis 
for any variable. Additionally, the flow cytometry phenotyping protocol was 
gradually developed with each individual experiment, resulting in variations 
in the number of mice included between markers. For all experiments, the 
BM and spleen were harvested after sacrifice, and tumour burden, along 
with the size of immune cell populations, and their respective activation 
state, was evaluated at both sites.  
Using i.v. injections, reovirus treatment resulted in a significant reduction in 
tumour burden in both the BM and the spleen, compared to PBS treatment 
(Figure 4-3 B and C). Tumour burden in the BM decreased from an average 
47.9% to 23.9% with reovirus treatment (Figure 4-3B). However, the effect 
was more pronounced in Expt. 2 (purple symbols), where male mice 
received eight reovirus injections (seven for females), with an average 
reduction in CD138+ cells in the BM from 59.5% to 9.9%. The homing of 
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tumour cells to the spleen was more variable, but overall, reovirus treatment 
resulted in an average 4.8% decrease in tumour burden in the spleen 
(Figure 4-3C). While these results were encouraging, it was uncertain 
whether the reduction in tumour burden was due to direct oncolysis or the 
activation of an anti-tumour immune response hence, this was next 
examined in more detail. 
The presence of reovirus in the BM at the time of sacrifice was examined by 
RT-qPCR, using the reovirus s3 capsid gene as a marker of reovirus 
particles. BM was harvested on average three days after the last reovirus 
injection and no reovirus could be detected in the BM at that time point 
(Figure 4-3D). Interestingly, the absence of reovirus at this time point could 
indicate that direct oncolysis has subsided and the virus has been cleared by 
the development of antiviral immune mechanism, however, it could also 
suggest that reovirus efficacy was mediated through the induction of an anti-
tumour immune response. 
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Table 4-2: Overview of in vivo experiments with i.v. administration of reovirus. 
In figures throughout sections 4.2.2.2-4.2.2.4 results from several individual in vivo 
experiments detailed below were pooled. All mice received 2x107 pfu/injection 
reovirus i.v. however, the number of injections varied depending on the time 
required for development of HLP in control mice. Details of the cohorts for each 
individual experiment, including the number of injections and age of the mice are 
shown. The phenotyping done for each experiment is also described. 
 
F: female, M: male, naïve: non-tumour bearing and untreated, HLP: hind limb 
paralysis. 
  
EXPT. 
NUMBER 
NO. OF  
MICE 
MOUSE AGE 
(WEEKS) 
DAYS TO 
HLP 
NO. OF 
INJECTIONS 
PHENOTYPING 
DONE 
 
1 
 
10 (F) 
 
4-6 
 
20 
 
5 
 
CD138, CD69,  
4-1BB 
 
 
2 
8 (F) 
8 (M) 
(+4 naïve) 
 
6-8 
 
25 (F) 
27 (M) 
 
7 (F) 
8 (M) 
 
CD138, CD69, 
CD25 (not shown), 
CD44 (not shown), 
RT-qPCR 
 
 
3 
 
10 (F) 
(+3 naïve) 
 
6-8 
 
23 
 
6 
CD138, CD69, 
4-1BB, PD-1, 
CTLA-4, 
naïve/memory T 
cells 
 
 
 
4 
 
 
10 (F) 
6 (M) 
 
 
6-8 
 
 
21 
 
 
5 
CD138, CD69,  
4-1BB, PD-1, 
CTLA-4, 
naïve/memory T 
cells, myeloid cells 
CD80, CD86, MHC 
Class II, RT-qPCR 
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Figure 4-3: Reduction in tumour burden following i.v. treatment with reovirus. 
A: Schematic demonstrating the in vivo treatment schedule. Mice were injected with 
2x106 5TGM1 cells i.v. on Day 0 (orange). Reovirus (or PBS vehicle) therapy (2x107 
pfu) was started on Day 7-9 (purple) and continued three times weekly until 
development of HLP in control mice (Day 21-25). Following sacrifice, the BM and 
spleen were harvested from all mice. B and C: The tumour burden in the BM (B) 
and spleen (C) after PBS or reovirus treatment was measured by flow cytometry 
and was estimated as the percentage of CD138+ cells (n=26 per group). Naïve mice 
were non-tumour bearing and untreated (n=7). D: The presence of reovirus in the 
BM on termination of experiments was examined by RT-qPCR using reovirus s3 
primers (n=12 per group). RNA was isolated using the RNEasy Mini Kit. Results 
were quantified using a standard curve method. Statistical significance was 
calculated using two-tailed, unpaired t-tests, ** = p<0.01, **** = p<0.0001, n.s = not 
significant, error bars indicate s.e.m. Purple symbols indicate mice from Expt. 2 
(Table 4-2).  
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4.2.2.3 Normalisation of immune cell populations in the BM and spleen 
following reovirus treatment i.v. 
As i.v. treatment with reovirus generated a significant reduction in tumour 
burden, the next step was to examine the possible onset of anti-tumour 
immunity. A multitude of immune mechanisms have the potential to be 
involved in an anti-tumour immune response generated by reovirus in vivo. 
As the in vitro experiments performed in Chapter 3 indicated a role for both 
NK cells and T cells in anti-myeloma immunity, these cell types were the 
main focus of the initial phenotyping experiments in vivo. First, the 
proportions of NK cells, CD4+, and CD8+ T cells in the BM and spleen were 
measured by flow cytometry to evaluate the potential for immune cell 
recruitment in response to reovirus treatment. In the BM, there was a 
significant enlargement of the NK cell, CD4+, and CD8+ T cell populations 
following reovirus treatment (Figure 4-4 A-C) compared to PBS treatment. 
On average, populations increased by 1.0%, 1.2%, and 1.7%, respectively. 
In the spleen, only the CD8+ T cell population was significantly enlarged in 
response to reovirus treatment (1.7%, comparable to the naïve BM), 
compared to PBS treatment (Figure 4-5C). While there was suggestion of an 
increase in the populations of both NK cells and CD4+ T cells compared to 
PBS treatment, neither was statistically significant (Figure 4-5 A and B). For 
all cell types in both locations, there was no significant difference in the 
population sizes between naïve mice and mice treated with reovirus, which 
may suggest a normalisation or reconstitution of the BM compartment, rather 
than recruitment of effector cells as part of an antiviral or anti-tumour 
immune response. Thus, the T cells in the BM and spleen were next 
characterised further to evaluate whether they were naïve T cells (part of a 
reconstitution) or effector cells (anti-tumour or antiviral T cells). 
The T cell populations were examined by evaluating the proportion of naïve 
(CD44-CD62L+) T cells to effector memory T cells (TEM, CD44+CD62L-). 
While naïve T cells have yet to encounter antigen, TEM have been primed 
against antigen, typically display rapid effector functions, and carry cytotoxic 
granules necessary for eradication of cells in an antigen-specific manner 
(407). Interestingly, while both CD4+ and CD8+ T cell populations in the BM 
were enlarged in response to reovirus treatment (Figure 4-4), there was no 
significant change in the proportion of naïve or TEM populations (Figure 4-6 A 
and B). In the spleen however, a significant increase in the TEM population 
(both CD4+ and CD8+) was observed in response to reovirus, along with a 
decrease in the population of naïve T cells (Figure 4-7 A and B). CD4+ TEM 
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increased from 25.2% to 35.7% and CD8+ TEM from 14.0% to 41.1%. 
Importantly, the size of the TEM populations increased beyond the level of 
naïve (non-tumour bearing) mice (28.9% and 20.0% TEM, respectively) in 
response to reovirus. Furthermore, a significant negative correlation was 
identified between the size of the CD8+ TEM population in the spleen and the 
population of CD138+ tumour cells in the BM (p=0.023, Pearson’s r=-0.62), 
suggesting a role of CD8+ T cells for the eradication of MM cells within the 
BM. Taken together, the results presented in this section demonstrate a 
normalisation of immune cell populations in the BM and spleen following 
reovirus treatment. Importantly, evidence of TEM was observed in the spleen, 
indicating that priming of either anti-tumour or antiviral cytotoxic CD8+ T cells 
might have occurred.  
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Figure 4-4: Normalisation of immune cell populations in the BM following 
reovirus treatment i.v. 
The percentage of NK cells (A), CD4+ T cells (B), and CD8+ T cells (C) in the BM 
was measured by flow cytometry following repetitive PBS or reovirus treatment as 
previously described (n=22 per group). Naïve control mice were non-tumour 
bearing and untreated (n=5). NK cells were identified as CD3-DX5+, CD4+ T cells as 
CD3+CD4+, and CD8+ T cells as CD3+CD8+. Purple symbols indicate mice from 
Expt. 2 (Table 4-2). Statistical significance was calculated using one-way ANOVA 
with Tukey’s post-hoc test, ** = p<0.01, *** = p<0.001, **** = p<0.0001, n.s = not 
significant, error bars indicate s.e.m. 
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Figure 4-5: Normalisation of immune cell populations in the spleen following 
reovirus treatment i.v. 
The percentage of NK cells (A), CD4+ T cells (B), and CD8+ T cells (C) in the 
spleen was measured by flow cytometry following repeated PBS or reovirus 
treatment as previously described (n=22 per group). Naïve control mice were non-
tumour bearing and untreated (n=5). NK cells were identified as CD3-DX5+, CD4+ T 
cells as CD3+CD4+, and CD8+ T cells as CD3+CD8+. Purple symbols indicate mice 
from Expt. 2 (Table 4-2). Statistical significance was calculated using one-way 
ANOVA with Tukey’s post-hoc test, ** = p<0.01, n.s = not significant, error bars 
indicate s.e.m. 
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Figure 4-6: Naïve and effector/memory T cell populations in the BM following 
reovirus treatment i.v. 
Following repeated reovirus or PBS treatment, the BM was harvested and the 
percentage of naïve T cells (CD44-CD62L+, black symbols) and effector/memory T 
cells (TEM, CD44+CD62L-, orange symbols) was evaluated by flow cytometry (n=13 
per group). Naïve control mice were non-tumour bearing and untreated (n=3) A: 
CD4+ naïve T cells and TEM. B: CD8+ naïve T cells and TEM. Statistical significance 
was calculated using one-way ANOVA with Tukey’s post-hoc test, n.s = not 
significant, error bars indicate s.e.m.  
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Figure 4-7: Naïve and effector/memory T cell populations in the spleen 
following reovirus treatment i.v. 
Following repeated reovirus or PBS treatment, the spleen was harvested and 
processed, and the percentage of naïve T cells (CD44-CD62L+, black symbols) and 
effector/memory T cells (TEM, CD44+CD62L-, orange symbols) was evaluated by 
flow cytometry (n=13 per group). Naïve control mice were non-tumour bearing and 
untreated (n=3) A: CD4+ naïve T cells and TEM. B: CD8+ naïve T cells and TEM. 
Statistical significance was calculated using one-way ANOVA with Tukey’s post-hoc 
test, * = p<0.05, ** = p<0.01, **** = p<0.0001, n.s = not significant, error bars 
indicate s.e.m.  
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4.2.2.4 Lymphocyte phenotyping following reovirus treatment i.v.  
Next, NK cells, CD4+, and CD8+ T cells were interrogated with a phenotyping 
panel consisting of CD69, 4-1BB, PD-1, and CTLA-4. As described in Table 
4-1, CD69 is a marker of lymphocyte activation (405), 4-1BB is a marker of 
antigen recognition on T cells (and activation of NK cells) (408-410), and 
both PD-1 and CTLA-4 are known immune checkpoints which can be up-
regulated both in response to T cell activation and exhaustion (411-414). 
Overall, few phenotypic changes were detected in both NK cells (Figure 
4-8), CD4+ T cells (Figure 4-9), and CD8+ T cells (Figure 4-10) in the BM in 
response to reovirus treatment. Figure 4-8 shows that only the expression of 
PD-1 on NK cells was significantly changed, with a 1.5% reduction in PD-1-
positive cells (Figure 4-8C). No significant changes in the expression of 
either CD69, 4-1BB, PD-1, or CTLA-4 were detected on CD4+ T cells in the 
BM in response to reovirus treatment (Figure 4-9). Similar to the NK cells but 
more pronounced, the only significantly changed marker on CD8+ T cells 
was PD-1, with a 21.3% reduction in PD-1-positive cells (Figure 4-10C). The 
overall CD8+ T cell expression of CD69, 4-1BB, and CTLA-4 was also 
decreased, but these changes were not statistically significant.  
Upon examination of immune cell populations in the spleen, the changes in 
response to reovirus treatment were again more notable. On splenic NK 
cells, 4-1BB expression was up-regulated with reovirus treatment (Figure 
4-11B). Previously, 4-1BB has been reported to be upregulated on NK cells 
following activation, but its involvement in the cytotoxic function of NK cells 
remains unclear (408, 409). Similar to the BM, the percentage of PD-1-
expressing NK cells was significantly reduced by 0.7% (Figure 4-11C). 
Moreover, on CD4+ T cells both immune checkpoint molecules, PD-1 and 
CTLA-4, were up-regulated following reovirus treatment (Figure 4-12 C and 
D). Up-regulation of several negative regulators might indicate a state of 
exhaustion in CD4+ T cells, in particular in response to chronic viral 
infections (415, 416). Examining responses in CD8+ T cells, PD-1 
expression was also up-regulated, with an average increase in PD-1-positive 
CD8+ T cells from 11.8% to 26.7% (Figure 4-13C). Importantly, expression of 
the activation marker CD69 was also significantly enhanced on CD8+ T cells 
in the spleen following reovirus treatment (Figure 4-13A). The dual 
expression of these markers may indicate an overall activation of CD8+ T 
cells in the spleen, which is encouraging in the light of the expanded TEM 
population (Figure 4-7). Disappointingly, there was no significant correlation 
between either CD69 or PD-1 expression on CD8+ T cells in the spleen and 
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a favourable outcome in terms of BM tumour burden. In an attempt to further 
clarify the involvement of tumour-specific CTLs in the reduction of tumour 
burden in response to reovirus treatment, splenocytes were re-challenged 
with 5TGM1 cells ex vivo to evaluate CTL antigen specificity; no increase in 
IFN-g secretion from splenocytes could be detected using an ELISA and a 
1:1 ratio of splenocytes to 5TGM1 cells for 24 or 48 hrs (data not shown). 
Further optimisation of these experiments, and complementary experiments 
evaluating the IFN-g response upon splenocyte stimulation with 5TGM1 
cells, MM antigens or reovirus by intracellular flow cytometry and ELISpot 
assays is required to establish the nature of the effector T cells present in 
the spleen following reovirus treatment. 
In summary, this section has evaluated the phenotype of lymphocytes (NK 
cells, CD4+, and CD8+ T cells) following reovirus treatment i.v. An overview 
of the phenotypic changes in each cell type with reovirus treatment is shown 
in Table 4-3. Phenotypic changes in the BM were modest, however, the 
reduction in PD-1 expression on NK cells and CD8+ T cells was encouraging 
and could indicate a disruption of the local immunosuppressive environment. 
The phenotypic effects of reovirus treatment were more pronounced in the 
spleen. Overall, the changes observed on NK cells and CD8+ T cells 
(increased expression of 4-1BB on NK cells and of CD69 and PD-1 on CD8+ 
T cells) in the spleen suggested that these cell populations were activated in 
response to reovirus treatment. In particular the CD8+ T cell response was 
encouraging considering the increased population of CD8+ T cells in the 
spleen, which was associated with an increased CD8+ TEM population, and a 
decrease in naïve CD8+ T cells (Section 4.2.2.3). Taken together, these 
findings demonstrate immunological changes in reovirus-treated mice, 
however the nature of these changes with regards to their anti-tumour or 
antiviral character requires further investigations.   
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Figure 4-8: Phenotyping of NK cells in the BM following reovirus treatment i.v. 
Following repeated treatment with either PBS or reovirus, the BM was harvested 
and NK cells (CD3-DX5+) were phenotyped for the expression of activation markers 
and immune checkpoint molecules by flow cytometry. Naïve control mice were non-
tumour bearing and untreated. Results are shown as the percentage positive cells 
determined using a fluorescence minus one control. A: CD69 expression. Purple 
symbols indicate mice from Expt 2 (Table 4-2), n=26 per group, naïve=5. B: 4-
1BB/CD137 expression (n=18 per group, naïve=3). C: PD-1/CD279 expression 
(n=13 per group, naïve=3). D: CTLA-4/CD152 expression (n=13 per group, 
naïve=3). Statistical significance was calculated using one-way ANOVA with 
Tukey’s post-hoc test, * = p<0.05, n.s = not significant, error bars indicate s.e.m. 
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Figure 4-9: Phenotyping of CD4+ T cells in the BM following reovirus 
treatment i.v. 
Following repeated treatment with either PBS or reovirus, the BM was harvested 
and CD4+ T cells (CD3+CD4+) were phenotyped for the expression of activation 
markers and immune checkpoint molecules by flow cytometry. Naïve control mice 
were non-tumour bearing and untreated. Results are shown as the percentage 
positive cells determined using a fluorescence minus one control. A: CD69 
expression. Purple symbols indicate mice from Expt 2 (Table 4-2), n=26 per group, 
naïve=5. B: 4-1BB/CD137 expression (n=18 per group, naïve=3). C: PD-1/CD279 
expression (n=13 per group, naïve=3). D: CTLA-4/CD152 expression (n=13 per 
group, naïve=3). Statistical significance was calculated using one-way ANOVA with 
Tukey’s post-hoc test, n.s = not significant, error bars indicate s.e.m. 
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Figure 4-10: Phenotyping of CD8+ T cells in the BM following reovirus 
treatment i.v. 
Following repeated treatment with either PBS or reovirus, the BM was harvested 
and CD8+ T cells (CD3+CD8+) were phenotyped for the expression of activation 
markers and immune checkpoint molecules by flow cytometry. Naïve control mice 
were non-tumour bearing and untreated. Results are shown as the percentage 
positive cells determined using a fluorescence minus one control. A: CD69 
expression. Purple symbols indicate mice from Expt 2 (Table 4-2), n=26 per group, 
naïve=5. B: 4-1BB/CD137 expression (n=18 per group, naïve=3). C: PD-1/CD279 
expression (n=13 per group, naïve=3). D: CTLA-4/CD152 expression (n=13 per 
group, naïve=3). Statistical significance was calculated using one-way ANOVA with 
Tukey’s post-hoc test, * = p<0.05, n.s = not significant, error bars indicate s.e.m. 
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Figure 4-11: Phenotyping of NK cells in the spleen following reovirus 
treatment i.v. 
5TGM1 tumour-bearing mice were repeatedly treated with either PBS or reovirus. 
The spleen was harvested and processed and NK cells (CD3-DX5+) were 
phenotyped for the expression of activation markers and immune checkpoint 
molecules by flow cytometry. Naïve control mice were non-tumour bearing and 
untreated. Results are shown as the percentage positive cells determined using a 
fluorescence minus one control. A: CD69 expression. Purple symbols indicate mice 
from Expt 2 (Table 4-2), n=26 per group, naïve=5. B: 4-1BB/CD137 expression 
(n=18 per group, naïve=3). C: PD-1/CD279 expression (n=13 per group, naïve=3). 
D: CTLA-4/CD152 expression (n=13 per group, naïve=3). Statistical significance 
was calculated using one-way ANOVA with Tukey’s post-hoc test, * = p<0.05, ** = 
p<0.01, n.s = not significant, error bars indicate s.e.m. 
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Figure 4-12: Phenotyping of CD4+ T cells in the spleen following reovirus 
treatment i.v. 
5TGM1 tumour-bearing mice were repeatedly treated with either PBS or reovirus. 
The spleen was harvested and processed and CD4+ T cells (CD3+CD4+) were 
phenotyped for the expression of activation markers and immune checkpoint 
molecules by flow cytometry. Naïve control mice were non-tumour bearing and 
untreated. Results are shown as the percentage positive cells determined using a 
fluorescence minus one control. A: CD69 expression. Purple symbols indicate mice 
from Expt 2 (Table 4-2), n=26 per group, naïve=5. B: 4-1BB/CD137 expression 
(n=18 per group, naïve=3). C: PD-1/CD279 expression (n=13 per group, naïve=3). 
D: CTLA-4/CD152 expression (n=13 per group, naïve=3). Statistical significance 
was calculated using one-way ANOVA with Tukey’s post-hoc test, * = p<0.05, **** = 
p<0.0001, n.s = not significant, error bars indicate s.e.m. 
 
  
 168 
 
Figure 4-13: Phenotyping of CD8+ T cells in the spleen following reovirus 
treatment i.v. 
5TGM1 tumour-bearing mice were repeatedly treated with either PBS or reovirus. 
The spleen was harvested and processed CD8+ T cells (CD3+CD8+) were 
phenotyped for the expression of activation markers and immune checkpoint 
molecules by flow cytometry. Naïve control mice were non-tumour bearing and 
untreated. Results are shown as the percentage positive cells determined using a 
fluorescence minus one control. A: CD69 expression. Purple symbols indicate mice 
from Expt 2 (Table 4-2), n=26 per group, naïve=5. B: 4-1BB/CD137 expression 
(n=18 per group, naïve=3). C: PD-1/CD279 expression (n=13 per group, naïve=3). 
D: CTLA-4/CD152 expression (n=13 per group, naïve=3). Statistical significance 
was calculated using one-way ANOVA with Tukey’s post-hoc test, * = p<0.05, **** = 
p<0.0001, n.s = not significant, error bars indicate s.e.m. 
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Table 4-3: Overview of phenotypic changes in immune cells following i.v. 
treatment with reovirus. 
NK cells, CD4+, and CD8+ T cells from the BM and spleen were phenotyped for the 
expression of CD69, 4-1BB, PD-1, and CTLA-4 using flow cytometry. Arrows 
indicate the overall change in expression with reovirus treatment, compared to PBS 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X = unchanged, ­ = increased expression compared to PBS, ¯ = decreased 
expression compared to PBS. 
  
BONE MARROW 
CELL TYPE CD69 4-1BB PD-1 CTLA-4 
 
NK CELLS 
 
X 
 
X 
 
¯ 
 
X 
 
CD4+ T 
CELLS 
 
X 
 
X 
 
X 
 
X 
 
CD8+ T 
CELLS 
 
X 
 
X 
 
¯ 
 
X 
SPLEEN 
 
NK CELLS 
 
X 
 
­ 
 
¯ 
 
X 
 
CD4+ T 
CELLS 
 
X 
 
X 
 
­ 
 
­ 
 
CD8+ T 
CELLS 
 
­ 
 
X 
 
­ 
 
X 
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4.2.2.5 Myeloid cell responses in vivo following i.v. treatment with 
reovirus 
Lymphocytes are not the only immune cell population involved in an anti-
tumour immune response and myeloid cells, including e.g. monocytes, 
macrophages, and MDSCs, are also pivotal in regulating anti-tumour 
immunity. Monocytes and macrophages are important regulators of the 
innate immune response, and act as APCs to facilitate the generation of 
adaptive immunity. By contrast, MDSCs (both monocytic and granulocytic) 
have immunosuppressive and tumour-promoting functions. To date, the 
effect of OV treatment on myeloid cells in vivo, in particular within the tumour 
microenvironment and sites of immune priming, such as the spleen, remain 
unclear (417). To examine the effect of reovirus on different myeloid cell 
subtypes, a flow cytometry phenotyping panel was developed to include 
myeloid cells in both the BM and the spleen, including monocytes, 
macrophage, and MDSC populations (Table 4-1 and Table 2-5). The 
treatment schedule and dosing remained the same as described in Figure 
4-3A. As for previous experiments, the BM and spleen were harvested upon 
sacrifice of the animals at the end of the experiment and cells were 
examined by flow cytometry. 
First, the percentage of monocytes (inflammatory), macrophages, and 
MDSCs in the BM and spleen, following reovirus treatment compared to 
PBS, was examined. Figure 4-14 shows that no significant changes were 
detected in the size of the myeloid populations in the BM in response to 
reovirus treatment, although there was suggestion of an enlargement, in 
particular for monocyte and macrophage populations. As observed for the 
lymphocyte populations, changes were again more pronounced in the 
spleen (Figure 4-15). For example, the monocyte population increased by 
20.7% (Figure 4-15A), and the percentage of conventional (CD11b+) 
macrophages increase by an average of 6.1% (Figure 4-15B) in response to 
reovirus treatment. By contrast, there was no change in the population size 
of red pulp macrophages (RPM) (Figure 4-15B). Interestingly, there was a 
significant reduction in the population of granulocytic MDSCs in the spleen 
from an average 27.6% to 17.2% (Figure 4-15C), whilst the monocytic 
MDSC population was unchanged. 
Next, the expression of co-stimulatory molecules CD80 and CD86, and MHC 
Class II was assessed on monocytes and macrophages. As shown in 
Chapter 3, reovirus treatment of human monocyte-derived DCs in vitro  
significantly increased the expression of these markers with subsequent 
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efficient priming of tumour-specific CTLs (Section 3.2.2.3). CD80, CD86, and 
MHC Class II are markers of M1-polarized macrophages, as opposed to the 
M2 subtype and tumour-associated macrophages (TAM) (418). 
Unexpectedly, there was an indication of reduced expression of all three 
markers on monocytes in the BM, however; only the expression of MHC 
Class II was significantly reduced following reovirus treatment (Figure 
4-16A). On BM macrophages, both CD80 and MHC Class II were 
significantly reduced (Figure 4-16B), indicating that macrophages might be 
polarised towards an M2 profile, but an extended phenotyping panel will be 
required to determine this. Despite the increase in the population sizes of 
both monocytes and conventional macrophages in the spleen (Figure 4-15), 
the expression of CD80, CD86, and MHC Class II remained unchanged on 
both cell types (Figure 4-17 A and B). However, on RPM in the spleen, all 
three markers were significantly upregulated (Figure 4-17C). Little is known 
about the function of RPM, and they are predominantly thought to be 
involved in the maintenance of red blood cell (RBC) homeostasis, however; 
a number of studies indicate that these macrophages might also be involved 
in antigen presentation. RPMs have been reported to phagocytose and 
display ovalbumin antigen on the cell surface in vitro, and importantly, they 
play a role in the priming of antiviral CTLs following VSV infection in mice 
(419, 420). 
While many of the findings presented in this chapter are preliminary, not 
least those regarding myeloid cells, a number of interesting results were 
obtained. Immune activation induced by reovirus treatment demonstrated 
the potential of reovirus to modulate immune effector cells, but whether this 
plays a role in anti-tumour immunity or is mainly an antiviral response 
remains unknown. Overall, the reduction in tumour burden in an 
immunocompetent model strengthens the applicability of reovirus as a 
therapeutic option in MM. While a lot of work remains to fully confirm a role 
of anti-tumour immunity in an in vivo setting, the phenotyping data obtained 
through this work is particularly interesting in the context of combination 
treatments, such as checkpoint inhibitors, which could be employed to 
further enhance the anti-tumour effects of reovirus. 
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Figure 4-14: Myeloid cell populations in the BM following reovirus treatment 
i.v. 
5TGM1 tumour-bearing mice were repeatedly treated with either PBS or reovirus. 
After sacrifice, the BM was harvested and the size of various myeloid cell 
populations was determined by flow cytometry (n=8 per group). A: Monocytes 
(inflammatory) were identified as CD45+CD11b+Ly6C+ cells. B: Macrophages were 
identified as CD45+CD11b+F4/80+ cells. C: MDSCs were identified as 
CD45+CD11b+ cells, with monocytic MDSCs being Ly6G-Ly6Chi and granulocytic 
MDSCs being Ly6G+Ly6Clo. Statistical significance was calculated using two-tailed, 
unpaired t-tests, all determined to have p>0.05 (not significant), error bars indicate 
s.e.m.  
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Figure 4-15: Myeloid cell populations in the spleen following reovirus 
treatment i.v. 
5TGM1 tumour-bearing mice were repeatedly treated with either PBS or reovirus. 
After sacrifice, the spleen was harvested and processed and the size of various 
myeloid cell populations was determined by flow cytometry (n=8 per group). A: 
Monocytes (inflammatory) were identified as CD45+CD11b+Ly6C+ cells. B: 
Conventional macrophages were identified as CD45+CD11b+F4/80+ cells, and red 
pulp macrophages (RPM) as CD45+CD11b-F4/80+ cells. C: MDSCs were identified 
as CD45+CD11b+ cells, with monocytic MDSCs being Ly6G-Ly6Chi and granulocytic 
MDSCs being Ly6G+Ly6Clo. Statistical significance was calculated using two-tailed, 
unpaired t-tests, * = p>0.05, **** = p<0.0001, error bars indicate s.e.m.  
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Figure 4-16: Phenotyping of monocytes and macrophages in the BM following 
reovirus treatment i.v. 
Following repeated reovirus or PBS treatment i.v., the BM from 5TGM1 tumour-
bearing mice was harvested and monocytes and macrophages were phenotyped 
for the expression of co-stimulatory markers CD80 and CD86, as well as MHC 
Class II by flow cytometry (n=8 per group). Results are shown as the percentage of 
positive cells, determined using a fluorescence minus one control. A: Expression of 
CD80, CD86, and MHC Class II on CD45+CD11b+Ly6C+ monocytes. B: Expression 
of CD80, CD86, and MHC Class II on CD45+CD11b+F4/80+ macrophages. 
Statistical significance was calculated using two-tailed, unpaired t-tests, ** = 
p>0.01, error bars indicate s.e.m. 
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Figure 4-17: Phenotyping of monocytes and macrophages in the spleen 
following reovirus treatment i.v. 
Following repeated reovirus or PBS treatment i.v., the spleen from 5TGM1 tumour-
bearing mice was harvested and processed and monocytes and macrophages were 
phenotyped for the expression of co-stimulatory markers CD80 and CD86, as well 
as MHC Class II by flow cytometry (n=8 per group). Results are shown as the 
percentage of positive cells, determined using a fluorescence minus one control. A: 
Expression of CD80, CD86, and MHC Class II on CD45+CD11b+Ly6C+ monocytes. 
B: Expression of CD80, CD86, and MHC Class II on CD45+CD11b+F4/80+ 
macrophages. C: Expression of CD80, CD86, and MHC Class II on CD45+CD11b-
F4/80+ red pulp macrophages (RPM). Statistical significance was calculated using 
two-tailed, unpaired t-tests, * = p<0.05, ** = p>0.01, *** = p<0.001, error bars 
indicate s.e.m. 
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4.3 Summary & Discussion 
This chapter has examined the use of reovirus as a therapeutic option in an 
immunocompetent in vivo model of MM with a particular focus on the 
examination of immune responses induced by reovirus treatment. The 
experiments were performed using the syngeneic 5TGM1 model in 
C57Bl/KaLwRij mice. This model closely resembles human MM with features 
such as development of lytic bone lesions, decreased bone mineral density, 
hypercalcaemia, and paraprotein secretion (401, 402). The model has many 
benefits compared to other models, such as its high reproducibility, cost-
effectiveness (due to short latency resulting from aggressiveness), 
pronounced osteolytic lesions, and the possibility to culture 5TGM1 cells in 
vitro (398, 400, 421, 422). 
The in vitro susceptibility of 5TGM1 cells to reovirus was first established 
(Figure 4-1). This demonstrated significant susceptibility, with >95% of 
5TGM1 cells eradicated at 72 hrs, even at low doses (0.01 pfu/cell). It is 
worth considering this high susceptibility in the context of developing an anti-
tumour immune response as rapid elimination of tumour might not give 
sufficient time for the establishment of successful immunological memory. 
As expected, the results presented in Figure 4-1 also confirmed that 5TGM1 
cells are completely resistant to CVA21, presumably due to the virus 
dependence on human ICAM-1 for its host cell entry rendering murine cells 
resistant (397). Genetically engineered models exist, which incorporate 
murine tumour cells transduced with human ICAM-1, however; the fact that 
CVA21 also does not activate murine immune cells (Section 4.2.1) makes it 
difficult to find a relevant immunocompetent in vivo model for studying 
immune responses induced by CVA21. The determinants of CVA21 immune 
activation are characterised in more detail in Chapter 5, which further 
demonstrated the dependence on human ICAM-1 for the induction of anti-
tumour immunity. 
Firstly, in vivo treatment with reovirus was tested using i.p. administration 
(Figure 4-2). With a treatment schedule based on repetitive reovirus 
administration, i.p. delivery was tested as a more accessible and less 
stressful route of administration for repeated dosing. Reovirus treatment was 
started on Day 13 after tumour cell injection and mice received four 
injections in total. Although not significant, some reduction in tumour burden 
in the BM was observed following reovirus treatment compared to PBS 
(Figure 4-2B), furthermore, there was suggestion of increased NK cell and 
CD4+ T cell populations in the BM compartment (Figure 4-2D). 
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Disappointingly, the effect of reovirus treatment overall was limited with this 
therapeutic schedule. It is possible that the i.p. delivery protocol could 
generate an enhanced response with further optimisation, such as utilising 
an increased dose of reovirus, earlier treatment start, and additional 
injections. However, while systemic, substances delivered i.p. can be 
absorbed into mesenteric blood vessels which drain into the hepatic vein 
and pass through the liver before systemic distribution, resulting in a 
reduction in the final dose delivered to tissues. Drug absorption and 
distribution is also considerably slower than for i.v. administration (423). 
Successful i.p. administration of OVs has previously been documented for 
MV, oncolytic Semliki Forest virus, and Sindbis virus with significant tumour 
regression in different subcutaneous tumour models. Virus doses used were 
similar to the one used in the present study, ranging from 106 to 108 pfu per 
injection, but efficacy was seen already after a single injection of Semliki 
Forest virus and Sindbis virus (424-426). 
In subsequent experiments, the administration route was changed to i.v. 
This administration route was proven successful in early pilot experiments 
with the 5TGM1 model and was also used by Kelly et al. in their reovirus and 
MM studies (318, 392, 406). Delivery i.v. is the preferred route of 
administration in human patients and thus, ultimately results in a more 
translational in vivo model. Successful distribution of virus to the BM 
following i.v. administration of both reovirus and measles virus in humans 
has previously been demonstrated in clinical trials (195, 198). In addition to 
switching administration routes, treatment was also started earlier in 
subsequent experiments and continued until development of HLP in control 
mice, resulting in varying numbers of injection repeats between experiments 
(Table 4-2). Treatment with reovirus i.v. resulted in a significant reduction of 
tumour burden in both the BM and the spleen (Figure 4-3 B and C). This was 
encouraging, and confirmed the observations made by Kelly et al., who first 
successfully demonstrated tumour reduction using reovirus in an 
immunocompetent in vivo model (318, 392). The experiments performed by 
Kelly et al. used a treatment protocol with a higher dose of reovirus per 
injection (5x108 TCID50, approximately 10-fold more than the dose used in 
this study), with one weekly injection over three weeks, starting from Day 7 
after tumour cell administration. In the present study, the extent of tumour 
reduction in the BM was variable with an overall reduction in the percentage 
of CD138+ cells in the BM from 47.9% to 23.9% (Figure 4-3B). As discussed, 
the effect was more pronounced in Expt. 2 (purple symbols), where mice 
received up to eight reovirus injections (seven for females), with an average 
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reduction in CD138+ cells in the BM from 59.5% to 9.9%. Many variables can 
account for the enhanced response seen in this experiment. Mice were of 
similar age in the majority of experiments (Table 4-2), however, both the 
number of injections, and the viability and proliferative state of 5TGM1 cells 
at the time of injection may be responsible for the variation observed. 
Although not directly comparable, Kelly et al. observed similar reductions of 
40-60% in 5TGM1 bioluminescence using reovirus as a monotherapy (318, 
392). As discussed in more detail below, combination treatments might be 
required to potentiate the effect of reovirus and induce a complete, sustained 
response in the extended population. Kelly et al. demonstrated synergistic 
effects using reovirus in combination with bortezomib in the 5TGM1 model to 
improve the direct cytotoxic effect of reovirus treatment. As the 
bortezomib/reovirus combination treatment was also efficacious in an 
immunocompromised human xenograft model of MM, tumour reduction in 
response to this therapy was thought to be mediated mainly by direct 
oncolysis (318). However, in a subsequent study, Kelly et al. expanded their 
work with the 5TGM1 model to explore the involvement of immune-mediated 
mechanisms in reovirus treatment. This study demonstrated up-regulation of 
PD-L1 on 5TGM1 cells following reovirus treatment, with subsequent 
potentiation of anti-PD-L1 treatment (392). While this is encouraging, it 
remains unclear whether this response was due to an enhancement of 
ADCC induced by the anti-PD-L1 antibody or due to the potentiation of an 
existing OV-induced anti-tumour immune response. 
The tumour eradication experiments performed in this chapter (Figure 4-3) 
were not sufficient to determine whether tumour eradication was due to 
direct oncolysis or the development of anti-tumour immune mechanisms. 
However, the absence of reovirus in the BM at termination of the experiment 
(Figure 4-3D) might indicate 1) early eradication of tumour by direct 
oncolysis and clearance of reovirus by antiviral mechanisms, or 2) the role 
for an anti-tumour immune response in tumour eradication (427). In light of 
the results presented in Chapter 3, it is encouraging that tumour reduction 
could be achieved in the context of a physiological BM microenvironment. 
BM stromal cells were shown in Chapter 3 to induce protection against 
reovirus direct oncolysis in MM, which might further suggest that anti-tumour 
immunity plays a role for tumour cell eradication at this site. Moreover, 
5TGM1 interactions within the BM microenvironment can induce dormancy 
of 5TGM1 cells in vivo, with subsequent resistance to melphalan therapy 
and disease relapse (428). Thus, it would be particularly interesting to test 
whether the dormant, non-dividing cells are also resistant to reovirus 
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oncolysis, and to determine whether they could be eradicated by anti-tumour 
immune mechanisms induced by OVT. However, additional experiments are 
required to address these remaining questions.  
Having confirmed efficacy in the immunocompetent model in vivo, the next 
sections in the chapter explored the immune response initiated following 
reovirus treatment, compared to PBS vehicle treatment. First, the 
composition of the BM (Figure 4-4) and spleen (Figure 4-5) in terms of 
lymphoid immune cell populations was examined. In the BM, both the NK 
cell, CD4+ T cell, and CD8+ T cell populations were significantly larger in 
mice treated with reovirus, compared to PBS. However, population sizes 
reached approximately that of naïve (non-tumour bearing, untreated) mice, 
which may suggest a normalisation and reconstitution of the BM composition 
due to tumour eradication, rather than an infiltration of immune cells as part 
of an ongoing immune response. In the spleen, the response was similar, 
however, only the CD8+ T cell population was significantly increased with 
reovirus treatment compared to PBS (Figure 4-5C). Immune reconstitution of 
the BM in particular is encouraging and has similarly been demonstrated in 
MM patients with long-term disease control, who experienced an expansion 
of NK cells and CD8+ T cells in the BM, along with a reduction in T 
regulatory (Treg) cells, compared to patients with symptomatic MM (429). 
Upon examination of the ratio of CD4+ and CD8+ naïve T cells to TEM in the 
BM and spleen, there were no significant changes in the populations of 
either CD4+ or CD8+ naïve T cells or TEM in the BM following reovirus 
treatment (Figure 4-6). This suggests a normalisation of the BM composition 
in response to reovirus treatment, rather than the onset of a T cell-mediated 
immune response. In contrast, a significant increase in both CD4+ and CD8+ 
TEM was confirmed in response to reovirus treatment in the spleen, 
concordant with a decrease in the naïve T cell populations. In light of the 
expanded population of CD8+ T cells in the spleen, this is encouraging for 
the onset of an adaptive immune response however, the specificity of this 
response remains to be elucidated. The spleen and lymph nodes are the 
main sites for priming of an adaptive T cell response and an expansion of 
the TEM population is characteristic following antigen recognition and 
generation of immunological memory (407). In particular CD8+ TEM, 
corresponding to CTLs, are important for the eradication of tumour cells and 
for generation of a long-term protective response against tumour recurrence 
(181-183). However, priming of reovirus-specific CTLs has also been 
confirmed as an important part of the host immune response to reovirus 
infection, with preferential priming against the viral protein, haemagglutinin 
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(430, 431). Further studies are required to characterise the specificity of the 
CTLs generated in 5TGM1 mice following reovirus treatment, in particular 
with regards to their antiviral vs. anti-TAA effects (173, 432). Similar to the 
experiments performed in Chapter 3, degranulation or intracellular flow 
cytometry for IFN-g secretion in splenocytes following re-challenge with 
tumour cells (± reovirus infections), reovirus alone, or specific TAA could be 
used to further determine the antigen specificity of CD8+ T cells generated in 
response to reovirus treatment. 
To further examine the immune response following reovirus treatment, NK 
cells, CD4+ T cells, and CD8+ T cells were phenotyped for the expression of 
the activation marker CD69, the marker of T cell antigen recognition 4-1BB, 
and the immune checkpoint molecules, PD-1 and CTLA-4. An overview of 
the phenotypic changes in each cell type in the BM and the spleen was 
provided in Table 4-3. Again, the responses seen in the BM were limited, 
with the only significant change observed following reovirus treatment being 
a decrease in the expression of PD-1 on NK cells and CD8+ T cells (Figure 
4-8C and Figure 4-10C). In particular the reduction of PD-1 expression on 
NK cells is interesting in this context. Similar to the results obtained in this 
study, NK cells from MM patients have been shown to upregulate the 
expression of PD-1 on the cell surface, while expression on healthy NK cells 
is low. This has prompted evaluation of the effect of anti-PD-1 antibody 
treatment on NK cell cytotoxicity. As described by Benson Jr et al., blockade 
of PD-1 enhanced both NK cell activation and cytotoxicity against MM cell 
targets, in particular in combination with lenalidomide which reduced the 
expression of PD-L1 on MM tumour cells (433). Accordingly, elevated PD-1 
expression on NK cells has been associated with exhaustion and reduced 
cytotoxicity in several types of cancers (434, 435). Thus, a reduction in PD-1 
expression following reovirus treatment could lead to improved function of 
NK cells in the BM.  
The spleen again provided more interesting changes with an increase in the 
expression of 4-1BB on NK cells, an increase in both PD-1 and CTLA-4 on 
CD4+ T cells, and an increase in CD69 as well as PD-1 expression on CD8+ 
T cells. Increased CD69 expression on splenic CD8+ T cells in response to 
i.v. reovirus administration has previously been demonstrated in WT, 
tumour-bearing C57Bl/6J mice, with a significant increase in expression two 
days after reovirus infusion. Splenic CD8+ T cells also showed an increased 
expression of CD107 following reovirus treatment, however, it was not 
determined whether this formed part of an antiviral or anti-tumour immune 
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response (436). While OV treatment has predominantly been associated 
with increased expression of PD-L1 on tumour cells, VSV treatment has also 
been reported to increase the expression of PD-1 on TEM cells in the 
peripheral circulation of mice. Similar to what was observed in this study, the 
proportion of CD44+CD62L-CD8+ effector T cells increased in response to 
VSV treatment, moreover, a majority of the T cells also had increased 
expression of both the inhibitory receptors, TIM-3 (T cell immunoglobulin and 
mucin-domain containing-3) and PD-1. Interestingly, combination therapy 
with VSV and either anti-PD-1 or anti-TIM-3 antibodies did not provide a 
survival advantage compared to VSV alone in this study, highlighting the 
importance of understanding exactly which immune subsets, if any, are 
required for tumour eradication during different forms of OVT (437). 
Nonetheless, combination treatment with reovirus and checkpoint inhibitors 
remains an interesting avenue to explore and the phenotypic analysis 
presented in this chapter further confirms this. PD-1 expression was reduced 
on NK cells and CD8+ T cells in both the BM and the spleen, although both 
PD-1 and CTLA-4 expression was increased in response to reovirus 
treatment on CD4+ T cells in the spleen, (Figure 4-12 C and D). This might 
indicate scope for successful combinations with both anti-PD-1 and/or anti-
CTLA-4 antibodies, to stimulate the CD4+ T cell compartment. 
Interestingly, the experiments performed here also allowed examination of 
the effect of MM itself on immune cells by comparing naïve mice with PBS-
treated mice. For example, this demonstrated that in the BM, but not the 
spleen, both PD-1 and CTLA-4 expression was up-regulated on NK cells, 
CD4+ and CD8+ T cells in the presence of established MM, suggesting that 
the presence of tumour cells induced an immunosuppressive environment in 
the BM (Figure 4-8 - Figure 4-10). CD69 expression was also increased on T 
cells in both the BM and spleen, as well as NK cells in the spleen. This could 
be explained by the fact that CD69 expression on lymphocytes can be 
induced in hypoxic environments, such as the BM. 
While these changes provide insight into the ongoing immune response, the 
activated state of CD8+ T cells is particularly interesting in the light of the 
expanded CD8+ TEM population. As discussed in Chapter 3, priming of 
tumour-specific CTLs has been previously established as an important 
mechanism of action following reovirus treatment in several different studies, 
both human and murine (247, 379, 393, 438). In a syngeneic in vivo model 
of breast cancer, antibody-mediated depletion of CD8+ T cells resulted in a 
loss of reovirus therapy efficacy, indicating the importance of CD8+ T cells for 
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the treatment response (393). Priming of a tumour-specific T cell response 
has also been confirmed using ex vivo re-stimulation of splenocytes 
obtained from melanoma-bearing reovirus-treated mice. Following re-
stimulation with either B16 tumour cell lysates or TAA, a Th1 response with 
secretion of IFN-g and IL-12 was elicited (246, 438). In a different approach, 
Prestwich et al. used non-antigen specific T cells as carriers for reovirus in 
the reovirus-resistant B16ova model of melanoma. Despite B16ova cells 
being non-permissive to reovirus replication both in vitro and in vivo, the 
metastatic burden in both lymph nodes and the spleen was reduced 
following reovirus treatment. In addition, splenocytes recovered from 
reovirus-treated animals showed specificity for TAA, and to further support a 
role for the immune system in generating this response, it was confirmed 
that the therapeutic efficacy against B16ova cells was lost in 
immunodeficient SCID mice (247). Similarly, using the reovirus-susceptible 
B16.F10 model of melanoma, treatment with UV-inactivated reovirus 
resulted in significant tumour regression (439). Furthermore, in an 
immunocompetent in vivo model of hepatocellular carcinoma, no significant 
difference in the anti-tumour effect of live and UV-inactivated reovirus was 
observed (394). Together, these results demonstrate that direct oncolysis is 
not strictly necessary for efficient reovirus therapy and that immune-
mediated mechanisms can play a role in tumour eradication. Other RNA 
viruses, including poliovirus, VSV, and MV have also been reported to rely 
on CD8+ T cell activation and anti-tumour immune priming, to some extent, 
for the induction of efficacious responses (362, 440-443). Notably, Bartee et 
al., used an immunocompetent in vivo model (MOPC-315 cells in Balb/c 
mice) to study myxoma virus efficacy in MM, which confirmed that 
eradication of MRD was mediated by tumour-specific CD8+ T cells (194). In 
line with previous studies which have confirmed a role for anti-tumour 
immunity and the priming of tumour-specific CTLs in response to reovirus 
treatment in vivo, CD8+ T cell depletion experiments and splenocyte re-
stimulation with tumour lysates or TAA will be required to clarify whether 
reovirus can induce an anti-tumour immune response in the 5TGM1 MM 
model. 
Similar to the lymphoid populations, the reovirus treatment effect on myeloid 
cells was most pronounced in the spleen. When examining the composition 
of the BM with regards to myeloid cells, there was a tendency towards 
increased monocyte and macrophage populations in response to reovirus 
treatment, but the increase was not statistically significant (Figure 4-14). 
However, both the expression of CD80 and CD86 was down-regulated in 
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response to reovirus treatment, compared to PBS, on both cells types 
(Figure 4-16). As no naïve control mice were included in this experiment, it 
remains unknown whether the expression observed is truly a down-
regulation or a normalisation as a result of reconstitution of the BM. Another 
reason for the lower expression of CD80/86 after reovirus treatment might 
be that myeloid cells have migrated away from the BM in response to 
treatment, e.g. to perform antigen presentation functions in the lymph nodes 
or spleen. Interestingly, the presence of malignant plasma cells can increase 
the expression of both CD80 and CD86 on myeloid-derived DC from MM 
patient BM samples (444, 445). However, increased expression of the 
CD80/86 receptor CD28 on plasma cells was also seen in response to 
progressing MM. The engagement of CD28 with CD80 or CD86 resulted in 
down-regulation of proteasome subunits in the malignant plasma cells, 
which has previously been associated with reduced susceptibility to CTL-
mediated killing (444, 445). Thus, a reduced expression of CD80/86 in the 
BM might indicate that immune evasion strategies present in MM are 
reduced as a consequence of reovirus treatment. In addition, reduced 
CD80/86 expression could be an indication of a normalisation of the BM 
microenvironment following the eradication of plasma cells. 
In the spleen on the other hand, both populations of monocytes and 
conventional (CD11b+) macrophages were enlarged in response to reovirus 
treatment (Figure 4-15), but no significant change in the expression of 
costimulatory markers or MHC Class II were detected (Figure 4-17 A and B). 
RPM are spleen-resident CD11b-negative macrophages which are important 
for RBC haemostasis and iron metabolism (446). Much remains unknown 
with regards to the immunological function of RPM, but they may be involved 
in the differentiation of Tregs, and IFN-a secretion in response to parasitic 
infections (447, 448). Their antigen presentation ability appears low 
compared to conventional DC, but they are able to present antigenic 
peptides to T cells (419, 448). While there was no significant increase in the 
RPM population size with reovirus (Figure 4-15B), both the expression of 
CD80, CD86, and MHC Class II was up-regulated on these cells following 
reovirus treatment, compared to PBS, suggesting an improved ability for 
antigen presentation and T cell activation (Figure 4-17C).  
Little is known about the role of myeloid cells in the generation of an anti-
tumour immune response by reovirus. One study has demonstrated a role 
for peripheral blood monocytes in the protected carriage of reovirus to 
tumour sites (252). Moreover, myeloid cells can be important for the 
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clearance of reovirus, which coincides with a transition from an M1 to an M2 
phenotype in macrophages (449). Overall, evidence for the importance of 
myeloid cells for successful OVT is sparse, and controversial. TAMs can 
enhance the oncolytic effects of both adenovirus, measles, and mumps virus 
(450-452). For example, both measles and mumps virus treatment induce a 
more anti-tumour or M1 like phenotype in macrophages, which contributes to 
tumour cell eradication (450). Macrophages as cell carriers can also protect 
adenovirus from neutralisation and improve local delivery to tumour sites 
(451, 452). On the contrary, several studies have demonstrated an 
impairment of OV efficiency caused by TAM-mediated immunosuppression, 
for example with the use of HSV-1 and VSV (453, 454), where TAMs 
increase viral clearance and induce a potent antiviral state in the local 
tumour microenvironment. The effect of OVT on MDSCs similarly remains 
unclear. Reovirus treatment has on one hand been shown to recruit MDSCs 
to the tumour microenvironment in an ovarian cancer model, something that 
was also indicated, although not significant, for the BM site in this study 
(325). On the other hand, reovirus has been shown to inhibit the 
immunosuppressive effect of MDSCs on T cells in the spleen, in a TLR3-
dependent manner (436). While there was no significant change in the size 
of the monocytic MDSC population in the spleen in this study, the population 
of granulocytic MDSCs was significantly reduced in response to reovirus 
treatment. It is likely that reduction of the MDSC population will be important 
for successful OVT in MM as MDSCs mediate suppression of tumour-
specific T cell responses through the induction of both T cell anergy and Treg 
development in the MM microenvironment (58). While both monocytic and 
granulocytic MDSCs can have immunosuppressive functions, granulocytic 
MDSC also have a pro-angiogenic effect in MM (455). Moreover, MDSC 
populations are significantly increased in MM patients and correlate with 
disease stage and clinical outcome (58). 
Successful generation of anti-tumour immunity in MM in vivo models using 
other therapeutic strategies has been previously documented. For example, 
the administration of IAP (inhibitor of apoptosis) agonists to transgenic MM 
mice resulted in long-term protection and cure of a subset of mice (456). The 
response was dependent on an initial type I IFN response with recruitment of 
macrophages and DC, followed by generation of an adaptive response with 
successful long-term protection which was potentiated in combination with 
anti-PD-1 checkpoint inhibitors (456). Also studies using the 5TGM1 model 
have demonstrated efficient mobilisation of anti-tumour immunity. 
Interestingly, as 5TGM1 cells are resistant to lenalidomide-induced 
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apoptosis, the model has been used to study the immunomodulatory effects 
of lenalidomide in isolation, confirming the crucial role of CD4+ T cells for the 
establishment of an anti-tumour immune response with generation of 
cytotoxic CTL following lenalidomide treatment (457). The 5TGM1 model 
has also been used to study the generation of idiotype-specific T cells with 
high ex vivo cytotoxicity against MM target cells. Following adoptive transfer 
of either idiotype-specific CTLs or Th1 cells, MM development was 
significantly impaired (458). The results from these previously published 
studies demonstrate that the 5TGM1 model is suitable for the study of anti-
tumour immune responses and that anti-tumour immunity is an important 
factor in the eradication of MM. 
Taken together, the results presented in this chapter demonstrate that while 
significant reduction in the BM tumour burden can be achieved with reovirus 
treatment, the most prominent immunological responses are seen in the 
spleen and it remains to be clarified whether this is an anti-tumour or 
antiviral response. As discussed, the 5TGM1 model has previously been 
used in combination with reovirus treatment in studies by Kelly et al. (318, 
392), confirming reovirus-mediated up-regulation of PD-L1 on 5TGM1 cells 
with subsequent enhanced efficacy of anti-PD-L1 treatment, but no other 
immune functions were explored in this study. This reveals the limited 
research efforts which have been invested in studying the potential for 
reovirus treatment to induce an anti-tumour immune response in MM. As 
discussed, the majority of in vivo studies of reovirus as a treatment for MM 
have employed immunocompromised murine models. While these models 
have their purpose in the study of mechanisms for direct cytotoxicity in 
isolation, it is a major limitation that the contribution of anti-tumour immunity 
to therapy efficacy cannot be evaluated. As demonstrated by the early work 
performed in this chapter, the 5TGM1 model has potential for revealing 
mechanisms behind anti-tumour immunity in response to reovirus treatment, 
as well as the importance of direct cytotoxicity and anti-tumour immunity, 
respectively, required for a durable treatment response. Continuation of this 
work has the potential to identify the immune cell types involved in MM 
eradication, as well as reveal suitable areas for combination strategies to 
further enhance therapy efficacy. While the work performed by Kelly et al. 
confirmed up-regulation of PD-L1 on tumour cells in response to reovirus 
treatment, the results obtained here indicated that the phenotypic changes 
on immune cells in response to reovirus treatment are extensive and many 
more opportunities for innovative combinations might still be unknown. A 
significant amount of work still remains to fully establish the contribution of 
 187 
anti-tumour immunity to reovirus efficacy in the 5TMG1 in vivo model. More 
specifically, some particularly important experiments are antibody-depletion 
of different immune cell population to confirm their individual contribution to 
therapy response, examination of antigen-specificity of CD8+ T cells in the 
spleen (antiviral vs anti-tumour), and temporal distribution of reovirus 
following i.v. injection. Furthermore, it is important to distinguish between 
anti-tumour immune responses and host antiviral responses. Thus, virus 
neutralization by nAb, and the role of the immune system in clearing the 
virus after injection need to be investigated to obtain a complete 
understanding of reovirus mechanisms of action. Full clarification of the 
mechanisms by which reovirus induces its effect remains important and will 
allow for new combinational therapies to be developed, to harness the true 
potential of reovirus and generate complete eradication of MM.   
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Chapter 5  
Anti-tumour immunity induced by coxsackievirus A21 in 
acute myeloid leukaemia 
 
5.1 Introduction 
With its oncolytic potential first discovered in 2004 (146), CVA21 is a more 
novel oncolytic agent than reovirus, and has not yet been tested to the same 
extent in either pre-clinical or clinical studies. The results presented in 
Chapter 3 demonstrated that CVA21 has the potential to be a viable 
therapeutic option in MM, and that an efficient anti-tumour immune response 
could be generated with induction of both innate and adaptive anti-tumour 
functions. However, very little is currently known about the immunobiology of 
CVA21, including how it is detected by the immune system and how an 
immune response towards the virus is initiated. 
Thus, the main aim of this chapter was to examine the anti-tumour immune 
response induced by CVA21 in more detail, with a particular focus on 
cellular mechanisms and elucidating the critical mediators of the immune 
response. In order to examine the anti-tumour immune response in isolation, 
the disease model was switched from MM to AML, which had been shown in 
preliminary experiments to be resistant to the direct oncolytic effect of 
CVA21. 
The secondary aim of the work performed in this chapter was to evaluate 
CVA21 as a treatment option in AML. As previously discussed, new 
treatments which are more tolerable and have better specificity, and efficacy, 
are urgently needed in AML. With a limited direct oncolytic effect on AML cell 
lines, efficient induction of anti-tumour immunity is particularly relevant in this 
disease setting. Thus, the onset of anti-tumour immunity induced by CVA21 
in AML was first established, prior to examining the cellular mechanisms 
responsible. While CVA21 has not previously been investigated in a 
haematological context, other OVs, including myxoma virus, VSV, HSV-1, 
and reovirus, have been suggested as potential treatments in AML (205-
208). However, rather disappointingly, only one OV so far (VSV genetically 
modified to express IFN-β and NIS genes), has been taken forward to 
clinical trials (196). In order to add clinical relevance to this study, a cohort of 
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primary samples from AML patients undertaking treatment at St. James’s 
University Hospital, Leeds, was examined for their response to CVA21 ex 
vivo (Table 5-1), including their ability to initiate an anti-tumour immune 
response. Additionally, the clinical trial samples from the STORM Phase I 
clinical trial, which was introduced in Chapter 3, were further analysed in this 
context to provide “proof of principle” evidence for the in vivo onset of an 
anti-tumour immune response following CVA21 administration i.v. – an 
important step in paving the way for future clinical translation of CVA21 as 
an immunotherapeutic agent.  
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5.2 Results 
5.2.1 CVA21-mediated direct oncolysis of AML cell lines and primary 
AML blast cells 
As discussed previously, ICAM-1 expression has been hypothesised to be 
the determining factor of tumour cell susceptibility to CVA21 (279, 397). 
Thus, ICAM-1 expression was first evaluated on six different human AML 
cell lines using flow cytometry. ICAM-1 expression on all AML cell lines was 
found to be low compared to the myeloma control cell line U266B, previously 
confirmed to be CVA21-susceptible (Figure 3-2 E and F), with the highest 
expression seen in KG-1 and kasumi-1 cells (Figure 5-1A). For these cell 
lines, the average ICAM-1 expression was three-fold higher than isotype 
control expression, compared to 13-fold for U266B cells. Next, direct 
susceptibility to the oncolytic effect of CVA21 was evaluated. As expected 
following confirmation of low ICAM-1 expression, direct oncolysis of AML cell 
lines after 72 hrs of treatment (up to 1 pfu/cell) was very limited compared to 
the control cell line U266B, with no significant oncolysis observed for any of 
the AML cell lines (Figure 5-1B).  
As a tool to further study the importance of ICAM-1 in AML oncolysis and 
anti-tumour immunity, ICAM-1-expressing KG-1 cells were generated using 
lentiviral transduction (described in Section 2.1.4). Using flow cytometry, 
ICAM-1-transduced cells were confirmed to express more ICAM-1 than 
parental KG-1 cells (Figure 5-1C), up to 15-fold more than the isotype 
control, which is comparable to the CVA21-susceptible U266B cells. 
Accordingly, transduced cells were susceptible to CVA21-mediated direct 
oncolysis (Figure 5-1D). Treatment of ICAM-1-expressing KG-1 with 1 
pfu/cell CVA21 for 72 hrs resulted in an average 61.9% cell death, compared 
to 15.7% for parental KG-1 cells. To determine whether ICAM-1 expression 
and susceptibility observed correlated with viral replication the ability of 
CVA21 to enter and replicate in AML cell lines and ICAM-1-transduced KG-1 
cells was examined. Using TCID50 assays (Section 2.7.1), low level 
replication was detected in one out of the six parental cell lines (KG-1) and, 
as expected, in ICAM-1-transduced KG-1 cells (Figure 5-1E). A 133-fold 
increase in the viral titre was detected following 72 hrs treatment of parental 
KG-1 cells, which is negligible in comparison to cell lines previously 
demonstrated to be susceptible to CVA21-mediated oncolysis (202, 459). 
Replication in ICAM-1-transduced KG-1 cells was lower than in parental KG-
1 cells, which might be due to the high susceptibility of ICAM-1-transduced 
cells which does not allow extended replication. Interestingly, this suggests 
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that most AML cell lines are resistant to CVA21-mediated oncolysis due to 
the absence of ICAM-1, while CVA21 is able to enter, and replicate in, KG-1 
cells indicating that another intrinsic mechanism of resistance might also be 
involved. However, as ICAM-1-transduced KG-1 cells with a higher 
expression of ICAM-1 were rendered susceptible, the absolute level of 
surface ICAM-1 also appeared to play a role in CVA21 susceptibility. 
It is commonly known that, with extensive propagation, cell lines can develop 
characteristics that are not true of the original primary cells. To ensure 
clinically relevant results, the direct oncolytic effect of CVA21 was next 
evaluated in primary AML patient samples. The cohort of primary samples 
consisted of peripheral blood taken from 31 patients undertaking treatment 
for various subtypes and stages of AML at St. James’s University Hospital, 
Leeds, between January 2016 and June 2017 (Table 5-1). Both males and 
females were included in the study, with an age range from 29 to 88 years 
(median 66 years). Mirroring the wide disease spectrum of AML, the 
diagnoses within the cohort were heterogeneous with a range of subtypes, 
mutations and cytogenetics identified. Most patients were on a designated 
treatment schedule before blood samples for this study were taken. As 
described in Section 2.2.1, blood samples were processed using density 
gradient centrifugation to obtain AML blasts as part of the PBMC fraction 
and thus, AML blasts were treated together with any recoverable immune 
cells within the PBMC fraction, depending on the clinical status of the 
patient. 
First, ICAM-1 expression on blast cells at the time of isolation was measured 
using flow cytometry. Blast cells were identified within the PBMC fraction 
using a combination of anti-CD45, anti-CD34, and anti-CD117 antibodies 
(Section 2.3). All AML blasts were considered CD45lo, with CD34 and 
CD117 expression varying depending on clinical diagnosis (460). An 
overview of the blast cell gating strategy is provided in Figure 2-2. Similar to 
the cell lines, ICAM-1 expression was low on AML blasts with an average 
4.5-fold increase in expression compared to the isotype control (Figure 
5-2A). However, there was significant variation within the cohort, from ICAM-
1 expression too low to detect, up to a 16-fold increase in expression over 
the isotype control in sample AML-31. Next, susceptibility to CVA21 was 
examined by treating AML blasts as part of the PBMC fraction with 0.1 or 1 
pfu/cell CVA21 for 72 hrs. Following staining with a Live/Deadâ 
discrimination stain, blast cell death was measured using the gating strategy 
described above (Figure 2-2). Interestingly, in contrast to the AML cell lines, 
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a number of samples were identified as being susceptible to CVA21 after 72 
hrs of treatment (Figure 5-2B). Using a 10% increase in cell death as a cut-
off limit, eight out of 16 samples tested were identified as CVA21 responsive 
(black solid lines). However, surprisingly, as shown in Figure 5-2C, CVA21 
susceptibility did not correlate significantly with the level of ICAM-1 
expression on AML blasts (p=0.65, Pearson’s r=0.122). Furthermore, low 
level CVA21 replication was only detected in one out of ten samples tested 
(data not shown), suggesting that cell death was not due to direct oncolysis 
and thus bringing into question the relevance of ICAM-1 on tumour cells as 
an independent cellular determinant of CVA21 susceptibility. 
As these findings were conflicting with present evidence, the role of ICAM-1 
in CVA21 susceptibility was further explored. To test the hypothesis that 
ICAM-1 expression confers susceptibility to CVA21, TNF-a treatment was 
used to increase the expression of ICAM-1 on AML cell lines and primary 
blasts. Following TNF-a  treatment with up to 10 000 U/ml for 24 hrs, ICAM-
1 expression was elevated on all cell lines tested (Figure 5-3A), and on 
some AML primary samples (Figure 5-3B). After TNF-a treatment, ICAM-1 
expression on THP-1 and kasumi-1 cells exceeded the levels on CVA21-
susceptible U266B cells (17-fold and 22-fold increase at the high treatment 
dose, respectively). For the primary blast cells, the response was more 
variable, but in responsive samples similar increases in ICAM-1 expression 
were seen in response to TNF-a treatment (Figure 5-3B). Next, to determine 
whether cells with an elevated expression of ICAM-1 became susceptible to 
CVA21-mediated oncolysis, cells were pre-treated with TNF-a for 24 hrs, 
followed by CVA21 treatment for 72 hrs, and cell death was measured by 
flow cytometry using a Live/Deadâ discrimination stain. Figure 5-3C shows 
that an increase in ICAM-1 expression only conferred susceptibility to the 
already replication-permissive KG-1 cells and not to the resistant THP-1 and 
kasumi-1 AML cell lines. There was an indication of a small increase in the 
cell death of THP-1 cells with the highest dose of TNF-a and CVA21, but this 
was not statistically significant. However, some cell death was observed in 
response to TNF-a alone, particularly in kasumi-1 cells. Primary samples 
were also highly susceptible to TNF-a treatment alone, but in one of the 
samples tested, susceptibility to CVA21 treatment was increased following 
pre-treatment with 1000 U/mL TNF-a (data not shown). These results also 
suggest that ICAM-1 expression is not the only factor involved in determining 
susceptibility to CVA21 infection and oncolysis. 
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Taken together, the results presented in this section have demonstrated that 
AML cell lines (KG-1, HL-60, THP-1, kasumi-1, ML-1, and OCI-M2) are 
resistant to CVA21-mediated direct oncolysis. However, in 50% of the tested 
AML patient samples, death of primary blasts was detected following CVA21 
treatment. Interestingly, there was no correlation between CVA21-mediated 
death and ICAM-1 expression (or CVA21 replication) in primary samples. 
Considering that primary blasts, as opposed to cell lines, were treated as 
part of a PBMC fraction in the experiments performed, these results 
suggested that anti-tumour immune mechanisms may be involved in the 
elimination of blast cells in primary samples. This possibility was further 
explored in the following sections. 
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Figure 5-1: CVA21-mediated direct oncolysis of AML cell lines. 
A: ICAM-1 expression on AML cell lines KG-1, HL-60, THP-1, kasumi-1, OCI-M2, 
and ML-1, and MM cell line U266B was measured using flow cytometry. Expression 
is presented as the fold increase in median fluorescence intensity (MFI) compared 
to an isotype control antibody (n=4). B: Direct oncolytic effect of CVA21. Six AML 
cell lines and the MM cell line U266B were either untreated or treated with 0.1 or 1 
pfu/cell CVA21 for 72 hrs. Cell death was measured by flow cytometry using a 
Live/Deadâ discrimination stain (n=3). Statistical significance was calculated using 
a two-way ANOVA with Tukey’s post-hoc test.  C: ICAM-1 expression on parental 
KG-1 cells, compared to KG-1 cells transduced with ICAM-1. ICAM-1 expression 
was measured by flow cytometry and is presented as the fold increase in MFI 
compared to an isotype control antibody (n=3). Statistical significance was 
calculated using an unpaired, two-tailed t-test. D: Susceptibility to CVA21 of 
parental KG-1 cells and KG-1 cells transduced with ICAM-1 following treatment with 
CVA21 for 72 hrs. (0, 0.1, or 1 pfu/cell). Cell death was measured by flow cytometry 
using a Live/Deadâ discrimination stain (n=3). Statistical significance was 
calculated using a two-way ANOVA with Šídák’s post-hoc test. E: CVA21 
replication in AML cell lines was measured using a TCID50 assay. Cells and 
supernatants were harvested at 0 hr and 72 hrs after CVA21 treatment and cells 
were lysed using repeated freeze-thaw cycles. The supernatants were serially 
diluted and added to SK-Mel-28 cells. After six days, SK-Mel-28 cells were stained 
with methylene blue and the cytopathic effect was counted for each dilution. The 
titre is presented as the fold increase in TCID50/ml 72 hrs after treatment (n=1). 
Error bars indicate s.e.m, * = p<0.05, *** = p<0.001, **** = p<0.0001. 
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Table 5-1: Demographics of AML patients included in the study. 
Diagnosis was confirmed by the Haematological Malignancy Diagnostic Service 
(HMDS) at St. James’s University Hospital (Leeds) using fluorescence in situ 
hybridisation and next generation sequencing. 
 
NOS: not otherwise specified, RAEB: refractory anemia with excess blasts, MDS: 
myelodysplastic syndrome, MLL: mixed lineage leukemia, ITD: internal tandem duplication, 
del: deletion, inv: inversion, t: translocation, TKD: tyrosine kinase domain.                                   
Sample  Symbol Age Sex AML subtype (WHO) Known mutations Cytogenetics 
 
AML-1 •  37  F  NOS  None detected  5q del. 
AML-2 ◼ 30 M inv(16)(p13;q22) CFS3R, WT-1, c-Kit 16 inv. 
AML-3 ▼ 74 M RAEB STAG2 Normal 
AML-4 ▲ 74 F NOS Not done Not done 
AML-5  43 F NOS CFS3R 16q del? 
AML-6  78 F MDS → AML Not done Not done 
AML-7  61 F AML relapse 
(monoblastic) 
FLT3-ITD Trisomy 8, 
Trisomy 11 
AML-8  72 M t(8;21)(q22;q22) FLT3-ITD, RUNX1-
RUNX1T1 fusion 
t(8;21)(q22;q22) 
AML-9 • 88 M NOS FLT3-ITD, NPM1, DNMT3A Normal 
AML-10 ◼ 70 F NOS DNMT3A, IDH2 Normal 
AML-11 ▼ 61 M NOS SRSF2, IDH1, TET2 Trisomy 8 
AML-12 ▲ 60 M NOS NRAS, TET2 t(2;3), -7 
AML-13  58 M NOS IDH2, NPM1 Normal 
AML-14  75 M AML with adverse 
cellular features 
FLT3-ITD, DNMT3A Normal 
AML-15  61 F t(8;21)(q22;q22) RUNX1-RUNX1T1 
fusion 
t(8;21) 
AML-16  35 M inv(16)(p13;q22) FLT3-TKD, c-Kit, 
TET2, EZH2 
16 inv. 
AML-17 • 68 M t(8;21)(q22;q22) RUNX1-RUNX1T1 fusion, WT-1 t(8;21) 
AML-18 ◼ 47 F AML with MLL (KMT2A) 
(11q23) rearrangement 
WT-1 t(9;11)(p21.3;q2
3.3) 
AML-19 ▼ 53 F NOS NPM1, DNMT3A Normal 
AML-20 ▲ 47 F inv(16)(p13;q22) CBFB-MYH11 fusion 16 inv. 
AML-21  73 F t(8;21)(q22;q22) FLT3-ITD, RUNX1-
RUNX1T1 fusion 
t(8;21)(q22;q22) 
AML-22  73 M MDS with excess blasts None detected Normal 
AML-23  55 M NOS Not done Incomplete 
AML-24  69 M AML:lymphoma mixed None detected Complex 
AML-25 • 71 F inv(16)(p13;q22) CBFB-MYH11 fusion 16 inv. 
AML-26 ◼ 58 M NOS CSF3R, TP53 Complex 
AML-27 ▼ 70 M AML with mutated NPM1 NPM1, TET2, FLT3-
ITD 
Normal 
AML-28 ▲ 66 M NOS CSF3R, DNMT3A Normal 
AML-29  61 M AML with mutated NPM1 NPM1, TET2 Normal 
AML-30  67 M AML with mutated NPM1 NPM1, TET2 Normal 
AML-31  29 M inv(16)(p13;q22) CBFB-MYH11 fusion 16 inv. 
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Figure 5-2: Primary AML sample ICAM-1 expression and susceptibility to 
CVA21. 
AML blast cells were isolated from peripheral blood samples as part of the PBMC 
fraction using density gradient centrifugation. Blast cells were identified within the 
PBMC fraction using flow cytometry and a panel of anti-CD45, anti-CD34, and anti-
CD117 antibodies. Symbols indicate individual samples and are detailed in Table 
5-1. A: ICAM-1 expression on primary blast cells at the time of isolation was 
measured using flow cytometry. Expression is presented as the fold increase in MFI 
compared to an isotype control antibody (n=13). B: Death of primary blast cells 
following CVA21 treatment (0, 0.1, or 1 pfu/cell) for 72 hrs as measured by flow 
cytometry using a Live/Deadâ discrimination stain (n=21). Solid black lines indicate 
samples with an increase in cell death >10%, compared to unresponsive samples 
(grey lines). C: Correlation of ICAM-1 expression on primary blast cells and the 
percentage of dead blast cells following CVA21 treatment for 72 hrs (n=15). 
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Figure 5-3: Increased ICAM-1 expression only sensitizes KG-1 cells to direct 
CVA21 oncolysis. 
A: AML cell lines KG-1, THP-1, and kasumi-1 were treated with TNF-a for 24 hrs, 
then ICAM-1 expression on the cell surface was measured by flow cytometry. TNF-
a doses were adjusted based on toxicity, for KG-1 and THP-1; Low=10 U/mL, 
Interm.=100 U/mL, High=1000 U/mL. For kasumi-1; Low=1 U/mL, Interm.=10 U/mL, 
High=100 U/mL. ICAM-1 expression is presented as the fold increase in MFI 
compared to untreated cells. Statistical significance was calculated using a two-way 
ANOVA with Tukey’s post-hoc test (n=3). B: Primary blast cells were treated with 
TNF-a (0/10/100/1000 U/mL) for 24 hrs, then ICAM-1 expression was measured by 
flow cytometry on CD45-CD34+ and/or CD117+ cells. ICAM-1 expression is 
presented as the fold increase in MFI compared to untreated cells, n=4. C: 
Susceptibility to CVA21 after up-regulation of ICAM-1 using TNF-a pre-treatment. 
KG-1, THP-1, and kasumi-1 cells were pre-treated with TNF-a as indicated for 24 
hrs, then treated with CVA21 (0, 0.1, or 1 pfu/cell) for 72 hrs. Cell death was 
measured by flow cytometry using a Live/Deadâ discrimination stain. Statistical 
significance was calculated using a two-way ANOVA with Tukey’s post-hoc test 
(n=3). Error bars indicate s.e.m, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001. 
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5.2.2 Interferon-mediated antiviral response to CVA21 treatment 
As confirmed in Chapter 3, PBMCs from healthy donors secrete large 
amounts of both IFN-a and IFN-g in response to 48 hrs of CVA21 treatment 
(Figure 3-4). To confirm a similar response in AML patient samples, the IFN-
a secretion from patient PBMCs treated with CVA21 was first examined 
using an ELISA. As expected, the response was largely variable between 
patients, but overall a significant secretion of IFN-a in response to 48 hrs 
CVA21 treatment (1 pfu/cell) was confirmed (Figure 5-5A). However, the 
levels were lower than those observed for healthy donors, with a maximum 
secretion of 2390 pg/mL in sample AML-65 at the 1 pfu/cell treatment dose, 
and an overall average of 540 pg/mL.  
Although cytokine secretion from immune cells in response to CVA21 can 
have a cytotoxic effect on tumour cells, as demonstrated in Chapter 3 
(Section 3.2.2.1), type I IFN secretion is also one of the first protective 
cellular responses initiated following viral infection (461). IFN-a acts both to 
activate NK cells which are important for the eradication of virally infected 
cells, and to induce a virus hostile environment in healthy cells through the 
transcription of multiple interferon-stimulated genes (ISG) via the Jak-STAT 
signalling pathway (179, 461, 462). To evaluate the antiviral potential of IFN-
a secreted in response to CVA21 treatment, the ICAM-1-transduced KG-1 
cells, confirmed to be susceptible to direct oncolysis, were utilised. Cells 
were treated with IFN-a in combination with CVA21 and cell death was 
evaluated by flow cytometry using a Live/Deadâ discrimination stain (Figure 
5-4B). A set standard 1 pfu/cell dose of CVA21 was used, which induced an 
average of 44.1% cell death (grey line). In the presence of IFN-a (purple 
line), as little as 500 pg/mL (comparable to the amount secreted by AML 
patient samples) significantly reduced CVA21-mediated oncolysis. 
Furthermore, at the 5000 pg/mL IFN-a dose, there was no significant 
difference in the level of cell death between IFN-a treatment alone and IFN-
a + CVA21 treatment, indicating that cell death observed was due to IFN-a 
toxicity and not mediated by CVA21 oncolysis. Therefore, this data suggests 
that the presence of IFN-a following CVA21 treatment may impede the direct 
oncolytic effect of CVA21. A time course of IFN-a secretion in response to 
CVA21 was generated by treating PBMC from healthy donors with 1 
pfu/PBMC CVA21 and harvesting cell-free supernatants for ELISA at various 
time points. Analysis of the supernatants obtained indicated that IFN-a 
secretion in response to CVA21 was detectable between 8 and 16 hrs after 
CVA21 treatment (Figure 5-4B). These findings are interesting, in particular 
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for the kinetics of direct oncolysis, and indicate that in a physiological 
system, efficient oncolysis might not take place before the virus has been 
effectively neutralised by IFN-a secreted as part of the innate antiviral 
immune response. 
In conclusion, this demonstrates that in addition to ICAM-1 expression, the 
levels of IFN-a secretion in response to CVA21 treatment may also be 
important for the generation of direct oncolysis. This indicates that the direct 
lytic effect of CVA21 may be inhibited in AML blasts which have the ability to 
produce IFN-a (Figure 5-4). Nonetheless, AML blast cells were killed in 
response to CVA21 treatment (Figure 5-2), which further suggested a 
potential role for anti-tumour immunity in the AML setting. Thus, anti-tumour 
immunity was next explored as the preferential mechanism of action of 
CVA21 in AML. 
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Figure 5-4: IFN-a secretion in response to CVA21 is detrimental for direct 
oncolytic killing of AML cells. 
A: PBMC were isolated from peripheral blood samples from AML patients and 
treated with CVA21 for 48 hrs. Cell-free supernatants were harvested and IFN-a 
secretion was measured using an ELISA assay with matched paired antibodies, 
n=21. B: KG-1 cells transduced with ICAM-1, confirmed to be susceptible to 
CVA21-mediated oncolysis, were used to measure the antiviral effect of IFN-a. 
Cells were treated either with IFN-a alone (0, 500, 2500, or 5000 pg/mL, black line), 
CVA21 alone (1 pfu/cell, grey line), or a combination of both (purple line). After 72 
hrs, cell death was measured by flow cytometry using a Live/Deadâ discrimination 
stain (n=3). Statistical significance was calculated using a two-way ANOVA with 
Šídák’s post-hoc test and refers to comparison between black and purple curves. C: 
PBMCs were isolated from healthy donors (n=4) and treated with 1 pfu/cell CVA21, 
cell-free supernatants were harvested at the indicated time points for use in an IFN-
a ELISA assay. Statistical  significance was calculated using a one-way ANOVA 
with Tukey’s post-hoc test and refers to comparison with the 1 hr time point. Error 
bars indicate s.e.m, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, n.s = 
not significant.  
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5.2.3 CVA21-mediated potentiation of innate and adaptive anti-tumour 
immunity 
Using a strategy similar to that demonstrated in Chapter 3, the ability of 
CVA21 to induce an anti-tumour immune response in AML was evaluated by 
examining both innate (cytokine-mediated bystander killing, and NK cell-
mediated cytotoxicity), and adaptive (priming of tumour-specific cytotoxic 
CTLs) immune mechanisms.  
 
5.2.3.1 Pro-inflammatory cytokines secreted in response to CVA21 
induce bystander killing of AML cells 
In Chapter 3, it was shown that CM generated from PBMC treated with 
CVA21 had a significant cytotoxic effect on oncolysis-resistant OPM2 cells 
(Figure 3-6). Accordingly, a similar strategy was applied for inducing a 
bystander killing effect in AML cells. Like in MM, IFN-a has also been tested 
as a therapeutic agent in AML due to its toxic effect on AML blasts (112, 
463, 464). Thus, the toxicity of IFN-a alone was first examined using KG-1 
and HL-60 cells. Surprisingly, following treatment with up to 5000 pg/mL 
recombinant IFN-a for 96 hrs, very little toxicity was observed in either cell 
line (Figure 5-5A). Although there was a significant increase in the death of 
KG-1 cells, this was only an average 9% increase at the highest treatment 
dose. However, when combining IFN-a treatment with recombinant IFN-g 
treatment, more extensive cytotoxicity was seen, with up to 59% of KG-1 
cells killed (Figure 5-5B). This was a promising indication for the  cytotoxic 
potential of combined cytokines present in CVA21-CM on AML cells. 
As described in Section 2.12.2, the cytokine and chemokine content of 
CVA21-CM was measured using a 48-plex Luminex assay (Figure 3-4E). As 
for MM, several of the identified cytokines (e.g. IL-2, IL-6, and IL-1b) have 
previously been reported as having a cytotoxic effect in AML, either alone or 
in various combination treatments (465-467). To assess the cytotoxic 
potential of this pro-inflammatory cytokine cocktail, PBMC-conditioned 
medium was generated by treating PBMC (from either healthy donors or 
primary AML samples) with CVA21 for 48 hrs with subsequent harvest of 
cell-free culture medium by centrifugation. AML cell lines were cultured in 
PBMC-conditioned medium for 96 hrs and cell viability was evaluated using 
an MTS assay (Figure 3-5A). As all cell lines were resistant to the direct 
oncolytic effect of CVA21, no UV treatment of CM was necessary; 96 hrs 
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culture in CVA21-CM significantly reduced the viability of all three cell lines 
tested (KG-1, HL-60, and kasumi-1). KG-1 cells were the most susceptible, 
with a 48.8% reduction in viability using the 1 pfu/PBMC CM (Figure 5-6A). 
This confirmed the induction of a bystander killing effect in response to 
CVA21 treatment, similar to that induced in the MM setting. Next, it was 
tested whether CM generated from primary AML sample PBMCs could 
induce a similar bystander killing effect on AML cell lines. CM from up to 20 
patients was tested and encouragingly, patient CM also induced significant 
cell death in KG-1, HL-60, and kasumi-1 cells (Figure 5-6B). KG-1 cells were 
consistently the most susceptible to the cytokine-induced death with a 21.5% 
reduction in viability being achieved using the 1 pfu/PBMC patient-derived 
CM. It is not surprising that the cytotoxic potential of patient CM was lower 
than that observed for healthy donors, considering that many patients had a 
reduced number of immune cells in the PBMC fraction, compared to healthy 
donors, and thereby lower potential for CVA21-induced cytokine secretion. 
These results demonstrate that, while cytokine secretion in response to 
CVA21 treatment might be detrimental to direct oncolysis, it also has the 
potential to induce a bystander killing effect on AML cells. Despite the 
potential for neutralisation of direct oncolysis, bystander killing contributed to 
a significant reduction in AML cell viability as part of an anti-tumour immune 
response. Cytokine secretion is also crucial for initiating downstream anti-
tumour immune mechanisms which will be examined in the following 
sections (468). 
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Figure 5-5: AML cell line toxicity of type I and type II IFNs. 
A: KG-1 and HL-60 cells were treated with human recombinant IFN-a (0, 500, 
2500, 5000 pg/mL) for 96 hrs, then cell death was measured by flow cytometry 
using a Live/Deadâ discrimination stain. B: Combination treatment of KG-1 and HL-
60 cells with human recombinant IFN-a and IFN-g. Low = 500 pg/mL IFN-a + 500 
pg/mL IFN-g, Interm. = 2500 pg/mL IFN-a + 1500 pg/mL IFN-g, High = 5000 pg/mL 
IFN-a + 3000 pg/mL IFN-g. Cells were treated for 96 hrs, then cell death was 
measured by flow cytometry using a Live/Deadâ discrimination stain (n=3). 
Statistical significance was calculated using one-way ANOVA with Tukey’s post-hoc 
test, * = p<0.05, ** = p<0.01, **** = p<0.0001. Error bars indicate s.e.m.  
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Figure 5-6: Conditioned medium from PBMCs treated with CVA21 induced a 
bystander killing effect on AML cell lines. 
PBMCs from healthy donors (A) and primary AML patient samples (B) were 
harvested and treated with CVA21 (0, 0.1, or 1 pfu/cell) for 48 hrs. The conditioned 
culture medium (CM) was harvested and KG-1, HL-60, and kasumi-1 cells were 
cultured in CM (diluted 1:1 in fresh medium) for 96 hrs. Cell viability was measured 
using an MTS assay, each CM was tested in triplicate. Cell viability was normalised 
to CM from PBMCs without CVA21 treatment. A: CM from healthy donors, KG-1 
and HL-60; n=6, kasumi-1; n=4. B: CM from patient samples PBMCs, KG-1; n=13, 
HL-60; n=20, kasumi-1; n=10. Statistical significance was calculated using one-way 
ANOVA with Dunnett’s post-hoc test, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001. Bars indicate the mean. 
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5.2.3.2 CVA21-mediated activation of NK cells enhances cellular 
cytotoxicity against AML cells 
To further investigate the ability of CVA21 to induce innate anti-tumour 
immune mechanisms in AML, its effect on NK cells was next examined. The 
results presented in Chapter 3 demonstrated that CVA21 significantly 
activated NK cells from healthy donors with an upregulation in the 
expression of CD69 after 48 hrs of treatment (Figure 3-8C). Moreover, 
CVA21-activated NK cells degranulated to an enhanced extent against MM 
target cells and were significantly better at killing MM target cells compared 
to NK cells without prior CVA21 treatment (Figure 3-9E). To examine if this 
response could also be induced in the AML setting, NK cells from healthy 
donors were similarly treated with CVA21 for 48 hrs as part of the total 
PBMC population and were then identified as the CD3-CD56+ population by 
flow cytometry (Figure 3-8A). First, NK cell degranulation against AML target 
cells (KG-1, HL-60, THP-1, kasumi-1, and OCI-M2) following activation with 
CVA21 was measured as the percentage of CD107-positive NK cells 
following five hours of co-culture with target cells. As shown in Figure 5-7A, 
NK cells that were pre-treated with CVA21 degranulated significantly more 
against all target cells except HL-60, compared to untreated NK cells; an 
increase in degranulation was observed when using HL-60 cells but was not 
statistically significant. Overall, NK cell degranulation against AML cell 
targets was higher than observed in MM. OCI-M2 cells were the most 
susceptible target cell line with an average 55.7% of NK cells degranulating 
against OCI-M2 cells at the 0.1 pfu/PBMC treatment dose. Next, CVA21-
treated PBMCs were included in a chromium release killing assay (Section 
2.15) to evaluate whether NK cell degranulation was associated with 
increased killing of target cells. Pre-treating PBMCs with CVA21 caused 
increased lysis of all target cell lines tested, compared to untreated PBMCs, 
although the increase was not statistically significant for kasumi-1 cells 
(Figure 5-7B). The potentiation of killing was most pronounced against THP-
1 cells with an average increase in lysis of 43.0% compared to using 
untreated PBMCs, resulting in an average of 51.5% of target cells killed. 
Although the increase in killing of OCI-M2 cells was smaller than for THP-1 
cells, due to a higher baseline killing from untreated PBMC, the overall cell 
lysis remained the highest of all cell lines tested, with an average of 54.1% 
OCI-M2 cells lysed. The balance between engagement of activating and 
inhibitory receptors by target cells determines the cytotoxic response in NK 
cells (469), thus all cell lines were subsequently phenotyped for their 
expression of activating NK cell ligands using flow cytometry. The 
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phenotyping panel consisted of both NKG2D ligands (MIC A/B, ULBP-1, and 
ULBP-2/5/6), and DNAM-1 ligands (PVR and Nectin-2). As expected from 
the favourable response in the NK cell experiments, THP-1 (purple) and 
OCI-M2 cells (orange) displayed the highest expression of activating NK cell 
ligands overall (Figure 5-7C). Both cell lines had higher expression of MIC 
A/B, ULBP-1, ULBP-2/5/6, and Nectin-2, but not PVR, than KG-1, HL-60, 
and kasumi-1 cell lines. In addition to NK cell activation, PVR is also 
involved in cell motility during metastasis and invasion, and is thought to 
promote tumorigenesis (470, 471). As OCI-M2 cells proved to be the overall 
best target in the NK cell-mediated cytotoxicity experiments, these cells were 
chosen as the preferred target cells in subsequent NK cell experiments. 
As all experiments so far were performed using PBMCs from healthy donors, 
the next step was to evaluate the NK cell response in the primary AML 
sample cohort. As expected, the percentage of NK cells in the PBMC 
fraction in most patient samples was much lower than in healthy donors 
(data not shown). Following CVA21 treatment for 48 hrs, NK cell activation 
and degranulation against OCI-M2 target cells was examined and, as 
expected, the results within the cohort were variable. Figure 5-8A shows the 
NK cell activation in response to CVA21 treatment. Overall, a significant 
increase in CD69 expression on NK cells was observed. Using a 15% 
increase in CD69 expression as a cut-off point, 12 out of 27 patients were 
classed as being able to mount an NK cell response following CVA21 
treatment. The best responses were seen in samples AML-42 and AML-70, 
with an average increase in CD69-positive NK cells of 65.5% and 79.8%, 
respectively. Having identified that AML patient NK cells are activated in 
response to CVA21, the ability of CVA21-activated patient NK cells to 
degranulate against OCI-M2 targets was tested. Encouragingly, NK cells 
treated with CVA21 for 48 hrs degranulated significantly more against OCI-
M2 target cells than untreated NK cells (Figure 5-8B). For some patients the 
0.1 pfu/PBMC dose generated the best response, while for others, 1 
pfu/PBMC was required to generate a more pronounced response. Both 
samples AML-42 and AML-70, which showed the largest increase in NK cell 
activation, also generated some of the best degranulation responses with a 
22.2% and 25.0% increase in the number of CD107-positive NK cells 
following CVA21 treatment, respectively. 
In an attempt to further enhance the clinical relevance of the study, 
autologous blast cells were next examined as NK cell targets. First, the 
expression of activating NK cell ligands on autologous blast cells was 
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examined by flow cytometry. Blast cells were identified as described in 
Section 5.2.1, and representative flow cytometry plots from patient sample 
AML-2 are shown in Figure 5-8C, demonstrating that the expression of both 
NKG2D and DNAM-1 ligands was low to non-existent, which was true for the 
majority of the samples obtained. Additionally, most samples expressed high 
levels of MHC Class I (HLA-ABC), which acts as an inhibitory ligand when 
binding to cognate NK cell receptors (469). To include autologous blast cells 
in the flow cytometry-based degranulation assay, untreated PBMC (including 
AML blasts) were kept in culture and stained with a Cell Tracker dye before 
inclusion in the degranulation assay together with CVA21-treated PBMCs. 
CD107 expression was then evaluated on unstained, CVA21-treated or 
untreated, NK cells. In line with the NK ligand expression profile, CVA21-
activated NK cells demonstrated a limited ability to degranulate against 
autologous AML blasts and no significant increase in the percentage of 
CD107-positive cells was identified (Figure 5-8D). The most prominent 
response was seen in AML-49 (black X symbol) with a 9.6% increase in the 
percentage of CD107-positive NK cells following CVA21 treatment, 
compared to untreated NK cells, however; on average the increase across 
all samples was negligible (~1.4%). As discussed later, several options for 
combination treatments exist with the potential to make AML blast cells more 
attractive targets for NK cells and thereby improve the efficacy of CVA21 
treated NK cells against AML. 
In summary, the results presented in this section confirm the data previously 
presented in Chapter 3 in a second malignancy; AML. Similar to the MM 
setting, NK cells pre-treated with CVA21 degranulated against AML target 
cells to a significantly enhanced extent and NK cell degranulation was 
associated with an increase in target cell killing. Importantly, enhanced NK 
cell degranulation was also observed in NK cells from primary patient 
samples. Despite limited efficacy against autologous blast cell targets, it was 
encouraging that NK cells from primary samples were able to degranulate 
against OCI-M2 cells which have high expression of activating NK ligands. 
This indicated that CVA21 has the ability to potentiate the function of NK 
cells against AML, and that innate anti-tumour immunity may contribute to 
achieving treatment efficacy in this setting. 
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Figure 5-7: Potentiation of NK cell-mediated cytotoxicity in healthy donors 
following CVA21 treatment. 
A and B: PBMCs from healthy donors were either untreated or treated with CVA21 
at the indicated doses for 48 hrs. A: Flow cytometry-based NK cell degranulation 
assay. PBMCs were co-cultured with AML target cells for 1 hr before addition of 
Brefeldin A, followed by another 4 hrs co-culture. Degranulation was measured as 
the CD107 expression on CD3-CD56+ cells (n=4). Statistical significance was 
calculated using one-way ANOVA and Tukey’s post-hoc test. B: Chromium release 
assay. AML target cells were labelled with 51Cr, then co-cultured with PBMCs at a 
25:1 E:T ratio for 4 hrs. Target cell lysis was estimated using a scintillation counter, 
and maximum and spontaneous release controls, n=3. Statistical significance was 
calculated using paired, two-tailed t-tests. C: Phenotypic analysis of KG-1, HL-60, 
kasumi-1, THP-1, and OCI-M2 cells. The expression of activating NK ligands MIC 
A/B, ULBP-1, ULBP-2/5/6, PVR, and Nectin-2 was measured using flow cytometry. 
Expression is presented as the fold increase in MFI over an isotype control antibody 
(n=3). Error bars indicate s.e.m, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001, n.s = not significant. 
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Figure 5-8: Potentiation of NK cell-mediated cytotoxicity in AML patient 
samples following CVA21 treatment. 
A, B, and D: PBMCs isolated from peripheral blood samples from AML patients 
were untreated or treated with CVA21 at the indicated doses for 48 hrs. A: NK cell 
activation after 48 hrs of CVA21 treatment was estimated by measuring CD69 
expression on CD3-CD56+ cells by flow cytometry (n=23). B: Flow cytometry-based 
NK cell degranulation assay. PBMCs were co-cultured with OCI-M2 target cells for 
1 hr before addition of Brefeldin A, followed by another 4 hrs co-culture. 
Degranulation was measured as the CD107 expression on CD3-CD56+ cells (n=21). 
C: Representative flow cytometry histograms from a phenotypic analysis of AML 
blast cells at the time of isolation. The expression of activating NK ligands MIC A/B, 
ULBP-1, ULBP-2/5/6, PVR, and Nectin-2 was measured using flow cytometry. D: A 
flow cytometry-based NK cell degranulation assay was performed as described in 
B, using autologous blast cells stained with Cell Tracker Violet as target cells 
(n=15). Statistical significance was calculated using one-way ANOVA with Tukey’s 
post-hoc test, * = p<0.05, ** = p<0.01. 
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5.2.3.3 Priming of AML-specific cytotoxic T cells using CVA21 
Innate anti-tumour immune mechanisms are important for the immediate 
eradication of tumour cells (472, 473), but as discussed previously, an 
adaptive response is thought to be necessary for long-term protection 
against tumour recurrence (181-183). Results presented in Chapter 3 
demonstrated that pre-treatment of MM cells with CVA21 resulted in priming 
of myeloma-specific CTLs with reactivity towards TAA commonly expressed 
in MM (Figure 3-17B). To examine if CVA21 could also induce the priming of 
AML-specific CTLs, the T cell priming protocol described in Chapter 3 was 
used, switching target cells to AML cell lines (Appendix, Figure A-1). Based 
on the results obtained in Chapter 3, which indicated that more efficient 
priming could be generated with oncolysis-susceptible target cells, ICAM-1-
expressing KG-1 cells were first explored as target cells for the AML priming. 
Briefly, the protocol involved long-term culture of CVA21-treated ICAM-1-
expressing KG-1 cells with conventional myeloid-derived dendritic cells 
(cDC) and autologous PBMC containing naïve T cells (Section 2.14.2). 
First, CTLs primed using either untreated ICAM-1+ KG-1 cells, or cells 
treated with 0.1 pfu/cell CVA21 for 24 hrs were included in a chromium 
release killing assay to examine the ability of primed CTLs to kill relevant 
target cells. As shown in Figure 5-9A, the CTLs generated in the presence of 
CVA21 were significantly better at killing KG-1 target cells than CTLs 
generated without prior CVA21 treatment of tumour cells. Using a 25:1 E:T 
ratio, an average 65.0% of target cells were lysed using CTLs primed in the 
presence of CVA21, compared to only 11.2% without CVA21 treatment. As a 
first step to examine the antigen-specificity of the primed CTLs, the 
degranulation of CD8+ T cells in response to relevant (ICAM-1+ KG-1) and 
irrelevant (Raji, non-Hodgkin lymphoma cell line) target cells was examined 
by flow cytometry after five hrs of co-culture at a 2:1 E:T ratio. Following co-
culture, CTLs primed in the presence of CVA21 degranulated specifically 
against ICAM-1+ KG-1 cells, while no potentiation of degranulation was 
observed against irrelevant Raji targets (Figure 5-9B). Using CTLs primed in 
the presence of CVA21, an average 28.4% of CTLs expressed CD107 when 
challenged with relevant targets, compared to only 6.2% using irrelevant 
target cells. Interestingly, this response was much more pronounced than in 
the MM setting, where only low levels of CTL degranulation could be 
detected when using CVA21 as the immunological agent (Figure 3-15B). To 
further characterise the generated CTLs, degranulation experiments were 
performed in the presence of an MHC Class I-blocking antibody, or an 
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isotype control antibody, to interrupt the interaction between the antigen-
presentation molecule, MHC Class I, and the CD8 co-stimulatory molecule, 
necessary for CTL degranulation. While the isotype antibody control had no 
significant effect, blocking MHC Class I (orange) completely abrogated CTL 
degranulation against relevant target cells with a reduction in CD107-positive 
CTLs from 19.3% to 7.0% (Figure 5-9C). Taken together, these results 
indicated antigen-specificity of the primed CTLs and confirmed that the 
generated CTLs were dependent on MHC Class I recognition of antigen, 
characteristic of antigen-primed CD8+ CTLs.  
As discussed in Chapter 3, IFN-g is a particularly important cytokine in the 
priming of a Th1 response with efficient CTLs. Thus, the IFN-g response in 
the priming cultures was examined. Initially, IFN-g secretion, during the CTL 
priming experiments, was examined by ELISA (Section 2.12.1). As 
described for the MM priming cultures (Figure 3-16B), enhanced IFN-g 
(average 21 600 pg/mL) secretion was observed in cultures primed in the 
presence of CVA21, compared to those primed without CVA21 (average 
7600 pg/mL) (Figure 5-10A). However, as the difference was not statistically 
significant, and to confirm that IFN-g was secreted from CD8+ T cells, and 
not as part of an innate antiviral immune response, intracellular flow 
cytometry was used. Following five hours co-culture of primed CTLs with 
either relevant (KG-1) or irrelevant (Raji)  target cells, cells were 
permeabilised and stained with an anti-IFN-g antibody prior to flow cytometry 
analysis (Section 2.13.4). These data confirmed a significant increase in 
IFN-g production following co-culture with relevant, but not irrelevant, target 
cells (Figure 5-10B). Using CTLs primed in the presence of CVA21, an 
average 7.6% of CTLs stained positive for IFN-g after co-culture with 
relevant target cells, compared to only 2.1% using CTLs primed in the 
absence of virus. Co-culture of  CVA21-primed CTLs with irrelevant targets 
only generated 0.2% IFN-g-positive CTLs, further confirming the AML-
specificity of in vitro generated CTLs. 
Next, the antigen-specificity of CTLs was further explored using a peptide 
library generated from the PRAME protein – a TAA commonly expressed in 
AML. As discussed in Chapter 3, PRAME is also a commonly expressed 
TAA in MM, but is also expressed at high frequency in AML, and importantly 
on KG-1 cells (26, 474). Autologous CD14+ cells were loaded with a PRAME 
peptide pool and subsequently co-cultured with KG-1-primed CTL at a 2:1 
E:T ratio for five hours. As described above, cells were then permeabilised 
and stained with an anti-IFN-g antibody for intracellular flow cytometry 
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analysis. Encouragingly, IFN-g, was detected in CVA21-primed CTL when 
they were presented with PRAME antigen (Figure 5-10C). These data 
suggest that CVA21 can induce priming of CTLs against known TAA in the 
AML setting. 
Two interesting questions related to CTL priming using CVA21 where 
highlighted in Chapter 3; the ability to efficiently prime CTLs despite very 
little maturation of DC induced by CVA21 (Figure 3-12B), and whether direct 
oncolysis is required for efficient priming (Figure 3-18). To further explore 
these questions, CTL priming was first performed without inclusion of 
autologous iDCs. As CVA21 treatment did not induce maturation of DCs, it 
was hypothesised that DCs might be dispensable for CVA21 priming. ICAM-
1-expressing KG-1 target cells were treated with 0.1 pfu/cell CVA21 for 24 
hrs as previously described, free virus was then removed and target cells 
were cultured for a further 48 hrs before addition to PBMCs containing naïve 
T cells. Subsequently, primed CTLs were included in chromium release 
killing assays and CTL degranulation assays, as previously described. 
Interestingly, as shown in Figure 5-11A, exclusion of DCs from the priming 
assay had no effect on the ability of primed CTLs to kill relevant target cells. 
At the 25:1 E:T ratio, the average target cell lysis achieved with CTLs primed 
using autologous DCs was 62.1%, compared to 54.1% without DCs. 
Furthermore, upon assessment of CTL degranulation CTLs primed without 
DCs, using CVA21-treated ICAM-1+ KG-1 cells, degranulated significantly 
more against relevant targets than CTLs primed with untreated targets cells 
(19.2% CD107-positive CTLs, compared to 4.9%), and levels were  
comparable to those obtained using CTLs primed using DCs (Figure 5-11B). 
Importantly, no significant degranulation against irrelevant Raji cells was 
observed, confirming the antigen-specificity of CTLs primed without addition 
of autologous in vitro generated DCs. 
As ICAM-1-transduced KG-1 cells susceptible to CVA21 oncolysis were 
used in CTL experiments presented so far, CTLs were next generated using 
parental KG-1 and THP-1 cells, both resistant to CVA21-mediated oncolysis, 
to explore the requirement for OV susceptibility. In Chapter 3, priming 
against CVA21-resistant OPM2 cells was unsuccessful as primed CTLs 
were unable to recognise and kill relevant OPM2 targets (Figure 3-18D). As 
shown in Figure 5-1D, CVA21 was able to enter and replicate at low levels in 
KG-1 cells, but not in THP-1 cells, which is similar to the OPM2 response to 
CVA21 (225). Initially, the priming protocol was used as originally described, 
including autologous DCs (Appendix, Figure A-1), and the primed CTLs 
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were examined using CTL degranulation assays. Encouragingly, CTLs with 
the ability to degranulate specifically against relevant (KG-1 or THP-1, 
respectively), but not irrelevant (Raji), target cells were successfully 
generated with both parental KG-1 cells (Figure 5-11C), and THP-1 cells 
(Figure 5-11D). Interestingly, using CTLs primed against parental KG-1 cells 
in the presence of CVA21, the average percentage of CD107-positive CTLs 
following co-culture with relevant targets was 13.7%, which was lower than 
the degranulation achieved using the CVA21 susceptible ICAM-1+ KG-1 
(28.4% CD107-positive CTLs). Moreover, with CTLs primed against THP-1 
cells, in the presence of CVA21, a total of 17.2% of CTLs degranulated 
against relevant target cells (Figure 5-11D). Although degranulation levels 
were reduced, these data suggest that efficient priming of tumour-specific 
CTLs is possible in cells which are less permissive to CVA21 infection and 
oncolysis. 
In summary, the results presented in this section have demonstrated that 
CVA21 can induce the priming of AML-specific CTLs. These CTLs display 
pronounced cytotoxicity against relevant target cells in an antigen-dependent 
manner, with CTL degranulation and specific secretion of IFN-g. Moreover, 
primed CTLs recognised a commonly expressed TAA in AML when 
presented as a peptide pool on autologous CD14+ cells. These results 
confirm and strengthen those obtained in Chapter 3, which also 
demonstrated successful priming of tumour-specific CTLs in the MM model. 
Furthermore, questions raised in Chapter 3 were explored by priming CTLs 
in the absence of autologous DC, as well as using oncolysis-resistant target 
cells. Both methods generated efficient antigen-specific CTLs, suggesting 
that conventional DCs may be of little importance for successful priming 
using CVA21, and that oncolysis may not be absolutely necessary for the 
induction of anti-tumour immunity. Given that conventional DC were not 
necessary for priming of anti-tumour specific CTLs, and little is known about 
CVA21 interaction with the human immune system, the cellular mechanisms 
responsible for the anti-tumour immunity induced by CVA21 were explored. 
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Figure 5-9: Priming of AML-specific CTLs using CVA21. 
Primed CTLs were generated after co-culturing PBMC with autologous DC, pre-
loaded with ICAM-1+ KG-1 cells treated with 0.1 pfu/cell CVA21 for 24 hrs. 
Following one re-stimulation with CVA21/ICAM-1+ KG-1-loaded DC, primed CTLs 
were examined in a chromium release assay (A) and CTL degranulation assays (B 
and C). A: CTLs generated with (purple) or without (black) CVA21 were co-cultured 
with 51Cr-labelled relevant (ICAM-1+ KG-1) target cells for 4 hours at different 
effector:target ratios. The percentage of cell lysis was determined after 4 hours 
(n=6). Statistical significance was calculated using two-way ANOVA with Tukey’s 
post-hoc test. B: PBMCs primed in the presence (+) or absence (-) of CVA21 were 
co-cultured with relevant (ICAM-1+ KG-1) or irrelevant (Raji) target cells at a 2:1 
effector:target ratio for 1 h, followed by another 4 hrs incubation in the presence of 
Brefeldin A. Surface expression of CD107a/b was measured by flow cytometry on 
CD3+CD8+ CTL (n=6). C: CTL degranulation assay as performed in B following pre-
incubation of relevant target cells with either HLA-ABC-blocking antibodies (orange) 
or an isotype control (n=3). Statistical significance in B and C was calculated using 
one-way ANOVA with Tukey’s post-hoc test, * = p<0.05, *** = p<0.001, **** = 
p<0.0001, n.s = not significant. Error bars indicate s.e.m. 
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Figure 5-10: IFN-g secretion from AML-specific CTLs following antigen 
recognition. 
A: IFN-g secretion into culture medium was measured at the end of the priming 
protocol using an ELISA with matched paired antibodies (n=4). B and C: 
Intracellular IFN-g in CTLs (CD3+CD8+) generated using CVA21-treated ICAM-1+ 
KG-1 cells was measured by flow cytometry after permeabilization of cells with 
saponin and staining with an anti-IFN-g antibody. B: PBMCs primed in the presence 
of CVA21 (n=3) were co-cultured with relevant (ICAM-1+ KG-1) or irrelevant (Raji) 
target cells at a 2:1 effector:target ratio for 1 h, followed by another 4 hrs incubation 
in the presence of Brefeldin A. C: Autologous CD14+ cells were loaded with a 
PRAME peptide pool (1 hr at 37°C) and co-cultured with PBMC primed using ICAM-
1+ KG-1 in the presence or absence of CVA21. Statistical significance was 
calculated using paired, two-tailed t-tests, * = p<0.05, n.s = not significant. Error 
bars indicate s.e.m. 
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Figure 5-11: Priming of AML-specific CTLs without addition of DC, or using 
target cells not susceptible to CVA21-mediated oncolysis. 
A and B: ICAM-1+ KG-1 were treated with 0.1 pfu/cell CVA21 for 24 hrs, then virus 
was washed off and cells were incubated for another 48 hrs. Primed CTLs were 
generated after co-culturing PBMCs with untreated or CVA21-treated ICAM-1+ KG-
1 cells. Following one re-stimulation with ICAM-1+ KG-1 (with or without prior 
CVA21 treatment), primed CTLs were examined in a chromium release assay (A) 
and a CTL degranulation assay (B). A: CTLs generated with (black) or without 
(purple) autologous DC were co-cultured with 51Cr-labelled relevant (ICAM-1+ KG-1) 
target cells for 4 hours at different effector:target ratios. The percentage of cell lysis 
was determined after 4 hours (n=3). p-value >0.05 for comparison of DC+ and DC- 
at each E:T ratio was calculated using two-way ANOVA with Tukey’s post-hoc test. 
B: PBMCs primed without addition of autologous DC in the presence (+) or 
absence (-) of CVA21 were co-cultured with relevant (ICAM-1+ KG-1) or irrelevant 
(Raji) target cells at a 2:1 effector:target ratio for 1 h, followed by another 4 hrs 
incubation in the presence of Brefeldin A. Surface expression of CD107a/b was 
measured by flow cytometry on CD3+CD8+ CTL (n=3). C and D: Primed CTLs were 
generated after co-culturing PBMC with autologous DC, pre-loaded with parental 
KG-1 cells (C) or THP-1 cells (D) treated with 0.1 pfu/cell CVA21 for 24 hrs. 
Following one re-stimulation with CVA21/target cell-loaded DC, primed CTLs were 
examined using CTL degranulation assays as described in B. Statistical 
significance in B-D was calculated using one-way ANOVA with Tukey’s post-hoc 
test, * = p<0.05, n.s = not significant. Error bars indicate s.e.m. 
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5.2.4 Cellular mechanisms of CVA21-mediated induction of anti-
tumour immunity  
The results presented so far have demonstrated that an anti-tumour immune 
response can be initiated by CVA21 in both MM and AML. As very little is 
known about the immunobiology of CVA21 and the mechanisms behind 
activation of the anti-tumour immune response, this was explored using the 
AML model to exclude the effect of direct oncolysis during the experiments. 
The first step in elucidating the mechanisms behind induction of anti-tumour 
immunity was to examine the ability of CVA21 to directly activate NK cells in 
isolation. CD56+ cells were isolated from healthy donor PBMCs using 
magnetic cell separation, and then treated with 0.1 or 1 pfu/cell CVA21 for 
48 hrs as previously described for PBMCs. CD69 expression was measured 
using flow cytometry, which confirmed that CVA21 was inefficient at directly 
activating NK cells (Figure 5-12A). Thus, it was hypothesized that the 
CVA21-mediated anti-tumour immune mechanisms are initiated by cross-
talk with another cell type in the PBMC population. The most likely candidate 
for immune activation in the scenario of a viral infection is type I IFN, but the 
lack of activation of isolated NK cells suggested another cell type was 
responsible for the production of this cytokine. To further investigate this, the 
importance of type I IFNs for the induction of anti-tumour immunity was 
explored. 
 
5.2.4.1 The importance of IFN-a for CVA21-mediated anti-tumour 
immunity 
While experiments in both this chapter and in Chapter 3 confirmed the direct 
toxic effect of IFN-a on tumour cells, the main role of type I IFNs is to initiate 
an antiviral response by recruiting immune cells and inducing a protective 
antiviral state in healthy cells (179, 461). To confirm the importance of type I 
IFNs for the CVA21-mediated NK cell response, NK cell activation and 
degranulation was examined in the presence or absence of a type I IFN-
blocking antibody cocktail (Section 2.9). Briefly, PBMCs were pre-treated 
with blocking antibodies against both the IFNA2 receptor, soluble IFN-a, and 
soluble IFN-b (or an isotype control mix) before treatment with CVA21 for 24 
hrs. Figure 5-12B shows NK cell activation as measured by CD69 
expression. When both the IFNA2 receptor and soluble IFN-a and IFN-b 
were inhibited, CVA21 treatment did not induce significant activation of NK 
cells (purple bars). At the 1 pfu/PBMC CVA21 dose, 84.4% of NK cells 
expressed CD69 in the absence of blocking antibody treatment while CD69 
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expression was reduced to just 20.2% in the presence of type I IFN-blocking 
antibodies. By contrast, when PBMCs were pre-treated with the isotype 
control antibody mix, NK cell activation was similar to levels observed for 
PBMCs without pre-treatment.  
To further confirm the role for type I IFNs, NK cell degranulation against 
OCI-M2 cells was examined following pre-treatment of PBMCs with the 
blocking antibody mix, isotype control mix, or culture medium alone, prior to 
treatment with 0.1 pfu/cell CVA21 for 24 hrs. Consistent with the previous 
data, NK cells treated with CVA21 degranulated to a significant extent 
against OCI-M2 target cells, with an average 32.1% CD107-positive NK cells 
(Figure 5-12C). Furthermore, the potentiation in NK cell degranulation was 
completely lost in the presence of type I IFN-blocking antibodies, with a 
reduction in CD107-positive NK cells to just 9.5%. As expected, the 
degranulation response was not affected by pre-treatment with the isotype 
control antibody mix. Interestingly, a correlation calculation (Figure 5-12C) 
confirmed that enhanced NK cell degranulation of primary patient NK cells 
following CVA21 treatment (Figure 5-8B) significantly correlated with IFN-a 
secretion in these samples (Figure 5-5A, p=0.0009, Pearson’s r=0.74), 
further indicating IFN-a secretion as a crucial factor for NK cell activation in 
response to CVA21. 
In summary, these experiments confirmed the importance of type I IFNs for 
the initiation of CVA21-mediated NK cell anti-tumour immunity in healthy 
donors, with indication that this might also be true in primary AML samples. 
The next step in identifying the cell type responsible for initiating the anti-
tumour immune response was to examine the importance of ICAM-1 
expression for the onset of anti-tumour immunity. 
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Figure 5-12: Secretion of type I IFNs is crucial for CVA21-mediated 
potentiation of NK cell-mediated cytotoxicity. 
A: Whole PBMC or CD56+ cells alone (purple), isolated using magnetic cell 
separation, were treated with CVA21 (0, 0.1, or 1 pfu/cell) for 48 hrs. NK cell 
activation was estimated by measuring CD69 expression on CD3-CD56+ cells using 
flow cytometry (n=2). B and C: PBMC were either untreated, pre-treated with a type 
I IFN-blocking antibody cocktail (purple), or corresponding isotype control 
antibodies (grey) for 30 min. All PBMCs were treated with CVA21 as indicated (+ = 
0.1 pfu/cell) for 24 hrs, then NK cell activation (B) and degranulation (C) was 
measured. Statistical significance was measured using one-way ANOVA with 
Tukey’s post-hoc test. B: CD69 expression measured on CD3-CD56+ cells using 
flow cytometry (n=4). C: Expression of CD107a/b on NK cells following co-culture 
with OCI-M2 target cells (2:1 E:T ratio) for 1 h, then in the presence of Brefeldin A 
for 4 hrs, was measured by flow cytometry (n=3). D: Correlation of IFN-a secretion 
in response to CVA21 from PBMCs isolated from AML patient samples and the 
percentage of NK cell degranulation against OCI-M2 target cells following CVA21 
treatment (n=16). Error bars indicate s.e.m, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001, n.s = not significant. 
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5.2.4.1 The importance of ICAM-1 for CVA21-mediated anti-tumour 
immunity 
As discussed, ICAM-1 has been confirmed as the entry receptor required for 
CVA21 entry into host tumour cells (279, 397), but its importance for immune 
detection of CVA21 has not been examined to date. Thus, similar to the 
experiments performed in the previous section, the NK cell response to 
CVA21 treatment was evaluated in the presence or absence of an ICAM-1-
blocking antibody (Section 2.10). PBMCs were pre-treated with the ICAM-1-
blocking antibody or an isotype control antibody, and then treated with 0.1 or 
1 pfu/PBMC CVA21 for 24 hrs. Without pre-treatment, or with pre-treatment 
using the isotype control antibody, the percentage of CD69-positive NK cells 
reached similar levels as observed in previous experiments (69.2% and 
67.9%, respectively). However, when PBMCs were pre-treated with the 
ICAM-1-blocking antibody, CVA21 was unable to induce CD69 expression 
on NK cells (Figure 5-13A). 
Next, the secretion of IFN-a from PBMCs in response to CVA21 was 
measured, with or without pre-treatment with the ICAM-1-blocking antibody. 
Cell-free supernatants were harvested from cell cultures and examined by 
ELISA (Section 2.12.1). In the absence of ICAM-1 blockade, PBMCs 
secreted an abundance of IFN-a (Figure 5-13B), which was also 
demonstrated in Chapter 3 (Figure 3-4B). However, when CVA21 was not 
able to interact with ICAM-1 following pre-treatment of PBMCs with the 
ICAM-1-blocking antibody, IFN-a secretion was completely abrogated 
(Figure 5-13B). Taken together, these findings suggested that ICAM-1 
expression is not only necessary for tumour cell entry of CVA21, but also for 
entry into immune cells and initiation of the IFN-a antiviral response. 
The importance of ICAM-1 for CVA21 efficacy was further confirmed by 
analysing the ICAM-1 expression on mature haematopoietic cells (CD45+) in 
the AML primary sample cohort using flow cytometry. Figure 5-14A shows 
that mature immune cells in the primary samples expressed ICAM-1, with 
some variability between samples (mean 2.6-fold higher expression than 
isotype control). Interestingly, the level of ICAM-1 expression on mature 
immune cells significantly correlated with the overall death of AML blasts in 
the primary samples (Figure 5-14B, p=0.009, Pearson’s r=0.67). This 
suggested that patients with higher ICAM-1 expression on functional 
immune cells, and therefore increased ability to detect CVA21 and initiate an 
antiviral immune response, have a better response to CVA21 treatment.  
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Lastly, to more specifically determine the cell types that might be responsible 
for the induction of an antiviral, and subsequent anti-tumour immune 
response following CVA21 treatment, ICAM-1 expression on different 
immune cell populations was examined by flow cytometry. Before ICAM-1 
phenotyping, the pDC population was enriched using magnetic cell 
separation (Section 2.11.2), the other, more common cell types were 
identified using antibodies described in Table 2-4. As shown in Figure 
5-14C, this experiment demonstrated that CD14+ monocytes and pDC 
express significantly more ICAM-1 than NK cells, CD4+ T cells and CD8+ T 
cells. Over 97.0% of both CD14+ monocytes and pDC expressed ICAM-1, 
compared to 25.6% of NK cells, 49.7% of CD4+ T cells, and 44.4% of CD8+.T 
cells, highlighting monocytes and pDC as the most interesting candidates to 
explore further. 
Collectively, the data presented have demonstrated the requirement for IFN-
a secretion and ICAM-1 expression on PBMCs for the generation of an NK 
cell-mediated anti-tumour immune response by CVA21. Moreover, ICAM-1 
phenotyping implicated CD14+ monocytes and pDC as the cell populations 
with the highest expression of ICAM-1. Both these cells types are known to 
be avid secretors of IFN-a (138, 475-477) and thus, CD14+ monocytes and 
pDC were examined for their role in coordinating the anti-tumour immune 
response induced by CVA21. 
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Figure 5-13: ICAM-1 expression is crucial for CVA21-mediated potentiation of 
NK cell-mediated cytotoxicity. 
PBMC were either untreated, pre-treated with an ICAM-1-blocking antibody 
(purple), or an isotype control antibody (grey) for 30 min. Subsequently, PBMCs 
were treated with CVA21 (0, 0.1, or 1 pfu/cell) for 24 hrs, then NK cell activation (A) 
and IFN-a secretion (B) was measured. A: CD69 expression measured on CD3-
CD56+ cells using flow cytometry (n=3). B: Cell-free supernatants were harvested 
from PBMCs following CVA21 treatment for 24 hrs and IFN-a secretion was 
measured by ELISA using matched paired antibodies. Statistical significance was 
calculated using one-way ANOVA with Tukey’s post-hoc test, * = p<0.05, *** = 
p<0.001, **** = p<0.0001, n.s = not significant. Error bars indicate s.e.m. 
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Figure 5-14: ICAM-1 expression on immune cells from healthy donors and 
primary AML samples. 
A: PBMCs were isolated from peripheral blood samples obtained from AML patients 
and ICAM-1 expression on mature haematopoietic cells (CD45+) was measured at 
the time of isolation using flow cytometry (n=15). ICAM-1 expression is presented 
as the fold increase in MFI compared to an isotype control antibody. B: Correlation 
of ICAM-1 expression on CD45+ cells in primary patient samples and the 
percentage of dead blast cells following CVA21 treatment (n=14). C: PBMC were 
isolated from peripheral blood samples obtained from healthy donors and ICAM-1 
expression was measured on NK cells (CD3-CD56+), CD4+ T cells (CD3+CD4+), 
CD8+ T cells (CD3+CD8+), CD14+ monocytes, and pDC (CD123+CD303+) using flow 
cytometry (n=4). pDC were enriched using magnetic cell separation before flow 
cytometry staining. ICAM-1 expression is presented as the percentage of ICAM-1+ 
cells. Statistical significance was calculated using a one-way ANOVA with Tukey’s 
post-hoc test, ** = p<0.01, *** = p<0.001, **** = p<0.0001. Error bars indicate s.e.m.  
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5.2.4.2 Plasmacytoid dendritic cells orchestrate innate and adaptive 
anti-tumour immunity induced by CVA21 
As discussed, both monocytes and pDC are important components in the 
innate immune response and avid secretors of IFN-a, which often kick-starts 
the innate immune response (138, 342, 461, 475, 477). The main roles of 
monocytes in the innate immune response are phagocytosis of antigens and 
ADCC (478-480). pDC can be developed via both lymphoid and myeloid 
differentiation routes and are innate sensors of viral infection by employment 
of TLR7 and -9, resulting in the secretion of IFN-a (481, 482). Both 
monocytes and pDC are able to activate NK cells in response to viral 
infection (483). To elucidate the role of CD14+ monocytes and pDC, 
respectively, for the induction of anti-tumour immunity by CVA21, whole 
PBMCs were depleted of either CD14+ monocytes, pDC, or both, using 
magnetic cell separation (Figure 5-15 and Section 2.11). Both whole and 
depleted PBMCs were then used in the experiments to evaluate the effect 
on both innate and adaptive anti-tumour immunity. 
First, IFN-a secretion in response to CVA21 treatment was examined under 
the different conditions. PBMCs from healthy donors were either depleted of 
CD14+ cells, pDC, or both, and were then treated with CVA21 for 48 hrs as 
previously described. Cell-free supernatants were harvested and the amount 
of IFN-a secreted in each culture was measured by ELISA  (Section 2.12.1). 
This indicated that depletion of pDC significantly reduced the amount of IFN-
a secreted, while depletion of CD14+ monocytes had no significant effect on 
IFN-a levels (Figure 5-16A). Using whole PBMC, an average 6530 pg/mL 
IFN-a was secreted in response to 0.1 pfu/PBMC CVA21. Without CD14+ 
monocytes the amount of secreted IFN-a remained at an average 7120 
pg/mL. However, without pDC present, IFN-a levels were reduced to 1080 
pg/mL, and similarly using double-depleted PBMCs to 1270 pg/mL. 
Accordingly, pDC in isolation (orange bars) secreted large amounts of IFN-a 
in response to 1 pfu/cell CVA21 (average 5990 pg/mL) while CD14+ cells in 
isolation only secreted minimal amounts (average 310 pg/mL). This strongly 
implied pDC as the source of IFN-a in response to CVA21 treatment.  
To further evaluate the importance of pDC in anti-tumour immunity, the 
various depleted PBMC populations were included in CM, NK cell, and CTL 
priming experiments, respectively. First, the toxicity of CM generated using 
whole, or depleted, PBMC populations was examined. Cell free-CM was 
collected from various PBMC populations following CVA21 treatment for 48 
hrs, and HL-60 and kasumi-1 cells were cultured in CM diluted 1:1 in fresh 
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medium for 96 hrs (Figure 3-5A). Cell viability was estimated using an MTS 
assay (Section 2.8). As demonstrated in Figure 5-16, and consistent with the 
data presented in Section 5.2.3.1, CM from whole PBMC treated with 
CVA21 was toxic to both HL-60 (Figure 5-16B) and kasumi-1 (Figure 5-16C) 
cells, with a significant reduction in viability (W.PBMC + CVA21). Despite 
some variability, depletion of CD14+ cells had no significant effect on CM 
toxicity on either cell line. However, CM generated in the absence of pDC 
(purple bars), or the absence of both pDC and CD14+ cells, lost its cytotoxic 
potential against both HL-60 and kasumi-1 cells. For example, the viability of 
HL-60 and kasumi-1 cells was similar to levels observed following treatment 
with CM generated in the absence of CVA21 treatment (W.PBMC). These 
results suggested that pDC were crucial for the induction of the innate anti-
tumour immune response mediated by CVA21-CM, with CD14+ monocytes 
being dispensable in this context. 
Next, the role of monocytes and pDC, respectively, in NK cell-mediated anti-
tumour immunity was examined. NK cell experiments, including NK cell 
activation and degranulation, were repeated using whole PBMC and PBMC 
depleted of CD14+ monocytes, pDC, or both. PBMCs were treated with 
CVA21 for 48 hrs and NK cell activation was estimated by measuring CD69 
expression on NK cells using flow cytometry. As outlined in Figure 5-17A, a 
significant increase in CD69 expression on NK cells was confirmed in 
response to CVA21 treatment of whole PBMC. Depleting PBMC of CD14+ 
cells again had no effect and the increase in CD69 expression remained 
similar to that observed for whole PBMC (11-fold increase compared to 
untreated NK cells). However, as depicted in the purple bars, depletion of 
pDC from the PBMC population resulted in a significant reduction in NK cell 
activation in response to CVA21 treatment. For example, at the 0.1 
pfu/PBMC dose of CVA21, the fold increase in CD69 expression over 
untreated PBMCs was just 2.4 in the absence of pDC. Using double-
depleted PBMC, the results were similar, with a complete loss of NK cell 
activation in response to CVA21 treatment. Additionally, NK cell 
degranulation assays were also performed using OCI-M2 cells as target 
cells (Section 2.13.3). Using whole PBMCs treated with CVA21, the 
percentage of CD107-positive NK cells following co-culture with OCI-M2 
cells was an average 35.2% (Figure 5-17B) and depletion of CD14+ 
monocytes had no effect on NK cell degranulation, with an average 40.4% 
CD107-positive cells. By contrast, depletion of pDC, or double-depleted 
cultures,  had more dramatic consequences with a significant reduction in 
NK cell degranulation to 21.8% and 19.0%, respectively. These experiments 
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again unanimously indicated the importance of pDC for successful induction 
of anti-tumour immunity and were consistent with the importance of both 
IFN-a and ICAM-1 for both NK cell activation and degranulation (Figure 5-12 
and Figure 5-13), as pDC were confirmed as the main producers of IFN-a in 
response to CVA21 treatment.  
Lastly, the importance of pDC for adaptive anti-tumour immunity was 
evaluated by repeating T cell priming experiments using whole PBMCs, and 
PBMCs depleted of either CD14+ cells or pDC. The CTL priming protocol 
with ICAM-1-expressing KG-1 cells was used, excluding autologous DCs 
(Appendix, Figure A-1), but before addition of autologous PBMCs containing 
the naïve T cells, CD14+ monocytes or pDC were depleted from the PBMCs. 
As demonstrated previously (Figure 5-9B), CTLs primed in the presence of 
CVA21 were significantly better at recognising, and degranulating against, 
relevant (ICAM-1+ KG-1) target cells than CTLs primed without CVA21 
(Figure 5-18). An average 17.0% of CD8+ T cells, primed in the presence of 
CVA21, expressed CD107 following co-culture with relevant targets, 
compared to only 3.7% of CD8+ T cells primed in the absence of CVA21 
treatment. When PBMCs without CD14+ cells were used, CTLs responsive 
to relevant targets were generated at a similar frequency with 13.7% of 
CVA21-primed CD8+ T cells degranulating against relevant targets. 
However, depletion of pDC during the course of the CTL priming assays 
significantly reduced the efficiency of CTL priming (purple bar), for example, 
following pDC depletion only 7.0% of CVA21-primed CD8+ T cells 
degranulated against relevant targets, a percentage similar to that observed 
for CTLs primed in the absence of CVA21. While this, in accordance with 
published literature (484, 485), suggests an important role for IFN-a for 
cross-priming of CD8+ T cells, the exact role of the pDC in the CTL priming 
system has not been established in this study. However, the fact that 
exclusion of conventional DCs from priming cultures had no effect on 
priming efficiency (Figure 5-11 A and B) indicates that another cell type, 
such as pDC, may be acting as the APC in this system. 
In summary, this section has introduced pDC as the predominant cell type 
for inducing anti-tumour immunity in response to CVA21 treatment. When 
pDC were depleted from PBMCs, CM toxicity, NK cell-mediated killing, and 
priming of tumour-specific CTLs were abrogated. Likely, CVA21 utilises 
ICAM-1 on the surface of pDC, and following cell entry CVA21 ssRNA is 
recognised by TLR7 in the endosomes of pDC (486, 487). This initiates a 
signalling cascade resulting in the secretion of large amounts of IFN-a 
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which, through its downstream effects, mediates anti-tumour immunity 
mechanisms including CM-mediated bystander killing, NK cell-mediated 
killing, and priming of tumour-specific CTLs.  
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Figure 5-15: Schematic showing depletion of CD14+ cells, pDC, or both from 
whole PBMC. 
Using magnetic cell sorting, whole PBMC were depleted of either CD14+ cells 
(orange), pDC (purple), or both. CD14+-depleted PBMC contained pDC but not 
CD14+ cells (left), pDC-depleted cells contained CD14+ cells but no pDC (middle), 
and double-depleted PBMC were depleted of both CD14+ cells and pDC (right). 
CD14+ cells were removed using a positive selection with CD14+-specific 
microbeads, pDC were removed by negative selection using a non-pDC biotin-
conjugated antibody and biotin-specific microbeads (Section 2.11). 
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Figure 5-16: The importance of CD14+ monocytes and pDC for IFN-a secretion 
and CVA21-mediated bystander killing. 
Whole PBMC were depleted of either CD14+ monocytes, pDC, or both using 
magnetic cell separation as described in Figure 5-15. PBMCs (whole and depleted), 
CD14+ cells alone, and pDC alone were then treated with CVA21 as indicated for 
48 hrs. A: Cell-free supernatants were harvested and IFN-a secretion was 
measured by ELISA using matched paired antibodies (n=4). Statistical significance 
was calculated using a one-way ANOVA with Tukey’s post-hoc test. B and C: 
Following treatment with 1 pfu/cell CVA21, conditioned medium (CM) from the 
various whole and depleted PBMC populations was harvested. HL-60 (B) and 
kasumi-1 (C) were cultured in CM for 96 hrs in triplicate and cell viability was 
measured using an MTS assay (n=6). Viability was normalised to CM from whole 
PBMC without CVA21 treatment. Statistical significance was calculated using one-
way ANOVA with Dunnett’s post-hoc test, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001, n.s = not significant. Error bars indicate s.e.m.  
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Figure 5-17: The importance of CD14+ monocytes and pDC for CVA21-induced 
potentiation of NK cell-mediated cytotoxicity. 
Whole PBMC from healthy donors were depleted of either CD14+ cells (dark grey), 
pDC (purple), or both, using magnetic cell separation as described in Figure 5-15. 
Whole and depleted PBMCs were then treated with CVA21 as indicated for 48 hrs 
(0, 0.1, or 1 pfu/cell, + = 0.1 pfu/cell). A: NK cell activation was estimated by the 
expression of CD69 on CD3-CD56+ following CVA21 treatment and was measured 
by flow cytometry (n=7). Expression is presented as the fold increase in MFI 
compared to untreated NK cells. B: PBMCs pre-treated with CVA21 were co-
cultured with OCI-M2 target cells at a 2:1 E:T ratio for 1 h, then for another 4 hrs in 
the presence of Brefeldin A. NK cell degranulation was estimated by CD107a/b 
expression on CD3-CD56+ cells (n=3). Statistical significance was calculated using 
one-way ANOVA with Tukey’s post-hoc test, * = p<0.05, ** = p<0.01, *** = p<0.001, 
**** = p<0.0001, n.s = not significant. Error bars indicate s.e.m.  
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Figure 5-18: The importance of CD14+ monocytes and pDC for efficient 
priming of AML-specific CTLs using CVA21. 
To generate primed CTLs, ICAM-1+ KG-1 cells pre-treated with 0.1 pfu/cell CVA21 
for 24 hrs. Autologous PBMCs were depleted of either CD14+ cells or pDC (purple) 
using magnetic cell separation, and ICAM-1+ KG-1 cells were then co-cultured with 
either whole or depleted PBMCs. Following one re-stimulation with CVA21-treated 
ICAM-1+ KG-1 cells, primed CTLs were examined in a CTL degranulation assay. 
Primed CTLs were co-cultured with relevant target cells (ICAM-1+ KG-1) at a 2:1 
E:T ratio for 1 h, and then for a further 4 hrs in the presence of Brefeldin A. CTL 
degranulation was estimated by CD107a/b expression on CD3+CD8+ cells (n=5). 
Statistical significance was calculated using a one-way ANOVA with Tukey’s post-
hoc test, ** = p<0.01, **** = p<0.0001, n.s = not significant. Error bars indicate 
s.e.m. 
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5.2.5 Intravenous infusion of CVA21 activates immune responses 
necessary for the onset of anti-tumour immunity 
Lastly, with the ultimate aim to evaluate the potential for translating CVA21 
into the clinic with a focus on exploiting anti-tumour immunity, samples from 
the STORM Phase I clinical trial introduced in Chapter 3 were further 
examined with regards to the onset of an IFN response. Additionally, the 
cytotoxicity of CVA21 against healthy, mature immune cells was evaluated. 
 
5.2.5.1 Initiation of an IFN response following i.v. administration of 
CVA21 
As described in Chapter 3, blood samples from the STORM Phase I clinical 
trial were obtained and used as a proof of principle for the induction of an 
immune response following i.v. infusion of CVA21. The STORM trial was a 
Phase I, non-randomised, dose escalation trial, recruiting patients with 
various solid malignancies (Figure 3-1B and Table 3-1). As discussed in 
Chapter 3, none of the patients recruited in the trial had a haematological 
malignancy, but the samples still serve as a useful indicator of whether an 
anti-tumour immune response could be induced following i.v. infusion of 
CVA21 in immunocompromised patients. As shown in Table 3-1, patients 
received a dose of either 1x108 TCID50 (orange symbols) or 1x109 TCID50 
(black symbols) of clinical grade CVA21 on Day 1, Day 3 and Day 5, and 
peripheral blood samples were collected prior to first infusion (Sample A), 
one hour post first infusion (Sample B), and on Day 3 (Sample C), prior to 
second CVA21 infusion (Figure 3-1B). The results presented from the 
STORM trial in Chapter 3 confirmed that by Day 3, patients experienced an 
activation of both NK cells, CD4+ T cells, and CD8+ T cells in response to 
CVA21 administration (Figure 3-8E and Figure 3-11). 
Initially, a Luminex screen was performed on the serum obtained from 
patients before CVA21 treatment (Sample A) and three days post CVA21 
treatment (Sample C) to examine the cytokine secretion in response to virus. 
Disappointingly, very few cytokines changed consistently between the 
patients, and no patient displayed a significant increase in the secretion of 
IFN-a at this time point (personal communication; data not shown). As IFN-a 
secretion can be detected 8-16 hrs following CVA21 treatment in vitro 
(Figure 5-4), and all data previously obtained on IFN-a secretion in this study 
was obtained 24 or 48 hrs after CVA21 treatment, it is possible that by Day 3 
after CVA21 infusion, soluble IFN-a in the circulation may have been 
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degraded or sequestered. Following immediate secretion of IFNs in 
response to virus treatment, downstream signalling cascades would be 
initiated with a subsequent increase in the transcription of ISGs, such as 
IFIT1, IFI44L, and OAS1 (388). Thus, in a further attempt to examine the 
onset of an IFN response in STORM trial samples, cDNA was generated 
from cryopreserved PBMCs (Samples A and C). Using qPCR, the 
expression of ISGs IFIT1, IFI44L, and OAS1 in the total PBMC population 
was measured at each time point. Encouragingly, an upregulation of both 
IFIT1, IFI44L, and OAS1 on Day 3 after CVA21 infusion was confirmed, 
indicating the onset of a type I IFN response (Figure 5-19A). Moreover, the 
effect was more pronounced in patients who received a higher dose of 
CVA21 (black symbols), with an overall higher fold increase in ISG 
expression. Sample C from patient STORM-4 and STORM-6 (both high 
dose CVA21) showed a 46- and 77-fold increase in IFIT1 expression, 
respectively, compared to Sample A, while the low dose samples from 
STORM-1 and STORM-2 displayed a 14- and 17-fold increase, respectively. 
The results were similar for IFI44L expression. Disappointingly, Patient 
STORM-5, who received high dose CVA21 showed very little expression of 
both IFIT1 and IFI44L. Interestingly, when analysing OAS1 expression, 
patient STORM-5 showed a high expression (23-fold increase compared to 
Sample A), while the expression in STORM-4 samples was similar to that of 
the low dose CVA21 samples (5-fold increase compared to Sample A). 
As activation of NK cells following CVA21 treatment was confirmed (Figure 
3-8E), an attempt was made to evaluate the ability of NK cells from STORM 
patients to degranulate against the well-known NK cell target cell line, K562, 
in vitro. Unfortunately, cryopreserved PBMCs only recovered well enough to 
perform the NK cell degranulation assay in one patient sample (STORM-6). 
Figure 5-19B shows the flow cytometry histograms from the degranulation 
assay after five hours co-culture of STORM PBMCs and K562 target cells, 
with CD107 expression presented on the x-axis. Albeit anecdotal, this assay 
showed a promising increase in the ability of NK cells to degranulate against 
target cells on Day 3 post CVA21 infusion (right panel, 40.1% CD107-
positive NK cells), compared to pre-infusion samples (left panel, 31.3% 
CD107-positive NK cells).  
Together with the data presented in Chapter 3, these results demonstrate 
the potential onset of an immune response mediated by type I IFN in the 
peripheral circulation of immunocompromised patients, a prerequisite for the 
induction of CVA21-mediated anti-tumour immunity. In particular, a response 
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observed following i.v. administration is encouraging, as this would be the 
preferred route of administration for both MM and AML. 
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Figure 5-19: Type I IFN response following i.v. infusion of CVA21. 
A: Cryopreserved PBMCs from patients taking part in the STORM clinical trial were 
thawed (Sample A and C) and RNA was isolated using an RNEasy Mini Kit. cDNA 
was generated by reverse transcription and the expression of IFIT1, IFI44L, and 
OAS1 was measured by qPCR. Results were normalized to 18S RNA expression 
and the fold increase in expression at Day 3 (calculated as DDCt) compared to pre-
infusion is presented. Black symbols = 109 TCID50 CVA21 dose, orange symbols = 
108 TCID50 CVA21 dose, n=5. B: PBMCs from patient STORM-6 were recovered 
from cryopreservation and included in an NK cell degranulation assay using K562 
cells as target cells. Following effector and target cell co-culture for 5 hrs, the 
expression of CD107a/b on CD3-CD56+ cells was measured using flow cytometry. 
The percentage of CD107-positive cells Pre-CVA21 infusion (left panel) and at Day 
3 (right panel) is indicated in the purple gate.  
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5.2.5.2 CVA21 shows no oncolytic effect on normal haematopoietic 
cells 
A further prerequisite for the onset of anti-tumour immunity in the peripheral 
circulation, and for patient safety, is that any normal, mature immune cells 
are not killed by CVA21 treatment. To confirm this, both resting and 
activated PBMCs from healthy volunteers were treated with CVA21 for 120 
hrs and the death of NK cells, CD4+ T cells, CD8+ T cells, and monocytes 
was determined by flow cytometry using a Live/Deadâ discrimination stain in 
combination with antibodies detailed in Table 2-4. To more closely model the 
proliferative intracellular milieu of a tumour cell NK cells, CD4+ T cells, and 
CD8+ T cells were activated with 10 µg/mL phytohaemagglutinin (PHA) for 
36 hrs before CVA21 treatment. Encouragingly, as shown in Figure 5-20A, 
no death of immune cell populations was detected, and activation prior to 
treatment did not affect survival of the lymphocytes. Additionally, the viability 
of the population of mature, CD45+ haematopoietic cells in the primary AML 
sample cohort was examined following CVA21 treatment in vitro for up to 6 
days. Importantly, this confirmed that CVA21 did not induce cell death in this 
population of healthy cells and hence, only displayed a cytotoxic effect on 
malignant cells, consistent with the current dogma of OVT (Figure 5-20B). 
In conclusion, the results presented in this chapter have demonstrated that 
despite CVA21 being unable to induce direct oncolysis in AML, it could still 
be a viable treatment option through the induction of anti-tumour immunity. 
As in MM, CVA21-mediated anti-tumour immunity consisted of both 
cytokine-induced bystander killing, NK cell-mediated cytotoxicity, and the 
priming of AML-specific cytotoxic CTLs. It is the first time that CVA21-
mediated anti-tumour immunity has been demonstrated in HM. Furthermore, 
using the oncolysis-resistant AML model, the cellular mechanisms 
responsible for induction of CVA21-mediated anti-tumour immunity were 
elucidated. The response was confirmed to rely on IFN-a secretion from 
pDC, which are dependent on ICAM-1 expression for the detection of 
CVA21. Thus, this is the first study to implicate ICAM-1 expression as the 
overall determinant of susceptibility to CVA21 therapy, including anti-tumour 
immunity, and not only to CVA21-mediated direct oncolysis. 
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Figure 5-20: CVA21 has no direct oncolytic effect on normal haematopoietic 
cells. 
A: CVA21 direct cytotoxicity on immune cells from healthy donors. PBMCs were 
isolated from healthy donors and were either left resting or activated with PHA for 
36 hrs before CVA21 treatment for 120 hrs (0, 0.1, or 1 pfu/cell). Cell death was 
measured on NK cells (CD3-CD56+), CD4+ T cells (CD3+CD4+), CD8+ T cells 
(CD3+CD8+), CD14+ monocytes using flow cytometry and a Live/Deadâ 
discrimination stain (n=3). B: PBMCs were harvested from primary AML patient 
samples and treated with CVA21 for 72 hrs as indicated. Cell death of CD45+ 
mature haematopoietic cells was measured by flow cytometry as described in A 
(n=15). p-values >0.05 were calculated for all conditions using one-way ANOVA 
with Tukey’s post-hoc test. 
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5.3 Summary & Discussion 
Expanding on the findings from Chapter 3, anti-tumour immunity induced by 
CVA21 was further explored in this chapter, using AML as a model to dissect 
mechanisms of anti-tumour immunity. Additionally, the results presented in 
this chapter demonstrated that CVA21 could have a role in the treatment of 
oncolysis-resistant AML due to the efficient onset of anti-tumour immunity. 
The data presented in Figure 5-1 confirmed that all six AML cell lines tested 
were resistant to CVA21-induced oncolysis, presumably due to the low 
expression of ICAM-1 on the cell surface (Figure 5-1 A and B). Interestingly, 
for KG-1 cells, replication of CVA21 was detected using a TCID50 assay 
(Figure 5-1E), which confirmed that the virus was able to enter these cells 
but remained incapable of inducing efficient oncolysis. However, replication 
was very limited (130-fold increase in TCID50/mL) compared to what has 
previously been reported for CVA21-susceptible cell lines (up to 4-log 
increase for breast cancer cell lines and 5-log increase for MM cell lines); 
experimental repetition is required to confirm this result as well as measuring 
replication at earlier time points (202, 459). Mechanisms which specifically 
make malignantly transformed cells susceptible to OV infection, including a 
dysfunctional IFN response, were discussed in the introduction (Section 
1.4.2.1). The fact that KG-1 cells were responsive to IFN-a, which protected 
them against CVA21 oncolysis (Figure 5-4B), suggests that the IFN 
response in this cell line may be functional and prevent successful oncolysis. 
In Figure 5-2, the primary AML sample cohort was introduced, which 
demonstrated that blast cells isolated from the peripheral blood of AML 
patients express low levels of ICAM-1 (Figure 5-2A), but following treatment 
with CVA21, some cell death was still observed in 50% of the samples 
tested (Figure 5-2B). The absence of correlation between the level of ICAM-
1 expression and the level of cell death observed (Figure 5-2C) indicated 
that ICAM-1 expression on tumour cells might not be the sole determining 
factor for CVA21 susceptibility. Moreover, primary blast cells were treated as 
a part of the entire PBMC fraction, which suggested that anti-tumour 
immunity could be responsible for death of the AML blasts. While it is the 
first time that CVA21 has been explored in AML, a number of other OVs 
have previously been examined for their direct oncolytic potential in this 
setting (Table 1-5), including myxoma virus (208), VSV (205), reovirus (206), 
and engineered adenoviruses (209, 488). The trend among these studies 
was to use cell line data and murine xenograft in vivo studies rather than 
primary AML patient samples ex vivo
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primary AML samples, which confirmed large variability in susceptibility, but 
identified approximately 50% of samples as susceptible to VSV infection 
(205). Disappointingly, only one OV, VSV genetically modified to express 
IFN-β and NIS, has progressed to early clinical trials dedicated to AML 
(196). 
ICAM-1 has been described as being crucial for oncolysis mediated by the 
Kuykendall prototype strain of CVA21 (489). As previously discussed, ICAM-
1 mediates cell entry, in collaboration with the DAF protein which acts as a 
co-receptor and facilitates virion adherence to the cell surface (279, 490). 
The exact mechanism by which cellular entry is processed via ICAM-1 has 
not been clarified. In accordance with this theory, both transduction of KG-1 
cells with the ICAM-1 protein (Figure 5-1 C and D), and upregulation of 
ICAM-1 expression using TNF-a, increased their susceptibility to CVA21-
mediated oncolysis (Figure 5-3C, left panel). Additionally, one primary AML 
sample pre-treated with TNF-a also showed increased susceptibility to 
CVA21 (data not shown). However, in THP-1 and kasumi-1 cells, which did 
not show any signs of CVA21 replication, increasing ICAM-1 expression with 
TNF-a pre-treatment had no effect on susceptibility to CVA21 oncolysis 
(Figure 5-3, middle and right panels). While TNF-a treatment did increase 
ICAM-1 expression, it also had a significant toxic effect in itself, in particular 
on kasumi-1 cells and primary samples. However, TNF-a would have 
multiple downstream consequences, in addition to modulating ICAM-1 
expression, e.g. induction of apoptosis and antiviral responses, which could 
ultimately synergise or abrogate OV treatment in a cell-type dependent 
manner (491). The role of DAF in infectivity has been thoroughly 
investigated and, in some circumstances, DAF has mediated cell entry of 
bioselected variants of CVA21 independent of ICAM-1 (152, 489). 
Preliminary data obtained in the lab demonstrated that all AML cell lines 
tested expressed DAF (data not shown) and hence, DAF expression was 
thought not to be a determining factor for susceptibility and resistance in this 
model. In contrast to this, the oncolysis results obtained in Chapter 3 
confirmed the importance of ICAM-1 as the MM cell lines that expressed 
high levels of ICAM-1 showed significant susceptibility to CVA21-induced 
death, while OPM2 cells expressed no ICAM-1 and were completely 
resistant to CVA21-mediated oncolysis (Section 3.2.1). 
In addition to ICAM-1 expression, the secretion of IFN-a in response to 
CVA21 treatment had a significant impact on the induction of direct 
oncolysis. As discussed in Chapter 3, CVA21 treatment of healthy donor 
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PBMCs induced secretion of a range of cytokines, including IFN-a. 
Moreover, in this chapter it was confirmed that PBMCs from primary AML 
samples also have the ability to secrete IFN-a in response to CVA21 
treatment (Figure 5-4A), which could have a detrimental effect on CVA21-
mediated oncolysis, as demonstrated using ICAM-1-transduced KG-1 cells 
(Figure 5-4B). It is possible the IFN secreted from primary samples could 
inhibit CVA21-mediated oncolysis, which suggests that the IFN response 
plays an important role for CVA21 efficacy. These findings were also in line 
with the absence of any correlation between ICAM-1 expression on AML 
blast and CVA21-mediated death in primary samples (Figure 5-2C) and 
highlights the importance of other mechanisms of action, such as anti-
tumour immunity, for the efficacy of CVA21 in AML. Susceptibility to IFN 
responses is not an uncommon feature in OVs and has been demonstrated 
for  recombinant Newcastle disease virus and Maraba virus (492, 493). 
Moreover, this study provides further evidence that an antiviral response 
might be insignificant for the efficacy of OVT as it still permits, and indeed 
may mediate, the onset of anti-tumour immunity regardless of efficient direct 
oncolysis. 
Interestingly, IFN-a has previously been shown to have a direct cytotoxic 
effect on AML blast cells and has been evaluated as a treatment option in 
multiple clinical trials in AML (112, 463, 464). Despite promising results in 
vitro, the trial outcomes were very variable and no clear benefit from IFN-a 
was confirmed. Several patients experienced acute GVHD when IFN-a was 
administered in connection with HSCT. While IFN-a alone showed very little 
toxicity against AML cell lines in this study, a mixture of cytokines (either a 
combination of IFN-a and IFN-g, or the CVA21-CM) significantly enhanced 
the toxic effect (Figure 5-5 and Figure 5-6). Encouragingly, a similar 
bystander killing effect was achieved using CM generated from patient 
PBMCs (Figure 5-6B). The Luminex assay performed on CVA21-CM in 
Chapter 3 outlined the changes in secretion levels of 48 different cytokines 
and chemokines following CVA21 treatment of PBMC (Figure 3-4E). Several 
cytokines showed an enhanced secretion following CVA21 treatment, for 
example IL-2, IL-6, and IL-1b, which have all been implicated as 
therapeutics in AML due to their direct toxic effect on AML cells (465-467). 
As discussed in Chapter 3, the toxicity of OV-CM has not previously been 
examined in a haematological setting. However, a number of studies have 
examined the toxicity of tumour-CM following OV treatment in solid 
malignancies. In a study examining VSV in combination with Smac mimetics, 
VSV was shown to induce the secretion of IFN-b, TNF-a, and TRAIL from 
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glioblastoma cells. The CM from VSV-treated cells was cytotoxic to fresh 
glioblastoma cells after 48 hrs, which was further potentiated by combination 
with the pro-apoptotic Smac mimetics (494). A similar approach was used by 
Cai et al., who demonstrated bystander killing induced by a toga virus (M1) 
which was mediated by IL-8, IL-1A, and TRAIL (495). Reovirus-treatment of 
melanoma cells also generates CM with a bystander toxicity against 
uninfected melanoma cells (496). It is interesting to note that several studies 
highlighted TRAIL secretion as important for bystander killing, as TRAIL was 
one of the most abundantly secreted cytokines in CVA21-CM besides IFN-a 
(Figure 3-4E). Moreover, TRAIL has been proven well-tolerated as a 
monotherapy for relapsed and refractory MM in clinical trials, and has also 
shown efficient toxicity in AML in combination with additional sensitizing 
agents such as pro-apoptotic XIAP inhibitors and bortezomib (497-499). 
In Chapter 3, it was confirmed that NK cells from healthy volunteers become 
activated in response to CVA21 treatment as measured by an upregulation 
of CD69 expression. In accordance with the results presented in Chapter 3, 
CVA21 treatment of NK cells also significantly enhanced their ability to 
degranulate against AML target cells, and degranulation was associated with 
an increase in NK cell-mediated killing of target cells (Figure 5-7 A and B). 
THP-1 and OCI-M2 cells were most susceptible to the NK cell-mediated 
killing, and this correlated with their high expression of activating NK cell 
ligands (Figure 5-7C). This was encouraging, as levels of cell death up to 
54.1% were observed for OCI-M2 cells, which clearly indicated a role for 
CVA21 in targeting AML despite the absence of direct oncolysis. In addition, 
NK cell activation in response to CVA21 treatment was confirmed also in 
primary AML patient samples, and although there was extensive variation 
between samples, a significant increase in NK cell degranulation against 
OCI-M2 targets was observed (Figure 5-8 A and B). However, unfortunately 
due to the overall low expression of activating NK cell ligands on primary 
blast cells, NK cell degranulation against autologous blasts was very limited 
(Figure 5-8D). Both HSV-1 and reovirus treatment have previously been 
shown to induce NK cell-mediated anti-tumour immunity in AML, resulting in 
significant eradication of AML cells (206, 207). Interestingly, in the study on 
reovirus, healthy virus-activated NK cells were able to recognise and 
degranulate against primary AML blast cells, indicating that with full 
functionality of NK cells, and allogeneic mismatch, eradication of AML blasts 
is possible (206). However, it would also be interesting to examine whether 
the different cytokine profiles induced by reovirus and CVA21, respectively, 
can lead to the activation of NK cells with different cytotoxicity profiles. 
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In Chapter 3, two main strategies for improving the recognition of MM cells 
by NK cell targets were discussed, which would also be relevant in the AML 
setting considering the very low expression of activating NK ligands on 
primary AML blast cells, and lack of killing in an autologous setting. First, 
based on the fact that rituximab treatment was able to potentiate NK cell-
mediated ADCC of blast cells in CLL (138), a combination treatment with a 
monoclonal antibody would be attractive. Anti-CD33 antibodies have been 
extensively studied in AML, but limited efficacy and safety issues in clinical 
trials have reduced interest in this strategy (500). Thus, the more novel anti-
CD123 antibodies could be a more interesting option for this combination 
approach. Encouragingly, a second generation anti-CD123 antibody was 
recently shown to enhance ADCC in a large cohort of AML patients in 
remission (136). Second, the HDAC inhibitor VPA, which is occasionally 
used in the treatment of AML, can increase the expression of NKG2D 
ligands on primary blast cells, similar to its effect in MM (501, 502). In 
addition, 5-azacitidine, a first-line treatment for patients with high-risk MDS 
and AML can boost NK cell recognition of malignant blasts both by 
increasing the expression of activating NK ligands on AML blasts, and 
through the alteration of KIR receptors on NK cells (503, 504). Similarly, a 
derivative of 5-azacitidine, the hypomethylating agent decitabine, has also 
been shown to increase NK ligand expression, and anti-CD33-mediated 
ADCC in AML patient samples (505). All these agents would be interesting 
options to explore in combination with CVA21 to improve NK cell targeting of 
primary blast cells. 
The ability of CVA21 to induce priming of AML-specific CTLs was examined 
in Section 5.2.3.3. Using CVA21-treated ICAM-1+ KG-1 cells, CTLs with 
specificity and high cytotoxicity against relevant, and not irrelevant, target 
cells were generated (Figure 5-9 and Figure 5-10). Importantly, CTLs were 
also able to recognise PRAME, one of the most frequent TAA in AML (26), 
when presented as a peptide pool on autologous PBMCs. PRAME has 
previously been implicated for the priming of AML-specific CTLs (506, 507), 
and interestingly, decitabine has been shown to increase the expression of 
PRAME on AML cells, further strengthening its relevance for combination 
treatment with CVA21 (506).  
Results generated in Chapter 3 indicated that CTL priming was ineffective 
against CVA21-resistant OPM2 cells (Figure 3-18D). This finding was further 
explored in the present chapter by investigating priming against parental KG-
1 and THP-1 cells, which were both resistant to direct oncolysis. 
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Interestingly, tumour specific CTLs were generated using both cell lines, 
suggesting that oncolysis was not a strict requirement for successful CTL 
priming (Figure 5-11 C and D). In line with this, UV-inactivated, non-
replicative rhabdoviruses (VSV and Maraba virus) have extensive toxicity 
against primary AML samples mediated by a strong T cell response, which 
resulted in long-term immunological protection (508). However, as opposed 
to THP-1 cells, KG-1 cells were permissive to CVA21 infection which 
resulted in a small amount of CVA21 replication (Figure 5-1E). This did not 
seem to affect the generation of tumour-specific CTLs as a higher number of 
degranulating CTLs were detected in priming cultures where THP-1 cells 
were used as targets, compared to parental KG-1 cells. 
The experiments described in Chapter 3 demonstrated that iDCs had a very 
weak response to CVA21 treatment with a limited change in the expression 
of the maturation markers CD80, CD86, and MHC Class II, which are 
essential for efficient activation and antigen presentation to T cells (509). 
Despite this, CVA21 was able to induce priming of tumour-specific CTLs in 
both MM and AML. Upon further exploration, these studies demonstrated 
that addition of autologous DCs was not required to generate CTLs (Figure 
5-11 A and B) and suggested that another cell type, such as pDC, might act 
as the APC in this system (510). While DCs are considered the prototype 
APC, several other cell types, including pDC, CD169+ macrophages, and 
neutrophils, have previously been used to successfully cross-prime CTLs 
(511-514).  
To date, only one study has previously examined the onset of adaptive anti-
tumour immunity in AML using a replication-competent OV (205). This in 
vivo study used a syngeneic murine model of AML (C1498 cells in C57Bl/6 
mice) which was treated with VSV engineered to express IFN-b and the NIS 
reporter. OV treatment generated CTLs with high specificity against a 
tumour-expressed GFP antigen, and treatment efficacy following VSV 
treatment was potentiated by combination treatment with an anti-PD-L1 
antibody. Batenchuk et al. performed a study examining non-replicative 
rhabdovirus-derived particles where DBA/2 mice with syngeneic L1210 cells 
were used as a model of blast crisis in AML (508). DBA/2 mice are 
considered immunocompetent, comparable to C57Bl/6 mice, but do have 
some immunocompromising traits such as a lack for NKG2A expression on 
NK cells which might be important for recognition of cells with low 
expression of MHC Class I (515). Nonetheless, Batenchuk et al. 
demonstrated the onset of a strong T cell-activating cytokine response and T 
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cell-mediated protection against tumour challenge following a vaccination 
strategy in combination with non-replicative viral particles (508). In general, 
studies of anti-tumour immunity using in vivo models of AML are sparse. The 
C1498 syngeneic model of murine orthotopic AML has been used to study 
the PD-1/PD-L1 axis in AML with successful generation of tumour-specific 
CTLs following treatment with an anti-PD-L1 antibody (516). Similarly, it has 
been used in various DC vaccine and adoptive transfer strategies, including 
a WT1 peptide vaccine and ex vivo tumour lysate stimulation of T cells, 
resulting in high frequency generation of tumour-specific CTLs (517, 518). 
However, as discussed previously and enforced in this chapter, using murine 
models for the study of CVA21-induced anti-tumour immunity is complicated 
due to the requirement for human ICAM-1 expression. The introduction 
outlined several types of immunotherapies which are currently being 
explored for the treatment of AML (Section 1.3), with adoptive transfer of 
DCs and genetically engineered NK cells particularly showing encouraging 
results in clinical trials. However, both immune checkpoint and CAR-T cells 
therapies have not yet produced the encouraging results of other 
malignancies in the context AML, which demonstrates the importance of 
continued exploration of immunotherapy treatments and novel combination 
strategies in AML. Taken together, the results presented throughout this 
section confirmed the potential for an anti-tumour immune response in AML 
following CVA21 treatment, and like in MM, this response consisted of both 
innate and adaptive tumour-clearing immune mechanisms. The fact that the 
observed responses were reduced in primary AML samples compared to 
healthy donors indicates that future studies should focus on potentiating this 
response, e.g. by exploiting other types of immunotherapies which might 
result in a synergistic response, such as CAR-T cells (106). 
 
Next, the mechanisms behind the onset of anti-tumour immunity in response 
to CVA21 treatment were explored in more detail. It was confirmed that NK 
cell-mediated cytotoxicity was dependent on type I IFN secretion from 
PBMCs (Figure 5-12 B and C), which is in accordance with previously 
published literature and an intrinsic part of the antiviral immune response 
with the aim to rapidly remove virally infected cells from the circulation to 
limit viral infections (179). Moreover, NK cell-mediated cytotoxicity was 
shown to also rely on ICAM-1 expression on PBMCs. This function of ICAM-
1 has previously not been documented in the context of CVA21. However, 
ICAM-1 is an adhesion molecule with several functions throughout the 
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immune system, with particular importance for lymphocyte migration, 
formation of the immunological synapse, and the generation of CD8+ T cell 
responses (519, 520). It is likely that CVA21 employs ICAM-1 also to enter 
immune cells, which can then recognise the virus via TLRs and initiate a 
downstream immune response (521, 522). TLR7 and -8 are the main PRRs 
recognising ssRNA (523). TLR7 is predominately expressed in pDC and B 
cells while TLR8 is known to be primarily expressed in 
monocytes/macrophages, myeloid DC, and neutrophils (524). However, both 
TLR7 and -8 are endosomal, which requires phagocytosis of virus or virally 
infected cells for successful recognition. There are also other cytosolic 
sensors of ssRNA, such as RIG-I and MDA5, which could be important in 
the immune detection of CVA21 and the subsequent IFN response (293). 
Due to their high expression of ICAM-1 on the cell surface and prominent 
roles in type I IFN secretion, monocytes and pDC were next examined for 
their importance in the onset of CVA21-mediated anti-tumour immunity. The 
results demonstrated that pDC were responsible for the majority of IFN-a 
secreted in response to CVA21 (Figure 5-16 A) and the toxic effect of CM on 
both HL-60 and kasumi-1 cells. No loss of CM efficacy was seen following 
depletion of CD14+ monocytes. Interestingly, recent studies have 
demonstrated that monocytes might only be able to produce pro-
inflammatory cytokines and type I IFN in response to TLR8, but not TLR7, 
stimulation (524). This suggests that TLR7 might be the key mediator of the 
CVA21 response and cytokine secretion in response to CVA21 in particular. 
Accordingly, TLR7 has previously been shown to be the main sensor of 
CVB3 infection in pDC, although IFN-a secretion required concurrent nAb 
opsonisation and engagement with Fc receptors (291). Moreover, this might 
also indicate that IFN-a is one of the main toxic components of CM in the 
AML model, which is consistent with the literature documenting IFN-a as a 
treatment modality in AML (112, 463, 464). However, CM generated with 
PBMC depleted of pDC was only examined for its IFN-a content in this study 
and it is not known whether pDC depletion affects other cytokines in the CM 
with potential toxicity against AML cells, such as TRAIL. Interestingly, in a 
study of melanoma and HSV-1, pDC were shown to be responsible for 
secretion of both IFN-a and TRAIL into CM, which induced a bystander 
killing effect on melanoma cells and synergised with the direct oncolytic 
effect of HSV-1 (525). Clarification of the exact cytokines involved in the CM 
toxic effect on AML cells would require future experiments to employ 
individual antibody-mediated neutralisation of relevant candidate cytokines. 
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The findings that both NK cell activation and degranulation, as well as the 
generation of efficient anti-tumour specific CTLs, was abrogated in the 
absence of pDC, but not CD14+ cells, further implicated pDC as crucial for 
induction of CVA21-mediated anti-tumour immunity. While it is not 
unexpected that pDC are the main sensors of CVA21 infection, this is the 
first study to confirm the importance of pDC for CVA21-mediated anti-tumour 
immunity and their role in orchestrating the anti-tumour immune response 
via IFN-a secretion. As discussed, pDC are important for the detection of 
viral infections and for initiation of antiviral immune responses. pDC have 
been shown to be important for the IFN-a response also following infection 
with the closely related CVB, with recognition of CVB ssRNA on TLR7 (291, 
526). However, CVB uptake into pDC was  mediated by antibody 
opsonisation and Fc receptors, rather than the ICAM-1 dependent 
mechanism of CVA21 which is proposed here (291). For OVs specifically, 
pDC are responsible for the recognition of both MV and myxoma virus as 
well, with ssRNA binding to TLR7 and generation of an antiviral response 
with IFN-a secretion being reported (527, 528). For MV, pDC engagement  
generated an anti-tumour response concordant with pDC phagocytosis of 
TAA and subsequent cross-presentation of antigen to CD8+ T cells (527). By 
contrast, monocytes are important for the detection of the dsRNA reovirus 
(138) and membrane-expressed TLR2 can mediate HSV-1 (dsDNA) 
detection in NK cells (207). The identification of pDC as crucial for CVA21-
mediated anti-tumour immunity provides an important contribution to CVA21 
immunobiology and indicates that the level of pDC could act as a key cellular 
determinant to inform patient stratification and CVA21 responsiveness. 
Moreover, several novel immunotherapy methods utilising adoptive transfer 
of pDC are currently being explored, which opens up interesting possibilities 
for combination treatments with CVA21. One study in ALL used patient-
derived CD34+ progenitor cells which were differentiated into pDC ex vivo. 
These cells were then activated with either TLR7 or -9 agonists and 
following adoptive transfer, pDC significantly enhanced the anti-tumour 
toxicity of NK cells (529). 
 
In addition to the data presented in Chapter 3, further analysis of STORM 
clinical trial samples in this chapter indicated the onset of an IFN response 
with increased expression of several ISGs and potential for enhanced NK 
cell cytotoxicity (Figure 5-19). The STORM trial is the only trial initiated to 
date with i.v. administration of CVA21. As discussed in Chapter 3, 
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unfortunately none of the patients included in the STORM clinical trial had a 
haematological malignancy diagnosis, however, the general ability of CVA21 
to induce a type I IFN response and activate immune cells in vivo in a state 
of malignancy following i.v. administration is encouraging and acts as a proof 
of principle for future studies. Early reports from the STORM trial confirmed 
that repeated dosing of CVA21 i.v. was well tolerated with no Grade 3 or 4 
adverse effects. Significant increases in nAb levels were not seen until Day 
7, which seemed to allow successful replication of CVA21 in tumours (305). 
This clinical  trial has now been extended to include combination treatment 
with the checkpoint inhibitor pembrolizumab in both bladder and lung cancer 
(309). Importantly, in the present study it was also confirmed that CVA21 
was non-toxic to healthy immune cells (both resting and activated), both 
from healthy donors (NK cells, CD4+ T cells, CD8+ T cells, and monocytes) 
and AML patient samples (CD45+ cells), which is crucial for clinical safety in 
HM (Figure 5-20). This is in line with the data previously presented by Au et 
al., which confirmed that CVA21 treatment for 48 hrs (1 TCID50/cell) induced 
no cytopathic effect in PBMCs, and PBMCs were unable to support 
productive CVA21 replication (202). 
The patient samples included in this study is one of the largest cohorts used 
for ex vivo studies of OV in AML. Extensive variation existed in the cohort 
both with regards to demographics, diagnoses, and responses to CVA21 
treatment. Taken together, the experiments performed throughout this 
chapter confirmed that CVA21 can have a toxic effect on primary AML blast 
cells, which did not seem to be determined by ICAM-1 expression. Overall, 
the evidence pointed to the onset of anti-tumour immunity with secretion of 
IFN-a in response to CVA21 treatment, and subsequent activation and 
degranulation of NK cells in a subset of samples. As discussed above, 
degranulation against autologous blast cells was disappointing, but several 
interesting dual treatment options for making blast cells more attractive 
targets for NK cells exist. With the extensive variation within the cohort, it 
was not possible to stratify a successful CVA21 response to a particular 
AML subtype, mutation, cytogenetic profile, or other variable. However, the 
FLT3-ITD subtype has been associated with a higher frequency of pDC 
(530) in AML therefore, patients with the FLT3-ITD mutation may show an 
enhanced benefit from CVA21 treatment. However, pDC from patients with 
this ITD could only be partially activated to secrete cytokines, which might 
explain the limited response to CVA21 observed in some of the primary 
samples used in this study, but could also again indicate the possibility for a 
treatment strategy with ex vivo expansion and activation of pDC in 
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combination with CVA21. Five patients in the cohort used in this study had 
confirmed FLT3-ITD (Table 5-1), and this group included both patients which 
produced IFN-a and displayed enhanced NK cell function (CD69/CD107 
expression) in response to CVA21, and those who did not. Thus, a larger 
cohort of patients would be required to fully elucidate the efficacy of CVA21 
against FLT3-ITD-mutated patients as well as those with other genotypes. 
Additionally, the majority of AML patient samples utilized for this study had 
limited numbers of immune effector cells. Hence, CVA21 treatment would 
likely be more beneficial for targeting MRD in patients nearing remission, or 
patients at early relapse, when disease burden may be low. Importantly, 
patients in remission have a reconstituted immune response with functional 
NK and T cells (531-533). CVA21 could potentially be used clinically as a 
mono-immunotherapy to target MRD, or as a maintenance treatment 
following completion of intensive chemotherapy. Personalised medicine 
approaches with CVA21 could also be considered, specifically targeting 
patients with normal to high pDC levels, or patients expressing high ICAM-1 
on immune cell subsets but not malignant blasts. As discussed, the progress 
in immunotherapy for AML is encouraging and the results presented in this 
chapter show that OVs may be a viable option for the treatment of AML 
which warrants further investigation both as a single modality and in 
combination with other promising treatments, to ultimately prolong and 
improve the life of AML patients. 
In conclusion, this chapter has demonstrated two major points using an AML 
model in vitro, 1) that pDC orchestrate the anti-tumour immune response 
induced by CVA21, and 2) that CVA21 could have a role in the treatment of 
AML despite low ICAM-1 expression on AML blasts. Furthermore, this work 
has also demonstrated that ICAM-1 expression is not only the determining 
factor of susceptibility to CVA21-mediated oncolysis, but overall 
susceptibility to CVA21 treatment, including anti-tumour immunity.  
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Conclusions and Future Work 
 
Overall conclusions and implications of the study 
The results presented within this study have demonstrated a role for OV-
induced anti-tumour immunity in two different HM; MM and AML. Both 
reovirus and CVA21 induced an anti-tumour immune response in MM in 
vitro, comprising innate and adaptive immune mechanisms. This is the first 
time that the contribution of anti-tumour immunity for reovirus and CVA21 
efficacy in MM has been examined. While CVA21 is a more novel OV, 
reovirus has been taken forward to clinical trials in MM and thus, it is 
important to fully clarify its mechanisms of action to optimise its therapeutic 
efficacy. To date, CVA21 had only been pre-clinically examined for its direct 
oncolytic effect in MM and the results presented here indicate that CVA21 
should be tested further in the context of MM, as it has the potential to 
induce both direct oncolysis and a potent anti-tumour immune response, 
which is a good foundation for successful OVT.  
Moreover, this study demonstrated that reovirus also has efficacy against 
MM in an immunocompetent in vivo model with successful onset of an 
immune response. While this response requires further characterisation, the 
use of this model will allow for future exploration of reovirus-induced anti-
tumour immunity in an in vivo setting. Due to the complex nature of the 
immune system, development of this model will be important to confirm the 
onset of anti-tumour immunity in a complete physiological system. 
This is the first study to examine CVA21 for the treatment of AML. 
Encouragingly, CVA21 was also able to induce an anti-tumour immune 
response with both innate and adaptive components in AML, and 
importantly, anti-tumour immunity was established in the absence of direct 
oncolysis. This indicates that OVT might have potential in malignancies 
which are not directly susceptible to viral infection. Furthermore, the results 
presented in this study demonstrated that ICAM-1 expression is not only the 
determinant of susceptibility to CVA21-mediated direct oncolysis, but the 
overall determinant of a successful response to CVA21 therapy, including 
anti-tumour immunity. Taken together, these findings might have 
implications for future stratification of CVA21 treatment and for the 
development of personalised treatment regimes, in both HM and solid 
malignancies. 
 252 
pDC were identified as the immune cell type with the overall highest 
expression of ICAM-1 on the cell surface, and accordingly pDC were 
confirmed to orchestrate the anti-tumour immune response generated 
following CVA21 treatment. In the absence of pDC, cytokine-induced 
toxicity, NK cell-mediated cytotoxicity, and the priming of tumour-specific 
CTLs were abrogated. Thus, this study contributes new knowledge to the 
mechanisms of action of CVA21. While it was not surprising that pDC are 
the main sensors of CVA21 infection, the critical role of pDC for induction of 
both innate and adaptive anti-tumour immunity is important information for 
future optimal development of CVA21 treatment strategies. Interestingly, 
these results also highlight the differences between OVs in their induction of 
anti-tumour immune responses, as monocytes have previously been shown 
to be the main sensors of reovirus infection. Thus, these data have 
implications for selection of the most appropriate OV in a given patient, as 
well as providing further options for personalised medicine strategies. 
The use of OVT in the context of HM is an under-investigated field, in 
particular in terms of anti-tumour immunity. The findings presented here 
demonstrate that OVT can be efficient in HM and provide a foundation for 
continued research in this area, with the ultimate aim to identify new 
treatment options and improve the outlook for HM patients.  
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Suggested future work 
The results obtained in this study have predominantly been generated using 
in vitro experimentation with established cell lines and PBMC from healthy 
individuals. While this provides proof of principle, future studies would 
require inclusion of more patient-derived samples, murine in vivo studies, 
and eventually clinical testing to fully clarify the role of OVT in HM. 
CVA21 has only been examined in one previous study in MM (202). The 
work presented here has highlighted the potential of CVA21 as a treatment 
option in MM, confirming the possibility for direct oncolysis, anti-tumour 
immunity, and the targeting of tumour cells in the BM microenvironment. 
This warrants further exploration and future studies should aim to fully 
establish if CVA21 is suited for development as a clinical tool in the 
treatment of MM. Preclinical work should initially include examination of 
CVA21 efficacy in primary MM samples to ensure the results can be 
reproduced in primary cells. However, as discussed, the in vivo testing of 
CVA21-induced anti-tumour immunity is difficult. While it is possible to 
transfect murine tumour cell lines with human ICAM-1 for the use in 
immunocompetent models, the results presented here have demonstrated 
that expression of human ICAM-1 on immune cells is required for the 
successful generation of anti-tumour immunity. It is possible that a 
transgenic system could be developed, however, it might be more relevant 
to establish a primary sample cohort, as well as advanced in vitro models of 
the BM microenvironment, to thoroughly test CVA21 efficacy (direct 
oncolysis and anti-tumour immunity) in MM ahead of clinical testing. A 
representative cohort would allow for stratification of treatment response to 
patient characteristics and identify any particular disease subtypes likely to 
gain benefit from CVA21 treatment. Several methods exist for advanced 
modelling of the BM in vitro, such as using various types of 3D scaffolds and 
microfluidic chips in combination with primary cells from BM aspirates (534, 
535). 
While efficient in experiments with established cell lines, the use of CVA21 in 
AML proved more difficult when expanding the work to primary samples. 
This demonstrates the importance of establishing efficacy in patient-derived 
samples and has highlighted the need for future work to focus on identifying 
combination strategies to enhance CVA21 efficacy in AML. As discussed, 
this could e.g. include methods to improve primary blasts as NK cell targets 
through pre-treatment with HDAC inhibitors or mAb. Additionally, the optimal 
timing of CVA21 administration in the treatment course needs to be 
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deciphered. Patients in remission have a reconstituted immune system with 
functional NK and T cells, hence patients nearing remission might benefit 
from the anti-tumour immune effects of CVA21 in the control of MRD (532, 
533), but additional work is required to fully clarify this. 
Furthermore, future work is required to establish in detail how pDC 
orchestrate anti-tumour immunity in response to CVA21. This work could be 
expanded by closer examination of the role of pDC in bystander killing and 
clarification of which cytokines are responsible for the cytotoxicity of virus-
CM. Clarification of the exact role of pDC in CTL priming also requires 
further work. The results presented indicated that conventional DCs are not 
required for the CVA21-induced priming of tumour-specific CTLs and thus, 
the role of pDC as APCs in the CTL priming system would be interesting to 
explore, along with the importance of IFN-a for successful priming. In 
addition, molecular mechanisms relating to pDC uptake and recognition of 
CVA21 still remain to be revealed. 
The identification of pDC as important for CVA21-mediated efficacy opens 
many questions regarding the optimal use of CVA21. It will be important for 
future studies to consider the impact of a low ICAM-1 expression or 
dysfunctional pDC on treatment outcomes. For example, it could become 
relevant to develop combination treatments designed to increase ICAM-1 
expression on immune cells prior to OV administration. Interestingly, 
preliminary data generated as part of this study indicated that virus-CM can 
increase the expression of ICAM-1 on AML cells (data not shown). While this 
did not confer susceptibility to CVA21-mediated oncolysis, it demonstrated 
that the inflammatory environment generated in response to CVA21 could 
potentially directly manipulate ICAM-1 expression also on immune cells. 
However, even though healthy cells should be protected by a functional IFN 
response, care should be taken not to cause off-target effects through a 
generalised induction of ICAM-1 expression. Several strategies for exploiting 
the dependence of CVA21 on pDC are possible. The development of pDC 
for adoptive transfer is interesting to consider in the context of OV. Ex vivo 
expansion and adoptive transfer of pDC could help those patients with low 
numbers of circulating pDC and improve the response to CVA21 treatment 
(529). In this context, CVA21 could be considered as an activating agent for 
ex vivo expanded pDC, similar to common TLR7 and -9 agonists, such as 
imiquimod and oligodeoxynucleotides (CpG). Another way of boosting the 
number of circulating pDC is FLT3 ligand treatment. FLT3 ligand is an 
important differentiation factor for pDC and significantly increases the 
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number of pDC in the blood (536, 537). In addition, pDC could potentially be 
harnessed to improve the adaptive anti-tumour immune responses of 
CVA21. Interestingly, pDC can cross-present antigen to CD8+ T cells and 
strategies of directing nanoparticles containing TAA to pDC, as well as 
vaccine regimens utilising ex vivo loading of pDC with TAA have been 
explored (538, 539).  
To further develop the reovirus work, the in vivo model of reovirus treatment 
in MM in particular requires more work to fully establish the contribution of 
anti-tumour immunity to treatment efficacy. Based on the experiments 
performed in this study, reovirus has the potential to induce an immune 
response, predominantly in the spleen, but the nature of this response 
remains to be determined with regards to its antiviral or anti-tumour 
specificity. In particular, experiments to identify the immune cells that are 
critical for reovirus efficacy using antibody depletion should be performed, as 
well as ex vivo characterisation of the antigen specificity of CD8+ T cells 
following reovirus treatment. In addition, experimental groups will need to be 
maintained at a minimum of 8-10 animals per group to ensure reliable 
results due to experimental variability. Although reovirus is already being 
tested in clinical trials for MM, it is important to fully establish its mechanism 
of action to allow for the identification of optimal combination therapies. 
A number of methods could be considered to further enhance the anti-
tumour immune responses described in this study. As discussed, Smac 
mimetics have been used in combination with OVs to potentiate bystander 
killing (494). This is an interesting avenue to explore in terms of cytokine-
mediated tumour cell killing, but also for the potential of Smac mimetics to 
activate immune cells, such as NK cells (540). Moreover, it would be 
interesting to examine the consequential use of two or more OVs working 
through different immune mechanisms in a prime-boost strategy to further 
enhance adaptive anti-tumour immune responses. Reovirus has previously 
been used in prime-boost experiments in combination with a TAA-
expressing VSV, which resulted in T cell-mediated long-term cures in vivo 
(438). Furthermore, it is worth considering options for genetic modification of 
both reovirus and CVA21 to enhance their immunogenicity. Identification of 
the cytokines specifically responsible for the cytotoxicity of virus-CM could 
provide cytokine candidates for conjugation to OVs. Similarly, OVs armed 
with TAA could potentially be used to improve the priming of tumour-specific 
CTLs. Another strategy would be to incorporate OV into current DC vaccine 
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regimens to harness both the enhanced antigen presentation of ex vivo 
manipulated DC and the T cell-stimulating effect of OV. 
It will also be important to consider the onset of anti-tumour immunity in the 
context of tumour immune evasion and the suppressive TME. Various armed 
viruses have been designed with the purpose of interfering with immune 
evasion, e.g. viruses expressing checkpoint inhibitors or the PGE2 
inactivating enzyme hydroxyprostaglandin dehydrogenase (541). Other 
strategies use standard chemotherapeutic drugs in combination with OV to 
modulate the TME, for example paclitaxel, which can increase the 
expression of MHC Class I and promote CTL responses, synergises with 
MG-1 OVT, and therapeutics such as gemcitabine and temozolomide can 
deplete the TME of MDSCs and Tregs, respectively, in advance of OV 
administration (542-544). Although the modest size of both reovirus and 
CVA21 genomes is a limiting factor, several of these strategies could be 
considered to promote the induction of anti-tumour immunity by both viruses, 
in particular in the context of the BM microenvironment. 
This work has demonstrated that reovirus and CVA21 could play a role in 
the treatment of HM, both MM and AML, in particular through the 
potentiation of anti-tumour immune responses. The results presented 
provide a solid foundation for development of these agents either alone or in 
combination with complementary therapeutics for translation to clinical trials 
and patient benefit. 
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Appendix 
 
List of manufacturers and suppliers 
 
Abcam 330 Cambridge Science Park 
Cambridge, CB4 0FL, UK 
 
Alpha Laboratories 40 Parham Drive, Eastleigh 
Hampshire, SO50 4NU, UK 
ATCC American Type Culture Collection 
(ATCC), 10801 University 
Boulevard, Manassas, VA 20110 
USA 
BD Biosciences 
Manufacturer of BD Falcon brand 
2350 Qume Drive  
San Jose, CA 95131, USA 
Beckman Coulter (UK) Ltd. Biomedical Research, Oakley 
Court, Kingsmead Business Park, 
London Road, High Wycombe, 
Bucks., HP11 1JU, UK 
BioLegend 9729 Pacific Heights Blvd 
San Diego, CA 92121, USA 
Bio-Rad Lab Ltd. 
 
 
Bio-Rad Laboratories Ltd., Bio-Rad 
House, Maxted Road, Hemel 
Hempstead, Hertfordshire, HP2 
7DX, UK 
eBioscience Ltd 2nd Floor, Titan Court, 3 Bishop 
Square, Hatfield, AL10 9NA,UK 
Fresenius Kabi AS Else-Kröner-Straße 1 
61352 Bad Homburg 
Germany 
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Fisher Scientific UK Ltd. 
Supplier of Eppendorf 
Bishop Meadow Road, 
Loughborough, Leicestershire, 
LE11 5RG, UK 
GeneTex®, Inc. 2456 Alton Parkway, Irvine, CA 
92606, USA 
Integrated DNA Technologies, Inc 8180 N. McCormick Blvd. 
Skokie, Illinois 60076, USA 
Greiner Bio-One GmBH Bad Haller Str. 32 
4550 Kremsmünster, Austria 
Mabtech Box 1233, SE-131 28 Nacka 
Strand, Sweden 
MBL International 
 
15A Constitution Way 
Woburn, MA 01801, USA 
Merck Millipore (UK) Ltd. Suite 3 & 5. Building 6. Croxley 
Green Business Park, Watford, 
WD18 8YH, UK 
Miltenyi Biotec GmBH Friedrich-Ebert-Straße 68, 
51429 Bergisch Gladbach, 
Germany 
Molecular Devices 3860 N First Street 
San Jose, CA 95134, USA 
National Health Service Blood 
and Transplant 
Bridle Path, Leeds, LS15 7TW, UK 
 
Nuaire Western Industrial Estate 
Caerphilly, CF83 1NA, UK 
Oncolytics Biotech Inc. 1167 Kensington Crescent NW 
Calgary, AB, Canada 
PBL Assay Science 
 
131 Ethel Road West, Suite 6 
Piscataway, NJ 08854, USA 
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PeproTech 
 
Princeton Business Park 
5 Crescent Avenue, P.O. Box 275 
Rocky Hill, NJ 08553, USA 
Perkin Elmer Kelvin Close, Birchwood Science 
Park, Risley, Warrington, Cheshire 
WA3 7PB, UK 
Qiagen Ltd. Boundary Court, Gatwick Road, 
Crawley, West Sussex, RH10 2AX, 
UK 
R & D Systems Europe Ltd. 19 Barton Lane, Abingdon Science 
Park, Abingdon,OX14 3NB, UK 
 
Sanyo Sanyo Gallenkamp Plc., Monarch 
Way, Belton Park, Loughborough, 
LE11 5XG, UK 
 Sera Laboratories Intl Ltd Unit 44 
Bolney Grange Business Park 
Haywards Heath,  RH17 5PB, UK 
Sigma-Aldrich Ltd. 
Supplier of Corning Costar 
3050 Spruce St. 
St. Louis, MO 63103, USA 
Thermo Fisher Scientific 
Supplier of Oxoid, Gibco, Invitrogen, 
Evos, Nunc, Applied Biosystems, and 
Life Technologies brands 
Unit 5, The Ringway Centre, Edison 
Rd., Basingstoke, Hampshire, 
RG21 6YH, UK 
UVP Llc. 2066 W. 11th St. 
Upland, CA 91786, USA 
Viralytics Ltd. Suite 305, Level 3, 66 Hunter Street 
Sydney NSW 2000 Australia 
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ELISA antibodies 
Human ELISA antibodies 
 
Target 
molecule 
Species 
of origin 
Clone Role Dilution Coating 
buffer/blocking 
solution 
IFN-a (pan) Mouse MT1/3/5 Capture 1:250 PBS 
IFN-a (pan) Mouse MT2/4/6 Detection 1:1000 10% FBS in 
PBS 
IFN-g Mouse NIB42 Capture 1:250 100nM NaHCO3 
in ddH2O 
IFN-g Mouse 4S.B3 Dilution 1:500 10% FBS in 
PBS 
IFN-a: Mabtech, IFN-g: BD Biosciences 
 
Murine ELISA antibodies 
 
Target 
Molecule 
Species 
of origin 
Clone Role Dilution Coating 
buffer/blocking 
solution 
IFN-g Rat R4-6A2 Capture 1:500 100nM NaHCO3 
in ddH2O 
IFN-g Rat XMG1.2 Detection 1:500 10% (v/v) FCS in 
PBS 
Source: BD Biosciences 
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Human ELISA standards 
 
Cytokine Top standard 
concentration 
Manufacturer 
IFN-a 2000 pg/mL R&D Systems 
IFN-g 10 000 pg/mL BD Biosciences 
 
 
 
Murine ELISA standards 
 
Cytokine Top standard 
concentration 
Manufacturer 
IFN-g 10 000 pg/mL R&D Systems 
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T cell priming protocol overview 
 
 
 
 
 
 
 
 
 
 
 
Figure A-1: Illustration of CTL priming protocol. 
PBMC were isolated from healthy donors and approx. 25% were used for the generation of dendritic cells (DC) and remaining PBMC were frozen. 
DC were generated by isolating CD14+ cells and culturing them in the presence of GM-CSF and IL-4 for 5 days. Simultaneously, target cells were 
either left untreated, or treated with virus for 24 hrs. DC were then loaded with untreated or treated target cells, respectively, by co-culture for 48 
hrs. Tumour-loaded DC were then co-cultured with autologous PBMC (thawed from frozen). Then, a round of re-stimulation was initiated with 
loading of new target cells onto freshly generated DC. After 7 days of culture, CTLs were re-stimulated with fresh tumour-loaded DC, and following 
culture for another 6 days, primed CTLs were analysed using 51Cr release assays and flow cytometry-based assays. 
